0001185185-23-000522.txt : 20230515 0001185185-23-000522.hdr.sgml : 20230515 20230515162350 ACCESSION NUMBER: 0001185185-23-000522 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230515 DATE AS OF CHANGE: 20230515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NovAccess Global Inc. CENTRAL INDEX KEY: 0001039466 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841384159 STATE OF INCORPORATION: CO FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-29621 FILM NUMBER: 23922911 BUSINESS ADDRESS: STREET 1: 8584 E. WASHINGTON STREET, NO. 127 CITY: CHAGRIN FALLS STATE: OH ZIP: 44023 BUSINESS PHONE: (213) 642-9268 MAIL ADDRESS: STREET 1: 8584 E. WASHINGTON STREET, NO. 127 CITY: CHAGRIN FALLS STATE: OH ZIP: 44023 FORMER COMPANY: FORMER CONFORMED NAME: XSUNX INC DATE OF NAME CHANGE: 20031001 FORMER COMPANY: FORMER CONFORMED NAME: SUN RIVER MINING INC DATE OF NAME CHANGE: 20000218 10-Q 1 novaccess20230331_10q.htm FORM 10-Q novaccess20230331_10q.htm


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 10-Q

 


 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2023

 

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number: 000-29621

 

NovAccess Global Inc.

(Exact name of registrant as specified in its charter)

 

Colorado

 

84-1384159

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. employer

Identification no.)

 

Address of principal executive offices, including zip code: 8584 E. Washington Street #127, Chagrin Falls, Ohio 44023

 

Registrant’s telephone number, including area code: (213) 642-9268

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

 

Indicate by check mark whether the Registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). ☒ Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (check one):

 

Large accelerated Filer ☐ Accelerated Filer ☐ Non-Accelerated Filer ☐ Smaller Reporting Company Emerging Growth Company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes  No

 

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date. There were 21,185,028 shares of common stock outstanding on May 15, 2023.

 

 

 

 

Table of Contents

 

PART I  FINANCIAL INFORMATION

 

Item 1. Financial Statements.

1

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

20

Cautionary and Forward-Looking Statements

20

Business Plan

20

Results of Operations for the Three Months Ended March 31, 2023 Compared to the Three Months Ended March 31, 2022

20

Results of Operations for the Six Months Ended March 31, 2023 Compared to the Six Months Ended March 31, 2022

21

Revenue and Cost of Sales

21

Selling, General and Administrative Expenses

21

Research and development expenses

21

Other Income/(Expenses)

21

Net Loss

21

Liquidity and Capital Resources

22

Off-Balance Sheet Arrangements

22

Critical Accounting Estimates

22

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

23

Item 4. Controls and Procedures.

23

Evaluation of Disclosure Controls and Procedures

23

Changes in Internal Control Over Financial Reporting

23

 

 

PART II  OTHER INFORMATION

 

Item 1. Legal Proceedings.

24

Item 1.A Risk Factors.

24

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

24

Item 3. Defaults Upon Senior Securities.

24

Item 4. Mine Safety Disclosures.

24

Item 5. Other Information.

24

Item 6. Exhibit and Financial Statement Schedules.

25

SIGNATURES

26

 

 

 

 

 

Part I- Financial Information

 

Item 1. Financial Statements

 

NOVACCESS GLOBAL INC.

CONSOLIDATED BALANCE SHEETS

 

   

March 31,

2023

   

September 30,

2022

 
   

Unaudited

         

ASSETS

               
                 

CURRENT ASSETS

               

Cash

  $ 21,991     $ 64,251  

Prepaid expenses

    81,468       60,650  
                 

TOTAL ASSETS

  $ 103,459     $ 124,901  
                 
                 

LIABILITIES AND SHAREHOLDERS' DEFICIT

               
                 

CURRENT LIABILITIES

               

Accounts payable

  $ 446,828     $ 375,682  

Accrued expenses and other current liabilities

    1,654,274       1,486,561  

Derivative and warrants liabilities

    1,769,259       1,440,012  

Due to related parties

    181,217       186,217  

Short term loan, related party

    21,000       12,500  

Convertible promissory notes, net of debt discount and debt issuance costs of $157,807 and $340,503 respectively

    1,745,073       1,266,627  

Convertible promissory note related party, net of debt discount and debt issuance cost of $0 and $2,132, respectively

    12,500       10,368  
                 

Total Current Liabilities

    5,830,151       4,777,967  
                 

TOTAL LIABILITIES

    5,830,151       4,777,967  
                 

SHAREHOLDERS' DEFICIT

               

Preferred stock 50,000,000 shares authorized, shares issued and outstanding designated as follows:

               

Preferred Stock Series B, $0.01 par value, 25,000 authorized

600 shares issued and outstanding, respectively

    6       6  

Common stock, no par value; 2,000,000,000 authorized common shares

21,185,028 and 18,669,507 shares issued and outstanding, respectively

    43,623,184       43,225,982  

Additional paid in capital

    6,047,212       5,340,398  

Paid in capital, common stock option and warrants

    4,747,108       4,747,108  

Paid in capital, preferred stock

    4,210,960       4,210,960  

Accumulated deficit

    (64,355,162 )     (62,177,520

)

                 

TOTAL SHAREHOLDERS' DEFICIT

    (5,726,692 )     (4,653,066

)

                 

TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT

  $ 103,459     $ 124,901  

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 

NOVACCESS GLOBAL INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2023 AND 2022

(Unaudited)

 

    Three Months Ended     Six Months Ended  
    March 31,     March 31,  
    2023     2022     2023     2022  
                                 

SALES

  $  -     $  -     $  -     $  -  

COST OF GOODS SOLD

    -       -       -       -  

GROSS PROFIT

    -       -       -       -  
                                 

OPERATING EXPENSES

                               

Research and development expenses

    41,036       45,516       76,000       87,915  

Selling, general and administrative expenses

    1,013,952       381,428       1,496,106       661,358  
                                 

TOTAL OPERATING EXPENSES

    1,054,988       426,944       1,572,106       749,273  
                                 

LOSS FROM OPERATIONS BEFORE OTHER INCOME/(EXPENSES)

    (1,054,988 )     (426,944 )     (1,572,106 )     (749,273 )
                                 

OTHER INCOME/(EXPENSES)

                               

Gain (Loss) on change in derivative liability

    1,825,730       (492,425 )     (255,854 )     (33,399 )

Extinguishment of derivatives

    138,863       -       138,863       96,205  

Extinguishment of debt

    -       (54,813 )     -       (54,813 )

Change in commitment fee guarantee

    (193,625 )     -       74,125       -  

Interest expense

    (262,216 )     (255,603 )     (562,670 )     (631,813 )
                                 

TOTAL OTHER INCOME/(EXPENSES)

    1,508,752       (802,841 )     (605,536 )     (623,820 )
                                 

NET INCOME (LOSS)

    453,764       (1,229,785 )     (2,177,642 )     (1,373,093 )
                                 

Deemed dividend on warrant re-pricing

    (44,241 )     -       (44,241 )     -  
                                 

Net income loss attributable to common shareholders

    409,523       (1,229,785 )     (2,221,883 )     (1,373,093 )
                                 

BASIC INCOME (LOSS) PER SHARE

  $ 0.02     $ (0.08 )   $ (0.11 )   $ (0.09 )
                                 

DILUTED INCOME (LOSS) PER SHARE

  $ 0.01     $ (0.08 )   $ (0.11 )   $ (0.09 )
                                 

WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING

                               

BASIC

    20,698,747       15,379,289       19,832,524       14,914,920  

DILUTED

    39,680,653       15,379,289       19,832,524       14,914,920  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

NOVACCESS GLOBAL INC.

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' DEFICIT

FOR THE SIX MONTHS ENDED MARCH 31, 2023 AND 2022

 

                                           

Stock

   

 

                 
   

Preferred Stock,

                   

Additional

   

Options/

Warrants
   

Paid in

Capital,

                 
   

Class B

    Common Stock    

Paid-in

   

Paid in

   

Preferred

    Accumulated          
   

Shares

   

Amount

   

Shares

   

Amount

   

Capital

   

Capital

   

Stock

   

Deficit

   

Total

 

Balance as of September 30, 2021

    25,000     $ 250       14,404,030     $ 41,882,535     $ 5,351,398     $ 4,210,960     $ 5,088,324     $ (60,461,561 )   $ (3,928,094 )
                                                                         

Preferred stock redemption

    (24,400 )     (244 )     1,502,670       525,935       -       -       (341,216 )     -       184,475  

Common Stock issued for services

    -       -       265,973       119,480       -       -       -       -       119,480  

Common Stock issued, subscriptions

    -       -       791,000       170,200       -       -       -       -       170,200  

Stock compensation cost

    -       -       10,000       8,000       -       -       -       -       8,000  

Common stock issued as repayment of loans

    -       -       250,000       104,813       -       -       -       -       104,813  

Common stock issued as commitment fee on promissory note payable

    -       -       300,000       111,000       -       -       -       -       111,000  

Common stock issuable, Subscriptions

    -       -       -       -       5,000       -       -       -       5,000  

Net Loss

    -       -       -       -       -       -       -       (1,373,093 )     (1,373,093 )

Balance as of March 31, 2022 (Unaudited)

    600     $ 6       17,523,673     $ 42,921,963     $ 5,356,398     $ 4,210,960     $ 4,747,108     $ (61,834,654 )   $ (4,598,219 )

 

                                           

Stock

                         
   

Preferred Stock,

                   

Additional

   

Options/

Warrants

   

Paid in

Capital,

               
   

Class B

    Common Stock    

Paid-in

   

Paid in

   

Preferred

    Accumulated            
   

Shares

   

Amount

   

Shares

   

Amount

   

Capital

   

Capital

   

Stock

   

Deficit

   

Total

 

Balance as of September 30, 2022

    600     $ 6       18,669,507     $ 43,225,982     $ 5,340,398     $ 4,210,960     $ 4,747,108     $ (62,177,520 )   $ (4,653,066 )
                                                                         

Common Stock issued for services

    -       -       1,490,521       259,702       -       -       -       -       259,702  

Common Stock issued, subscriptions

    -       -       525,000       55,000       (5,000 )     -       -       -       50,000  

Common stock issued for commitment fees

    -       -       500,000       82,500       -       -       -       -       82,500  

Stock compensation cost for options

    -       -       -       -       563,314       -       -       -       563,314  

Stock compensation cost for warrants

    -       -       -       -       148,500       -       -       -       148,500  

Net Loss

    -       -       -       -       -       -       -       (2,177,642

)

    (2,177,642

)

Balance as of March 31, 2023 (Unaudited)

    600     $ 6       21,185,028     $ 43,623,184     $ 6,047,212     $ 4,210,960     $ 4,747,108     $ (64,355,162

)

  $ (5,726,692

)

 

 

NOVACCESS GLOBAL INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED MARCH 31, 2023 AND 2022

(Unaudited)

 

   

For the Six Months Ended

 
   

March 31, 2023

   

March 31, 2022

 

CASH FLOWS FROM OPERATING ACTIVITIES:

               

Net Loss

  $ (2,177,642 )   $ (1,373,093 )

Adjustment to reconcile net loss to net cash provided by (used in) operating activities

               

Amortization of debt discount and debt issuance costs recorded as interest expense

    432,083       479,689  

Loss on change in derivative liability

    255,854       33,399  

Extinguishment of derivatives

    (138,863 )     (96,205 )

Extinguishment of debt

            54,813  

Stock compensation expense

    711,814       53,619  

Stock issued and issuable for services

    259,702       73,861  

Stock issued as commitment fee on promissory note payable

    82,500       79,043  

Non-cash interest expense on bridge loan

    -       546  
                 

Changes in Assets and Liabilities:

               

Prepaid expenses

    (20,818 )     5,568  

Accounts payable

    71,147       39,700  

Accrued expenses and interest on notes payable

    167,713       210,216  
                 

NET CASH USED IN OPERATING ACTIVITIES

    (356,510 )     (438,844 )
                 

CASH FLOWS FROM FINANCING ACTIVITIES:

               

Stock subscriptions received

    50,000       175,200  

Due to related party

    -       3,151  

Proceeds from convertible notes payable

    340,000       213,000  

Payments related party for redemption of preferred stock

    (5,000 )     (50,000 )

Payments on convertible notes payable

    -       -  

Proceeds from related parties notes payable

    8,500       75,000  

Payment on the related parties loans payable

    -       (2,316 )

Principal payments on convertible debt

    (79,250 )     (94,250 )
                 

NET CASH PROVIDED BY FINANCING ACTIVITIES

    314,250       319,785  
                 

NET INCREASE (DECREASE) IN CASH

    (42,260 )     (119,059 )
                 

CASH, BEGINNING OF PERIOD

    64,251       180,668  
                 

CASH, END OF PERIOD

  $ 21,991     $ 61,609  
                 

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION

               

Interest paid

  $ 17,711     $ 71,245  

Taxes paid

  $ 800     $ -  
                 

SUPPLEMENTAL DISCLOSURES OF NON CASH TRANSACTIONS

               

Accrued interest capitalized into convertible note

  $ -     $ 546  

Cash payable to TN3 for preferred stock

  $ -     $ 200,000  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- UNAUDITED

MARCH 31, 2023 AND 2022

 

1. ORGANIZATION AND LINE OF BUSINESS

 

Organization

NovAccess Global Inc. (“NovAccess” or the “Company”) is a Colorado corporation formerly known as Sun River Mining Inc. and XsunX, Inc.. The Company was originally incorporated in Colorado on February 25, 1997. Effective September 24, 2003, the Company completed a plan of reorganization and name change to XsunX, Inc. Effective August 25, 2020, we filed articles of amendment to our articles of incorporation with the Colorado Secretary of State to: effectuate a 1-for-1,000 reverse stock split of the Company’s outstanding shares of common stock; and change the name of the Company to “NovAccess Global Inc.” After completing the acquisition of StemVax, in September, 2020, we exited the solar business and focused all our efforts on our biopharmaceutical business.

 

Line of Business

NovAccess Global Inc. is a biopharmaceutical company that is developing novel immunotherapies to treat brain tumor patients in the United States with plans to expand globally. We specialize in cutting-edge research related to utilizing a patient’s own immune system to attack the cancer. We are filing an Investigational New Drug Application (IND) and working closely with the Food and Drug Administration (FDA) to obtain approval for human clinical trials to determine safety and efficacy of our drug product for brain cancer patients. Once we have successfully completed the clinical trials and proven that the new therapy is safe and efficacious, we plan to commercialize the product. We also have expertise in successfully executing clinical trials, bringing products to market and increasing the market size of products through our advisory board. Our scientists are well versed in immunology, stem cell biology, neuroscience, molecular biology, imaging, small molecules development, gene therapy and other technical assays needed for protein and genetic analysis of cancer cells.

 

NovAccess operates as a research and development (R&D) company out of Ohio and California, and our executive management and scientific advisory board provide over 15 years of extensive experience in all aspects of biopharmaceutical R&D and commercialization of drug candidates.

 

Going Concern

The accompanying financial statements have been prepared on a going concern basis of accounting, which contemplates continuity of operations, realization of assets and liabilities and commitments in the normal course of business. The accompanying financial statements do not reflect any adjustments that might result if the Company is unable to continue as a going concern. The Company does not generate significant revenue, and has negative cash flows from operations, which raise substantial doubt about the Company’s ability to continue as a going concern.

 

The ability of the Company to continue as a going concern and appropriateness of using the going concern basis is dependent upon, among other things, additional cash infusion. The Company has obtained funds from its shareholders since its inception through the period ended March 31, 2023. Management believes the existing shareholders and the prospective new investors will provide the additional cash needed to meet the Company’s obligations as they become due and will allow the development of its business.

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

This summary of significant accounting policies of NovAccess Global Inc. is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements.

 

Basis of Presentation

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary StemVax, LLC. All significant inter-company accounts and transactions between these entities have been eliminated in these consolidated financial statements.

 

 

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2023 AND 2022

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying consolidated financial statements. Significant estimates made in preparing these consolidated financial statements include the estimate of the deferred tax valuation allowance, the fair value of stock options, and derivative liabilities. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

For purposes of the statements of cash flows, cash and cash equivalents include cash in banks and money markets with an original maturity of three months or less.

 

Stock-Based Compensation

Share-based Payment applies to transactions in which an entity exchanges its equity instruments for goods or services and also applies to liabilities an entity may incur for goods or services that are to follow a fair value of those equity instruments. We are required to follow a fair value approach using an option-pricing model, such as the Binomial lattice valuation model, at the date of a stock option grant. The deferred compensation calculated under the fair value method would then be amortized over the respective vesting period of the stock option. This has not had a material impact on our results of operations.

 

Net Earnings (Loss) per Share Calculations

Net earnings (Loss) per share dictates the calculation of basic earnings (loss) per share and diluted earnings (loss) per share. Basic earnings (loss) per share are computed by dividing by the weighted average number of common shares outstanding during the period. Diluted net earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the effect of stock options and stock-based awards plus the assumed conversion of convertible debt (see notes 4 and 5). 

 

   

For the three months ended

   

For the Six months ended

 
   

March 31,

   

March 31,

 
   

2023

   

2022

   

2023

      2022  
                                 

Income (Loss) to common shareholders (Numerator)

  $ 409,523       (1,229,785 )   $ (2,221,883 )     (1,373,093 )
                                 

Basic weighted average number of common shares outstanding (Denominator)

    20,698,747       15,379,289       19,832,524       14,914,920  
                                 

Diluted weighted average number of common shares outstanding

    39,680,653       15,379,289       19,832,524,       14,914,920  

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of March 31, 2023, the balances reported for cash, prepaid expenses, accounts payable, accrued expenses approximate the fair value because of their short maturities.

 

We adopted Accounting Standards Codification (“ASC”) Topic 820 for financial instruments measured as fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States and expands disclosures about fair value measurements.

 

 

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2023 AND 2022

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Fair Value of Financial Instruments (continued)

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:

 

 

Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;

 

 

Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

 

 

Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

We measure certain financial instruments at fair value on a recurring basis. The Company had no assets that are required to be valued on a recurring basis as of March 31, 2023 and September 30, 2022. The Company had liabilities that are required to be measured at fair value on a recurring basis as follows at March 31 2023 and September 30, 2022:

 

   

Total

   

(Level 1)

   

(Level 2)

   

(Level 3)

 
                                 

Assets:

  $ -     $ -     $ -     $ -  
                                 

Liabilities:

                               
                                 

Derivative Liability at fair value as of September 30, 2022

  $ 1,207,403     $ -     $ -     $ 1,207,403  

Derivative Liability warrants at fair value as of September 30, 2022

  $ 232,609     $ -     $ -     $ 232,609  

Total Derivative Liability as of September 30, 2022

  $ 1,440,012       -       -     $ 1,440,012  

Derivative Liability at fair value as of March 31, 2023

  $ 1,211,565       -       -     $ 1,211,565  

Derivative Liability warrants at fair value as of March 31, 2023

  $ 557,694       -       -     $ 557,694  

Total Derivative Liability as of March 31, 2023

  $ 1,769,259       -       -     $ 1,769,259  

 

The following is a reconciliation of the derivative liability for which Level 3 inputs were used in determining the approximate fair value:

 

   

Derivative Liability

Promissory Notes

   

Derivative

Liability Warrants

   

Total

Derivative Liability

 

Balance as of September 30, 2021

  $ 2,553,979     $ 372,643     $ 2,926,622  

Fiscal year 2022 initial derivative liabilities

    593,297       282,051       875,348  

Net (Gain)/Loss on change in fair value of derivative liability

    (1,662,156

)

    (422,086

)

    (2,084,242

)

Extinguishment of derivative

    (277,716

)

    -       (277,716 )

Ending balance as of September 30, 2022

  $ 1,207,403     $ 232,609     $ 1,440,012  

Six Months ended March 31, 2023, initial derivative liabilities

    212,256       -       212,256  

Net (Gain)/Loss on change in fair value of derivative liability

    (69,231 )     325,085       255,854  

Extinguishment of derivative

    (138,863 )     -       (138,863 )

Ending balance as of March 31, 2023

  $ 1,211,565     $ 557,694     $ 1,769,259  

 

 

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2023 AND 2022

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Recent Accounting Pronouncements

In September 2022, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2022-04, "Liabilities-Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations". This guidance requires annual and interim disclosures for entities that use supplier finance programs in connection with the purchase of goods and services. The ASU is effective for fiscal years beginning after December 15, 2022, with early adoption permitted, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 15, 2023. We are currently evaluating the extent of the impact of this ASU, but do not expect the adoption of this standard to have a significant impact on our consolidated financial statements.

 

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sales Restrictions, which (1) clarifies the guidance in Topic 820 on the fair value measurement of an equity security that is subject to contractual restrictions that prohibit the sale of an equity security and (2) requires specific disclosures related to such an equity security. We are currently evaluating the extent of the impact of this ASU, but do not expect the adoption of this standard to have a significant impact on our consolidated financial statements.

 

In March 2022, the FASB issued ASU No. 2022-02, Troubled Debt Restructurings and Vintage Disclosures ("ASU 2022-02"). ASU 2022-02 eliminates the accounting guidance on troubled debt restructurings for creditors in ASC Topic 310 and amends the guidance on "vintage disclosures" to require disclosure of current-period gross write-offs by year of origination. ASU 2022-02 also updates the requirements related to accounting for credit losses under ASC Topic 326 and adds enhanced disclosures for creditors with respect to loan refinancings and restructurings for borrowers experiencing financial difficulty. ASU 2022-02 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We are currently evaluating the extent of the impact of this ASU, but do not expect the adoption of this standard to have a significant impact on our consolidated financial statements.

 

Management does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

 

3. CAPITAL STOCK

 

As of March 31, 2023 the Company’s authorized stock consisted of 2,000,000,000 shares of common stock, with no par value. Effective August 25, 2020, we filed articles of amendment to our articles of incorporation with the Colorado Secretary of State to effectuate a 1-for-1,000 reverse stock split of the Company’s outstanding shares of common stock.

 

The Company is also authorized to issue 50,000,000 shares of preferred stock with a par value of $0.01 per share. The rights, preferences and privileges of the holders of the preferred stock are determined by the Board of Directors prior to issuance of such shares.

 

Preferred Stock

 

As of March 31, 2023, the Company had 600 shares of issued and outstanding Series B Preferred. On September 4, 2020, the Company issued 25,000 shares of unregistered Series B Convertible Preferred stock, $0.01 par value per share, to TN3, LLC, a Wyoming limited liability company owned by Daniel G. Martin (“TN3”), in exchange for the redemption of all 5,000 shares of Series A preferred stock that TN3 previously held. At the time, Mr. Martin was our Chief Executive Officer and sole Board Member. On March 14, 2022, NovAccess redeemed 24,400 shares of the Company’s Series B Convertible Preferred Stock held by TN3. Irvin Consulting LLC, a company owned by Dwain Irvin, the CEO of NovAccess, purchased the remaining 600 shares (please refer to Note 11 for more details).

 

Each share of outstanding Series B Preferred Stock entitles the holder to cast 40,000 votes. Each share of Series B Preferred Stock is convertible at the option of the holder into 10,000 common shares. In the event of any voluntary or involuntary liquidation, dissolution, or winding-up of the Corporation, the holders of shares of Series B Preferred Stock shall be paid out based on an as converted basis. Dividends for Series B Preferred Stock shall be declared on an as converted basis.

 

 

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2023 AND 2022

 

3. CAPITAL STOCK (Continued)

 

Common Stock

 

During the six months ended March 31, 2023, the Company issued 2,515,521 shares of common stock.

 

The Company issued 1,490,521 shares to various vendors for services provided, including 216,500 shares issued to a related party for services provided, amounting to $259,702 recorded at the fair value of shares on the respective grant dates.

 

The Company issued 525,000 shares in relation to stock subscriptions.

 

The Company issued 500,000 shares as commitment fees in connection with the letter agreement issued on February 9, 2023. These shares were recorded at fair value as on the date of issuance.

 

During the six months ended March 31, 2022, the Company issued 3,119,643 shares of common stock. 1,502,670 shares were issued to TN3 as part of the transaction to redeem 24,400 shares of Series B Preferred Stock, 265,973 shares were issued to various vendors for services provided; 791,000 shares were issued in relation to stock subscriptions; 300,000 shares were issued as a commitment fee on a promissory note payable; 250,000 shares were issued as repayment of bridge loans (please refer to Note 4 for more details); and 10,000 shares were issued to related parties (please refer to Note 12 for more details).

 

4. CONVERTIBLE PROMISSORY NOTES

 

Convertible Promissory notes

as on March 31, 2023

 

Principal Amount

   

Unamortized balance of Debt Discount

   

Outstanding balance as on March 31, 2023

   

Derivative balance as on March 31, 2023

   

Warrant liability balance as on March 31, 2023

 
                                         

2013 Note

    12,000       -       12,000       -       -  

2014 Note

    50,880       -       50,880       215,591       -  

2017 Note

    115,000       -       115,000       453,384       -  

August 2021 Note

    -       -       -       -       151,920  

February 2022 Note

    250,000       -       250,000       81,815       76,762  

May 2022 Note

    1,000,000       -       1,000,000       245,784       171,753  

August 2022 Note

    100,000       27,517       72,483       48,797       -  

November 2022 Note

    55,000       32,937       22,063       48,883       -  

December 2022 Note

    55,000       37,207       17,793       49,719       -  

February 2023 Note

    265,000       60,146       204,854       63,650       157,259  

Total

    1,902,880       157,807       1,745,073       1,207,624       557,694  

 

Convertible Promissory note,

related party as on March 31, 2023

 

Principal Amount

   

Unamortized balance of Debt Discount

   

Outstanding balance as on March 31, 2023

   

Derivative balance as on March 31, 2023

   

Warrant liability balance as on March 31, 2023

 
                                         

July 2022 Note

    12,500       -       12,500       3,941       -  

 

2013 Note

 

On October 1, 2013, Company issued an unsecured convertible promissory note (the “2013 Note”) in the amount of $12,000 to a former Board member (the “Holder”) in exchange for retention as a director during the fiscal year ending September 30, 2014. The Note can be converted into shares of common stock by the Holder for $4.50 per share. The Note matured on October 1, 2015 and bore a one-time interest charge of $1,200 which was applied to the principal on October 1, 2014. As of March 31, 2023, the outstanding principal balance was $12,000.

 

 

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2023 AND 2022

 

4. CONVERTIBLE PROMISSORY NOTES (Continued)

 

2014 Note

 

On November 20, 2014, the Company issued a 10% unsecured convertible promissory note (the “2014 Note”) for the principal sum of up to $400,000 plus accrued interest on any advanced principal funds. The 2014 Note matured eighteen months from each advance. The 2014 Note may be converted by the lender into shares of common stock of the Company at the lesser of $12.50 per share or (b) fifty percent (50%) of the lowest traded prices following issuance of the 2014 Note or (c) the lowest effective price per share granted to any person or entity. On November 20, 2014, the lender advanced $50,000 to the Company under the 2014 Note at inception. On various dates from February 18, 2015 through September 30, 2016, the lender advanced an additional $350,000 under the 2014 Note. During the period ended September 30, 2021, the Company and lender agreed to extend the maturity date for the outstanding balance to June 30, 2023. As of March 31, 2023, outstanding principal balance was $50,880.

 

2017 Note

 

On May 10, 2017, the Company issued a 10% unsecured convertible promissory note (the “2017 Note”) for the principal sum of up to $150,000 plus accrued interest on any advanced principal funds. The lender may pay additional consideration at the lender’s discretion. The Company received a tranche in the amount of $25,000 upon execution of the 2017 Note. On various dates, the Company received additional tranches in the aggregate sum of $90,000. The 2017 Note matured twelve months from each tranche. Within thirty (30) days prior to the maturity date, the lender may extend the maturity date to sixty (60) months. During the period ended September 30, 2021, the Company and lender agreed to extend the maturity date for the outstanding balance to June 30, 2023. The 2017 Note may be converted by the lender into shares of common stock of the Company at the lesser of $10 per share or (b) fifty percent (50%) of the lowest traded price of common stock recorded on any trade day after the effective date, or (c) the lowest effective price per share granted to any person or entity. As of March 31, 2023 the outstanding principal balance was $115,000.

 

May 2021 Note

 

On May 28, 2021, the Company issued a 12% unsecured convertible promissory note (the “May 2021 Note”) for the principal sum of $55,500 plus accrued interest. The May 2021 Note was to mature on May 28, 2022. The May 2021 Note was convertible after November 23, 2021, by the lender into shares of common stock of the Company at sixty-one percent (61%) of the lowest traded price of common stock recorded during the fifteen (15) trading days prior to conversion. On October 5, 2021, the Company paid the balance of this note to the lender. As of March 31, 2023, the balance of the May 2021 Note was $0.

 

July 2021 Note

 

On July 6, 2021, the Company issued a 12% unsecured convertible promissory note (the “July 2021 Note”) for the principal sum of $38,750 plus accrued interest with a maturity date of July 6, 2022. The July 2021 Note was convertible after January 1, 2022, by the lender into shares of common stock of the Company at sixty-one percent (61%) of the lowest trade price of common stock recorded during the fifteen (15) trading days prior to conversion. On December 30, 2021, the Company paid the balance of this note to the lender. As of March 31, 2023, the balance of the July 2021 Note was $0.

 

August 2021 Note

 

On August 20, 2021, the Company issued a 10% secured promissory note (the “August 2021 Note”) for the principal sum of $500,000 plus accrued interest. The August 2021 Note was to mature on February 20, 2022, unless extended for up to an additional six months. The August 2021 Note could be converted, only following an event of default, by the lender into shares of common stock of the Company at the lesser of 90% (representing a 10% discount) multiplied by the lowest trading price during the previous twenty (20) trading day period ending on the issuance date, or during the previous twenty (20) trading day period. The Company issued 1,000,000 warrants at a price of $1.50 in connection with the note (note 7 below) and issued 400,000 shares as a commitment fee. In February 2022, the Company extended the term of the August 2021 Note for an additional six months. The Company repaid the August 2021 Note on May 9, 2022 in connection with the issuance of the May 2022 Note described below. As of March 31, 2023, the balance on the August 2021 Note was $0.

 

On February 9, 2023, the Company entered into a letter agreement in connection with the August 2021 Note, whereby the exercise price of the warrants issued on the August 2021 Note was reduced to $0.20 per share.

 

 

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2023 AND 2022

 

4. CONVERTIBLE PROMISSORY NOTES (Continued)

 

February 2022 Note

 

On February 15, 2022, the Company issued a 10% secured promissory note (the “February 2022 Note”) for the principal sum of $250,000 plus accrued interest. The February 2022 Note was to mature on August 15, 2022, unless extended for up to an additional six months. The February 2022 Note may be converted, only following an event of default, by the lender into shares of common stock of the Company at the lesser of 90% (representing a 10% discount) multiplied by the lowest trading price during the previous twenty (20) trading day period ending on the issuance date, or during the previous twenty (20) trading day period. In July 2022, the Company extended the term of the February 2022 note for another six months until February 16, 2023. In connection with the note, the Company issued 500,000 warrants with an exercise price of $1.50 (see note 7 below). The February 2022 Note had an original issuance discount amounting to $25,000, debt issuance cost amounting to $12,000 and the Company issued 300,000 shares as a commitment fee valued at $111,000 based on the share price on the date of the agreement, amortized over the term of the loan. The initial recognition of derivative and warrant liability was recorded as debt discount and amortized over the term of the loan. The debt discount is fully amortized and the balance in debt discount as on March 31, 2023, was $0. As of March 31, 2023, the balance outstanding net of debt discount was $250,000.

 

On February 9, 2023, the Company entered into a letter agreement in connection with the February 2022 Note, whereby the Company extended the due date of the loan to May 9, 2023 and deferred all interest payments for the period from January 1, 2023 until May 9, 2023. Pursuant to the letter agreement the exercise price of the warrants issued with the February 2022 Note was reduced to $0.20 per share. The warrants contained a ratchet provision and the difference in fair value of $44,241 upon the reduction of exercise price as mentioned above  is being treated as a deemed dividend for the down round provision.

 

The company did not make the payment of $258,958 due on May 9, 2023. The lender has agreed to waive the default provisions until June 1, 2023, or pending conclusion of negotiations on an extension of the loans.

 

May 2022 Note

 

On May 5, 2022, the Company issued a 12% secured promissory note (the “May 2022 Note”) for the principal sum of $1,000,000 plus accrued interest. The May 2022 Note was to mature on November 5, 2022, unless extended for up to an additional six months. If extended, the interest rate increased to 15% for the remaining six months. The May 2022 Note may be converted, only following an event of default, by the lender into shares of common stock of the Company at the lesser of the lowest trading price during the previous twenty (20) trading day period ending on the issuance date, or during the previous twenty (20) trading day period before conversion. The Company used some of the proceeds from the May 2022 Note to pay off the August 2021 Note. In November 2022, the Company extended the May 2022 Note for another six months until May 5, 2023. In connection with the loan the Company issued 1,000,000 warrants at an exercise price of $0.01 (see note 7 below). The May 2022 Note had an original issuance discount amounting to $100,000, debt issuance costs of $ 25,500 and the Company issued 875,000 shares as a commitment fee valued at $259,875 based on the share price on the date of the agreement. The initial recognition of derivative liability of $412,065 and warrant liability amounting to $282,051 was recorded as debt discount and amortized over the term of the loan. The balance in debt discount as on March 31, 2023, was $0. As of March 31, 2023, the balance outstanding net of debt discount was $1,000,000.

 

On February 9, 2023, the Company entered into a letter agreement in connection with the May 2022 Note deferring all interest payments from January 1, 2023 until May 9, 2023.

 

The company did not make the payment of $1,053,750 due on May 9, 2023. The lender has agreed to waive the default provisions until June 1, 2023, or pending conclusion of negotiations on an extension of the loans.

 

August 2022 Note

 

On August 8, 2022, the Company issued a 12% unsecured promissory note (the “August 2022 Note”) for the principal sum of $100,000 plus accrued interest. The August 2022 Note matures on August 8, 2023, provided, however that after October 31, 2022, if the Company receives debt or equity financing of at least $3 million, the holder may call for payments of outstanding principal and interest at any time from such date giving notice of at least five business days before the date the payment is due. The holder shall have the right, until the date of payment in full of all amounts outstanding to convert unpaid principal and interest and any other amounts into fully paid shares of common stock of the Company at a conversion price of $0.15. The initial recognition of derivative liability of $77,259 was recorded as debt discount and amortized over the term of the loan. The balance in debt discount as on March 31, 2023 was $27,517. As of March 31, 2023 the balance outstanding net of debt discount was $72,483.

 

 

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2023 AND 2022

 

4. CONVERTIBLE PROMISSORY NOTES (Continued)

 

September 2022 Note

 

On September 22, 2022, the Company issued an 8% secured promissory note (the “September 2022 Note”) for the principal sum of $79,250 plus accrued interest. The September 2022 Note matures on September 22, 2023. In case of default in repayment of the outstanding amount on the due date the balance shall bear interest of 22% per annum. The holder shall have the right, after six months, until the date of payment in full of all amounts outstanding to convert unpaid principal and interest and any other amounts into fully paid shares of common stock of the Company at a variable conversion price equal to 65% multiplied by the market price. Market price means the average of the three lowest trading prices for the Common Stock during the fifteen-trading day period ending on the latest complete trading day prior to the conversion date. The initial recognition of derivative liability amounting to $75,000 was recorded as debt discount and amortized over the term of the loan. The debt issuance cost of $4,250 was recorded as debt discount and amortized over the term of the loan. The Company repaid the loan in full including interest of $3,127 on March 12, 2023. The prepayment penalty amounted to $20,594. The balance in debt discount as on March 31, 2023 was $0. As of March 31, 2023 the balance outstanding net of debt discount was $0.

 

November 2022 Note

 

On November 1, 2022, the Company issued an 8% secured promissory note (the “November 2022 Note”) for the principal sum of $55,000 plus accrued interest. The November 2022 Note matures on November 1, 2023. In case of default in repayment of the outstanding amount on the due date the balance shall bear interest of 22% per annum. Beginning on April 30, 2023, 1800 Diagonal Lending may convert the amount outstanding under the note into shares of NovAccess common stock at a conversion price equal to 65% of the average of the three lowest trading prices of the stock during the fifteen trading days before the conversion date. The initial recognition of derivative liability amounting to $50,700 was recorded as debt discount and amortized over the term of the loan. The debt issuance cost of $4,250 was recorded as debt discount and amortized over the term of the loan. The balance in debt discount as on March 31, 2023, was $32,938. As of March 31, 2023, the balance outstanding net of debt discount was $22,063.

 

December 2022 Note

 

On December 7, 2022, the Company issued an 8% secured promissory note (the “December 2022 Note”) for the principal sum of $55,000 plus accrued interest. The December 2022 Note matures on December 7, 2023. In case of default in repayment of the outstanding amount on the due date the balance shall bear interest of 22% per annum. Beginning on June 5, 2023, 1800 Diagonal Lending may convert the amount outstanding under the note into shares of NovAccess common stock at a conversion price equal to 65% of the average of the three lowest trading prices of the stock during the fifteen trading days before the conversion date. The initial recognition of derivative liability amounting to $50,700 was recorded as debt discount and amortized over the term of the loan. The debt issuance cost of $4,250 was recorded as debt discount and amortized over the term of the loan. The balance in debt discount as on March 31, 2023, was $37,207. As of March 31, 2023, the balance outstanding net of debt discount was $17,793.

 

February 2023 Letter Agreement

 

On February 9, 2023 the Company entered into a letter agreement, whereby the Company drew an additional loan amounting to $265,000, which was added to the May 2022 Note. The $265,000 loan has an original issuance discount of 10% of the principal and bears interest at 10% a year. This loan is due on May 9, 2023. The initial recognition of derivative liability amounting to $110,576 was recorded as debt discount and amortized over the term of the loan. The original issuance discount of $26,500 was recorded as debt discount and amortized over the term of the loan. The balance in debt discount as on March 31, 2023, was $60,146. As of March 31, 2023, the balance outstanding net of debt discount was $204,854.

 

 

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2023 AND 2022

 

4. CONVERTIBLE PROMISSORY NOTES (Continued)

 

Also pursuant to the letter agreement , the Company paid a commitment fee of 500,000 unregistered shares of the Company’s common stock (the “commitment fee shares”). If the investor is unable to sell the commitment fee shares for $0.20 a share, then investor may require the Company to issue additional shares or pay cash in the amount of the shortfall. The Company also issued a common stock purchase warrant to purchase 1.0 million shares of the company’s Common stock for $0.20 a share. The warrant expires on February 9, 2028. The company recorded expense of 82,500 in respect of the commitment fee shares and 157,933 in respect of the warrant.

 

The Company did not make the payment of $271,551 due on May 9, 2023. The lender has agreed to waive the default provisions until June 1, 2023, or pending conclusion of negotiations on an extension of the loans.

 

We evaluated the financing transactions in accordance with ASC Topic 815, Derivatives and Hedging, and determined that the conversion feature of the convertible promissory notes was not afforded the exemption for conventional convertible instruments due to its variable conversion rate. The notes have no explicit limit on the number of shares issuable so they did not meet the conditions set forth in current accounting standards for equity classification. The Company elected to recognize the notes under paragraph 815-15-25-4, whereby, there would be a separation into a host contract and derivative instrument. The Company elected to initially and subsequently measure the notes in their entirety at fair value, with changes in fair value recognized in earnings. The Company recorded a derivative liability representing the imputed interest associated with the embedded derivative. The derivative liability is adjusted periodically according to the stock price fluctuations based upon the Binomial lattice model calculation.

 

The convertible notes issued and described in this Note do not have fixed settlement provisions because their conversion prices are not fixed. The conversion feature has been characterized as a derivative liability to be re-measured at the end of every reporting period with the change in value reported in the statement of operations.

 

We record the full value of the derivative as a liability at issuance with an offset to valuation discount, which will be amortized over the life of the notes.

 

For purpose of determining the fair market value of the derivative liability for the embedded conversion, the Company used Binomial lattice valuation model. The significant assumptions used in the Binomial lattice valuation of the derivatives are as follows:

 

Risk free interest rate

 

Between 4.74% and 4.955%

Stock volatility factor

 

Between 141% and 177.6%

Years to Maturity

 

0.28 years

Expected dividend yield

 

None

 

5. CONVERTIBLE PROMISSORY NOTES, RELATED PARTY

 

July 2022 Note, related party

 

On July 28, 2022, the Company issued a 12% unsecured promissory note (the “July 2022 Note”) for the principal sum of $12,500 plus accrued interest. All amounts outstanding under the July 2022 Note were payable on the earlier of: (a) October 31, 2022, or (b) the receipt by the Company of debt or equity financing of $3 million. In November 2022, the holder agreed to extend the term of the note until April 2023 and in April 2023 agreed to a further extension until August 31, 2023. The holder has the right, until the date of payment in full of all amounts outstanding to convert unpaid principal and interest and any other amounts into fully paid shares of common stock of the Company at conversion price of $0.15. The initial recognition of derivative liability of $12,500 was recorded as debt discount and amortized over the term of the loan. The balance in debt discount as on March 31, 2023, was $0. As of March 31, 2023, the balance outstanding net of debt discount was $12,500.

 

 

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2023 AND 2022

 

6. SHORT TERM LOAN, RELATED PARTY

 

On July 28, 2022, the Company entered into a short-term interest free loan agreement amounting to $12,500, with Jason M. Anderson, an independent member of our board of directors, to fund the operations until longer term financing can be obtained by the Company. The loan terms required repayment of all amounts outstanding under the loan on the earlier of: (a) October 31, 2022 or (b) the receipt by the Company of debt or equity financing of $3 million In November, 2022, the Board Member signed a waiver and extension agreement changing the due date to April 30, 2023 and in April 2023, agreed to a further extension until August 31, 2023.

 

On February 9, 2023, NovAccess entered into a second interest-free loan agreement with Mr. Anderson. Reflecting his faith in NovAccess and our management team, Mr. Anderson loaned the Company $8,500. The loan does not bear interest (except on default) and is due on the earlier of August 31, 2023 or our receipt of debt or equity financing of at least $3.0 million.

 

7. WARRANTS

 

On August 20, 2021, for value received in connection with the issuance of the August 2021 Note (see note 4 for more details), the Company issued 1,000,000 warrants to the lender with an exercise price of $1.50 per share with a five-year exercise period. On February 9, 2023, the Company entered into a letter agreement in connection with the August 2021 Note, whereby the exercise price of the warrants issued on the August 2021 Note was reduced to $0.20 per share.

 

On February 16, 2022, for value received in connection with the issuance of the February 2022 Note (see note 4 for more details), the Company issued 500,000 warrants to the lender with an exercise price of $1.50 per share with a five-year exercise period. On February 9, 2023, the Company entered into a letter agreement in connection with the August 2021 Note, whereby the exercise price of the warrants issued on the August 2021 Note was reduced to $0.20 per share.

 

On May 10, 2022, for value received in connection with the issuance of the May 2022 Note (see note 4 for more details), the Company issued 1,000,000 warrants to the lender with an exercise price of $0.01 per share with a five-year exercise period. On February 9, 2023, for value received in connection with the issuance of the February 2023 Note (see note 4 for more details), the Company issued 1,000,000 warrants to the lender with an exercise price of $0.20 per share with a five-year exercise period. The fair value of the warrant issued in relation to the letter agreement issued on February 2023 , is recorded as stock compensation expense amounting to $148,500.

 

On March 31, 2023 the fair value of the derivative liability of the warrants was $557,694 and $232,609 as of September 30, 2022.

 

For the purpose of determining the fair market value of the derivative liability for the embedded conversion, the Company used the Binomial lattice valuation model. The significant assumptions used in the Binomial lattice valuation of the derivatives are as follows:

 

Risk free interest rate

 

Between 3.6% and 3.81%

Stock volatility factor

 

Between 147% and 164%

Years to Maturity

 

4.25 years

Expected dividend yield

 

None

 

Per guidance on ASC 260, the Company determined that the repricing of warrants discussed above, was an exchange of the existing 1,500,000 warrants and the difference between the fair value of the warrants immediately prior to modification of terms and immediately after the adjustment was a s a deemed dividend. The difference between the fair value of the warrants immediately prior to modification of terms and immediately after the adjustment was calculated as $44,241, using a Black Scholes model based on the following significant inputs: On February 9, 2023: common stock price of $0.165; company volatility of 156%-159%; remaining term 3.2-4.1 years; dividend yield of 0% and risk-free interest rate of 3.81-3.71%.

 

8. OPTIONS

 

On June 2, 2020, the Company issued 2,000,000,000 options, on a pre reverse split basis, to purchase common stock to the then directors of the Company as compensation for serving on the board during 2019. These options are exercisable on a cashless basis for a period of ten years from September 30, 2022 at an exercise price of $0.00001. The number of options on the post stock split basis is 2,000,000, and the exercise price of $0.01 per share.

 

 

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2023 AND 2022

 

8. OPTIONS (Continued)

 

For purpose of determining the fair market value of the options issued on June 2, 2020, the Company used the Black Scholes valuation model. The significant assumptions used in the Black Scholes valuation model for the options are as follows:

 

Risk Free Interest Rate

 

0.32%

Stock Volatility Factor

 

146.0%

Weighted Average Expected Option Life

 

5 Years

Expected Dividend Yield

 

None

 

On March 13, 2023, the Company entered into non-qualified stock option agreements and granted vested ten-year options to purchase shares of the Company’s common stock for $0.175 a share, the closing price on the grant date. The Company issued options to purchase a total of 3,542,857 shares as follows: (a) 857,143 to each of the independent directors, (b) 428,571 to the chief financial officer, and 571,429 to the president of our StemVax Therapeutics subsidiary; (c) 57,143 to each of our scientific advisory board members; and (d) the remaining 542,857 to staff members and other officers.

 

Vesting Schedule. The Options are 100% vested and exercisable on the grant date, March 31, 2023.

 

Expiration. The Option will expire on the tenth anniversary from the grant date which falls on March 31, 2033.

 

For purpose of determining the fair market value of the options, the Company used the Black Scholes valuation model. The significant assumptions used in the Black Scholes valuation model for the options are as follows:

 

Risk Free Interest Rate

 

3.68%

Stock Volatility Factor

 

146.79%

Weighted Average Expected Option Life

 

5 Years

Expected Dividend Yield

 

None

 

A summary of the Company’s options activity and related information follows for the quarter ended March 31, 2023:

 

   

 March 31, 2023

 
           

Weighted

 
   

Number

   

average

 
   

Of

   

exercise

 
   

Options

   

price

 

Outstanding - beginning of period

    2,000,000     $ .01  

Granted

    3,542,857     $ 0.175  

Exercised

    -     $ -  

Forfeited

    -     $ -  

Outstanding - end of period

    5,542,857     $ 0.115  

 

At March 31, 2023, the weighted average remaining contractual life of options outstanding:

 

 

 

 

 

 

 March 31, 2023

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Average

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Remaining

 

 

Exercisable

 

 

Options

 

 

Options

 

 

Contractual

 

 

Prices

 

 

Outstanding

 

 

Exercisable

 

 

Life (years)

 

 

$

.01

 

 

 

2,000,000

 

 

 

2,000,000

 

 

 

7.17

 

 

$

0.175

     

3,542,857

     

3,542,857

     

9.95

 

 

The entire stock-based compensation expense amounting to $563,314 was recorded in the income statement on the grant date as the options are fully vested and exercisable on the grant date.

 

 

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2023 AND 2022

 

9. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

 

Accrued expenses and accrued other current liabilities consisted of the following at March 31, 2023 and September 30, 2022:

 

   

March 31, 2023

   

September 30, 2022

 

Accrued liabilities

    5,570       4,370  

Interest payable

    159,506       94,251  

Provision for guaranteed commitment fees *

    886,875       961,000  

Accrued payroll

    7,367       4,740  

Deferred compensation

    485,421       344,983  

License Fees Payable

    40,402       40,402  

Insurance finance liability

    69,133       36,815  
    $ 1,654,274     $ 1,486,561  

 

* Under the terms of the August 2021 Note, February 2022 Note, May 2022 Note and February 2023 Note the Company issued a total of 2,075,000 shares of common stock as commitment fees. If the lender is unable to sell the shares for more than $1,250,000, it may make a one-time claim for each note to be reimbursed for the difference between their sale proceeds and $1,250,000. The difference between the fair value of the 2,075,000 shares as on March 31, 2023 and the exercise amount of $1,250,000 was recorded as a provision for guaranteed commitment fees and included in the table above.

 

10. BRIDGE LOAN PAYABLE

 

Related parties

 

In December 2021, the Company’s CEO and CFO each advanced funds to the Company for operating expenses in the total amount of $50,000. The notes were payable on demand with a five business day written notice and bore interest at a rate of 10% per annum. The Company could prepay all or any part of the balance owed without penalty.

 

In March, 2022, our CEO purchased 600 shares of Series B Preferred stock and the Company applied $18,616 of the loan balance against this purchase. The remaining balance of $6,384 was paid to our CEO in several payments with the final balance being paid in May, 2022. The Company recognized and paid interest expense in the amount of $583 to our CEO during the year ended September 30, 2022. No balance is due to our CEO as March 31, 2023.

 

On January 25, 2022, the Company issued 125,000 shares of its common stock in settlement of the bridge loan to the Company’s CFO and recognized a loss on extinguishment of debt in the amount of $17,313. Any potential gain would not have been recognized on extinguishment of this loan due to the nature of the relationship between the parties. The Company recognized and paid interest expense in the amount of $237 to our CFO during the year ended September 30, 2022. No balance is due to our CFO as of March 31, 2023.

 

Service provider, related party

 

In December 2021, one of the Company’s service providers advanced funds to the Company for operating expenses in the total amount of $25,000. On February 14, 2022, the Company issued 125,000 shares of its common stock to the service provider in settlement of the note payable. The Company recognized a loss on extinguishment of debt in the amount of $37,500. During the year ended September 30, 2022, the Company recognized and paid interest expense of $226 in relation to this loan. No balance was outstanding on the note payable to our service provider as of March 31, 2023.

 

The total loss on account of extinguishment of debt on the CFO Note and service provider note amounting to $54,813 was recorded in the income statement.

 

 

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2023 AND 2022

 

11. DUE TO RELATED PARTIES

 

Due to Innovest Global

 

During the periods prior to the year ended September 30, 2022, Innovest Global, Inc. (“Innovest”) advanced funds to the Company for operating expenses in the amount of $86,217. As of March 31, 2023, the amount has not been reimbursed to Innovest. Our former Chairman Daniel Martin was the CEO of Innovest when the funds were advanced.

 

Due to TN3 LLC

 

On January 31, 2022, the Company entered into a preferred stock redemption agreement with Daniel G. Martin, at the time, our sole board member and chairman, TN3, LLC, a company owned by Mr. Martin, Dwain K. Irvin, our chief executive officer, and Irvin Consulting, LLC, a company owned by Dr. Irvin. TN3 owned 25,000 shares of the Series B convertible preferred stock. Pursuant to the redemption agreement, on March 14, 2022, NovAccess redeemed 24,400 of the preferred shares and Irvin Consulting purchased 600 of the preferred shares from TN3. The Company also issued to TN3 1,502,670 shares of unregistered common stock, at $ 0.35 amounting to $525,934 which was equal to 10% of our outstanding common stock on the date the redemption agreement was signed. Upon completion of the redemption transaction, the Company is obligated to pay to TN3 a total of $250,000 over a period of eleven months, with payment accelerated if the Company raises at least $2.5 million of equity capital. As of March 31, 2023, the Company owed TN3 $95,000 of the redemption price.

 

12. COMMITMENTS AND CONTINGENCIES

 

There are no material pending legal proceedings to which we are a party, nor are there any such proceedings known to be contemplated by governmental authorities. None of our directors, officers, or affiliates is involved in a proceeding adverse to our business or has a material interest adverse to our business.

 

Under the terms of the August 2021 Note, February 2022 Note, May 2022 Note and February 2023 Note the Company issued a total of 2,075,000 shares of common stock as commitment fees. If the lender is unable to sell the shares for more than $1,250,000, it may make a onetime claim for each note to be reimbursed for the difference between their sale proceeds and $1,250,000. The difference between the fair value of the 1,575,000 shares as on March 31, 2023, and the exercise amount of $1,250,000 was recorded as a make-whole provision for commitment fees and included in the accrued expenses.

 

13. RELATED PARTY TRANSACTIONS

 

On February 9, 2023, NovAccess entered into an interest-free loan agreement with Jason M. Anderson, an independent member of our board of directors. Reflecting his faith in NovAccess and our management team, Mr. Anderson loaned the company $8,500. The loan does not bear interest (except on default) and is due on the earlier of August 31, 2023 or our receipt of debt or equity financing of at least $3.0 million. We will use the proceeds of the loan for general working capital purposes.

 

On July 28, 2022, the Company entered into a short-term interest free loan agreement amounting to $12,500 with Mr. Anderson to fund operations until longer term financing can be obtained by the Company. The loan terms required repayment of all amounts outstanding under this agreement on the earlier of: (a) October 31, 2022 or (b) the receipt by the Company of debt or equity financing of $3 million. In November 2022 Mr. Anderson signed a waiver and extension agreement changing the due date to April 30, 2023 and in April 2023 Mr. Anderson agreed to extend the due date to August 31, 2023. The balance outstanding on March 31, 2023 was $12,500.

 

On July 28, 2022, the Company issued a convertible promissory note to Letzhangout, LLC, a company that provides accounting consulting services to NovAccess and also employs our chief financial officer, Neil J. Laird. Pursuant to the note, Letzhangout loaned the Company $12,500 on July 29, 2022. All amounts outstanding under this agreement were payable on the earlier of: (a) October 31, 2022, or (b) the receipt by the Company of debt or equity financing of $3 million. In November 2022, the holder agreed to extend the term of the note until April 2023 and in April 2023 agreed to extend the due date to August 31, 2023. The holder has the right, until the date of payment in full. to convert all amounts outstanding under the note and unpaid principal and interest and any other amounts into fully paid shares of common stock of the Company at conversion price of $0. 15. As of March 31, 2023, the balance of the July 2022 Note was $12,500.

 

 

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2023 AND 2022

 

13. RELATED PARTY TRANSACTIONS (Continued)

 

On January 31, 2022, the Company entered into a preferred stock redemption agreement with Daniel G. Martin, at the time our sole board member and chairman, TN3, LLC, a company owned by Mr. Martin, Dwain K. Irvin, our chief executive officer, and Irvin Consulting, LLC, a company owned by Dr. Irvin. TN3 owned 25,000 shares of the Series B convertible preferred stock. Pursuant to the redemption agreement, on March 14, 2022, NovAccess redeemed 24,400 of the preferred shares and Irvin Consulting purchased 600 of the preferred shares from TN3.

 

Upon completion of the redemption transaction, the Company was obligated to pay to TN3 a total of $250,000 over a period of eleven months, with payment accelerated if the Company raises at least $2.5 million of equity capital. As of March 31, 2023, the Company owed TN3 $95,000 of the redemption price. Pursuant to the redemption agreement, the Company also issued to TN3 1,502,670 shares of unregistered common stock, which was equal to 10% of our outstanding common stock on the date the redemption agreement was signed. Upon completion of the redemption transaction, Mr. Martin resigned from the NovAccess board and was replaced by John A. Cassarini and Dr. Irvin.

 

Also in connection with closing the redemption transaction, on March 14, 2022, the Company entered into a common stock distribution agreement with Innovest Global, Inc. Innovest acquired 7.5 million shares of the Company’s common stock when Innovest sold StemVax, LLC to NovAccess in September 2020. Pursuant to the stock distribution agreement, Innovest agreed to distribute its NovAcess common stock to Innovest’s shareholders. Innovest is currently in the process of effectuating the distribution.

 

In December 2021, the Company’s CEO and CFO each advanced funds to the Company for operating expenses in the total amount of $25,000 each. The notes were payable on demand with a five business-day written notice and bore interest at a rate of 10% per annum. The Company could prepay all or any part of the balance owed without penalty. On January 25, 2022, the Company issued 125,000 shares of its common stock in settlement of a bridge loan to the Company’s CFO and recognized a loss on extinguishment of debt in the amount of $17,313. Any potential gain would not have been recognized on extinguishment of this loan due to the nature of the relationship between the parties. The Company recognized and paid interest expense in the amount of $237 to our CFO during the year ended September 30, 2022. No balance is due to our CFO as March 31, 2023. In March, 2022, our CEO purchased 600 shares of Series B Preferred stock and the Company applied $18,616 of the loan balance against this purchase. The remaining balance of $6,384 was paid to our CEO in several payments with the final balance being paid in May, 2022. The Company recognized and paid interest expense in the amount of $583 to our CEO during the year ended March 31, 2023. No balance is due to our CEO as of March 31, 2023.

 

On September 4, 2020, the Company entered into a management services agreement with TN3, LLC. Pursuant to the agreement, TN3 provided the Company with office space in Chesterland, Ohio and management, administrative, marketing, bookkeeping and IT services for a fee of $30,000 a month. The initial term of the agreement was three years, with subsequent one-year renewals. We paid TN3 $40,000 under the agreement in fiscal 2022. In connection with the redemption of TN3’s preferred shares, the management services agreement was terminated and outstanding amounts cancelled, and as of March 31, 2023 there were no amounts owed under this agreement.

 

14. SUBSEQUENT EVENTS

 

On April 11, 2023, the Company entered into a securities purchase agreement (the “SPA”) with a lender and issued a convertible promissory note in the original principal amount of $79,250 (the “note”) pursuant to the SPA. The loan funded on April 14, 2023. The Company will use the proceeds of the loan for general working capital purposes.

 

The Company provided typical representations and agreed to standard covenants pursuant to the SPA. The SPA does not include any financial covenants.

 

 

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2023 AND 2022

 

14. SUBSEQUENT EVENTS (Continued)

 

The note bears interest at 8% a year and is due on April 11, 2024. The Company may prepay the note upon payment of a prepayment penalty ranging from 15-25% of the amount outstanding on the note when prepaid. Under the terms of the note, the Company may not sell a significant portion of its assets without the approval of the lender, must comply with the company’s reporting requirements under the Securities Exchange Act of 1934, and must maintain the listing of the Company’s common stock on the OTCQB Market or other exchange. The Company’s failure to comply with any of these covenants, among other matters, would constitute an event of default. Upon an event of default, the note will bear interest at 22% and the lender will be entitled to its costs of collection.

 

Beginning on October 8, 2023, the lender may convert the amount outstanding under the note into shares of the Company’s common stock at a conversion price equal to 65% of the average of the three lowest trading prices of the stock during the fifteen trading days before the conversion date.

 

On April 24, 2023, the Company entered into a securities purchase agreement (the “SPA”) with a lender and issued a convertible promissory note in the original principal amount of $54,250 (the “note”) to the lender pursuant to the SPA. The loan funded on April 28, 2023. The Company will use the proceeds of the loan for general working capital purposes.

 

The note bears interest at 8% a year and is due on April 24, 2024. The Company may prepay the note upon payment of a prepayment penalty ranging from 15-25% of the amount outstanding on the note when prepaid. Under the terms of the note, the Company may not sell a significant portion of its assets without the approval of 1800 Diagonal Lending, must comply with the Company’s reporting requirements under the Securities Exchange Act of 1934, and must maintain the listing of the Company’s common stock on the OTCQB Market or other exchange. The Company’s failure to comply with any of these covenants, among other matters, would constitute an event of default. Upon an event of default, the note will bear interest at 22% and the lender will be entitled to its costs of collection.

 

Beginning on October 21, 2023, the lender may convert the amount outstanding under the note into shares of the Company’s common stock at a conversion price equal to 65% of the average of the three lowest trading prices of the stock during the fifteen trading days before the conversion date.

 

The Company did not make the payment of $1,584,260 including principal and interest, due on May 9, 2023 on the notes issued on Feb 2022, May 2022 and Feb 2023. The lender has agreed to waive the default provisions until June 1, 2023, or pending conclusion of negotiations on an extension of the loans.

 

 

 

Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations.

 

Cautionary and Forward-Looking Statements

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q. In addition to historical consolidated financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results could differ materially from those anticipated by these forward-looking statements as a result of many factors, including those discussed in this Quarterly Report and under Item 1A: Risk Factors in our Annual Report on Form 10-K for the year ended September 30, 2022.

 

We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date of this report. Readers should carefully review the factors described in other documents that the Company files from time to time with the SEC.

 

Business Plan

 

In 2020, we transitioned our operations from solar contracting operations to the commercialization of developmental healthcare solutions in the biotechnology, medical, and health and wellness markets. On June 2, 2020, we entered into a membership interest purchase agreement with Innovest Global, Inc. to acquire StemVax for 7.5 million shares of our unregistered common stock. The acquisition was completed on September 8, 2020.

 

StemVax, LLC (“StemVax”) is a biopharmaceutical company developing novel therapies for brain tumor patients that holds an exclusive patent license from Cedars-Sinai Medical Center in Los Angeles, California (Cedars-Sinai) known as StemVax Glioblast (SVX-GB/TLR-AD1). TLR-AD1 specifically targets glioblastoma, the most common and lethal type of adult brain tumor. Christopher Wheeler, President of StemVax, has been involved in the pre-clinical research and development of the drug candidate at Cedars-Sinai Department of Neurosurgery since 1997. Dr. Wheeler began preparing the pre-IND application to obtain FDA approval to start human clinical trials. In 2021, Dr. Wheeler led pre-IND interactions with the FDA and obtained a recommended roadmap from the FDA to facilitate the filing of an IND application for a Phase I application or a Phase IIa application. We are currently executing on their recommendations and plan to submit an IND application in 2023. In August 2022, we filed an application with the U.S. Food and Drug Administration for orphan drug designation (“ODD”) for TLR-AD1, which was granted in October 2022. Receiving ODD status represents a milestone in the development of TLR-AD1 and provides us with multiple incentives, including seven-year marketing exclusivity and federal tax credits, among other benefits.

 

We believe that investing in the biotechnology industry will significantly increase value for our shareholders. However, we cannot guarantee that we will be successful in this endeavor or that we can locate, acquire and finance the acquisition of additional biotechnology companies.

 

Results of Operations for the three months ended March 31, 2023, compared to three months ended March 31, 2022

 

Revenue and Cost of Sales

 

We are in research and development phase, and generated no revenue or cost of goods sold in the three months ended March 31, 2023, and 2022.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative (SG&A) expenses increased by $632,524 during the three months ended March 31, 2023, to $1,013,952 as compared to $381,428 for the three months ended March 31, 2022. The increase in SG&A expenses during the three months ended March 31, 2023, was related primarily to the increase in stock- based compensation by $794,313 on account of stock options issued during the current quarter, offset by in part by a decrease in consulting and professional fees by $135,592. The payroll costs increased by $18,554 during the quarter and insurance costs were reduced by $11,331.

 

Research and development expenses

 

The research and development expense marginally decreased by $4,479 for the three months ended March 31, 2023, to $41,036 as compared to $45,516 for the three months ended March 31, 2022. The primary reason for the decrease was on account of the decrease in costs for bio-technical services by $4,000.

 

 

Other Income/(Expenses)

 

Other income increased by $2,311,593 from other expense of $802,841 for the three months ended March 31, 2022 to other income of $1,08,752 for the three months ended March 31, 2023. The change was primarily due to the increase in gain on change in derivative liability by $2,318,155 and increase in gain on extinguishment of derivative liability amounting to $138,863. During the three months ended March 31, 2023, the Company recorded gain on account of the change in make whole provision on shares issued as loan commitment fees amounting to $193,625 to partially offset the increase in other income. The increase in other income was also partially offset by an increase in interest expense of $6,613 during the current quarter. The estimates of fair market value are based on multiple inputs, including the market price of our stock, interest rates, our stock price, volatility, variable conversion prices based on market prices defined in the respective agreements and probabilities of certain outcomes based on managements’ estimates. These inputs are subject to significant changes from period to period, therefore, the estimated fair value of the derivative liabilities will fluctuate from period to period, and the fluctuation may be material.

 

Net Income/(Loss)

 

For the three months ended March 31, 2023, our net income was $453,764 as compared to a net loss of $1,229,785 for the same period in 2022. The increase in net income of $1,683,5495 was due to the decrease in other expenses on account of gain on change in derivative liability, partially offset by increase in SG&A, as described above.

 

Results of Operations for the six months ended March 31, 2023, compared to six months ended March 31, 2022

 

Revenue and Cost of Sales

 

We are in research and development phase, and generated no revenue or cost of goods sold in the six months ended March 31, 2023, and 2022.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative (SG&A) expenses increased by $834,748 during the six months ended March 31, 2023, to $1,496,106 as compared to $661,358 for the six months ended March 31, 2022. The increase in SG&A expenses during the six months ended March 31, 2023, was related primarily to the increase in stockbased compensation by $794,313 on account of stock options issued during the second quarter, the increase in consulting and professional fees by $22,928, the increase in payroll costs by $31,415 and the increase in insurance costs by $32,074 during the six month period ended March 31, 2023.

 

Research and development expenses

 

The research and development expense marginally decreased by $11,915 for the six months ended March 31, 2023, to $76,000 as compared to $87,915 for the six months ended March 31, 2022. The primary reason for the decrease was on account of the decrease in costs for bio-technical services by $11,000.

 

Other Income/(Expenses)

 

Other expenses decreased by $18,284 from other expense of $623,820 for the six months ended March 31, 2022 to other expenses of $605,536 for the six months ended March 31, 2023. The change was primarily due to the Company recording a gain on account of the change in make whole provision on shares issued as loan commitment fees of $74,125, and an increase in gain on extinguishment of derivative liability of $42,658 during the six months ended March 31, 2023. These gains were partly offset by an increase in loss on change in derivative liability by $222,455, and an decrease in interest expense of $69,143 during the six months ended March 31, 2023. The estimates of fair market value are based on multiple inputs, including the market price of our stock, interest rates, our stock price, volatility, variable conversion prices based on market prices defined in the respective agreements and probabilities of certain outcomes based on managements’ estimates. These inputs are subject to significant changes from period to period, therefore, the estimated fair value of the derivative liabilities will fluctuate from period to period, and the fluctuation may be material.

 

Net Loss

 

For the six months ended March 31, 2023, our net loss was $2,177,642 as compared to a net loss of $1,373,093 for the same period in 2022. The increase in net loss of $804,549 was due to the increase in SG&A, offset in part by the decrease in other expenses as described above.

 

 

Liquidity and Capital Resources

 

We had a working capital deficit at March 31, 2023 of $5,726,692 as compared to a working capital deficit of $4,653,066, as of September 30, 2022. The increase of $1,073,627 in the working capital deficit was the result of an increase in the derivative liability on convertible notes amounting to $329,247, an increase in convertible notes payable of $480,578, an increase in the short term loan from a related party, an increase in accounts payable of $71,149, and an increase in accrued expenses and other current liabilities amounting to $167,713 and a decrease in cash of $21,442. This was partially offset by a decrease in amounts due to related parties of $5,000.

 

For the six months ended March 31, 2023, our cash flow used by operating activities was $356,510, as compared to cash flow used by operating activities of $438,844 for the six months ended March 3l, 2022. The decrease in cash flow used by operating activities was primarily due to changes in assets and liabilities described above as well as the increase in net loss being primarily the result of non-cash charges recorded in the statement of operations.

 

Cash flow used by investing activities was $0 during the six months ended March 31, 2023 or 2022.

 

Cash flow provided by financing activities was $314,250 for the six months ended March 31, 2023, as compared to cash provided by financing activities of $319,785 during same period in 2022. The decrease in cash flow provided by financing activities was primarily the result of the mix of funds raised by selling equity and debt instruments and repayment of convertible notes and bridge loans.

 

The Company will need to raise additional funds to finance its ongoing operations, complete its IND application to the FDA and to make payments under its loan agreements. We expect this will require at least $3.0 million through December 31, 2023. We plan to raise this capital through the issuance of additional common stock as well as obtaining additional debt as needed.

 

Off-Balance Sheet Arrangements

 

We do not have any relationships with unconsolidated entities or financial partnerships such as entities often referred to as structured finance or special purpose entities that would have been established for the purpose of facilitating off-balance-sheet arrangements or for other contractually narrow or limited purposes. As a result, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships.

 

Critical Accounting Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying consolidated financial statements. Significant estimates made in preparing these consolidated financial statements include the estimate of useful lives of property and equipment, the deferred tax valuation allowance, the fair value of stock options, and derivative liabilities. Actual results could differ materially from those estimates.

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Because NovAccess is a “smaller reporting company” as defined by the Securities and Exchange Commission we are not required to provide additional market risk disclosure.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Our management team, with the participation of our chief executive officer, Dwain K. Irvin, and chief financial officer, Neil J. Laird, evaluated the effectiveness of the design and operation of NovAccess’ disclosure controls and procedures (as defined under the Securities Exchange Act) as of March 31, 2023. Based upon this evaluation, Messrs. Irvin and Laird concluded that the Company’s disclosure controls and procedures were effective as of March 31.

 

Changes in Internal Control Over Financial Reporting

 

Our senior management team is responsible for establishing and maintaining adequate internal control over financial reporting, defined under the Exchange Act as a process designed by, or under the supervision of, our principal executive and principal financial officers, or persons performing similar functions, and effected by our board, senior management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with United States generally accepted accounting principles.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. We continue to review our internal control over financial reporting and may from time to time make changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business.

 

During the quarter the Company implemented enhanced review procedures for the accounting of certain derivatives and other income. This included engaging a third party to review the assumptions and calculation. There were no other changes in our internal control over financial reporting identified in connection with the evaluation required by the Securities Exchange Act that occurred during our second fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

 

Part II Other Information

 

Item 1. Legal Proceedings.

 

We are not involved in any legal proceedings.

 

Item 1A. Risk Factors.

 

Please refer to the risk factors listed under “Item 1A: Risk Factors” in our Annual Report on Form 10-K for the year ended September 30, 2022., for information relating to certain risk factors applicable to NovAccess.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

During the quarter ended March 31, 2023, we issued 858,752 unregistered shares of our common stock for capital raising and compensatory purposes as described in more detail below.

 

On February 9, 2023, we entered into a letter agreement with AJB Capital Investments, LLC. Pursuant to the letter agreement, AJB loaned us $265,000, which was added to the principal of a promissory note we had previously issued to AJB in May 2022. Also pursuant to the letter agreement, NovAccess paid AJB a commitment fee of 500,000 unregistered shares of the company’s common stock. If AJB is unable to sell the commitment fee shares for $0.20 a share, then AJB may require NovAccess to issue additional shares or pay cash in the amount of the shortfall. We are also required to register the commitment fee shares for resale under the Securities Act. Pursuant to the letter agreement, NovAccess also issued to AJB a common stock purchase warrant to purchase 1.0 million shares of the company’s common stock for $0.20 a share. The warrant expires on February 9, 2028. The issuances of the commitment fee shares and warrant to AJB were exempt from registration under Section 4(a)(2) of the Securities Act.

 

Effective April 4, 2023, we issued 108,750 unregistered shares of our common stock to Letzhangout, LLC for accounting services provided to NovAccess during the second quarter. Also, effective April 4, 2023, we issued 100,002 shares of our unregistered shares to Darrow Associates for investor relations services provided to NovAccess during the second quarter. The issuances of shares to our service providers were exempt from registration under Section 4(a)(2) of the Securities Act.

 

During January and February 2023, we offered unregistered shares of our common stock in a private placement to accredited investors to fund our working capital needs. During the quarter we sold to two investors 150,000 shares for an aggregate amount of $15,000. The issuance of shares in the private placement was exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506(b) under the Securities Act.

 

On March 13, 2023, we entered into non-qualified stock option agreements and granted vested ten-year options to purchase shares of the Company’s common stock for $0.175 a share, the closing price on the grant date. We issued options to purchase a total of 3,542,857 shares as follows: (a) 857,143 to each of our independent directors, Jason M. Anderson and John A. Cassarini; (b) 428,571 to Neil J. Laird, our chief financial officer, and 571,429 to Dr. Christopher Wheeler, president of our StemVax Therapeutics subsidiary; (c) 57,143 to each of our scientific advisory board members; and (d) the remaining 542,857 to staff members and other officers.

 

Item 3. Defaults Upon Senior Securities.

 

During the quarter ended March 31, 2023, NovAccess was not in material default with respect to any of its material indebtedness.

 

Item 4. Mine Safety Disclosures.

 

We are not engaged in mining operations.

 

Item 5. Other Information.

 

We have disclosed on Form 8-K all reportable events that occurred in the quarter ended March 31, 2023.

 

 

Item 6. Exhibit and Financial Statement Schedules.

 

(a) Financial Statement Schedules (see Item 1 Financial Statements and Supplementary Data)

 

(b) Exhibits

 

Exhibit

 

Description

31.1*

 

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act — Dwain K. Irvin

31.2*

 

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act — Neil J. Laird

32.1*

 

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act

101

 

The following materials from the NovAccess Global Inc. Quarterly Report on Form 10-Q for the period ended March 31, 2023, formatted in iXBRL (Inline eXtensible Business Reporting Language):

 

 

(i) the Condensed Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022

 

 

(ii) the Condensed Consolidated Statements of Operations for the Three and Six Months Ended March 31, 2023 and March 31, 2022,

 

 

(iii) the Condensed Consolidated Statements of Shareholders’ Deficit for the Three and Six Months Ended March 31, 2023 and March 31, 2022,

 

 

(iv) the Condensed Consolidated Statements of Cash Flows for the Three and Six Months Ended March 31, 2023 and March 31, 2022, and

 

 

(v) Related Notes to the Condensed Consolidated Financial Statements

104

 

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

 

Signatures

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, NovAccess has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

NovAccess Global Inc.

 

 

Date: May 15, 2023

/s/ Dwain K. Irvin

 

By Dwain K. Irvin, Chief Executive Officer

 

(Principal Executive Officer)

 

 

Date: May 15, 2023

/s/ Neil J. Laird

 

Neil J. Laird, Chief Financial Officer

 

(Principal Financial and Accounting Officer)

 

 

 

26
false --09-30 Q2 2023 0001039466 true NONE 0001039466 2022-10-01 2023-03-31 0001039466 2023-05-15 0001039466 2023-03-31 0001039466 2022-09-30 0001039466 us-gaap:SeriesBPreferredStockMember 2023-03-31 0001039466 us-gaap:SeriesBPreferredStockMember 2022-09-30 0001039466 2023-01-01 2023-03-31 0001039466 2022-01-01 2022-03-31 0001039466 2021-10-01 2022-03-31 0001039466 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0001039466 us-gaap:SeriesBPreferredStockMember us-gaap:CommonStockMember 2021-09-30 0001039466 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001039466 xsnx:AdditionalPaidInCapitalStockOptionsWarrantsMember 2021-09-30 0001039466 xsnx:AdditionalPaidInCapitalPreferredStockMember 2021-09-30 0001039466 us-gaap:RetainedEarningsMember 2021-09-30 0001039466 2021-09-30 0001039466 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-10-01 2022-03-31 0001039466 us-gaap:SeriesBPreferredStockMember us-gaap:CommonStockMember 2021-10-01 2022-03-31 0001039466 xsnx:AdditionalPaidInCapitalPreferredStockMember 2021-10-01 2022-03-31 0001039466 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2022-03-31 0001039466 xsnx:CommonStockIssuableMember 2021-10-01 2022-03-31 0001039466 us-gaap:RetainedEarningsMember 2021-10-01 2022-03-31 0001039466 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001039466 us-gaap:SeriesBPreferredStockMember us-gaap:CommonStockMember 2022-03-31 0001039466 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001039466 xsnx:AdditionalPaidInCapitalStockOptionsWarrantsMember 2022-03-31 0001039466 xsnx:AdditionalPaidInCapitalPreferredStockMember 2022-03-31 0001039466 us-gaap:RetainedEarningsMember 2022-03-31 0001039466 2022-03-31 0001039466 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-09-30 0001039466 us-gaap:SeriesBPreferredStockMember us-gaap:CommonStockMember 2022-09-30 0001039466 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001039466 xsnx:AdditionalPaidInCapitalStockOptionsWarrantsMember 2022-09-30 0001039466 xsnx:AdditionalPaidInCapitalPreferredStockMember 2022-09-30 0001039466 us-gaap:RetainedEarningsMember 2022-09-30 0001039466 us-gaap:SeriesBPreferredStockMember us-gaap:CommonStockMember 2022-10-01 2023-03-31 0001039466 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2023-03-31 0001039466 us-gaap:RetainedEarningsMember 2022-10-01 2023-03-31 0001039466 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0001039466 us-gaap:SeriesBPreferredStockMember us-gaap:CommonStockMember 2023-03-31 0001039466 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001039466 xsnx:AdditionalPaidInCapitalStockOptionsWarrantsMember 2023-03-31 0001039466 xsnx:AdditionalPaidInCapitalPreferredStockMember 2023-03-31 0001039466 us-gaap:RetainedEarningsMember 2023-03-31 0001039466 2020-08-25 2020-08-25 0001039466 us-gaap:FairValueInputsLevel1Member 2022-09-30 0001039466 us-gaap:FairValueInputsLevel2Member 2022-09-30 0001039466 us-gaap:FairValueInputsLevel3Member 2022-09-30 0001039466 us-gaap:FairValueInputsLevel1Member 2023-03-31 0001039466 us-gaap:FairValueInputsLevel2Member 2023-03-31 0001039466 us-gaap:FairValueInputsLevel3Member 2023-03-31 0001039466 us-gaap:FairValueInputsLevel3Member 2021-09-30 0001039466 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:FairValueInputsLevel3Member 2021-09-30 0001039466 us-gaap:FairValueInputsLevel3Member 2021-10-01 2022-09-30 0001039466 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:FairValueInputsLevel3Member 2021-10-01 2022-09-30 0001039466 2021-10-01 2022-09-30 0001039466 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:FairValueInputsLevel3Member 2022-09-30 0001039466 us-gaap:FairValueInputsLevel3Member 2022-10-01 2023-03-31 0001039466 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:FairValueInputsLevel3Member 2022-10-01 2023-03-31 0001039466 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:FairValueInputsLevel3Member 2023-03-31 0001039466 us-gaap:SeriesBPreferredStockMember 2020-09-04 2020-09-04 0001039466 us-gaap:SeriesBPreferredStockMember 2020-09-04 0001039466 xsnx:TN3LLCMember us-gaap:SeriesBPreferredStockMember 2022-03-14 2022-03-14 0001039466 xsnx:TN3LLCMember us-gaap:SeriesBPreferredStockMember xsnx:IrvinConsultingLLCICMember 2022-03-14 2022-03-14 0001039466 us-gaap:RelatedPartyMember 2022-10-01 2023-03-31 0001039466 xsnx:StockSubscriptionsMember 2022-10-01 2023-03-31 0001039466 us-gaap:SeriesBPreferredStockMember 2021-10-01 2022-03-31 0001039466 xsnx:StockSubscriptionsMember 2021-10-01 2022-03-31 0001039466 us-gaap:RelatedPartyMember 2021-10-01 2022-03-31 0001039466 2013-10-01 0001039466 xsnx:ConvertibleNotePayableTwoMember us-gaap:ConvertibleDebtMember 2014-11-20 0001039466 xsnx:ConvertibleNotePayableTwoMember us-gaap:ConvertibleDebtMember 2014-11-20 2014-11-20 0001039466 xsnx:ConvertibleNotePayableTwoMember us-gaap:ConvertibleDebtMember 2015-02-18 2016-09-30 0001039466 xsnx:ConvertibleNotePayableTwoMember us-gaap:ConvertibleDebtMember 2023-03-31 0001039466 us-gaap:ConvertibleDebtMember 2017-05-10 0001039466 us-gaap:ConvertibleDebtMember 2017-05-10 2017-05-10 0001039466 us-gaap:ConvertibleDebtMember 2017-07-31 2017-09-18 0001039466 us-gaap:ConvertibleDebtMember 2023-03-31 0001039466 xsnx:MayNoteMember 2021-05-28 0001039466 xsnx:MayNoteMember 2021-05-28 2021-05-28 0001039466 xsnx:JulyNoteMember 2023-03-31 0001039466 xsnx:JulyNoteMember 2021-07-06 0001039466 xsnx:JulyNoteMember 2021-07-06 2021-07-06 0001039466 xsnx:MayNoteMember 2023-03-31 0001039466 xsnx:AugustNoteMember 2021-08-20 0001039466 xsnx:AugustNoteMember 2021-08-20 2021-08-20 0001039466 xsnx:AugustNoteMember 2023-03-31 0001039466 xsnx:AugustNoteMember 2023-02-09 0001039466 xsnx:FebruaryNoteMember 2022-02-15 0001039466 xsnx:FebruaryNoteMember 2022-02-15 2022-02-15 0001039466 2022-02-15 0001039466 xsnx:FebruaryNoteMember 2023-03-31 0001039466 xsnx:FebruaryNoteMember 2023-02-09 0001039466 xsnx:FebruaryNoteMember 2023-02-09 2023-02-09 0001039466 xsnx:FebruaryNoteMember 2023-05-09 0001039466 xsnx:May2022NoteMember 2022-05-05 0001039466 xsnx:May2022NoteMember 2022-05-05 2022-05-05 0001039466 xsnx:May2022NoteMember 2023-03-31 0001039466 xsnx:May2022NoteMember 2023-05-09 0001039466 xsnx:August2022NoteMember 2022-08-08 0001039466 xsnx:August2022NoteMember 2022-08-08 2022-08-08 0001039466 xsnx:September2022NoteMember 2023-03-31 0001039466 xsnx:August2022NoteMember 2023-03-31 0001039466 xsnx:September2022NoteMember 2022-09-22 0001039466 xsnx:September2022NoteMember 2022-09-22 2022-09-22 0001039466 xsnx:September2022NoteMember 2022-09-22 2022-09-22 0001039466 xsnx:September2022NoteMember 2023-03-12 2023-03-12 0001039466 xsnx:September2022NoteMember 2023-03-12 0001039466 xsnx:November2022NoteMember 2022-11-01 0001039466 xsnx:November2022NoteMember 2022-11-01 2022-11-01 0001039466 xsnx:November2022NoteMember 2023-03-31 0001039466 xsnx:December2022NoteMember 2022-12-07 0001039466 xsnx:December2022NoteMember 2022-12-07 2022-12-07 0001039466 xsnx:December2022NoteMember 2023-03-31 0001039466 xsnx:February2023NoteMember 2023-02-09 0001039466 xsnx:February2023NoteMember 2023-02-09 2023-02-09 0001039466 xsnx:February2023NoteMember 2023-03-31 0001039466 xsnx:February2023NoteMember 2022-10-01 2023-03-31 0001039466 xsnx:February2023NoteMember xsnx:CommitmentFeeMember 2023-02-09 0001039466 2023-05-09 0001039466 xsnx:Note2013Member 2023-03-31 0001039466 xsnx:Note2013Member us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-03-31 0001039466 xsnx:Note2013Member us-gaap:WarrantMember 2023-03-31 0001039466 xsnx:Note2014Member 2023-03-31 0001039466 xsnx:Note2014Member us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-03-31 0001039466 xsnx:Note2014Member us-gaap:WarrantMember 2023-03-31 0001039466 xsnx:Note2017Member 2023-03-31 0001039466 xsnx:Note2017Member us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-03-31 0001039466 xsnx:Note2017Member us-gaap:WarrantMember 2023-03-31 0001039466 xsnx:AugustNoteMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-03-31 0001039466 xsnx:AugustNoteMember us-gaap:WarrantMember 2023-03-31 0001039466 xsnx:FebruaryNoteMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-03-31 0001039466 xsnx:FebruaryNoteMember us-gaap:WarrantMember 2023-03-31 0001039466 xsnx:May2022NoteMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-03-31 0001039466 xsnx:May2022NoteMember us-gaap:WarrantMember 2023-03-31 0001039466 xsnx:August2022NoteMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-03-31 0001039466 xsnx:August2022NoteMember us-gaap:WarrantMember 2023-03-31 0001039466 xsnx:November2022NoteMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-03-31 0001039466 xsnx:November2022NoteMember us-gaap:WarrantMember 2023-03-31 0001039466 xsnx:December2022NoteMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-03-31 0001039466 xsnx:December2022NoteMember us-gaap:WarrantMember 2023-03-31 0001039466 xsnx:February2023NoteMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-03-31 0001039466 xsnx:February2023NoteMember us-gaap:WarrantMember 2023-03-31 0001039466 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-03-31 0001039466 us-gaap:WarrantMember 2023-03-31 0001039466 xsnx:July2022NoteMember us-gaap:RelatedPartyMember 2023-03-31 0001039466 xsnx:July2022NoteMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:RelatedPartyMember 2023-03-31 0001039466 xsnx:July2022NoteMember us-gaap:WarrantMember us-gaap:RelatedPartyMember 2023-03-31 0001039466 us-gaap:ConvertibleDebtMember 2022-10-01 2023-03-31 0001039466 srt:MinimumMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-03-31 0001039466 srt:MaximumMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-03-31 0001039466 srt:MinimumMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:MeasurementInputPriceVolatilityMember 2023-03-31 0001039466 srt:MaximumMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:MeasurementInputPriceVolatilityMember 2023-03-31 0001039466 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:MeasurementInputExpectedTermMember 2023-03-31 0001039466 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:MeasurementInputExpectedDividendRateMember 2023-03-31 0001039466 xsnx:July2022NoteMember 2022-07-28 0001039466 xsnx:July2022NoteMember 2022-07-28 2022-07-28 0001039466 xsnx:July2022NoteMember 2023-03-31 0001039466 srt:DirectorMember 2022-07-28 0001039466 2022-07-28 2022-07-28 0001039466 2022-11-01 2022-11-30 0001039466 2023-02-09 2023-02-09 0001039466 xsnx:FebruaryNoteMember 2022-02-16 2022-02-16 0001039466 xsnx:FebruaryNoteMember 2022-02-16 0001039466 2022-05-10 2022-05-10 0001039466 2022-05-10 0001039466 2023-02-09 0001039466 srt:MaximumMember us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-02-09 0001039466 us-gaap:WarrantMember 2023-02-09 0001039466 srt:MinimumMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2023-02-09 0001039466 srt:MaximumMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2023-02-09 0001039466 srt:MinimumMember us-gaap:WarrantMember us-gaap:MeasurementInputExpectedTermMember 2023-02-09 0001039466 srt:MaximumMember us-gaap:WarrantMember us-gaap:MeasurementInputExpectedTermMember 2023-02-09 0001039466 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2023-02-09 0001039466 srt:MinimumMember us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-02-09 0001039466 us-gaap:WarrantMember 2022-10-01 2023-03-31 0001039466 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-03-31 0001039466 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-03-31 0001039466 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2023-03-31 0001039466 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2023-03-31 0001039466 us-gaap:MeasurementInputExpectedTermMember 2023-03-31 0001039466 us-gaap:MeasurementInputExpectedDividendRateMember 2023-03-31 0001039466 2020-06-02 2020-06-02 0001039466 2020-08-25 0001039466 2023-03-13 2023-03-13 0001039466 srt:DirectorMember 2023-03-13 2023-03-13 0001039466 srt:ChiefFinancialOfficerMember 2023-03-13 2023-03-13 0001039466 xsnx:PresidentOfStemVaxTherapeuticsMember 2023-03-13 2023-03-13 0001039466 xsnx:ScientificAdvisoryBoardMember 2023-03-13 2023-03-13 0001039466 xsnx:StaffMembersAndOfficersMember 2023-03-13 2023-03-13 0001039466 us-gaap:EmployeeStockOptionMember 2022-10-01 2023-03-31 0001039466 xsnx:OptionsAt01Member 2022-10-01 2023-03-31 0001039466 xsnx:OptionsAt01Member 2023-03-31 0001039466 xsnx:OptionsAt0175Member 2022-10-01 2023-03-31 0001039466 xsnx:OptionsAt0175Member 2023-03-31 0001039466 xsnx:CommitmentFeeMember 2022-10-01 2023-03-31 0001039466 srt:ChiefFinancialOfficerMember 2022-01-25 0001039466 us-gaap:SeriesBPreferredStockMember 2022-03-01 2022-03-31 0001039466 srt:ChiefExecutiveOfficerMember 2022-05-01 2022-05-31 0001039466 srt:ChiefFinancialOfficerMember 2022-01-25 2022-01-25 0001039466 srt:ChiefFinancialOfficerMember 2021-10-01 2022-09-30 0001039466 2021-12-01 2021-12-31 0001039466 srt:AffiliatedEntityMember 2022-10-01 2023-03-31 0001039466 us-gaap:SeriesBPreferredStockMember xsnx:TN3LLCMember 2022-01-31 0001039466 2022-03-14 2022-03-14 0001039466 2022-03-14 0001039466 2022-07-28 0001039466 xsnx:BoardMemberMember 2023-03-31 0001039466 xsnx:LetzhangoutLLCMember 2022-07-28 0001039466 xsnx:LetzhangoutLLCMember 2023-03-31 0001039466 xsnx:TN3LLCMember 2022-01-31 0001039466 2022-01-31 0001039466 xsnx:IrvinConsultingLLCICMember 2022-01-31 0001039466 xsnx:TN3LLCMember 2022-01-31 2022-01-31 0001039466 2021-12-31 0001039466 2022-01-25 2022-01-25 0001039466 srt:ChiefFinancialOfficerMember 2022-05-01 2022-05-31 0001039466 srt:ChiefExecutiveOfficerMember 2022-10-01 2023-03-31 0001039466 2020-09-04 2020-09-04 0001039466 us-gaap:SubsequentEventMember 2023-04-11 0001039466 srt:MinimumMember us-gaap:SubsequentEventMember 2023-04-11 2023-04-11 0001039466 srt:MaximumMember us-gaap:SubsequentEventMember 2023-04-11 2023-04-11 0001039466 us-gaap:SubsequentEventMember 2023-04-11 2023-04-11 0001039466 us-gaap:SubsequentEventMember 2023-04-24 0001039466 srt:MinimumMember us-gaap:SubsequentEventMember 2023-04-24 2023-04-24 0001039466 srt:MaximumMember us-gaap:SubsequentEventMember 2023-04-24 2023-04-24 0001039466 us-gaap:SubsequentEventMember 2023-04-24 2023-04-24 0001039466 us-gaap:SubsequentEventMember 2023-05-09 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure
EX-31.1 2 ex_519542.htm EXHIBIT 31.1 ex_519542.htm

 

Exhibit 31.1

 

OFFICERS CERTIFICATE

PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

 

I, Dwain Irvin, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of NovAccess Global Inc. for the period ending March 31, 2023;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer (s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 15, 2023

 

 

 

/s/ Dwain Irvin, PhD, MPH

Name: Dwain Irvin

Title: Chief Executive Officer

 

 

 
EX-31.2 3 ex_519543.htm EXHIBIT 31.2 ex_519543.htm

 

Exhibit 31.2

 

OFFICERS CERTIFICATE

PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

 

I, Neil J. Laird, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of NovAccess Global Inc. for the period ending March 31, 2023;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer (s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 15, 2023

 

 

 

/s/ Neil J. Laird

Name: Neil J. Laird

Title: Chief Financial Officer

 

 

 

 
EX-32.1 4 ex_519544.htm EXHIBIT 32.1 ex_519544.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the filing of the Quarterly Report of NovAccess Global Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2023 (the “Report”) with the Securities and Exchange Commission, I, Dwain Morris-Irvin, Chief Executive Officer of the Company, and I, Neil J. Laird, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Report fairly presents, in all material respects, the financial condition and the results of operations of the Company for such period.

 

 

Date: May 15, 2023

 

/s/ Dwain Irvin, PhD, MPH

Name: Dwain Irvin

Title: Chief Executive Officer

 

 

Date: May 15, 2023

 

/s/ Neil J. Laird

Name: Neil J. Laird

Title: Chief Financial Officer

 

 

 

 
EX-101.SCH 5 xsnx-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 004 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - ORGANIZATION AND LINE OF BUSINESS link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - CAPITAL STOCK link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - CONVERTIBLE PROMISSORY NOTES link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - CONVERTIBLE PROMISSORY NOTE, RELATED PARTY link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - SHORT TERM LOAN, RELATED PARTY link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - WARRANTS link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - OPTIONS link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - BRIDGE LOANS PAYABLE link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - DUE TO RELATED PARTIES link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - WARRANTS (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - OPTIONS (Tables) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - ORGANIZATION AND LINE OF BUSINESS (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Earnings Per Share, Basic and Diluted link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - CAPITAL STOCK (Details) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details) - Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - CONVERTIBLE PROMISSORY NOTE, RELATED PARTY (Details) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - SHORT TERM LOAN, RELATED PARTY (Details) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - WARRANTS (Details) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - WARRANTS (Details) - Fair Value Measurement Inputs and Valuation Techniques link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - OPTIONS (Details) link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - OPTIONS (Details) - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - OPTIONS (Details) - Share-Based Payment Arrangement, Option, Activity link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - OPTIONS (Details) - Share-based Payment Arrangement, Option, Exercise Price Range link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - Schedule of Accounts Payable and Accrued Liabilities link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - BRIDGE LOANS PAYABLE (Details) link:presentationLink link:definitionLink link:calculationLink 045 - Disclosure - DUE TO RELATED PARTIES (Details) link:presentationLink link:definitionLink link:calculationLink 046 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:definitionLink link:calculationLink 047 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:definitionLink link:calculationLink 048 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 xsnx-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 xsnx-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 xsnx-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 9 xsnx-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document And Entity Information - shares
6 Months Ended
Mar. 31, 2023
May 15, 2023
Document Information Line Items    
Entity Registrant Name NovAccess Global Inc.  
Document Type 10-Q  
Current Fiscal Year End Date --09-30  
Entity Common Stock, Shares Outstanding   21,185,028
Amendment Flag false  
Entity Central Index Key 0001039466  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Document Period End Date Mar. 31, 2023  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q2  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 000-29621  
Entity Incorporation, State or Country Code CO  
Entity Tax Identification Number 84-1384159  
Entity Address, Address Line One 8584 E. Washington Street #127  
Entity Address, City or Town Chagrin Falls  
Entity Address, State or Province OH  
Entity Address, Postal Zip Code 44023  
City Area Code 213  
Local Phone Number 642-9268  
Title of 12(b) Security None  
Entity Interactive Data Current Yes  
No Trading Symbol Flag true  
Security Exchange Name NONE  
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2023
Sep. 30, 2022
CURRENT ASSETS    
Cash $ 21,991 $ 64,251
Prepaid expenses 81,468 60,650
TOTAL ASSETS 103,459 124,901
CURRENT LIABILITIES    
Accounts payable 446,828 375,682
Accrued expenses and other current liabilities 1,654,274 1,486,561
Derivative and warrants liabilities 1,769,259 1,440,012
Due to related parties 181,217 186,217
Short term loan, related party 21,000 12,500
Convertible promissory notes, net of debt discount and debt issuance costs of $157,807 and $340,503 respectively 1,745,073 1,266,627
Convertible promissory note related party, net of debt discount and debt issuance cost of $0 and $2,132, respectively 12,500 10,368
Total Current Liabilities 5,830,151 4,777,967
TOTAL LIABILITIES 5,830,151 4,777,967
Preferred stock 50,000,000 shares authorized, shares issued and outstanding designated as follows:    
Preferred Stock Series B, $0.01 par value, 25,000 authorized 25,000 and 25,000 shares issued and outstanding, respectively 6 6
Common stock, no par value; 2,000,000,000 authorized common shares 21,185,028 and 18,669,507 shares issued and outstanding, respectively 43,623,184 43,225,982
Additional paid in capital 6,047,212 5,340,398
Paid in capital, common stock option and warrants 4,747,108 4,747,108
Paid in capital, preferred stock 4,210,960 4,210,960
Accumulated deficit (64,355,162) (62,177,520)
TOTAL SHAREHOLDERS' DEFICIT (5,726,692) (4,653,066)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT $ 103,459 $ 124,901
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)
Mar. 31, 2023
Sep. 30, 2022
Convertible promissory notes, debt discount and debt issuance costs (in Dollars) $ 157,807 $ 340,503
Convertible promissory note related party, debt discount and debt issuance cost (in Dollars) $ 0 $ 2,132
Preferred stock, shares issued 25,000 25,000
Preferred stock, par (in Dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized 50,000,000  
Common stock, shares authorized 2,000,000,000 2,000,000,000
Common stock, shares issued 21,185,028 18,669,507
Common stock, shares outstanding 21,185,028 18,669,507
Common stock, no par value (in Dollars per share) $ 0 $ 0
Series B Preferred Stock [Member]    
Preferred stock, shares authorized 25,000 25,000
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 6 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]        
SALES $ 0 $ 0 $ 0 $ 0
COST OF GOODS SOLD 0 0 0 0
GROSS PROFIT 0 0 0 0
OPERATING EXPENSES        
Research and development expenses 41,036 45,516 76,000 87,915
Selling, general and administrative expenses 1,013,952 381,428 1,496,106 661,358
TOTAL OPERATING EXPENSES 1,054,988 426,944 1,572,106 749,273
LOSS FROM OPERATIONS BEFORE OTHER INCOME/(EXPENSES) (1,054,988) (426,944) (1,572,106) (749,273)
OTHER INCOME/(EXPENSES)        
Gain (Loss) on change in derivative liability 1,825,730 (492,425) (255,854) (33,399)
Extinguishment of derivatives 138,863 0 138,863 96,205
Extinguishment of debt 0 (54,813) 0 (54,813)
Change in commitment fee guarantee (193,625) 0 74,125 0
Interest expense (262,216) (255,603) (562,670) (631,813)
TOTAL OTHER INCOME/(EXPENSES) 1,508,752 (802,841) (605,536) (623,820)
NET INCOME (LOSS) 453,764 (1,229,785) (2,177,642) (1,373,093)
Deemed dividend on warrant re-pricing (44,241) 0 (44,241) 0
Net income loss attributable to common shareholders $ 409,523 $ (1,229,785) $ (2,221,883) $ (1,373,093)
BASIC INCOME (LOSS) PER SHARE (in Dollars per share) $ 0.02 $ (0.08) $ (0.11) $ (0.09)
DILUTED INCOME (LOSS) PER SHARE (in Dollars per share) $ 0.01 $ (0.08) $ (0.11) $ (0.09)
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING        
BASIC (in Shares) 20,698,747 15,379,289 19,832,524 14,914,920
DILUTED (in Shares) 39,680,653 15,379,289 19,832,524 14,914,920
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
Series A Preferred Stock [Member]
Preferred Stock [Member]
Series B Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Additional Paid in Capital Stock Options / Warrants [Member]
Additional Paid in Capital Preferred Stock [Member]
Retained Earnings [Member]
Common Stock Issuable [Member]
Total
Balance at Sep. 30, 2021 $ 250 $ 41,882,535 $ 5,351,398 $ 4,210,960 $ 5,088,324 $ (60,461,561)   $ (3,928,094)
Balance (in Shares) at Sep. 30, 2021 25,000 14,404,030            
Preferred stock redemption $ (244) $ 525,935     (341,216)     184,475
Preferred stock redemption (in Shares) (24,400) 1,502,670            
Common Stock issued for services   $ 119,480           $ 119,480
Common Stock issued for services (in Shares)   265,973           265,973
Common Stock issued, subscriptions   $ 170,200 5,000       $ 5,000 $ 170,200
Common Stock issued, subscriptions (in Shares)   791,000            
Net loss           (1,373,093)   (1,373,093)
Stock compensation cost   $ 8,000           8,000
Stock compensation cost (in Shares)   10,000            
Common stock issued as repayment of loans   $ 104,813           104,813
Common stock issued as repayment of loans (in Shares)   250,000            
Common stock issued as commitment fee on promissory note payable   $ 111,000           $ 111,000
Common stock issued as commitment fee on promissory note payable (in Shares)   300,000           300,000
Balance at Mar. 31, 2022 $ 6 $ 42,921,963 5,356,398 4,210,960 4,747,108 (61,834,654)   $ (4,598,219)
Balance (in Shares) at Mar. 31, 2022 600 17,523,673            
Balance at Sep. 30, 2022 $ 6 $ 43,225,982 5,340,398 4,210,960 4,747,108 (62,177,520)   (4,653,066)
Balance (in Shares) at Sep. 30, 2022 600 18,669,507            
Common Stock issued for services   $ 259,702           $ 259,702
Common Stock issued for services (in Shares)   1,490,521           1,490,521
Common Stock issued, subscriptions   $ 55,000 (5,000)         $ 50,000
Common Stock issued, subscriptions (in Shares)   525,000            
Net loss           (2,177,642)   (2,177,642)
Stock compensation cost     563,314         563,314
Deemed dividend warrant protection reserve     148,500         148,500
Common stock issued as commitment fee on promissory note payable   $ 82,500           82,500
Common stock issued as commitment fee on promissory note payable (in Shares)   500,000            
Balance at Mar. 31, 2023 $ 6 $ 43,623,184 $ 6,047,212 $ 4,210,960 $ 4,747,108 $ (64,355,162)   $ (5,726,692)
Balance (in Shares) at Mar. 31, 2023 600 21,185,028            
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net Loss $ 453,764 $ (1,229,785) $ (2,177,642) $ (1,373,093)  
Adjustment to reconcile net loss to net cash provided by (used in) operating activities          
Amortization of debt discount and debt issuance costs recorded as interest expense     432,083 479,689  
Loss on change in derivative liability (1,825,730) 492,425 255,854 33,399  
Extinguishment of derivatives (138,863) 0 (138,863) (96,205)  
Extinguishment of debt 0 54,813 0 54,813 $ 54,813
Stock compensation expense     711,814 53,619  
Stock issued and issuable for services     259,702 73,861  
Stock issued as commitment fee on promissory note payable     82,500 79,043  
Non-cash interest expense on bridge loan     0 546  
Changes in Assets and Liabilities:          
Prepaid expenses     (20,818) 5,568  
Accounts payable     71,147 39,700  
Accrued expenses and interest on notes payable     167,713 210,216  
NET CASH USED IN OPERATING ACTIVITIES     (356,510) (438,844)  
CASH FLOWS FROM FINANCING ACTIVITIES:          
Stock subscriptions received     50,000 175,200  
Due to related party     0 3,151  
Proceeds from convertible notes payable     340,000 213,000  
Payments related party for redemption of preferred stock     (5,000) (50,000)  
Proceeds from related parties notes payable     8,500 75,000  
Payment on the related parties loans payable     0 (2,316)  
Principal payments on convertible debt     (79,250) (94,250)  
NET CASH PROVIDED BY FINANCING ACTIVITIES     314,250 319,785  
NET INCREASE (DECREASE) IN CASH     (42,260) (119,059)  
CASH, BEGINNING OF PERIOD     64,251 180,668 180,668
CASH, END OF PERIOD $ 21,991 $ 61,609 21,991 61,609 $ 64,251
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION          
Interest paid     17,711 71,245  
Taxes paid     800 0  
SUPPLEMENTAL DISCLOSURES OF NON CASH TRANSACTIONS          
Accrued interest capitalized into convertible note     0 546  
Cash payable to TN3 for preferred stock     $ 0 $ 200,000  
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION AND LINE OF BUSINESS
6 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

1. ORGANIZATION AND LINE OF BUSINESS

 

Organization

NovAccess Global Inc. (“NovAccess” or the “Company”) is a Colorado corporation formerly known as Sun River Mining Inc. and XsunX, Inc.. The Company was originally incorporated in Colorado on February 25, 1997. Effective September 24, 2003, the Company completed a plan of reorganization and name change to XsunX, Inc. Effective August 25, 2020, we filed articles of amendment to our articles of incorporation with the Colorado Secretary of State to: effectuate a 1-for-1,000 reverse stock split of the Company’s outstanding shares of common stock; and change the name of the Company to “NovAccess Global Inc.” After completing the acquisition of StemVax, in September, 2020, we exited the solar business and focused all our efforts on our biopharmaceutical business.

 

Line of Business

NovAccess Global Inc. is a biopharmaceutical company that is developing novel immunotherapies to treat brain tumor patients in the United States with plans to expand globally. We specialize in cutting-edge research related to utilizing a patient’s own immune system to attack the cancer. We are filing an Investigational New Drug Application (IND) and working closely with the Food and Drug Administration (FDA) to obtain approval for human clinical trials to determine safety and efficacy of our drug product for brain cancer patients. Once we have successfully completed the clinical trials and proven that the new therapy is safe and efficacious, we plan to commercialize the product. We also have expertise in successfully executing clinical trials, bringing products to market and increasing the market size of products through our advisory board. Our scientists are well versed in immunology, stem cell biology, neuroscience, molecular biology, imaging, small molecules development, gene therapy and other technical assays needed for protein and genetic analysis of cancer cells.

 

NovAccess operates as a research and development (R&D) company out of Ohio and California, and our executive management and scientific advisory board provide over 15 years of extensive experience in all aspects of biopharmaceutical R&D and commercialization of drug candidates.

 

Going Concern

The accompanying financial statements have been prepared on a going concern basis of accounting, which contemplates continuity of operations, realization of assets and liabilities and commitments in the normal course of business. The accompanying financial statements do not reflect any adjustments that might result if the Company is unable to continue as a going concern. The Company does not generate significant revenue, and has negative cash flows from operations, which raise substantial doubt about the Company’s ability to continue as a going concern.

 

The ability of the Company to continue as a going concern and appropriateness of using the going concern basis is dependent upon, among other things, additional cash infusion. The Company has obtained funds from its shareholders since its inception through the period ended March 31, 2023. Management believes the existing shareholders and the prospective new investors will provide the additional cash needed to meet the Company’s obligations as they become due and will allow the development of its business.

XML 17 R8.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Significant Accounting Policies [Text Block]

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

This summary of significant accounting policies of NovAccess Global Inc. is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements.

 

Basis of Presentation

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary StemVax, LLC. All significant inter-company accounts and transactions between these entities have been eliminated in these consolidated financial statements.

 

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying consolidated financial statements. Significant estimates made in preparing these consolidated financial statements include the estimate of the deferred tax valuation allowance, the fair value of stock options, and derivative liabilities. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

For purposes of the statements of cash flows, cash and cash equivalents include cash in banks and money markets with an original maturity of three months or less.

 

Stock-Based Compensation

Share-based Payment applies to transactions in which an entity exchanges its equity instruments for goods or services and also applies to liabilities an entity may incur for goods or services that are to follow a fair value of those equity instruments. We are required to follow a fair value approach using an option-pricing model, such as the Binomial lattice valuation model, at the date of a stock option grant. The deferred compensation calculated under the fair value method would then be amortized over the respective vesting period of the stock option. This has not had a material impact on our results of operations.

 

Net Earnings (Loss) per Share Calculations

Net earnings (Loss) per share dictates the calculation of basic earnings (loss) per share and diluted earnings (loss) per share. Basic earnings (loss) per share are computed by dividing by the weighted average number of common shares outstanding during the period. Diluted net earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the effect of stock options and stock-based awards plus the assumed conversion of convertible debt (see notes 4 and 5). 

 

   

For the three months ended

   

For the Six months ended

 
   

March 31,

   

March 31,

 
   

2023

   

2022

   

2023

      2022  
                                 

Income (Loss) to common shareholders (Numerator)

  $ 409,523       (1,229,785 )   $ (2,221,883 )     (1,373,093 )
                                 

Basic weighted average number of common shares outstanding (Denominator)

    20,698,747       15,379,289       19,832,524       14,914,920  
                                 

Diluted weighted average number of common shares outstanding

    39,680,653       15,379,289       19,832,524,       14,914,920  

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of March 31, 2023, the balances reported for cash, prepaid expenses, accounts payable, accrued expenses approximate the fair value because of their short maturities.

 

We adopted Accounting Standards Codification (“ASC”) Topic 820 for financial instruments measured as fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States and expands disclosures about fair value measurements.

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:

 

 

Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;

 

 

Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

 

 

Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

We measure certain financial instruments at fair value on a recurring basis. The Company had no assets that are required to be valued on a recurring basis as of March 31, 2023 and September 30, 2022. The Company had liabilities that are required to be measured at fair value on a recurring basis as follows at March 31 2023 and September 30, 2022:

 

   

Total

   

(Level 1)

   

(Level 2)

   

(Level 3)

 
                                 

Assets:

  $ -     $ -     $ -     $ -  
                                 

Liabilities:

                               
                                 

Derivative Liability at fair value as of September 30, 2022

  $ 1,207,403     $ -     $ -     $ 1,207,403  

Derivative Liability warrants at fair value as of September 30, 2022

  $ 232,609     $ -     $ -     $ 232,609  

Total Derivative Liability as of September 30, 2022

  $ 1,440,012       -       -     $ 1,440,012  

Derivative Liability at fair value as of March 31, 2023

  $ 1,211,565       -       -     $ 1,211,565  

Derivative Liability warrants at fair value as of March 31, 2023

  $ 557,694       -       -     $ 557,694  

Total Derivative Liability as of March 31, 2023

  $ 1,769,259       -       -     $ 1,769,259  

 

The following is a reconciliation of the derivative liability for which Level 3 inputs were used in determining the approximate fair value:

 

   

Derivative Liability

Promissory Notes

   

Derivative

Liability Warrants

   

Total

Derivative Liability

 

Balance as of September 30, 2021

  $ 2,553,979     $ 372,643     $ 2,926,622  

Fiscal year 2022 initial derivative liabilities

    593,297       282,051       875,348  

Net (Gain)/Loss on change in fair value of derivative liability

    (1,662,156

)

    (422,086

)

    (2,084,242

)

Extinguishment of derivative

    (277,716

)

    -       (277,716 )

Ending balance as of September 30, 2022

  $ 1,207,403     $ 232,609     $ 1,440,012  

Six Months ended March 31, 2023, initial derivative liabilities

    212,256       -       212,256  

Net (Gain)/Loss on change in fair value of derivative liability

    (69,231 )     325,085       255,854  

Extinguishment of derivative

    (138,863 )     -       (138,863 )

Ending balance as of March 31, 2023

  $ 1,211,565     $ 557,694     $ 1,769,259  

 

Recent Accounting Pronouncements

In September 2022, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2022-04, "Liabilities-Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations". This guidance requires annual and interim disclosures for entities that use supplier finance programs in connection with the purchase of goods and services. The ASU is effective for fiscal years beginning after December 15, 2022, with early adoption permitted, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 15, 2023. We are currently evaluating the extent of the impact of this ASU, but do not expect the adoption of this standard to have a significant impact on our consolidated financial statements.

 

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sales Restrictions, which (1) clarifies the guidance in Topic 820 on the fair value measurement of an equity security that is subject to contractual restrictions that prohibit the sale of an equity security and (2) requires specific disclosures related to such an equity security. We are currently evaluating the extent of the impact of this ASU, but do not expect the adoption of this standard to have a significant impact on our consolidated financial statements.

 

In March 2022, the FASB issued ASU No. 2022-02, Troubled Debt Restructurings and Vintage Disclosures ("ASU 2022-02"). ASU 2022-02 eliminates the accounting guidance on troubled debt restructurings for creditors in ASC Topic 310 and amends the guidance on "vintage disclosures" to require disclosure of current-period gross write-offs by year of origination. ASU 2022-02 also updates the requirements related to accounting for credit losses under ASC Topic 326 and adds enhanced disclosures for creditors with respect to loan refinancings and restructurings for borrowers experiencing financial difficulty. ASU 2022-02 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We are currently evaluating the extent of the impact of this ASU, but do not expect the adoption of this standard to have a significant impact on our consolidated financial statements.

 

Management does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

XML 18 R9.htm IDEA: XBRL DOCUMENT v3.23.1
CAPITAL STOCK
6 Months Ended
Mar. 31, 2023
Stockholders' Equity Note [Abstract]  
Equity [Text Block]

3. CAPITAL STOCK

 

As of March 31, 2023 the Company’s authorized stock consisted of 2,000,000,000 shares of common stock, with no par value. Effective August 25, 2020, we filed articles of amendment to our articles of incorporation with the Colorado Secretary of State to effectuate a 1-for-1,000 reverse stock split of the Company’s outstanding shares of common stock.

 

The Company is also authorized to issue 50,000,000 shares of preferred stock with a par value of $0.01 per share. The rights, preferences and privileges of the holders of the preferred stock are determined by the Board of Directors prior to issuance of such shares.

 

Preferred Stock

 

As of March 31, 2023, the Company had 600 shares of issued and outstanding Series B Preferred. On September 4, 2020, the Company issued 25,000 shares of unregistered Series B Convertible Preferred stock, $0.01 par value per share, to TN3, LLC, a Wyoming limited liability company owned by Daniel G. Martin (“TN3”), in exchange for the redemption of all 5,000 shares of Series A preferred stock that TN3 previously held. At the time, Mr. Martin was our Chief Executive Officer and sole Board Member. On March 14, 2022, NovAccess redeemed 24,400 shares of the Company’s Series B Convertible Preferred Stock held by TN3. Irvin Consulting LLC, a company owned by Dwain Irvin, the CEO of NovAccess, purchased the remaining 600 shares (please refer to Note 11 for more details).

 

Each share of outstanding Series B Preferred Stock entitles the holder to cast 40,000 votes. Each share of Series B Preferred Stock is convertible at the option of the holder into 10,000 common shares. In the event of any voluntary or involuntary liquidation, dissolution, or winding-up of the Corporation, the holders of shares of Series B Preferred Stock shall be paid out based on an as converted basis. Dividends for Series B Preferred Stock shall be declared on an as converted basis.

 

Common Stock

 

During the six months ended March 31, 2023, the Company issued 2,515,521 shares of common stock.

 

The Company issued 1,490,521 shares to various vendors for services provided, including 216,500 shares issued to a related party for services provided, amounting to $259,702 recorded at the fair value of shares on the respective grant dates.

 

The Company issued 525,000 shares in relation to stock subscriptions.

 

The Company issued 500,000 shares as commitment fees in connection with the letter agreement issued on February 9, 2023. These shares were recorded at fair value as on the date of issuance.

 

During the six months ended March 31, 2022, the Company issued 3,119,643 shares of common stock. 1,502,670 shares were issued to TN3 as part of the transaction to redeem 24,400 shares of Series B Preferred Stock, 265,973 shares were issued to various vendors for services provided; 791,000 shares were issued in relation to stock subscriptions; 300,000 shares were issued as a commitment fee on a promissory note payable; 250,000 shares were issued as repayment of bridge loans (please refer to Note 4 for more details); and 10,000 shares were issued to related parties (please refer to Note 12 for more details).

XML 19 R10.htm IDEA: XBRL DOCUMENT v3.23.1
CONVERTIBLE PROMISSORY NOTES
6 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
Debt Disclosure [Text Block]

4. CONVERTIBLE PROMISSORY NOTES

 

Convertible Promissory notes

as on March 31, 2023

 

Principal Amount

   

Unamortized balance of Debt Discount

   

Outstanding balance as on March 31, 2023

   

Derivative balance as on March 31, 2023

   

Warrant liability balance as on March 31, 2023

 
                                         

2013 Note

    12,000       -       12,000       -       -  

2014 Note

    50,880       -       50,880       215,591       -  

2017 Note

    115,000       -       115,000       453,384       -  

August 2021 Note

    -       -       -       -       151,920  

February 2022 Note

    250,000       -       250,000       81,815       76,762  

May 2022 Note

    1,000,000       -       1,000,000       245,784       171,753  

August 2022 Note

    100,000       27,517       72,483       48,797       -  

November 2022 Note

    55,000       32,937       22,063       48,883       -  

December 2022 Note

    55,000       37,207       17,793       49,719       -  

February 2023 Note

    265,000       60,146       204,854       63,650       157,259  

Total

    1,902,880       157,807       1,745,073       1,207,624       557,694  

 

Convertible Promissory note,

related party as on March 31, 2023

 

Principal Amount

   

Unamortized balance of Debt Discount

   

Outstanding balance as on March 31, 2023

   

Derivative balance as on March 31, 2023

   

Warrant liability balance as on March 31, 2023

 
                                         

July 2022 Note

    12,500       -       12,500       3,941       -  

 

2013 Note

 

On October 1, 2013, Company issued an unsecured convertible promissory note (the “2013 Note”) in the amount of $12,000 to a former Board member (the “Holder”) in exchange for retention as a director during the fiscal year ending September 30, 2014. The Note can be converted into shares of common stock by the Holder for $4.50 per share. The Note matured on October 1, 2015 and bore a one-time interest charge of $1,200 which was applied to the principal on October 1, 2014. As of March 31, 2023, the outstanding principal balance was $12,000.

 

2014 Note

 

On November 20, 2014, the Company issued a 10% unsecured convertible promissory note (the “2014 Note”) for the principal sum of up to $400,000 plus accrued interest on any advanced principal funds. The 2014 Note matured eighteen months from each advance. The 2014 Note may be converted by the lender into shares of common stock of the Company at the lesser of $12.50 per share or (b) fifty percent (50%) of the lowest traded prices following issuance of the 2014 Note or (c) the lowest effective price per share granted to any person or entity. On November 20, 2014, the lender advanced $50,000 to the Company under the 2014 Note at inception. On various dates from February 18, 2015 through September 30, 2016, the lender advanced an additional $350,000 under the 2014 Note. During the period ended September 30, 2021, the Company and lender agreed to extend the maturity date for the outstanding balance to June 30, 2023. As of March 31, 2023, outstanding principal balance was $50,880.

 

2017 Note

 

On May 10, 2017, the Company issued a 10% unsecured convertible promissory note (the “2017 Note”) for the principal sum of up to $150,000 plus accrued interest on any advanced principal funds. The lender may pay additional consideration at the lender’s discretion. The Company received a tranche in the amount of $25,000 upon execution of the 2017 Note. On various dates, the Company received additional tranches in the aggregate sum of $90,000. The 2017 Note matured twelve months from each tranche. Within thirty (30) days prior to the maturity date, the lender may extend the maturity date to sixty (60) months. During the period ended September 30, 2021, the Company and lender agreed to extend the maturity date for the outstanding balance to June 30, 2023. The 2017 Note may be converted by the lender into shares of common stock of the Company at the lesser of $10 per share or (b) fifty percent (50%) of the lowest traded price of common stock recorded on any trade day after the effective date, or (c) the lowest effective price per share granted to any person or entity. As of March 31, 2023 the outstanding principal balance was $115,000.

 

May 2021 Note

 

On May 28, 2021, the Company issued a 12% unsecured convertible promissory note (the “May 2021 Note”) for the principal sum of $55,500 plus accrued interest. The May 2021 Note was to mature on May 28, 2022. The May 2021 Note was convertible after November 23, 2021, by the lender into shares of common stock of the Company at sixty-one percent (61%) of the lowest traded price of common stock recorded during the fifteen (15) trading days prior to conversion. On October 5, 2021, the Company paid the balance of this note to the lender. As of March 31, 2023, the balance of the May 2021 Note was $0.

 

July 2021 Note

 

On July 6, 2021, the Company issued a 12% unsecured convertible promissory note (the “July 2021 Note”) for the principal sum of $38,750 plus accrued interest with a maturity date of July 6, 2022. The July 2021 Note was convertible after January 1, 2022, by the lender into shares of common stock of the Company at sixty-one percent (61%) of the lowest trade price of common stock recorded during the fifteen (15) trading days prior to conversion. On December 30, 2021, the Company paid the balance of this note to the lender. As of March 31, 2023, the balance of the July 2021 Note was $0.

 

August 2021 Note

 

On August 20, 2021, the Company issued a 10% secured promissory note (the “August 2021 Note”) for the principal sum of $500,000 plus accrued interest. The August 2021 Note was to mature on February 20, 2022, unless extended for up to an additional six months. The August 2021 Note could be converted, only following an event of default, by the lender into shares of common stock of the Company at the lesser of 90% (representing a 10% discount) multiplied by the lowest trading price during the previous twenty (20) trading day period ending on the issuance date, or during the previous twenty (20) trading day period. The Company issued 1,000,000 warrants at a price of $1.50 in connection with the note (note 7 below) and issued 400,000 shares as a commitment fee. In February 2022, the Company extended the term of the August 2021 Note for an additional six months. The Company repaid the August 2021 Note on May 9, 2022 in connection with the issuance of the May 2022 Note described below. As of March 31, 2023, the balance on the August 2021 Note was $0.

 

On February 9, 2023, the Company entered into a letter agreement in connection with the August 2021 Note, whereby the exercise price of the warrants issued on the August 2021 Note was reduced to $0.20 per share.

 

February 2022 Note

 

On February 15, 2022, the Company issued a 10% secured promissory note (the “February 2022 Note”) for the principal sum of $250,000 plus accrued interest. The February 2022 Note was to mature on August 15, 2022, unless extended for up to an additional six months. The February 2022 Note may be converted, only following an event of default, by the lender into shares of common stock of the Company at the lesser of 90% (representing a 10% discount) multiplied by the lowest trading price during the previous twenty (20) trading day period ending on the issuance date, or during the previous twenty (20) trading day period. In July 2022, the Company extended the term of the February 2022 note for another six months until February 16, 2023. In connection with the note, the Company issued 500,000 warrants with an exercise price of $1.50 (see note 7 below). The February 2022 Note had an original issuance discount amounting to $25,000, debt issuance cost amounting to $12,000 and the Company issued 300,000 shares as a commitment fee valued at $111,000 based on the share price on the date of the agreement, amortized over the term of the loan. The initial recognition of derivative and warrant liability was recorded as debt discount and amortized over the term of the loan. The debt discount is fully amortized and the balance in debt discount as on March 31, 2023, was $0. As of March 31, 2023, the balance outstanding net of debt discount was $250,000.

 

On February 9, 2023, the Company entered into a letter agreement in connection with the February 2022 Note, whereby the Company extended the due date of the loan to May 9, 2023 and deferred all interest payments for the period from January 1, 2023 until May 9, 2023. Pursuant to the letter agreement the exercise price of the warrants issued with the February 2022 Note was reduced to $0.20 per share. The warrants contained a ratchet provision and the difference in fair value of $44,241 upon the reduction of exercise price as mentioned above  is being treated as a deemed dividend for the down round provision.

 

The company did not make the payment of $258,958 due on May 9, 2023. The lender has agreed to waive the default provisions until June 1, 2023, or pending conclusion of negotiations on an extension of the loans.

 

May 2022 Note

 

On May 5, 2022, the Company issued a 12% secured promissory note (the “May 2022 Note”) for the principal sum of $1,000,000 plus accrued interest. The May 2022 Note was to mature on November 5, 2022, unless extended for up to an additional six months. If extended, the interest rate increased to 15% for the remaining six months. The May 2022 Note may be converted, only following an event of default, by the lender into shares of common stock of the Company at the lesser of the lowest trading price during the previous twenty (20) trading day period ending on the issuance date, or during the previous twenty (20) trading day period before conversion. The Company used some of the proceeds from the May 2022 Note to pay off the August 2021 Note. In November 2022, the Company extended the May 2022 Note for another six months until May 5, 2023. In connection with the loan the Company issued 1,000,000 warrants at an exercise price of $0.01 (see note 7 below). The May 2022 Note had an original issuance discount amounting to $100,000, debt issuance costs of $ 25,500 and the Company issued 875,000 shares as a commitment fee valued at $259,875 based on the share price on the date of the agreement. The initial recognition of derivative liability of $412,065 and warrant liability amounting to $282,051 was recorded as debt discount and amortized over the term of the loan. The balance in debt discount as on March 31, 2023, was $0. As of March 31, 2023, the balance outstanding net of debt discount was $1,000,000.

 

On February 9, 2023, the Company entered into a letter agreement in connection with the May 2022 Note deferring all interest payments from January 1, 2023 until May 9, 2023.

 

The company did not make the payment of $1,053,750 due on May 9, 2023. The lender has agreed to waive the default provisions until June 1, 2023, or pending conclusion of negotiations on an extension of the loans.

 

August 2022 Note

 

On August 8, 2022, the Company issued a 12% unsecured promissory note (the “August 2022 Note”) for the principal sum of $100,000 plus accrued interest. The August 2022 Note matures on August 8, 2023, provided, however that after October 31, 2022, if the Company receives debt or equity financing of at least $3 million, the holder may call for payments of outstanding principal and interest at any time from such date giving notice of at least five business days before the date the payment is due. The holder shall have the right, until the date of payment in full of all amounts outstanding to convert unpaid principal and interest and any other amounts into fully paid shares of common stock of the Company at a conversion price of $0.15. The initial recognition of derivative liability of $77,259 was recorded as debt discount and amortized over the term of the loan. The balance in debt discount as on March 31, 2023 was $27,517. As of March 31, 2023 the balance outstanding net of debt discount was $72,483.

 

September 2022 Note

 

On September 22, 2022, the Company issued an 8% secured promissory note (the “September 2022 Note”) for the principal sum of $79,250 plus accrued interest. The September 2022 Note matures on September 22, 2023. In case of default in repayment of the outstanding amount on the due date the balance shall bear interest of 22% per annum. The holder shall have the right, after six months, until the date of payment in full of all amounts outstanding to convert unpaid principal and interest and any other amounts into fully paid shares of common stock of the Company at a variable conversion price equal to 65% multiplied by the market price. Market price means the average of the three lowest trading prices for the Common Stock during the fifteen-trading day period ending on the latest complete trading day prior to the conversion date. The initial recognition of derivative liability amounting to $75,000 was recorded as debt discount and amortized over the term of the loan. The debt issuance cost of $4,250 was recorded as debt discount and amortized over the term of the loan. The Company repaid the loan in full including interest of $3,127 on March 12, 2023. The prepayment penalty amounted to $20,594. The balance in debt discount as on March 31, 2023 was $0. As of March 31, 2023 the balance outstanding net of debt discount was $0.

 

November 2022 Note

 

On November 1, 2022, the Company issued an 8% secured promissory note (the “November 2022 Note”) for the principal sum of $55,000 plus accrued interest. The November 2022 Note matures on November 1, 2023. In case of default in repayment of the outstanding amount on the due date the balance shall bear interest of 22% per annum. Beginning on April 30, 2023, 1800 Diagonal Lending may convert the amount outstanding under the note into shares of NovAccess common stock at a conversion price equal to 65% of the average of the three lowest trading prices of the stock during the fifteen trading days before the conversion date. The initial recognition of derivative liability amounting to $50,700 was recorded as debt discount and amortized over the term of the loan. The debt issuance cost of $4,250 was recorded as debt discount and amortized over the term of the loan. The balance in debt discount as on March 31, 2023, was $32,938. As of March 31, 2023, the balance outstanding net of debt discount was $22,063.

 

December 2022 Note

 

On December 7, 2022, the Company issued an 8% secured promissory note (the “December 2022 Note”) for the principal sum of $55,000 plus accrued interest. The December 2022 Note matures on December 7, 2023. In case of default in repayment of the outstanding amount on the due date the balance shall bear interest of 22% per annum. Beginning on June 5, 2023, 1800 Diagonal Lending may convert the amount outstanding under the note into shares of NovAccess common stock at a conversion price equal to 65% of the average of the three lowest trading prices of the stock during the fifteen trading days before the conversion date. The initial recognition of derivative liability amounting to $50,700 was recorded as debt discount and amortized over the term of the loan. The debt issuance cost of $4,250 was recorded as debt discount and amortized over the term of the loan. The balance in debt discount as on March 31, 2023, was $37,207. As of March 31, 2023, the balance outstanding net of debt discount was $17,793.

 

February 2023 Letter Agreement

 

On February 9, 2023 the Company entered into a letter agreement, whereby the Company drew an additional loan amounting to $265,000, which was added to the May 2022 Note. The $265,000 loan has an original issuance discount of 10% of the principal and bears interest at 10% a year. This loan is due on May 9, 2023. The initial recognition of derivative liability amounting to $110,576 was recorded as debt discount and amortized over the term of the loan. The original issuance discount of $26,500 was recorded as debt discount and amortized over the term of the loan. The balance in debt discount as on March 31, 2023, was $60,146. As of March 31, 2023, the balance outstanding net of debt discount was $204,854.

 

Also pursuant to the letter agreement , the Company paid a commitment fee of 500,000 unregistered shares of the Company’s common stock (the “commitment fee shares”). If the investor is unable to sell the commitment fee shares for $0.20 a share, then investor may require the Company to issue additional shares or pay cash in the amount of the shortfall. The Company also issued a common stock purchase warrant to purchase 1.0 million shares of the company’s Common stock for $0.20 a share. The warrant expires on February 9, 2028. The company recorded expense of 82,500 in respect of the commitment fee shares and 157,933 in respect of the warrant.

 

The Company did not make the payment of $271,551 due on May 9, 2023. The lender has agreed to waive the default provisions until June 1, 2023, or pending conclusion of negotiations on an extension of the loans.

 

We evaluated the financing transactions in accordance with ASC Topic 815, Derivatives and Hedging, and determined that the conversion feature of the convertible promissory notes was not afforded the exemption for conventional convertible instruments due to its variable conversion rate. The notes have no explicit limit on the number of shares issuable so they did not meet the conditions set forth in current accounting standards for equity classification. The Company elected to recognize the notes under paragraph 815-15-25-4, whereby, there would be a separation into a host contract and derivative instrument. The Company elected to initially and subsequently measure the notes in their entirety at fair value, with changes in fair value recognized in earnings. The Company recorded a derivative liability representing the imputed interest associated with the embedded derivative. The derivative liability is adjusted periodically according to the stock price fluctuations based upon the Binomial lattice model calculation.

 

The convertible notes issued and described in this Note do not have fixed settlement provisions because their conversion prices are not fixed. The conversion feature has been characterized as a derivative liability to be re-measured at the end of every reporting period with the change in value reported in the statement of operations.

 

We record the full value of the derivative as a liability at issuance with an offset to valuation discount, which will be amortized over the life of the notes.

 

For purpose of determining the fair market value of the derivative liability for the embedded conversion, the Company used Binomial lattice valuation model. The significant assumptions used in the Binomial lattice valuation of the derivatives are as follows:

 

Risk free interest rate

 

Between 4.74% and 4.955%

Stock volatility factor

 

Between 141% and 177.6%

Years to Maturity

 

0.28 years

Expected dividend yield

 

None

XML 20 R11.htm IDEA: XBRL DOCUMENT v3.23.1
CONVERTIBLE PROMISSORY NOTE, RELATED PARTY
6 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
Long-Term Debt [Text Block]

5. CONVERTIBLE PROMISSORY NOTES, RELATED PARTY

 

July 2022 Note, related party

 

On July 28, 2022, the Company issued a 12% unsecured promissory note (the “July 2022 Note”) for the principal sum of $12,500 plus accrued interest. All amounts outstanding under the July 2022 Note were payable on the earlier of: (a) October 31, 2022, or (b) the receipt by the Company of debt or equity financing of $3 million. In November 2022, the holder agreed to extend the term of the note until April 2023 and in April 2023 agreed to a further extension until August 31, 2023. The holder has the right, until the date of payment in full of all amounts outstanding to convert unpaid principal and interest and any other amounts into fully paid shares of common stock of the Company at conversion price of $0.15. The initial recognition of derivative liability of $12,500 was recorded as debt discount and amortized over the term of the loan. The balance in debt discount as on March 31, 2023, was $0. As of March 31, 2023, the balance outstanding net of debt discount was $12,500.

XML 21 R12.htm IDEA: XBRL DOCUMENT v3.23.1
SHORT TERM LOAN, RELATED PARTY
6 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
Short-Term Debt [Text Block]

6. SHORT TERM LOAN, RELATED PARTY

 

On July 28, 2022, the Company entered into a short-term interest free loan agreement amounting to $12,500, with Jason M. Anderson, an independent member of our board of directors, to fund the operations until longer term financing can be obtained by the Company. The loan terms required repayment of all amounts outstanding under the loan on the earlier of: (a) October 31, 2022 or (b) the receipt by the Company of debt or equity financing of $3 million In November, 2022, the Board Member signed a waiver and extension agreement changing the due date to April 30, 2023 and in April 2023, agreed to a further extension until August 31, 2023.

 

On February 9, 2023, NovAccess entered into a second interest-free loan agreement with Mr. Anderson. Reflecting his faith in NovAccess and our management team, Mr. Anderson loaned the Company $8,500. The loan does not bear interest (except on default) and is due on the earlier of August 31, 2023 or our receipt of debt or equity financing of at least $3.0 million.

XML 22 R13.htm IDEA: XBRL DOCUMENT v3.23.1
WARRANTS
6 Months Ended
Mar. 31, 2023
Disclosure Text Block Supplement [Abstract]  
Shareholders' Equity and Share-Based Payments [Text Block]

7. WARRANTS

 

On August 20, 2021, for value received in connection with the issuance of the August 2021 Note (see note 4 for more details), the Company issued 1,000,000 warrants to the lender with an exercise price of $1.50 per share with a five-year exercise period. On February 9, 2023, the Company entered into a letter agreement in connection with the August 2021 Note, whereby the exercise price of the warrants issued on the August 2021 Note was reduced to $0.20 per share.

 

On February 16, 2022, for value received in connection with the issuance of the February 2022 Note (see note 4 for more details), the Company issued 500,000 warrants to the lender with an exercise price of $1.50 per share with a five-year exercise period. On February 9, 2023, the Company entered into a letter agreement in connection with the August 2021 Note, whereby the exercise price of the warrants issued on the August 2021 Note was reduced to $0.20 per share.

 

On May 10, 2022, for value received in connection with the issuance of the May 2022 Note (see note 4 for more details), the Company issued 1,000,000 warrants to the lender with an exercise price of $0.01 per share with a five-year exercise period. On February 9, 2023, for value received in connection with the issuance of the February 2023 Note (see note 4 for more details), the Company issued 1,000,000 warrants to the lender with an exercise price of $0.20 per share with a five-year exercise period. The fair value of the warrant issued in relation to the letter agreement issued on February 2023 , is recorded as stock compensation expense amounting to $148,500.

 

On March 31, 2023 the fair value of the derivative liability of the warrants was $557,694 and $232,609 as of September 30, 2022.

 

For the purpose of determining the fair market value of the derivative liability for the embedded conversion, the Company used the Binomial lattice valuation model. The significant assumptions used in the Binomial lattice valuation of the derivatives are as follows:

 

Risk free interest rate

 

Between 3.6% and 3.81%

Stock volatility factor

 

Between 147% and 164%

Years to Maturity

 

4.25 years

Expected dividend yield

 

None

 

Per guidance on ASC 260, the Company determined that the repricing of warrants discussed above, was an exchange of the existing 1,500,000 warrants and the difference between the fair value of the warrants immediately prior to modification of terms and immediately after the adjustment was a s a deemed dividend. The difference between the fair value of the warrants immediately prior to modification of terms and immediately after the adjustment was calculated as $44,241, using a Black Scholes model based on the following significant inputs: On February 9, 2023: common stock price of $0.165; company volatility of 156%-159%; remaining term 3.2-4.1 years; dividend yield of 0% and risk-free interest rate of 3.81-3.71%.

XML 23 R14.htm IDEA: XBRL DOCUMENT v3.23.1
OPTIONS
6 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Share-Based Payment Arrangement [Text Block]

8. OPTIONS

 

On June 2, 2020, the Company issued 2,000,000,000 options, on a pre reverse split basis, to purchase common stock to the then directors of the Company as compensation for serving on the board during 2019. These options are exercisable on a cashless basis for a period of ten years from September 30, 2022 at an exercise price of $0.00001. The number of options on the post stock split basis is 2,000,000, and the exercise price of $0.01 per share.

 

For purpose of determining the fair market value of the options issued on June 2, 2020, the Company used the Black Scholes valuation model. The significant assumptions used in the Black Scholes valuation model for the options are as follows:

 

Risk Free Interest Rate

 

0.32%

Stock Volatility Factor

 

146.0%

Weighted Average Expected Option Life

 

5 Years

Expected Dividend Yield

 

None

 

On March 13, 2023, the Company entered into non-qualified stock option agreements and granted vested ten-year options to purchase shares of the Company’s common stock for $0.175 a share, the closing price on the grant date. The Company issued options to purchase a total of 3,542,857 shares as follows: (a) 857,143 to each of the independent directors, (b) 428,571 to the chief financial officer, and 571,429 to the president of our StemVax Therapeutics subsidiary; (c) 57,143 to each of our scientific advisory board members; and (d) the remaining 542,857 to staff members and other officers.

 

Vesting Schedule. The Options are 100% vested and exercisable on the grant date, March 31, 2023.

 

Expiration. The Option will expire on the tenth anniversary from the grant date which falls on March 31, 2033.

 

For purpose of determining the fair market value of the options, the Company used the Black Scholes valuation model. The significant assumptions used in the Black Scholes valuation model for the options are as follows:

 

Risk Free Interest Rate

 

3.68%

Stock Volatility Factor

 

146.79%

Weighted Average Expected Option Life

 

5 Years

Expected Dividend Yield

 

None

 

A summary of the Company’s options activity and related information follows for the quarter ended March 31, 2023:

 

   

 March 31, 2023

 
           

Weighted

 
   

Number

   

average

 
   

Of

   

exercise

 
   

Options

   

price

 

Outstanding - beginning of period

    2,000,000     $ .01  

Granted

    3,542,857     $ 0.175  

Exercised

    -     $ -  

Forfeited

    -     $ -  

Outstanding - end of period

    5,542,857     $ 0.115  

 

At March 31, 2023, the weighted average remaining contractual life of options outstanding:

 

 

 

 

 

 

 March 31, 2023

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Average

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Remaining

 

 

Exercisable

 

 

Options

 

 

Options

 

 

Contractual

 

 

Prices

 

 

Outstanding

 

 

Exercisable

 

 

Life (years)

 

 

$

.01

 

 

 

2,000,000

 

 

 

2,000,000

 

 

 

7.17

 

 

$

0.175

     

3,542,857

     

3,542,857

     

9.95

 

 

The entire stock-based compensation expense amounting to $563,314 was recorded in the income statement on the grant date as the options are fully vested and exercisable on the grant date.

XML 24 R15.htm IDEA: XBRL DOCUMENT v3.23.1
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
6 Months Ended
Mar. 31, 2023
Payables and Accruals [Abstract]  
Accounts Payable and Accrued Liabilities Disclosure [Text Block]

9. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

 

Accrued expenses and accrued other current liabilities consisted of the following at March 31, 2023 and September 30, 2022:

 

   

March 31, 2023

   

September 30, 2022

 

Accrued liabilities

    5,570       4,370  

Interest payable

    159,506       94,251  

Provision for guaranteed commitment fees *

    886,875       961,000  

Accrued payroll

    7,367       4,740  

Deferred compensation

    485,421       344,983  

License Fees Payable

    40,402       40,402  

Insurance finance liability

    69,133       36,815  
    $ 1,654,274     $ 1,486,561  

 

* Under the terms of the August 2021 Note, February 2022 Note, May 2022 Note and February 2023 Note the Company issued a total of 2,075,000 shares of common stock as commitment fees. If the lender is unable to sell the shares for more than $1,250,000, it may make a one-time claim for each note to be reimbursed for the difference between their sale proceeds and $1,250,000. The difference between the fair value of the 2,075,000 shares as on March 31, 2023 and the exercise amount of $1,250,000 was recorded as a provision for guaranteed commitment fees and included in the table above.

XML 25 R16.htm IDEA: XBRL DOCUMENT v3.23.1
BRIDGE LOANS PAYABLE
6 Months Ended
Mar. 31, 2023
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]  
Other Liabilities Disclosure [Text Block]

10. BRIDGE LOAN PAYABLE

 

Related parties

 

In December 2021, the Company’s CEO and CFO each advanced funds to the Company for operating expenses in the total amount of $50,000. The notes were payable on demand with a five business day written notice and bore interest at a rate of 10% per annum. The Company could prepay all or any part of the balance owed without penalty.

 

In March, 2022, our CEO purchased 600 shares of Series B Preferred stock and the Company applied $18,616 of the loan balance against this purchase. The remaining balance of $6,384 was paid to our CEO in several payments with the final balance being paid in May, 2022. The Company recognized and paid interest expense in the amount of $583 to our CEO during the year ended September 30, 2022. No balance is due to our CEO as March 31, 2023.

 

On January 25, 2022, the Company issued 125,000 shares of its common stock in settlement of the bridge loan to the Company’s CFO and recognized a loss on extinguishment of debt in the amount of $17,313. Any potential gain would not have been recognized on extinguishment of this loan due to the nature of the relationship between the parties. The Company recognized and paid interest expense in the amount of $237 to our CFO during the year ended September 30, 2022. No balance is due to our CFO as of March 31, 2023.

 

Service provider, related party

 

In December 2021, one of the Company’s service providers advanced funds to the Company for operating expenses in the total amount of $25,000. On February 14, 2022, the Company issued 125,000 shares of its common stock to the service provider in settlement of the note payable. The Company recognized a loss on extinguishment of debt in the amount of $37,500. During the year ended September 30, 2022, the Company recognized and paid interest expense of $226 in relation to this loan. No balance was outstanding on the note payable to our service provider as of March 31, 2023.

 

The total loss on account of extinguishment of debt on the CFO Note and service provider note amounting to $54,813 was recorded in the income statement.

XML 26 R17.htm IDEA: XBRL DOCUMENT v3.23.1
DUE TO RELATED PARTIES
6 Months Ended
Mar. 31, 2023
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]  
Other Liabilities [Table Text Block]

11. DUE TO RELATED PARTIES

 

Due to Innovest Global

 

During the periods prior to the year ended September 30, 2022, Innovest Global, Inc. (“Innovest”) advanced funds to the Company for operating expenses in the amount of $86,217. As of March 31, 2023, the amount has not been reimbursed to Innovest. Our former Chairman Daniel Martin was the CEO of Innovest when the funds were advanced.

 

Due to TN3 LLC

 

On January 31, 2022, the Company entered into a preferred stock redemption agreement with Daniel G. Martin, at the time, our sole board member and chairman, TN3, LLC, a company owned by Mr. Martin, Dwain K. Irvin, our chief executive officer, and Irvin Consulting, LLC, a company owned by Dr. Irvin. TN3 owned 25,000 shares of the Series B convertible preferred stock. Pursuant to the redemption agreement, on March 14, 2022, NovAccess redeemed 24,400 of the preferred shares and Irvin Consulting purchased 600 of the preferred shares from TN3. The Company also issued to TN3 1,502,670 shares of unregistered common stock, at $ 0.35 amounting to $525,934 which was equal to 10% of our outstanding common stock on the date the redemption agreement was signed. Upon completion of the redemption transaction, the Company is obligated to pay to TN3 a total of $250,000 over a period of eleven months, with payment accelerated if the Company raises at least $2.5 million of equity capital. As of March 31, 2023, the Company owed TN3 $95,000 of the redemption price.

XML 27 R18.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES
6 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Disclosure [Text Block]

12. COMMITMENTS AND CONTINGENCIES

 

There are no material pending legal proceedings to which we are a party, nor are there any such proceedings known to be contemplated by governmental authorities. None of our directors, officers, or affiliates is involved in a proceeding adverse to our business or has a material interest adverse to our business.

 

Under the terms of the August 2021 Note, February 2022 Note, May 2022 Note and February 2023 Note the Company issued a total of 2,075,000 shares of common stock as commitment fees. If the lender is unable to sell the shares for more than $1,250,000, it may make a onetime claim for each note to be reimbursed for the difference between their sale proceeds and $1,250,000. The difference between the fair value of the 1,575,000 shares as on March 31, 2023, and the exercise amount of $1,250,000 was recorded as a make-whole provision for commitment fees and included in the accrued expenses.

XML 28 R19.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTIONS
6 Months Ended
Mar. 31, 2023
Related Party Transactions [Abstract]  
Related Party Transactions Disclosure [Text Block]

13. RELATED PARTY TRANSACTIONS

 

On February 9, 2023, NovAccess entered into an interest-free loan agreement with Jason M. Anderson, an independent member of our board of directors. Reflecting his faith in NovAccess and our management team, Mr. Anderson loaned the company $8,500. The loan does not bear interest (except on default) and is due on the earlier of August 31, 2023 or our receipt of debt or equity financing of at least $3.0 million. We will use the proceeds of the loan for general working capital purposes.

 

On July 28, 2022, the Company entered into a short-term interest free loan agreement amounting to $12,500 with Mr. Anderson to fund operations until longer term financing can be obtained by the Company. The loan terms required repayment of all amounts outstanding under this agreement on the earlier of: (a) October 31, 2022 or (b) the receipt by the Company of debt or equity financing of $3 million. In November 2022 Mr. Anderson signed a waiver and extension agreement changing the due date to April 30, 2023 and in April 2023 Mr. Anderson agreed to extend the due date to August 31, 2023. The balance outstanding on March 31, 2023 was $12,500.

 

On July 28, 2022, the Company issued a convertible promissory note to Letzhangout, LLC, a company that provides accounting consulting services to NovAccess and also employs our chief financial officer, Neil J. Laird. Pursuant to the note, Letzhangout loaned the Company $12,500 on July 29, 2022. All amounts outstanding under this agreement were payable on the earlier of: (a) October 31, 2022, or (b) the receipt by the Company of debt or equity financing of $3 million. In November 2022, the holder agreed to extend the term of the note until April 2023 and in April 2023 agreed to extend the due date to August 31, 2023. The holder has the right, until the date of payment in full. to convert all amounts outstanding under the note and unpaid principal and interest and any other amounts into fully paid shares of common stock of the Company at conversion price of $0. 15. As of March 31, 2023, the balance of the July 2022 Note was $12,500.

 

On January 31, 2022, the Company entered into a preferred stock redemption agreement with Daniel G. Martin, at the time our sole board member and chairman, TN3, LLC, a company owned by Mr. Martin, Dwain K. Irvin, our chief executive officer, and Irvin Consulting, LLC, a company owned by Dr. Irvin. TN3 owned 25,000 shares of the Series B convertible preferred stock. Pursuant to the redemption agreement, on March 14, 2022, NovAccess redeemed 24,400 of the preferred shares and Irvin Consulting purchased 600 of the preferred shares from TN3.

 

Upon completion of the redemption transaction, the Company was obligated to pay to TN3 a total of $250,000 over a period of eleven months, with payment accelerated if the Company raises at least $2.5 million of equity capital. As of March 31, 2023, the Company owed TN3 $95,000 of the redemption price. Pursuant to the redemption agreement, the Company also issued to TN3 1,502,670 shares of unregistered common stock, which was equal to 10% of our outstanding common stock on the date the redemption agreement was signed. Upon completion of the redemption transaction, Mr. Martin resigned from the NovAccess board and was replaced by John A. Cassarini and Dr. Irvin.

 

Also in connection with closing the redemption transaction, on March 14, 2022, the Company entered into a common stock distribution agreement with Innovest Global, Inc. Innovest acquired 7.5 million shares of the Company’s common stock when Innovest sold StemVax, LLC to NovAccess in September 2020. Pursuant to the stock distribution agreement, Innovest agreed to distribute its NovAcess common stock to Innovest’s shareholders. Innovest is currently in the process of effectuating the distribution.

 

In December 2021, the Company’s CEO and CFO each advanced funds to the Company for operating expenses in the total amount of $25,000 each. The notes were payable on demand with a five business-day written notice and bore interest at a rate of 10% per annum. The Company could prepay all or any part of the balance owed without penalty. On January 25, 2022, the Company issued 125,000 shares of its common stock in settlement of a bridge loan to the Company’s CFO and recognized a loss on extinguishment of debt in the amount of $17,313. Any potential gain would not have been recognized on extinguishment of this loan due to the nature of the relationship between the parties. The Company recognized and paid interest expense in the amount of $237 to our CFO during the year ended September 30, 2022. No balance is due to our CFO as March 31, 2023. In March, 2022, our CEO purchased 600 shares of Series B Preferred stock and the Company applied $18,616 of the loan balance against this purchase. The remaining balance of $6,384 was paid to our CEO in several payments with the final balance being paid in May, 2022. The Company recognized and paid interest expense in the amount of $583 to our CEO during the year ended March 31, 2023. No balance is due to our CEO as of March 31, 2023.

 

On September 4, 2020, the Company entered into a management services agreement with TN3, LLC. Pursuant to the agreement, TN3 provided the Company with office space in Chesterland, Ohio and management, administrative, marketing, bookkeeping and IT services for a fee of $30,000 a month. The initial term of the agreement was three years, with subsequent one-year renewals. We paid TN3 $40,000 under the agreement in fiscal 2022. In connection with the redemption of TN3’s preferred shares, the management services agreement was terminated and outstanding amounts cancelled, and as of March 31, 2023 there were no amounts owed under this agreement.

XML 29 R20.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS
6 Months Ended
Mar. 31, 2023
Subsequent Events [Abstract]  
Subsequent Events [Text Block]

14. SUBSEQUENT EVENTS

 

On April 11, 2023, the Company entered into a securities purchase agreement (the “SPA”) with a lender and issued a convertible promissory note in the original principal amount of $79,250 (the “note”) pursuant to the SPA. The loan funded on April 14, 2023. The Company will use the proceeds of the loan for general working capital purposes.

 

The Company provided typical representations and agreed to standard covenants pursuant to the SPA. The SPA does not include any financial covenants.

 

The note bears interest at 8% a year and is due on April 11, 2024. The Company may prepay the note upon payment of a prepayment penalty ranging from 15-25% of the amount outstanding on the note when prepaid. Under the terms of the note, the Company may not sell a significant portion of its assets without the approval of the lender, must comply with the company’s reporting requirements under the Securities Exchange Act of 1934, and must maintain the listing of the Company’s common stock on the OTCQB Market or other exchange. The Company’s failure to comply with any of these covenants, among other matters, would constitute an event of default. Upon an event of default, the note will bear interest at 22% and the lender will be entitled to its costs of collection.

 

Beginning on October 8, 2023, the lender may convert the amount outstanding under the note into shares of the Company’s common stock at a conversion price equal to 65% of the average of the three lowest trading prices of the stock during the fifteen trading days before the conversion date.

 

On April 24, 2023, the Company entered into a securities purchase agreement (the “SPA”) with a lender and issued a convertible promissory note in the original principal amount of $54,250 (the “note”) to the lender pursuant to the SPA. The loan funded on April 28, 2023. The Company will use the proceeds of the loan for general working capital purposes.

 

The note bears interest at 8% a year and is due on April 24, 2024. The Company may prepay the note upon payment of a prepayment penalty ranging from 15-25% of the amount outstanding on the note when prepaid. Under the terms of the note, the Company may not sell a significant portion of its assets without the approval of 1800 Diagonal Lending, must comply with the Company’s reporting requirements under the Securities Exchange Act of 1934, and must maintain the listing of the Company’s common stock on the OTCQB Market or other exchange. The Company’s failure to comply with any of these covenants, among other matters, would constitute an event of default. Upon an event of default, the note will bear interest at 22% and the lender will be entitled to its costs of collection.

 

Beginning on October 21, 2023, the lender may convert the amount outstanding under the note into shares of the Company’s common stock at a conversion price equal to 65% of the average of the three lowest trading prices of the stock during the fifteen trading days before the conversion date.

 

The Company did not make the payment of $1,584,260 including principal and interest, due on May 9, 2023 on the notes issued on Feb 2022, May 2022 and Feb 2023. The lender has agreed to waive the default provisions until June 1, 2023, or pending conclusion of negotiations on an extension of the loans.

XML 30 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Accounting Policies, by Policy (Policies)
6 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary StemVax, LLC. All significant inter-company accounts and transactions between these entities have been eliminated in these consolidated financial statements.

 

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying consolidated financial statements. Significant estimates made in preparing these consolidated financial statements include the estimate of the deferred tax valuation allowance, the fair value of stock options, and derivative liabilities. Actual results could differ from those estimates.

 

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

For purposes of the statements of cash flows, cash and cash equivalents include cash in banks and money markets with an original maturity of three months or less.

 

Share-Based Payment Arrangement [Policy Text Block]

Stock-Based Compensation

Share-based Payment applies to transactions in which an entity exchanges its equity instruments for goods or services and also applies to liabilities an entity may incur for goods or services that are to follow a fair value of those equity instruments. We are required to follow a fair value approach using an option-pricing model, such as the Binomial lattice valuation model, at the date of a stock option grant. The deferred compensation calculated under the fair value method would then be amortized over the respective vesting period of the stock option. This has not had a material impact on our results of operations.

 

Earnings Per Share, Policy [Policy Text Block]

Net Earnings (Loss) per Share Calculations

Net earnings (Loss) per share dictates the calculation of basic earnings (loss) per share and diluted earnings (loss) per share. Basic earnings (loss) per share are computed by dividing by the weighted average number of common shares outstanding during the period. Diluted net earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the effect of stock options and stock-based awards plus the assumed conversion of convertible debt (see notes 4 and 5). 

 

   

For the three months ended

   

For the Six months ended

 
   

March 31,

   

March 31,

 
   

2023

   

2022

   

2023

      2022  
                                 

Income (Loss) to common shareholders (Numerator)

  $ 409,523       (1,229,785 )   $ (2,221,883 )     (1,373,093 )
                                 

Basic weighted average number of common shares outstanding (Denominator)

    20,698,747       15,379,289       19,832,524       14,914,920  
                                 

Diluted weighted average number of common shares outstanding

    39,680,653       15,379,289       19,832,524,       14,914,920  

 

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

Fair Value of Financial Instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of March 31, 2023, the balances reported for cash, prepaid expenses, accounts payable, accrued expenses approximate the fair value because of their short maturities.

 

We adopted Accounting Standards Codification (“ASC”) Topic 820 for financial instruments measured as fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States and expands disclosures about fair value measurements.

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:

 

 

Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;

 

 

Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

 

 

Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

We measure certain financial instruments at fair value on a recurring basis. The Company had no assets that are required to be valued on a recurring basis as of March 31, 2023 and September 30, 2022. The Company had liabilities that are required to be measured at fair value on a recurring basis as follows at March 31 2023 and September 30, 2022:

 

   

Total

   

(Level 1)

   

(Level 2)

   

(Level 3)

 
                                 

Assets:

  $ -     $ -     $ -     $ -  
                                 

Liabilities:

                               
                                 

Derivative Liability at fair value as of September 30, 2022

  $ 1,207,403     $ -     $ -     $ 1,207,403  

Derivative Liability warrants at fair value as of September 30, 2022

  $ 232,609     $ -     $ -     $ 232,609  

Total Derivative Liability as of September 30, 2022

  $ 1,440,012       -       -     $ 1,440,012  

Derivative Liability at fair value as of March 31, 2023

  $ 1,211,565       -       -     $ 1,211,565  

Derivative Liability warrants at fair value as of March 31, 2023

  $ 557,694       -       -     $ 557,694  

Total Derivative Liability as of March 31, 2023

  $ 1,769,259       -       -     $ 1,769,259  

 

The following is a reconciliation of the derivative liability for which Level 3 inputs were used in determining the approximate fair value:

 

   

Derivative Liability

Promissory Notes

   

Derivative

Liability Warrants

   

Total

Derivative Liability

 

Balance as of September 30, 2021

  $ 2,553,979     $ 372,643     $ 2,926,622  

Fiscal year 2022 initial derivative liabilities

    593,297       282,051       875,348  

Net (Gain)/Loss on change in fair value of derivative liability

    (1,662,156

)

    (422,086

)

    (2,084,242

)

Extinguishment of derivative

    (277,716

)

    -       (277,716 )

Ending balance as of September 30, 2022

  $ 1,207,403     $ 232,609     $ 1,440,012  

Six Months ended March 31, 2023, initial derivative liabilities

    212,256       -       212,256  

Net (Gain)/Loss on change in fair value of derivative liability

    (69,231 )     325,085       255,854  

Extinguishment of derivative

    (138,863 )     -       (138,863 )

Ending balance as of March 31, 2023

  $ 1,211,565     $ 557,694     $ 1,769,259  

 

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

In September 2022, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2022-04, "Liabilities-Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations". This guidance requires annual and interim disclosures for entities that use supplier finance programs in connection with the purchase of goods and services. The ASU is effective for fiscal years beginning after December 15, 2022, with early adoption permitted, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 15, 2023. We are currently evaluating the extent of the impact of this ASU, but do not expect the adoption of this standard to have a significant impact on our consolidated financial statements.

 

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sales Restrictions, which (1) clarifies the guidance in Topic 820 on the fair value measurement of an equity security that is subject to contractual restrictions that prohibit the sale of an equity security and (2) requires specific disclosures related to such an equity security. We are currently evaluating the extent of the impact of this ASU, but do not expect the adoption of this standard to have a significant impact on our consolidated financial statements.

 

In March 2022, the FASB issued ASU No. 2022-02, Troubled Debt Restructurings and Vintage Disclosures ("ASU 2022-02"). ASU 2022-02 eliminates the accounting guidance on troubled debt restructurings for creditors in ASC Topic 310 and amends the guidance on "vintage disclosures" to require disclosure of current-period gross write-offs by year of origination. ASU 2022-02 also updates the requirements related to accounting for credit losses under ASC Topic 326 and adds enhanced disclosures for creditors with respect to loan refinancings and restructurings for borrowers experiencing financial difficulty. ASU 2022-02 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We are currently evaluating the extent of the impact of this ASU, but do not expect the adoption of this standard to have a significant impact on our consolidated financial statements.

 

Management does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

XML 31 R22.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
6 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

Net earnings (Loss) per share dictates the calculation of basic earnings (loss) per share and diluted earnings (loss) per share. Basic earnings (loss) per share are computed by dividing by the weighted average number of common shares outstanding during the period. Diluted net earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the effect of stock options and stock-based awards plus the assumed conversion of convertible debt (see notes 4 and 5). 

 

   

For the three months ended

   

For the Six months ended

 
   

March 31,

   

March 31,

 
   

2023

   

2022

   

2023

      2022  
                                 

Income (Loss) to common shareholders (Numerator)

  $ 409,523       (1,229,785 )   $ (2,221,883 )     (1,373,093 )
                                 

Basic weighted average number of common shares outstanding (Denominator)

    20,698,747       15,379,289       19,832,524       14,914,920  
                                 

Diluted weighted average number of common shares outstanding

    39,680,653       15,379,289       19,832,524,       14,914,920  

 

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

We measure certain financial instruments at fair value on a recurring basis. The Company had no assets that are required to be valued on a recurring basis as of March 31, 2023 and September 30, 2022. The Company had liabilities that are required to be measured at fair value on a recurring basis as follows at March 31 2023 and September 30, 2022:

 

   

Total

   

(Level 1)

   

(Level 2)

   

(Level 3)

 
                                 

Assets:

  $ -     $ -     $ -     $ -  
                                 

Liabilities:

                               
                                 

Derivative Liability at fair value as of September 30, 2022

  $ 1,207,403     $ -     $ -     $ 1,207,403  

Derivative Liability warrants at fair value as of September 30, 2022

  $ 232,609     $ -     $ -     $ 232,609  

Total Derivative Liability as of September 30, 2022

  $ 1,440,012       -       -     $ 1,440,012  

Derivative Liability at fair value as of March 31, 2023

  $ 1,211,565       -       -     $ 1,211,565  

Derivative Liability warrants at fair value as of March 31, 2023

  $ 557,694       -       -     $ 557,694  

Total Derivative Liability as of March 31, 2023

  $ 1,769,259       -       -     $ 1,769,259  

 

Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

The following is a reconciliation of the derivative liability for which Level 3 inputs were used in determining the approximate fair value:

 

   

Derivative Liability

Promissory Notes

   

Derivative

Liability Warrants

   

Total

Derivative Liability

 

Balance as of September 30, 2021

  $ 2,553,979     $ 372,643     $ 2,926,622  

Fiscal year 2022 initial derivative liabilities

    593,297       282,051       875,348  

Net (Gain)/Loss on change in fair value of derivative liability

    (1,662,156

)

    (422,086

)

    (2,084,242

)

Extinguishment of derivative

    (277,716

)

    -       (277,716 )

Ending balance as of September 30, 2022

  $ 1,207,403     $ 232,609     $ 1,440,012  

Six Months ended March 31, 2023, initial derivative liabilities

    212,256       -       212,256  

Net (Gain)/Loss on change in fair value of derivative liability

    (69,231 )     325,085       255,854  

Extinguishment of derivative

    (138,863 )     -       (138,863 )

Ending balance as of March 31, 2023

  $ 1,211,565     $ 557,694     $ 1,769,259  

 

XML 32 R23.htm IDEA: XBRL DOCUMENT v3.23.1
CONVERTIBLE PROMISSORY NOTES (Tables)
6 Months Ended
Mar. 31, 2023
CONVERTIBLE PROMISSORY NOTES (Tables) [Line Items]  
Schedule of Debt [Table Text Block]

Convertible Promissory notes

as on March 31, 2023

 

Principal Amount

   

Unamortized balance of Debt Discount

   

Outstanding balance as on March 31, 2023

   

Derivative balance as on March 31, 2023

   

Warrant liability balance as on March 31, 2023

 
                                         

2013 Note

    12,000       -       12,000       -       -  

2014 Note

    50,880       -       50,880       215,591       -  

2017 Note

    115,000       -       115,000       453,384       -  

August 2021 Note

    -       -       -       -       151,920  

February 2022 Note

    250,000       -       250,000       81,815       76,762  

May 2022 Note

    1,000,000       -       1,000,000       245,784       171,753  

August 2022 Note

    100,000       27,517       72,483       48,797       -  

November 2022 Note

    55,000       32,937       22,063       48,883       -  

December 2022 Note

    55,000       37,207       17,793       49,719       -  

February 2023 Note

    265,000       60,146       204,854       63,650       157,259  

Total

    1,902,880       157,807       1,745,073       1,207,624       557,694  

 

Convertible Promissory note,

related party as on March 31, 2023

 

Principal Amount

   

Unamortized balance of Debt Discount

   

Outstanding balance as on March 31, 2023

   

Derivative balance as on March 31, 2023

   

Warrant liability balance as on March 31, 2023

 
                                         

July 2022 Note

    12,500       -       12,500       3,941       -  

 

Convertible Debt [Member]  
CONVERTIBLE PROMISSORY NOTES (Tables) [Line Items]  
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

For purpose of determining the fair market value of the derivative liability for the embedded conversion, the Company used Binomial lattice valuation model. The significant assumptions used in the Binomial lattice valuation of the derivatives are as follows:

 

Risk free interest rate

 

Between 4.74% and 4.955%

Stock volatility factor

 

Between 141% and 177.6%

Years to Maturity

 

0.28 years

Expected dividend yield

 

None

XML 33 R24.htm IDEA: XBRL DOCUMENT v3.23.1
WARRANTS (Tables)
6 Months Ended
Mar. 31, 2023
Warrant [Member]  
WARRANTS (Tables) [Line Items]  
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

For the purpose of determining the fair market value of the derivative liability for the embedded conversion, the Company used the Binomial lattice valuation model. The significant assumptions used in the Binomial lattice valuation of the derivatives are as follows:

 

Risk free interest rate

 

Between 3.6% and 3.81%

Stock volatility factor

 

Between 147% and 164%

Years to Maturity

 

4.25 years

Expected dividend yield

 

None

 

XML 34 R25.htm IDEA: XBRL DOCUMENT v3.23.1
OPTIONS (Tables)
6 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

For purpose of determining the fair market value of the options issued on June 2, 2020, the Company used the Black Scholes valuation model. The significant assumptions used in the Black Scholes valuation model for the options are as follows:

 

Risk Free Interest Rate

 

0.32%

Stock Volatility Factor

 

146.0%

Weighted Average Expected Option Life

 

5 Years

Expected Dividend Yield

 

None

 

Risk Free Interest Rate

 

3.68%

Stock Volatility Factor

 

146.79%

Weighted Average Expected Option Life

 

5 Years

Expected Dividend Yield

 

None

 

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

A summary of the Company’s options activity and related information follows for the quarter ended March 31, 2023:

 

   

 March 31, 2023

 
           

Weighted

 
   

Number

   

average

 
   

Of

   

exercise

 
   

Options

   

price

 

Outstanding - beginning of period

    2,000,000     $ .01  

Granted

    3,542,857     $ 0.175  

Exercised

    -     $ -  

Forfeited

    -     $ -  

Outstanding - end of period

    5,542,857     $ 0.115  

 

Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]

At March 31, 2023, the weighted average remaining contractual life of options outstanding:

 

 

 

 

 

 

 March 31, 2023

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Average

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Remaining

 

 

Exercisable

 

 

Options

 

 

Options

 

 

Contractual

 

 

Prices

 

 

Outstanding

 

 

Exercisable

 

 

Life (years)

 

 

$

.01

 

 

 

2,000,000

 

 

 

2,000,000

 

 

 

7.17

 

 

$

0.175

     

3,542,857

     

3,542,857

     

9.95

 

 

XML 35 R26.htm IDEA: XBRL DOCUMENT v3.23.1
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)
6 Months Ended
Mar. 31, 2023
Payables and Accruals [Abstract]  
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]

Accrued expenses and accrued other current liabilities consisted of the following at March 31, 2023 and September 30, 2022:

 

   

March 31, 2023

   

September 30, 2022

 

Accrued liabilities

    5,570       4,370  

Interest payable

    159,506       94,251  

Provision for guaranteed commitment fees *

    886,875       961,000  

Accrued payroll

    7,367       4,740  

Deferred compensation

    485,421       344,983  

License Fees Payable

    40,402       40,402  

Insurance finance liability

    69,133       36,815  
    $ 1,654,274     $ 1,486,561  

 

* Under the terms of the August 2021 Note, February 2022 Note, May 2022 Note and February 2023 Note the Company issued a total of 2,075,000 shares of common stock as commitment fees. If the lender is unable to sell the shares for more than $1,250,000, it may make a one-time claim for each note to be reimbursed for the difference between their sale proceeds and $1,250,000. The difference between the fair value of the 2,075,000 shares as on March 31, 2023 and the exercise amount of $1,250,000 was recorded as a provision for guaranteed commitment fees and included in the table above.

XML 36 R27.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION AND LINE OF BUSINESS (Details)
Aug. 25, 2020
Accounting Policies [Abstract]  
Stockholders' Equity, Reverse Stock Split 1-for-1,000
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Earnings Per Share, Basic and Diluted - USD ($)
3 Months Ended 6 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Schedule Of Earnings Per Share Basic And Diluted Abstract        
(Loss) to common shareholders (Numerator) (in Dollars) $ 409,523 $ (1,229,785) $ (2,221,883) $ (1,373,093)
Basic weighted average number of common shares outstanding (Denominator) 20,698,747 15,379,289 19,832,524 14,914,920
Diluted weighted average number of common shares outstanding (Denominator) 39,680,653 15,379,289 19,832,524 14,914,920
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis - USD ($)
Mar. 31, 2023
Sep. 30, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Assets:   $ 0
Derivative Liability at fair value $ 1,211,565 1,207,403
Derivative Liability warrants at fair value 557,694 232,609
Total Derivative Liability 1,769,259 1,440,012
Fair Value, Inputs, Level 1 [Member]    
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Assets:   0
Derivative Liability at fair value 0 0
Derivative Liability warrants at fair value 0 0
Total Derivative Liability 0 0
Fair Value, Inputs, Level 2 [Member]    
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Assets:   0
Derivative Liability at fair value 0 0
Derivative Liability warrants at fair value 0 0
Total Derivative Liability 0 0
Fair Value, Inputs, Level 3 [Member]    
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Assets:   0
Derivative Liability at fair value 1,211,565 1,207,403
Derivative Liability warrants at fair value 557,694 232,609
Total Derivative Liability $ 1,769,259 $ 1,440,012
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation - USD ($)
6 Months Ended 12 Months Ended
Mar. 31, 2023
Sep. 30, 2022
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Balance $ 1,440,012 $ 2,926,622
Initial derivative liabilities 212,256 875,348
Net (Gain)/Loss on change in fair value of derivative liability 255,854 (2,084,242)
Extinguishment of derivative (138,863) (277,716)
Balance 1,769,259 1,440,012
Fair Value, Inputs, Level 3 [Member]    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Balance 1,207,403 2,553,979
Initial derivative liabilities 212,256 593,297
Net (Gain)/Loss on change in fair value of derivative liability (69,231) (1,662,156)
Extinguishment of derivative (138,863) (277,716)
Balance 1,211,565 1,207,403
Fair Value, Inputs, Level 3 [Member] | Embedded Derivative Financial Instruments [Member]    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Balance 232,609 372,643
Initial derivative liabilities 0 282,051
Net (Gain)/Loss on change in fair value of derivative liability 325,085 (422,086)
Extinguishment of derivative 0 0
Balance $ 557,694 $ 232,609
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.23.1
CAPITAL STOCK (Details) - USD ($)
1 Months Ended 6 Months Ended
Mar. 14, 2022
Jan. 25, 2022
Sep. 04, 2020
Aug. 25, 2020
Mar. 31, 2022
Dec. 31, 2021
Mar. 31, 2023
Mar. 31, 2022
Sep. 30, 2022
CAPITAL STOCK (Details) [Line Items]                  
Common Stock, Shares Authorized             2,000,000,000   2,000,000,000
Stockholders' Equity, Reverse Stock Split       1-for-1,000          
Preferred Stock, Shares Authorized             50,000,000    
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)             $ 0.01   $ 0.01
Conversion of Stock, Shares Issued 1,502,670           1,502,670 1,502,670  
Stock Issued During Period, Shares, Other               300,000  
Stock Issued During Period, Shares, Period Increase (Decrease)             2,515,521 3,119,643  
Stock Issued During Period, Shares, Issued for Services             1,490,521 265,973  
Stock Issued During Period, Value, Issued for Services (in Dollars)             $ 259,702 $ 119,480  
Debt Conversion, Converted Instrument, Shares Issued   125,000       125,000 500,000 250,000  
Stock Subscriptions [Member]                  
CAPITAL STOCK (Details) [Line Items]                  
Stock Issued During Period, Value, Issued for Services (in Dollars)             $ 259,702    
Stock Issued During Period, Shares, New Issues             525,000 791,000  
Series B Preferred Stock [Member]                  
CAPITAL STOCK (Details) [Line Items]                  
Preferred Stock, Shares Authorized             25,000   25,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)     $ 0.01            
Preferred Stock, Shares Outstanding             600    
Conversion of Stock, Shares Issued     25,000            
Preferred Stock, Voting Rights     Each share of outstanding Series B Preferred Stock entitles the holder to cast 40,000 votes.            
Preferred Stock, Conversion Basis     Each share of Series B Preferred Stock is convertible at the option of the holder into 10,000 common shares            
Stock Issued During Period, Shares, New Issues         600        
Conversion of Stock, Shares Converted               24,400  
TN3, LLC [Member] | Series B Preferred Stock [Member]                  
CAPITAL STOCK (Details) [Line Items]                  
Stock Issued During Period, Shares, Other 24,400                
TN3, LLC [Member] | Series B Preferred Stock [Member] | Irvin Consulting, LLC ("IC") [Member]                  
CAPITAL STOCK (Details) [Line Items]                  
Stock Issued During Period, Shares, Other 600                
Related Party [Member]                  
CAPITAL STOCK (Details) [Line Items]                  
Stock Issued During Period, Shares, Issued for Services             216,500    
Stock Issued During Period, Shares, New Issues               10,000  
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.23.1
CONVERTIBLE PROMISSORY NOTES (Details) - USD ($)
1 Months Ended 2 Months Ended 6 Months Ended 19 Months Ended
Mar. 12, 2023
Feb. 09, 2023
Dec. 07, 2022
Nov. 01, 2022
Sep. 22, 2022
Aug. 08, 2022
Jul. 28, 2022
May 10, 2022
May 05, 2022
Feb. 16, 2022
Feb. 15, 2022
Aug. 20, 2021
Jul. 06, 2021
May 28, 2021
May 10, 2017
Nov. 20, 2014
Nov. 30, 2022
Dec. 31, 2021
Sep. 18, 2017
Mar. 31, 2023
Mar. 31, 2022
Sep. 30, 2016
May 09, 2023
Sep. 30, 2022
Oct. 01, 2013
CONVERTIBLE PROMISSORY NOTES (Details) [Line Items]                                                  
Debt Instrument, Face Amount             $ 12,500                         $ 1,902,880         $ 12,000
Debt Instrument, Convertible, Conversion Price (in Dollars per share)                                                 $ 4.5
Debt Instrument, Fee Amount                                                 $ 1,200
Debt Instrument, Interest Rate, Stated Percentage                                   10.00%              
Proceeds from Convertible Debt                                       (79,250) $ (94,250)        
Convertible Debt                                       1,745,073          
Class of Warrant or Rights, Granted (in Shares)   1,000,000           1,000,000                                  
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)   $ 0.2           $ 0.01     $ 1.5                            
Stock Issued During Period, Shares, Other (in Shares)                                         300,000        
Debt Instrument, Unamortized Discount                                       157,807          
Stock Issued During Period, Value, Other                                       82,500 $ 111,000        
Fair Value Adjustment of Warrants   $ 44,241                                              
Debt Instrument, Debt Default, Amount                                             $ 271,551    
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net                                       157,807       $ 340,503  
Debt Instrument, Maturity Date, Description             The loan terms required repayment of all amounts outstanding under the loan on the earlier of: (a) October 31, 2022 or (b) the receipt by the Company of debt or equity financing of $3 million                     The notes were payable on demand with a five business-day written notice              
Debt Instrument, Maturity Date                                 Apr. 30, 2023                
September 2022 Note [Member]                                                  
CONVERTIBLE PROMISSORY NOTES (Details) [Line Items]                                                  
Debt Instrument, Maturity Date         Sep. 22, 2023                                        
May Note [Member                                                  
CONVERTIBLE PROMISSORY NOTES (Details) [Line Items]                                                  
Debt Instrument, Face Amount                           $ 55,500                      
Debt Instrument, Interest Rate, Stated Percentage                           12.00%                      
Debt Instrument, Convertible, Terms of Conversion Feature                           The May 2021 Note was convertible after November 23, 2021, by the lender into shares of common stock of the Company at sixty-one percent (61%) of the lowest traded price of common stock recorded during the fifteen (15) trading days prior to conversion.                      
Convertible Debt                                       0          
July Note [Member]                                                  
CONVERTIBLE PROMISSORY NOTES (Details) [Line Items]                                                  
Debt Instrument, Face Amount                         $ 38,750                        
Debt Instrument, Interest Rate, Stated Percentage                         12.00%                        
Debt Instrument, Convertible, Terms of Conversion Feature                         The July 2021 Note was convertible after January 1, 2022, by the lender into shares of common stock of the Company at sixty-one percent (61%) of the lowest trade price of common stock recorded during the fifteen (15) trading days prior to conversion.                        
Convertible Debt                                       0          
August Note [Member]                                                  
CONVERTIBLE PROMISSORY NOTES (Details) [Line Items]                                                  
Debt Instrument, Face Amount                       $ 500,000               0          
Debt Instrument, Interest Rate, Stated Percentage                       10.00%                          
Debt Instrument, Convertible, Terms of Conversion Feature                       The August 2021 Note could be converted, only following an event of default, by the lender into shares of common stock of the Company at the lesser of 90% (representing a 10% discount) multiplied by the lowest trading price during the previous twenty (20) trading day period ending on the issuance date, or during the previous twenty (20) trading day period.                          
Convertible Debt                                       0          
Class of Warrant or Rights, Granted (in Shares)                       1,000,000                          
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)   $ 0.2                   $ 1.5                          
Stock Issued During Period, Shares, Other (in Shares)                       400,000                          
Debt Instrument, Unamortized Discount                                       0          
February Note [Member]                                                  
CONVERTIBLE PROMISSORY NOTES (Details) [Line Items]                                                  
Debt Instrument, Face Amount                     $ 250,000                 250,000          
Debt Instrument, Convertible, Conversion Price (in Dollars per share)   0.2                                              
Debt Instrument, Interest Rate, Stated Percentage                     10.00%                            
Debt Instrument, Convertible, Terms of Conversion Feature                     The February 2022 Note may be converted, only following an event of default, by the lender into shares of common stock of the Company at the lesser of 90% (representing a 10% discount) multiplied by the lowest trading price during the previous twenty (20) trading day period ending on the issuance date, or during the previous twenty (20) trading day period                            
Convertible Debt                                       250,000          
Class of Warrant or Rights, Granted (in Shares)                   500,000 500,000                            
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)   $ 0.2               $ 1.5                              
Stock Issued During Period, Shares, Other (in Shares)                     300,000                            
Debt Instrument, Unamortized Discount                     $ 25,000                 0          
Unamortized Debt Issuance Expense                     12,000                            
Stock Issued During Period, Value, Other                     $ 111,000                            
Fair Value Adjustment of Warrants   $ 44,241                                              
Debt Instrument, Debt Default, Amount                                             258,958    
May 2022 Note [Member]                                                  
CONVERTIBLE PROMISSORY NOTES (Details) [Line Items]                                                  
Debt Instrument, Face Amount                 $ 1,000,000                     1,000,000          
Debt Instrument, Interest Rate, Stated Percentage                 12.00%                                
Debt Instrument, Convertible, Terms of Conversion Feature                 The May 2022 Note may be converted, only following an event of default, by the lender into shares of common stock of the Company at the lesser of the lowest trading price during the previous twenty (20) trading day period ending on the issuance date, or during the previous twenty (20) trading day period before conversion                                
Convertible Debt                                       1,000,000          
Class of Warrant or Rights, Granted (in Shares)                 1,000,000                                
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)                 $ 0.01                                
Stock Issued During Period, Shares, Other (in Shares)                 875,000                                
Debt Instrument, Unamortized Discount                 $ 100,000                     0          
Unamortized Debt Issuance Expense                 25,500                                
Stock Issued During Period, Value, Other                 $ 259,875                                
Debt Instrument, Debt Default, Amount                                             $ 1,053,750    
Debt Instrument, Description                 If extended, the interest rate increased to 15% for the remaining six months                                
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net                 $ 282,051                                
August 2022 Note [Member]                                                  
CONVERTIBLE PROMISSORY NOTES (Details) [Line Items]                                                  
Debt Instrument, Face Amount           $ 100,000                           100,000          
Debt Instrument, Convertible, Conversion Price (in Dollars per share)           $ 0.15                                      
Debt Instrument, Interest Rate, Stated Percentage           12.00%                                      
Convertible Debt                                       72,483          
Debt Instrument, Unamortized Discount                                       27,517          
Debt Instrument, Maturity Date, Description           The August 2022 Note matures on August 8, 2023, provided, however that after October 31, 2022, if the Company receives debt or equity financing of at least $3 million, the holder may call for payments of outstanding principal and interest at any time from such date giving notice of at least five business days before the date the payment is due                                      
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances           $ 77,259                                      
September 2022 Note [Member]                                                  
CONVERTIBLE PROMISSORY NOTES (Details) [Line Items]                                                  
Debt Instrument, Face Amount         $ 79,250                                        
Debt Instrument, Fee Amount $ 20,594                                                
Debt Instrument, Interest Rate, Stated Percentage         8.00%                                        
Debt Instrument, Convertible, Terms of Conversion Feature         The holder shall have the right, after six months, until the date of payment in full of all amounts outstanding to convert unpaid principal and interest and any other amounts into fully paid shares of common stock of the Company at a variable conversion price equal to 65% multiplied by the market price. Market price means the average of the three lowest trading prices for the Common Stock during the fifteen-trading day period ending on the latest complete trading day prior to the conversion date.                                        
Convertible Debt                                       0          
Debt Instrument, Unamortized Discount                                       0          
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances         $ 75,000                                        
Debt Instrument, Unamortized Discount, Noncurrent         $ 4,250                             27,517          
Debt, Default Interest Rate         22.00%                                        
Repayments of Debt $ 3,127                                                
November 2022 Note [Member]                                                  
CONVERTIBLE PROMISSORY NOTES (Details) [Line Items]                                                  
Debt Instrument, Face Amount       $ 55,000                               55,000          
Debt Instrument, Interest Rate, Stated Percentage       8.00%                                          
Debt Instrument, Convertible, Terms of Conversion Feature       Beginning on April 30, 2023, 1800 Diagonal Lending may convert the amount outstanding under the note into shares of NovAccess common stock at a conversion price equal to 65% of the average of the three lowest trading prices of the stock during the fifteen trading days before the conversion date.                                          
Convertible Debt                                       22,063          
Debt Instrument, Unamortized Discount                                       32,937          
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances       $ 50,700                                          
Debt Instrument, Unamortized Discount, Noncurrent       $ 4,250                               32,938          
Debt Instrument, Maturity Date       Nov. 01, 2023                                          
Debt, Default Interest Rate       22.00%                                          
December 2022 Note [Member]                                                  
CONVERTIBLE PROMISSORY NOTES (Details) [Line Items]                                                  
Debt Instrument, Face Amount     $ 55,000                                 55,000          
Debt Instrument, Interest Rate, Stated Percentage     8.00%                                            
Convertible Debt                                       17,793          
Debt Instrument, Unamortized Discount                                       37,207          
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances     $ 50,700                                            
Debt Instrument, Unamortized Discount, Noncurrent     $ 4,250                                 37,207          
Debt Instrument, Maturity Date     Dec. 07, 2023                                            
February 2023 Note [Member]                                                  
CONVERTIBLE PROMISSORY NOTES (Details) [Line Items]                                                  
Debt Instrument, Face Amount   265,000                                   265,000          
Debt Instrument, Fee Amount   $ 157,933                                              
Debt Instrument, Interest Rate, Stated Percentage   10.00%                                              
Convertible Debt                                       $ 204,854          
Class of Warrant or Rights, Granted (in Shares)   1,000,000                                              
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)   $ 0.2                                              
Stock Issued During Period, Shares, Other (in Shares)                                       500,000          
Debt Instrument, Unamortized Discount                                       $ 60,146          
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances   $ 110,576                                              
Debt Instrument, Unamortized Discount, Noncurrent   $ 26,500                                              
Debt Instrument, Maturity Date   May 09, 2023                                              
Debt, Discount Rate   10.00%                                              
Debt Instrument, Fee   If the investor is unable to sell the commitment fee shares for $0.20 a share, then investor may require the Company to issue additional shares or pay cash in the amount of the shortfall.                                              
February 2023 Note [Member] | Commitment Fee [Member]                                                  
CONVERTIBLE PROMISSORY NOTES (Details) [Line Items]                                                  
Debt Instrument, Fee Amount   $ 82,500                                              
Convertible Debt [Member]                                                  
CONVERTIBLE PROMISSORY NOTES (Details) [Line Items]                                                  
Debt Instrument, Face Amount                             $ 150,000                    
Debt Instrument, Interest Rate, Stated Percentage                             10.00%                    
Debt Instrument, Convertible, Terms of Conversion Feature                                     The 2017 Note may be converted by the lender into shares of common stock of the Company at the lesser of $10 per share or (b) fifty percent (50%) of the lowest traded price of common stock recorded on any trade day after the effective date, or (c) the lowest effective price per share granted to any person or entity            
Proceeds from Convertible Debt                             $ 25,000       $ 90,000            
Convertible Debt                                       115,000          
Convertible Debt [Member] | Convertible Note Payable Two [Member]                                                  
CONVERTIBLE PROMISSORY NOTES (Details) [Line Items]                                                  
Debt Instrument, Face Amount                               $ 400,000                  
Debt Instrument, Interest Rate, Stated Percentage                               10.00%                  
Debt Instrument, Term                               18 months                  
Debt Instrument, Convertible, Terms of Conversion Feature                               The 2014 Note may be converted by the lender into shares of common stock of the Company at the lesser of $12.50 per share or (b) fifty percent (50%) of the lowest traded prices following issuance of the 2014 Note or (c) the lowest effective price per share granted to any person or entity                  
Proceeds from Convertible Debt                               $ 50,000           $ 350,000      
Convertible Debt                                       $ 50,880          
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.23.1
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt - USD ($)
Mar. 31, 2023
Feb. 09, 2023
Dec. 07, 2022
Nov. 01, 2022
Sep. 30, 2022
Aug. 08, 2022
Jul. 28, 2022
May 05, 2022
Feb. 15, 2022
Aug. 20, 2021
Oct. 01, 2013
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Principal Amount $ 1,902,880           $ 12,500       $ 12,000
Unamortized balance of Debt Discount 157,807                    
Outstanding balance 1,745,073                    
Derivative balance 1,769,259       $ 1,440,012            
Embedded Derivative Financial Instruments [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Derivative balance 1,207,624                    
Warrant [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Derivative balance 557,694                    
2013 Note [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Principal Amount 12,000                    
Unamortized balance of Debt Discount 0                    
Outstanding balance 12,000                    
2013 Note [Member] | Embedded Derivative Financial Instruments [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Derivative balance 0                    
2013 Note [Member] | Warrant [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Derivative balance 0                    
2014 Note [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Principal Amount 50,880                    
Unamortized balance of Debt Discount 0                    
Outstanding balance 50,880                    
2014 Note [Member] | Embedded Derivative Financial Instruments [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Derivative balance 215,591                    
2014 Note [Member] | Warrant [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Derivative balance 0                    
2017 Note [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Principal Amount 115,000                    
Unamortized balance of Debt Discount 0                    
Outstanding balance 115,000                    
2017 Note [Member] | Embedded Derivative Financial Instruments [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Derivative balance 453,384                    
2017 Note [Member] | Warrant [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Derivative balance 0                    
August Note [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Principal Amount 0                 $ 500,000  
Unamortized balance of Debt Discount 0                    
Outstanding balance 0                    
August Note [Member] | Embedded Derivative Financial Instruments [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Derivative balance 0                    
August Note [Member] | Warrant [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Derivative balance 151,920                    
February Note [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Principal Amount 250,000               $ 250,000    
Unamortized balance of Debt Discount 0               $ 25,000    
Outstanding balance 250,000                    
February Note [Member] | Embedded Derivative Financial Instruments [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Derivative balance 81,815                    
February Note [Member] | Warrant [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Derivative balance 76,762                    
May 2022 Note [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Principal Amount 1,000,000             $ 1,000,000      
Unamortized balance of Debt Discount 0             $ 100,000      
Outstanding balance 1,000,000                    
May 2022 Note [Member] | Embedded Derivative Financial Instruments [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Derivative balance 245,784                    
May 2022 Note [Member] | Warrant [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Derivative balance 171,753                    
August 2022 Note [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Principal Amount 100,000         $ 100,000          
Unamortized balance of Debt Discount 27,517                    
Outstanding balance 72,483                    
August 2022 Note [Member] | Embedded Derivative Financial Instruments [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Derivative balance 48,797                    
August 2022 Note [Member] | Warrant [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Derivative balance 0                    
November 2022 Note [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Principal Amount 55,000     $ 55,000              
Unamortized balance of Debt Discount 32,937                    
Outstanding balance 22,063                    
November 2022 Note [Member] | Embedded Derivative Financial Instruments [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Derivative balance 48,883                    
November 2022 Note [Member] | Warrant [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Derivative balance 0                    
December 2022 Note [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Principal Amount 55,000   $ 55,000                
Unamortized balance of Debt Discount 37,207                    
Outstanding balance 17,793                    
December 2022 Note [Member] | Embedded Derivative Financial Instruments [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Derivative balance 49,719                    
December 2022 Note [Member] | Warrant [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Derivative balance 0                    
February 2023 Note [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Principal Amount 265,000 $ 265,000                  
Unamortized balance of Debt Discount 60,146                    
Outstanding balance 204,854                    
February 2023 Note [Member] | Embedded Derivative Financial Instruments [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Derivative balance 63,650                    
February 2023 Note [Member] | Warrant [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Derivative balance 157,259                    
July 2022 Note [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Principal Amount             $ 12,500        
Unamortized balance of Debt Discount 0                    
Related Party [Member] | July 2022 Note [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Principal Amount 12,500                    
Unamortized balance of Debt Discount 0                    
Outstanding balance 12,500                    
Related Party [Member] | July 2022 Note [Member] | Embedded Derivative Financial Instruments [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Derivative balance 3,941                    
Related Party [Member] | July 2022 Note [Member] | Warrant [Member]                      
CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]                      
Derivative balance $ 0                    
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.23.1
CONVERTIBLE PROMISSORY NOTES (Details) - Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques - Embedded Derivative Financial Instruments [Member]
Mar. 31, 2023
Measurement Input, Expected Term [Member]  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Fair Value Measurement Input 0.28
Measurement Input, Expected Dividend Rate [Member]  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Fair Value Measurement Input 0
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Fair Value Measurement Input 4.74
Minimum [Member] | Measurement Input, Price Volatility [Member]  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Fair Value Measurement Input 141
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Fair Value Measurement Input 4.955
Maximum [Member] | Measurement Input, Price Volatility [Member]  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Fair Value Measurement Input 177.6
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.23.1
CONVERTIBLE PROMISSORY NOTE, RELATED PARTY (Details) - July 2022 Note [Member] - USD ($)
Jul. 28, 2022
Mar. 31, 2023
CONVERTIBLE PROMISSORY NOTE, RELATED PARTY (Details) [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage 12.00%  
Debt Instrument, Face Amount $ 12,500  
Debt Instrument, Maturity Date, Description the earlier of: (a) October 31, 2022, or (b) the receipt by the Company of debt or equity financing of $3 million  
Debt Instrument, Convertible, Conversion Price (in Dollars per share) $ 0.15  
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances $ 12,500  
Debt Instrument, Unamortized Discount   $ 0
Notes Payable, Current   $ 12,500
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.23.1
SHORT TERM LOAN, RELATED PARTY (Details) - USD ($)
1 Months Ended
Feb. 09, 2023
Jul. 28, 2022
Nov. 30, 2022
Dec. 31, 2021
Mar. 31, 2023
Oct. 01, 2013
SHORT TERM LOAN, RELATED PARTY (Details) [Line Items]            
Debt Instrument, Face Amount   $ 12,500     $ 1,902,880 $ 12,000
Debt Instrument, Maturity Date, Description   The loan terms required repayment of all amounts outstanding under the loan on the earlier of: (a) October 31, 2022 or (b) the receipt by the Company of debt or equity financing of $3 million   The notes were payable on demand with a five business-day written notice    
Debt Instrument, Maturity Date     Apr. 30, 2023      
Proceeds from Short-Term Debt $ 8,500          
Director [Member]            
SHORT TERM LOAN, RELATED PARTY (Details) [Line Items]            
Debt Instrument, Face Amount   $ 12,500        
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.23.1
WARRANTS (Details)
Feb. 09, 2023
USD ($)
$ / shares
shares
May 10, 2022
$ / shares
shares
Feb. 16, 2022
$ / shares
shares
Feb. 15, 2022
$ / shares
shares
Aug. 20, 2021
$ / shares
shares
Mar. 31, 2023
USD ($)
Sep. 30, 2022
USD ($)
WARRANTS (Details) [Line Items]              
Class of Warrant or Rights, Granted | shares 1,000,000 1,000,000          
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 0.2 $ 0.01   $ 1.5      
Adjustments to Additional Paid in Capital, Warrant Issued | $ $ 148,500            
Embedded Derivative, Fair Value of Embedded Derivative Liability | $           $ 557,694 $ 232,609
Class of Warrant or Right, Outstanding | shares 1,500,000            
Fair Value Adjustment of Warrants | $ $ 44,241            
Measurement Input, Expected Term [Member]              
WARRANTS (Details) [Line Items]              
Embedded Derivative Liability, Measurement Input           4.25  
Measurement Input, Expected Dividend Rate [Member]              
WARRANTS (Details) [Line Items]              
Embedded Derivative Liability, Measurement Input           0  
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]              
WARRANTS (Details) [Line Items]              
Embedded Derivative Liability, Measurement Input           3.81  
Maximum [Member] | Measurement Input, Price Volatility [Member]              
WARRANTS (Details) [Line Items]              
Embedded Derivative Liability, Measurement Input           164  
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]              
WARRANTS (Details) [Line Items]              
Embedded Derivative Liability, Measurement Input           3.6  
Minimum [Member] | Measurement Input, Price Volatility [Member]              
WARRANTS (Details) [Line Items]              
Embedded Derivative Liability, Measurement Input           147  
August Note [Member]              
WARRANTS (Details) [Line Items]              
Class of Warrant or Rights, Granted | shares         1,000,000    
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 0.2       $ 1.5    
February Note [Member]              
WARRANTS (Details) [Line Items]              
Class of Warrant or Rights, Granted | shares     500,000 500,000      
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 0.2   $ 1.5        
Fair Value Adjustment of Warrants | $ $ 44,241            
Warrant [Member]              
WARRANTS (Details) [Line Items]              
Share Price | $ / shares $ 0.165            
Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]              
WARRANTS (Details) [Line Items]              
Embedded Derivative Liability, Measurement Input 0            
Warrant [Member] | Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]              
WARRANTS (Details) [Line Items]              
Embedded Derivative Liability, Measurement Input 3.71            
Warrant [Member] | Maximum [Member] | Measurement Input, Price Volatility [Member]              
WARRANTS (Details) [Line Items]              
Embedded Derivative Liability, Measurement Input (159)            
Warrant [Member] | Maximum [Member] | Measurement Input, Expected Term [Member]              
WARRANTS (Details) [Line Items]              
Embedded Derivative Liability, Measurement Input 4.1            
Warrant [Member] | Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]              
WARRANTS (Details) [Line Items]              
Embedded Derivative Liability, Measurement Input 3.81            
Warrant [Member] | Minimum [Member] | Measurement Input, Price Volatility [Member]              
WARRANTS (Details) [Line Items]              
Embedded Derivative Liability, Measurement Input 156            
Warrant [Member] | Minimum [Member] | Measurement Input, Expected Term [Member]              
WARRANTS (Details) [Line Items]              
Embedded Derivative Liability, Measurement Input 3.2            
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.23.1
WARRANTS (Details) - Fair Value Measurement Inputs and Valuation Techniques
Mar. 31, 2023
Measurement Input, Expected Term [Member]  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Embedded Derivative Liability, Measurement Input 4.25
Measurement Input, Expected Dividend Rate [Member]  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Embedded Derivative Liability, Measurement Input 0
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Embedded Derivative Liability, Measurement Input 3.6
Minimum [Member] | Measurement Input, Price Volatility [Member]  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Embedded Derivative Liability, Measurement Input 147
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Embedded Derivative Liability, Measurement Input 3.81
Maximum [Member] | Measurement Input, Price Volatility [Member]  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Embedded Derivative Liability, Measurement Input 164
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.23.1
OPTIONS (Details) - USD ($)
6 Months Ended
Mar. 13, 2023
Aug. 25, 2020
Jun. 02, 2020
Mar. 31, 2023
Mar. 31, 2022
OPTIONS (Details) [Line Items]          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross 3,542,857 2,000,000 2,000,000,000 3,542,857  
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period     10 years    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in Dollars per share)     $ 0.00001    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price (in Dollars per share)   $ 0.01      
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) $ 0.175     $ 0.175  
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage 100.00%        
Share-Based Payment Arrangement, Noncash Expense (in Dollars)       $ 711,814 $ 53,619
Share-Based Payment Arrangement, Option [Member]          
OPTIONS (Details) [Line Items]          
Share-Based Payment Arrangement, Noncash Expense (in Dollars)       $ 563,314  
Director [Member]          
OPTIONS (Details) [Line Items]          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross 857,143        
Chief Financial Officer [Member]          
OPTIONS (Details) [Line Items]          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross 428,571        
President of StemVax Therapeutics [Member]          
OPTIONS (Details) [Line Items]          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross 571,429        
Scientific Advisory Board [Member]          
OPTIONS (Details) [Line Items]          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross 57,143        
Staff Members and Officers [Member]          
OPTIONS (Details) [Line Items]          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross 542,857        
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.23.1
OPTIONS (Details) - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions
Mar. 13, 2023
Jun. 02, 2020
Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Abstract    
Risk Free Interest Rate 3.68% 0.32%
Stock Volatility Factor 146.79% 146.00%
Weighted Average Expected Option Life 5 years 5 years
Expected Dividend Yield 0.00% 0.00%
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.23.1
OPTIONS (Details) - Share-Based Payment Arrangement, Option, Activity - $ / shares
6 Months Ended
Mar. 13, 2023
Aug. 25, 2020
Jun. 02, 2020
Mar. 31, 2023
Share Based Payment Arrangement Option Activity Abstract        
Outstanding, Number of Options       2,000,000
Outstanding, Weighted average exercise price       $ 0.01
Granted, Number of Options 3,542,857 2,000,000 2,000,000,000 3,542,857
Granted, Weighted average exercise price $ 0.175     $ 0.175
Exercised, Number of Options       0
Exercised, Weighted average exercise price       $ 0
Forfeited, Number of Options       0
Forfeited, Weighted average exercise price       $ 0
Outstanding, Number of Options       5,542,857
Outstanding, Weighted average exercise price       $ 0.115
XML 51 R42.htm IDEA: XBRL DOCUMENT v3.23.1
OPTIONS (Details) - Share-based Payment Arrangement, Option, Exercise Price Range
6 Months Ended
Mar. 31, 2023
$ / shares
shares
Options at .01 [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercisable Prices (in Dollars per share) | $ / shares $ 0.01
Options Outstanding 2,000,000
Options Exercisable 2,000,000
Weighted Average Remaining Contractual Life 7 years 2 months 1 day
Options at $0.175 [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercisable Prices (in Dollars per share) | $ / shares $ 0.175
Options Outstanding 3,542,857
Options Exercisable 3,542,857
Weighted Average Remaining Contractual Life 9 years 11 months 12 days
XML 52 R43.htm IDEA: XBRL DOCUMENT v3.23.1
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - Commitment Fee [Member]
6 Months Ended
Mar. 31, 2023
USD ($)
shares
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) [Line Items]  
Stock Issued During Period, Shares, Other | shares 2,075,000
Debt Instrument, Fee If the lender is unable to sell the shares for more than $1,250,000, it may make a one-time claim for each note to be reimbursed for the difference between their sale proceeds and $1,250,000.
Stock Issued During Period, Value, Other | $ $ 1,250,000
XML 53 R44.htm IDEA: XBRL DOCUMENT v3.23.1
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)
Mar. 31, 2023
Sep. 30, 2022
Schedule Of Accounts Payable And Accrued Liabilities Abstract    
Accrued liabilities $ 5,570 $ 4,370
Interest payable 159,506 94,251
Provision for guaranteed commitment fees * [1] 886,875 961,000
Accrued payroll 7,367 4,740
Deferred compensation 485,421 344,983
License Fees Payable 40,402 40,402
Insurance finance liability 69,133 36,815
Accrued expenses and accrued other current liabilities $ 1,654,274 $ 1,486,561
[1] Under the terms of the August 2021 Note, February 2022 Note, May 2022 Note and February 2023 Note the Company issued a total of 2,075,000 shares of common stock as commitment fees. If the lender is unable to sell the shares for more than $1,250,000, it may make a one-time claim for each note to be reimbursed for the difference between their sale proceeds and $1,250,000. The difference between the fair value of the 2,075,000 shares as on March 31, 2023 and the exercise amount of $1,250,000 was recorded as a provision for guaranteed commitment fees and included in the table above.
XML 54 R45.htm IDEA: XBRL DOCUMENT v3.23.1
BRIDGE LOANS PAYABLE (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Feb. 09, 2023
Jan. 25, 2022
May 31, 2022
Mar. 31, 2022
Dec. 31, 2021
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Sep. 30, 2022
BRIDGE LOANS PAYABLE (Details) [Line Items]                    
Debt Instrument, Interest Rate, Stated Percentage         10.00%          
Interest Paid, Including Capitalized Interest, Operating and Investing Activities                   $ 583
Debt Conversion, Converted Instrument, Shares Issued (in Shares)   125,000     125,000     500,000 250,000  
Gain (Loss) on Extinguishment of Debt   $ (17,313)     $ (37,500) $ 0 $ (54,813) $ 0 $ (54,813) (54,813)
Proceeds from Other Debt $ 8,500       $ 25,000          
Interest Expense, Debt                   226
Series B Preferred Stock [Member]                    
BRIDGE LOANS PAYABLE (Details) [Line Items]                    
Stock Issued During Period, Shares, New Issues (in Shares)       600            
Proceeds from Issuance of Convertible Preferred Stock       $ 18,616            
Chief Financial Officer [Member]                    
BRIDGE LOANS PAYABLE (Details) [Line Items]                    
Debt Instrument, Interest Rate, Stated Percentage   10.00%                
Repayments of Debt     $ 6,384              
Interest Paid, Including Capitalized Interest, Operating and Investing Activities                   $ 237
Debt Conversion, Converted Instrument, Shares Issued (in Shares)   125,000                
Gain (Loss) on Extinguishment of Debt   $ (17,313)                
Chief Executive Officer [Member]                    
BRIDGE LOANS PAYABLE (Details) [Line Items]                    
Repayments of Debt     $ 6,384              
Interest Paid, Including Capitalized Interest, Operating and Investing Activities               $ 583    
XML 55 R46.htm IDEA: XBRL DOCUMENT v3.23.1
DUE TO RELATED PARTIES (Details) - USD ($)
1 Months Ended 6 Months Ended
Mar. 14, 2022
Jan. 31, 2022
Sep. 04, 2020
Dec. 31, 2021
Mar. 31, 2023
Mar. 31, 2022
DUE TO RELATED PARTIES (Details) [Line Items]            
Proceeds from Related Party Debt       $ 25,000    
Investment Owned, Balance, Shares   24,400        
Stock Issued During Period, Shares, Other           300,000
Conversion of Stock, Shares Issued 1,502,670       1,502,670 1,502,670
Preferred Stock, Convertible, Conversion Price $ 0.35          
Conversion of Stock, Amount Issued $ 525,934          
Common Stock Outstanding, Percentage 10.00%       10.00%  
Payments to Acquire Investments $ 250,000          
Preferred Stock, Redemption Amount         $ 95,000  
TN3, LLC [Member]            
DUE TO RELATED PARTIES (Details) [Line Items]            
Investment Owned, Balance, Shares   25,000        
Payments to Acquire Investments   $ 250,000        
Irvin Consulting, LLC ("IC") [Member]            
DUE TO RELATED PARTIES (Details) [Line Items]            
Investment Owned, Balance, Shares   600        
Series B Preferred Stock [Member]            
DUE TO RELATED PARTIES (Details) [Line Items]            
Conversion of Stock, Shares Issued     25,000      
Series B Preferred Stock [Member] | TN3, LLC [Member]            
DUE TO RELATED PARTIES (Details) [Line Items]            
Investment Owned, Balance, Shares   25,000        
TN3, LLC [Member] | Series B Preferred Stock [Member]            
DUE TO RELATED PARTIES (Details) [Line Items]            
Stock Issued During Period, Shares, Other 24,400          
TN3, LLC [Member] | Series B Preferred Stock [Member] | Irvin Consulting, LLC ("IC") [Member]            
DUE TO RELATED PARTIES (Details) [Line Items]            
Stock Issued During Period, Shares, Other 600          
Affiliated Entity [Member]            
DUE TO RELATED PARTIES (Details) [Line Items]            
Proceeds from Related Party Debt         $ 86,217  
XML 56 R47.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES (Details) - Commitment Fee [Member]
6 Months Ended
Mar. 31, 2023
USD ($)
shares
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]  
Stock Issued During Period, Shares, Other | shares 2,075,000
Stock Issued During Period, Value, Other | $ $ 1,250,000
XML 57 R48.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTIONS (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Feb. 09, 2023
Jul. 28, 2022
Mar. 14, 2022
Jan. 31, 2022
Jan. 25, 2022
Sep. 04, 2020
May 31, 2022
Mar. 31, 2022
Dec. 31, 2021
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Sep. 30, 2022
Oct. 01, 2013
RELATED PARTY TRANSACTIONS (Details) [Line Items]                              
Proceeds from Other Debt $ 8,500               $ 25,000            
Debt Instrument, Face Amount   $ 12,500               $ 1,902,880   $ 1,902,880     $ 12,000
Convertible Debt                   1,745,073   $ 1,745,073      
Debt Instrument, Convertible, Conversion Price (in Dollars per share)                             $ 4.5
Investment Owned, Balance, Shares (in Shares)       24,400                      
Payments to Acquire Investments     $ 250,000                        
Conversion of Stock, Shares Issued (in Shares)     1,502,670                 1,502,670 1,502,670    
Common Stock Outstanding, Percentage     10.00%                 10.00%      
Stock Issued During Period, Shares, Acquisitions (in Shares)     7,500,000                        
Proceeds from Related Party Debt                 $ 25,000            
Debt Instrument, Maturity Date, Description   The loan terms required repayment of all amounts outstanding under the loan on the earlier of: (a) October 31, 2022 or (b) the receipt by the Company of debt or equity financing of $3 million             The notes were payable on demand with a five business-day written notice            
Debt Instrument, Interest Rate, Stated Percentage                 10.00%            
Debt Conversion, Converted Instrument, Shares Issued (in Shares)         125,000       125,000     500,000 250,000    
Gain (Loss) on Extinguishment of Debt         $ (17,313)       $ (37,500) 0 $ (54,813) $ 0 $ (54,813) $ (54,813)  
Interest Paid, Including Capitalized Interest, Operating and Investing Activities                           583  
Agreement, Monthly Amount           $ 30,000                  
Agreement, Term           3 years                  
Related Party Transaction, Amounts of Transaction                           40,000  
TN3, LLC [Member]                              
RELATED PARTY TRANSACTIONS (Details) [Line Items]                              
Investment Owned, Balance, Shares (in Shares)       25,000                      
Payments to Acquire Investments       $ 250,000                      
Debt Instrument, Payment Terms       over a period of eleven months, with payment accelerated if the Company raises at least $2.5 million of equity capital                      
Irvin Consulting, LLC ("IC") [Member]                              
RELATED PARTY TRANSACTIONS (Details) [Line Items]                              
Investment Owned, Balance, Shares (in Shares)       600                      
Series B Preferred Stock [Member]                              
RELATED PARTY TRANSACTIONS (Details) [Line Items]                              
Conversion of Stock, Shares Issued (in Shares)           25,000                  
Stock Issued During Period, Shares, New Issues (in Shares)               600              
Proceeds from Issuance of Convertible Preferred Stock               $ 18,616              
Series B Preferred Stock [Member] | TN3, LLC [Member]                              
RELATED PARTY TRANSACTIONS (Details) [Line Items]                              
Investment Owned, Balance, Shares (in Shares)       25,000                      
Board Member [Member]                              
RELATED PARTY TRANSACTIONS (Details) [Line Items]                              
Convertible Debt                   12,500   12,500      
Letzhangout, LLC [Member]                              
RELATED PARTY TRANSACTIONS (Details) [Line Items]                              
Debt Instrument, Face Amount   $ 12,500                          
Convertible Debt                   $ 12,500   12,500      
Debt Instrument, Convertible, Conversion Price (in Dollars per share)   $ 0                          
Chief Financial Officer [Member]                              
RELATED PARTY TRANSACTIONS (Details) [Line Items]                              
Debt Instrument, Interest Rate, Stated Percentage         10.00%                    
Debt Conversion, Converted Instrument, Shares Issued (in Shares)         125,000                    
Gain (Loss) on Extinguishment of Debt         $ (17,313)                    
Interest Paid, Including Capitalized Interest, Operating and Investing Activities                           $ 237  
Repayments of Debt             $ 6,384                
Chief Executive Officer [Member]                              
RELATED PARTY TRANSACTIONS (Details) [Line Items]                              
Interest Paid, Including Capitalized Interest, Operating and Investing Activities                       $ 583      
Repayments of Debt             $ 6,384                
XML 58 R49.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS (Details) - Subsequent Event [Member] - USD ($)
Apr. 24, 2023
Apr. 11, 2023
May 09, 2023
SUBSEQUENT EVENTS (Details) [Line Items]      
Debt Instrument, Face Amount (in Dollars) $ 54,250 $ 79,250  
Debt Instrument, Interest Rate, Stated Percentage 8.00% 8.00%  
Debt, Default Interest Rate 22.00% 22.00%  
Debt Instrument, Convertible, Terms of Conversion Feature the lender may convert the amount outstanding under the note into shares of the Company’s common stock at a conversion price equal to 65% of the average of the three lowest trading prices of the stock during the fifteen trading days before the conversion date the lender may convert the amount outstanding under the note into shares of the Company’s common stock at a conversion price equal to 65% of the average of the three lowest trading prices of the stock during the fifteen trading days before the conversion date  
Debt Instrument, Debt Default, Amount (in Dollars)     $ 1,584,260
Minimum [Member]      
SUBSEQUENT EVENTS (Details) [Line Items]      
Debt Prepayment Penalty, Percentage 15.00% 15.00%  
Maximum [Member]      
SUBSEQUENT EVENTS (Details) [Line Items]      
Debt Prepayment Penalty, Percentage 25.00% 25.00%  
XML 59 novaccess20230331_10q_htm.xml IDEA: XBRL DOCUMENT 0001039466 2022-10-01 2023-03-31 0001039466 2023-05-15 0001039466 2023-03-31 0001039466 2022-09-30 0001039466 us-gaap:SeriesBPreferredStockMember 2023-03-31 0001039466 us-gaap:SeriesBPreferredStockMember 2022-09-30 0001039466 2023-01-01 2023-03-31 0001039466 2022-01-01 2022-03-31 0001039466 2021-10-01 2022-03-31 0001039466 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0001039466 us-gaap:SeriesBPreferredStockMember us-gaap:CommonStockMember 2021-09-30 0001039466 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001039466 xsnx:AdditionalPaidInCapitalStockOptionsWarrantsMember 2021-09-30 0001039466 xsnx:AdditionalPaidInCapitalPreferredStockMember 2021-09-30 0001039466 us-gaap:RetainedEarningsMember 2021-09-30 0001039466 2021-09-30 0001039466 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-10-01 2022-03-31 0001039466 us-gaap:SeriesBPreferredStockMember us-gaap:CommonStockMember 2021-10-01 2022-03-31 0001039466 xsnx:AdditionalPaidInCapitalPreferredStockMember 2021-10-01 2022-03-31 0001039466 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2022-03-31 0001039466 xsnx:CommonStockIssuableMember 2021-10-01 2022-03-31 0001039466 us-gaap:RetainedEarningsMember 2021-10-01 2022-03-31 0001039466 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001039466 us-gaap:SeriesBPreferredStockMember us-gaap:CommonStockMember 2022-03-31 0001039466 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001039466 xsnx:AdditionalPaidInCapitalStockOptionsWarrantsMember 2022-03-31 0001039466 xsnx:AdditionalPaidInCapitalPreferredStockMember 2022-03-31 0001039466 us-gaap:RetainedEarningsMember 2022-03-31 0001039466 2022-03-31 0001039466 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-09-30 0001039466 us-gaap:SeriesBPreferredStockMember us-gaap:CommonStockMember 2022-09-30 0001039466 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001039466 xsnx:AdditionalPaidInCapitalStockOptionsWarrantsMember 2022-09-30 0001039466 xsnx:AdditionalPaidInCapitalPreferredStockMember 2022-09-30 0001039466 us-gaap:RetainedEarningsMember 2022-09-30 0001039466 us-gaap:SeriesBPreferredStockMember us-gaap:CommonStockMember 2022-10-01 2023-03-31 0001039466 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2023-03-31 0001039466 us-gaap:RetainedEarningsMember 2022-10-01 2023-03-31 0001039466 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0001039466 us-gaap:SeriesBPreferredStockMember us-gaap:CommonStockMember 2023-03-31 0001039466 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001039466 xsnx:AdditionalPaidInCapitalStockOptionsWarrantsMember 2023-03-31 0001039466 xsnx:AdditionalPaidInCapitalPreferredStockMember 2023-03-31 0001039466 us-gaap:RetainedEarningsMember 2023-03-31 0001039466 2020-08-25 2020-08-25 0001039466 us-gaap:FairValueInputsLevel1Member 2022-09-30 0001039466 us-gaap:FairValueInputsLevel2Member 2022-09-30 0001039466 us-gaap:FairValueInputsLevel3Member 2022-09-30 0001039466 us-gaap:FairValueInputsLevel1Member 2023-03-31 0001039466 us-gaap:FairValueInputsLevel2Member 2023-03-31 0001039466 us-gaap:FairValueInputsLevel3Member 2023-03-31 0001039466 us-gaap:FairValueInputsLevel3Member 2021-09-30 0001039466 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:FairValueInputsLevel3Member 2021-09-30 0001039466 us-gaap:FairValueInputsLevel3Member 2021-10-01 2022-09-30 0001039466 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:FairValueInputsLevel3Member 2021-10-01 2022-09-30 0001039466 2021-10-01 2022-09-30 0001039466 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:FairValueInputsLevel3Member 2022-09-30 0001039466 us-gaap:FairValueInputsLevel3Member 2022-10-01 2023-03-31 0001039466 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:FairValueInputsLevel3Member 2022-10-01 2023-03-31 0001039466 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:FairValueInputsLevel3Member 2023-03-31 0001039466 us-gaap:SeriesBPreferredStockMember 2020-09-04 2020-09-04 0001039466 us-gaap:SeriesBPreferredStockMember 2020-09-04 0001039466 xsnx:TN3LLCMember us-gaap:SeriesBPreferredStockMember 2022-03-14 2022-03-14 0001039466 xsnx:TN3LLCMember us-gaap:SeriesBPreferredStockMember xsnx:IrvinConsultingLLCICMember 2022-03-14 2022-03-14 0001039466 us-gaap:RelatedPartyMember 2022-10-01 2023-03-31 0001039466 xsnx:StockSubscriptionsMember 2022-10-01 2023-03-31 0001039466 us-gaap:SeriesBPreferredStockMember 2021-10-01 2022-03-31 0001039466 xsnx:StockSubscriptionsMember 2021-10-01 2022-03-31 0001039466 us-gaap:RelatedPartyMember 2021-10-01 2022-03-31 0001039466 2013-10-01 0001039466 xsnx:ConvertibleNotePayableTwoMember us-gaap:ConvertibleDebtMember 2014-11-20 0001039466 xsnx:ConvertibleNotePayableTwoMember us-gaap:ConvertibleDebtMember 2014-11-20 2014-11-20 0001039466 xsnx:ConvertibleNotePayableTwoMember us-gaap:ConvertibleDebtMember 2015-02-18 2016-09-30 0001039466 xsnx:ConvertibleNotePayableTwoMember us-gaap:ConvertibleDebtMember 2023-03-31 0001039466 us-gaap:ConvertibleDebtMember 2017-05-10 0001039466 us-gaap:ConvertibleDebtMember 2017-05-10 2017-05-10 0001039466 us-gaap:ConvertibleDebtMember 2017-07-31 2017-09-18 0001039466 us-gaap:ConvertibleDebtMember 2023-03-31 0001039466 xsnx:MayNoteMember 2021-05-28 0001039466 xsnx:MayNoteMember 2021-05-28 2021-05-28 0001039466 xsnx:JulyNoteMember 2023-03-31 0001039466 xsnx:JulyNoteMember 2021-07-06 0001039466 xsnx:JulyNoteMember 2021-07-06 2021-07-06 0001039466 xsnx:MayNoteMember 2023-03-31 0001039466 xsnx:AugustNoteMember 2021-08-20 0001039466 xsnx:AugustNoteMember 2021-08-20 2021-08-20 0001039466 xsnx:AugustNoteMember 2023-03-31 0001039466 xsnx:AugustNoteMember 2023-02-09 0001039466 xsnx:FebruaryNoteMember 2022-02-15 0001039466 xsnx:FebruaryNoteMember 2022-02-15 2022-02-15 0001039466 2022-02-15 0001039466 xsnx:FebruaryNoteMember 2023-03-31 0001039466 xsnx:FebruaryNoteMember 2023-02-09 0001039466 xsnx:FebruaryNoteMember 2023-02-09 2023-02-09 0001039466 xsnx:FebruaryNoteMember 2023-05-09 0001039466 xsnx:May2022NoteMember 2022-05-05 0001039466 xsnx:May2022NoteMember 2022-05-05 2022-05-05 0001039466 xsnx:May2022NoteMember 2023-03-31 0001039466 xsnx:May2022NoteMember 2023-05-09 0001039466 xsnx:August2022NoteMember 2022-08-08 0001039466 xsnx:August2022NoteMember 2022-08-08 2022-08-08 0001039466 xsnx:September2022NoteMember 2023-03-31 0001039466 xsnx:August2022NoteMember 2023-03-31 0001039466 xsnx:September2022NoteMember 2022-09-22 0001039466 xsnx:September2022NoteMember 2022-09-22 2022-09-22 0001039466 xsnx:September2022NoteMember 2022-09-22 2022-09-22 0001039466 xsnx:September2022NoteMember 2023-03-12 2023-03-12 0001039466 xsnx:September2022NoteMember 2023-03-12 0001039466 xsnx:November2022NoteMember 2022-11-01 0001039466 xsnx:November2022NoteMember 2022-11-01 2022-11-01 0001039466 xsnx:November2022NoteMember 2023-03-31 0001039466 xsnx:December2022NoteMember 2022-12-07 0001039466 xsnx:December2022NoteMember 2022-12-07 2022-12-07 0001039466 xsnx:December2022NoteMember 2023-03-31 0001039466 xsnx:February2023NoteMember 2023-02-09 0001039466 xsnx:February2023NoteMember 2023-02-09 2023-02-09 0001039466 xsnx:February2023NoteMember 2023-03-31 0001039466 xsnx:February2023NoteMember 2022-10-01 2023-03-31 0001039466 xsnx:February2023NoteMember xsnx:CommitmentFeeMember 2023-02-09 0001039466 2023-05-09 0001039466 xsnx:Note2013Member 2023-03-31 0001039466 xsnx:Note2013Member us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-03-31 0001039466 xsnx:Note2013Member us-gaap:WarrantMember 2023-03-31 0001039466 xsnx:Note2014Member 2023-03-31 0001039466 xsnx:Note2014Member us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-03-31 0001039466 xsnx:Note2014Member us-gaap:WarrantMember 2023-03-31 0001039466 xsnx:Note2017Member 2023-03-31 0001039466 xsnx:Note2017Member us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-03-31 0001039466 xsnx:Note2017Member us-gaap:WarrantMember 2023-03-31 0001039466 xsnx:AugustNoteMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-03-31 0001039466 xsnx:AugustNoteMember us-gaap:WarrantMember 2023-03-31 0001039466 xsnx:FebruaryNoteMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-03-31 0001039466 xsnx:FebruaryNoteMember us-gaap:WarrantMember 2023-03-31 0001039466 xsnx:May2022NoteMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-03-31 0001039466 xsnx:May2022NoteMember us-gaap:WarrantMember 2023-03-31 0001039466 xsnx:August2022NoteMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-03-31 0001039466 xsnx:August2022NoteMember us-gaap:WarrantMember 2023-03-31 0001039466 xsnx:November2022NoteMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-03-31 0001039466 xsnx:November2022NoteMember us-gaap:WarrantMember 2023-03-31 0001039466 xsnx:December2022NoteMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-03-31 0001039466 xsnx:December2022NoteMember us-gaap:WarrantMember 2023-03-31 0001039466 xsnx:February2023NoteMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-03-31 0001039466 xsnx:February2023NoteMember us-gaap:WarrantMember 2023-03-31 0001039466 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-03-31 0001039466 us-gaap:WarrantMember 2023-03-31 0001039466 xsnx:July2022NoteMember us-gaap:RelatedPartyMember 2023-03-31 0001039466 xsnx:July2022NoteMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:RelatedPartyMember 2023-03-31 0001039466 xsnx:July2022NoteMember us-gaap:WarrantMember us-gaap:RelatedPartyMember 2023-03-31 0001039466 us-gaap:ConvertibleDebtMember 2022-10-01 2023-03-31 0001039466 srt:MinimumMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-03-31 0001039466 srt:MaximumMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-03-31 0001039466 srt:MinimumMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:MeasurementInputPriceVolatilityMember 2023-03-31 0001039466 srt:MaximumMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:MeasurementInputPriceVolatilityMember 2023-03-31 0001039466 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:MeasurementInputExpectedTermMember 2023-03-31 0001039466 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:MeasurementInputExpectedDividendRateMember 2023-03-31 0001039466 xsnx:July2022NoteMember 2022-07-28 0001039466 xsnx:July2022NoteMember 2022-07-28 2022-07-28 0001039466 xsnx:July2022NoteMember 2023-03-31 0001039466 srt:DirectorMember 2022-07-28 0001039466 2022-07-28 2022-07-28 0001039466 2022-11-01 2022-11-30 0001039466 2023-02-09 2023-02-09 0001039466 xsnx:FebruaryNoteMember 2022-02-16 2022-02-16 0001039466 xsnx:FebruaryNoteMember 2022-02-16 0001039466 2022-05-10 2022-05-10 0001039466 2022-05-10 0001039466 2023-02-09 0001039466 srt:MaximumMember us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-02-09 0001039466 us-gaap:WarrantMember 2023-02-09 0001039466 srt:MinimumMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2023-02-09 0001039466 srt:MaximumMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2023-02-09 0001039466 srt:MinimumMember us-gaap:WarrantMember us-gaap:MeasurementInputExpectedTermMember 2023-02-09 0001039466 srt:MaximumMember us-gaap:WarrantMember us-gaap:MeasurementInputExpectedTermMember 2023-02-09 0001039466 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2023-02-09 0001039466 srt:MinimumMember us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-02-09 0001039466 us-gaap:WarrantMember 2022-10-01 2023-03-31 0001039466 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-03-31 0001039466 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-03-31 0001039466 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2023-03-31 0001039466 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2023-03-31 0001039466 us-gaap:MeasurementInputExpectedTermMember 2023-03-31 0001039466 us-gaap:MeasurementInputExpectedDividendRateMember 2023-03-31 0001039466 2020-06-02 2020-06-02 0001039466 2020-08-25 0001039466 2023-03-13 2023-03-13 0001039466 srt:DirectorMember 2023-03-13 2023-03-13 0001039466 srt:ChiefFinancialOfficerMember 2023-03-13 2023-03-13 0001039466 xsnx:PresidentOfStemVaxTherapeuticsMember 2023-03-13 2023-03-13 0001039466 xsnx:ScientificAdvisoryBoardMember 2023-03-13 2023-03-13 0001039466 xsnx:StaffMembersAndOfficersMember 2023-03-13 2023-03-13 0001039466 us-gaap:EmployeeStockOptionMember 2022-10-01 2023-03-31 0001039466 xsnx:OptionsAt01Member 2022-10-01 2023-03-31 0001039466 xsnx:OptionsAt01Member 2023-03-31 0001039466 xsnx:OptionsAt0175Member 2022-10-01 2023-03-31 0001039466 xsnx:OptionsAt0175Member 2023-03-31 0001039466 xsnx:CommitmentFeeMember 2022-10-01 2023-03-31 0001039466 srt:ChiefFinancialOfficerMember 2022-01-25 0001039466 us-gaap:SeriesBPreferredStockMember 2022-03-01 2022-03-31 0001039466 srt:ChiefExecutiveOfficerMember 2022-05-01 2022-05-31 0001039466 srt:ChiefFinancialOfficerMember 2022-01-25 2022-01-25 0001039466 srt:ChiefFinancialOfficerMember 2021-10-01 2022-09-30 0001039466 2021-12-01 2021-12-31 0001039466 srt:AffiliatedEntityMember 2022-10-01 2023-03-31 0001039466 us-gaap:SeriesBPreferredStockMember xsnx:TN3LLCMember 2022-01-31 0001039466 2022-03-14 2022-03-14 0001039466 2022-03-14 0001039466 2022-07-28 0001039466 xsnx:BoardMemberMember 2023-03-31 0001039466 xsnx:LetzhangoutLLCMember 2022-07-28 0001039466 xsnx:LetzhangoutLLCMember 2023-03-31 0001039466 xsnx:TN3LLCMember 2022-01-31 0001039466 2022-01-31 0001039466 xsnx:IrvinConsultingLLCICMember 2022-01-31 0001039466 xsnx:TN3LLCMember 2022-01-31 2022-01-31 0001039466 2021-12-31 0001039466 2022-01-25 2022-01-25 0001039466 srt:ChiefFinancialOfficerMember 2022-05-01 2022-05-31 0001039466 srt:ChiefExecutiveOfficerMember 2022-10-01 2023-03-31 0001039466 2020-09-04 2020-09-04 0001039466 us-gaap:SubsequentEventMember 2023-04-11 0001039466 srt:MinimumMember us-gaap:SubsequentEventMember 2023-04-11 2023-04-11 0001039466 srt:MaximumMember us-gaap:SubsequentEventMember 2023-04-11 2023-04-11 0001039466 us-gaap:SubsequentEventMember 2023-04-11 2023-04-11 0001039466 us-gaap:SubsequentEventMember 2023-04-24 0001039466 srt:MinimumMember us-gaap:SubsequentEventMember 2023-04-24 2023-04-24 0001039466 srt:MaximumMember us-gaap:SubsequentEventMember 2023-04-24 2023-04-24 0001039466 us-gaap:SubsequentEventMember 2023-04-24 2023-04-24 0001039466 us-gaap:SubsequentEventMember 2023-05-09 shares iso4217:USD iso4217:USD shares pure 10-Q true 2023-03-31 false 000-29621 NovAccess Global Inc. CO 84-1384159 8584 E. Washington Street #127 Chagrin Falls OH 44023 213 642-9268 None Yes Yes Non-accelerated Filer true false false 21185028 21991 64251 81468 60650 103459 124901 446828 375682 1654274 1486561 1769259 1440012 181217 186217 21000 12500 157807 340503 1745073 1266627 0 2132 12500 10368 5830151 4777967 5830151 4777967 0.01 0.01 25000 25000 25000 25000 6 6 0 0 2000000000 2000000000 21185028 21185028 18669507 18669507 43623184 43225982 6047212 5340398 4747108 4747108 4210960 4210960 -64355162 -62177520 -5726692 -4653066 103459 124901 0 0 0 0 0 0 0 0 0 0 0 0 41036 45516 76000 87915 1013952 381428 1496106 661358 1054988 426944 1572106 749273 -1054988 -426944 -1572106 -749273 1825730 -492425 -255854 -33399 138863 0 138863 96205 0 -54813 0 -54813 -193625 0 74125 0 262216 255603 562670 631813 1508752 -802841 -605536 -623820 453764 -1229785 -2177642 -1373093 44241 0 44241 0 409523 -1229785 -2221883 -1373093 0.02 -0.08 -0.11 -0.09 0.01 -0.08 -0.11 -0.09 20698747 15379289 19832524 14914920 39680653 15379289 19832524 14914920 25000 250 14404030 41882535 5351398 4210960 5088324 -60461561 -3928094 -24400 -244 1502670 525935 -341216 184475 265973 119480 119480 791000 170200 170200 10000 8000 8000 250000 104813 104813 300000 111000 111000 5000 5000 -1373093 -1373093 600 6 17523673 42921963 5356398 4210960 4747108 -61834654 -4598219 600 6 18669507 43225982 5340398 4210960 4747108 -62177520 -4653066 1490521 259702 259702 525000 55000 -5000 50000 500000 82500 82500 563314 563314 148500 148500 -2177642 -2177642 600 6 21185028 43623184 6047212 4210960 4747108 -64355162 -5726692 -2177642 -1373093 432083 479689 -255854 -33399 138863 96205 -54813 711814 53619 259702 73861 82500 79043 0 546 20818 -5568 71147 39700 167713 210216 -356510 -438844 50000 175200 0 3151 340000 213000 5000 50000 8500 75000 0 2316 -79250 -94250 314250 319785 -42260 -119059 64251 180668 21991 61609 17711 71245 800 0 0 546 0 200000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1. ORGANIZATION AND LINE OF BUSINESS</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">Organization</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NovAccess Global Inc. (“NovAccess” or the “Company”) is a Colorado corporation formerly known as Sun River Mining Inc. and XsunX, Inc.. The Company was originally incorporated in Colorado on February 25, 1997. Effective September 24, 2003, the Company completed a plan of reorganization and name change to XsunX, Inc. Effective August 25, 2020, we filed articles of amendment to our articles of incorporation with the Colorado Secretary of State to: effectuate a 1-for-1,000 reverse stock split of the Company’s outstanding shares of common stock; and change the name of the Company to “NovAccess Global Inc.” After completing the acquisition of StemVax, in September, 2020, we exited the solar business and focused all our efforts on our biopharmaceutical business.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">Line of Business</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NovAccess Global Inc. is a biopharmaceutical company that is developing novel immunotherapies to treat brain tumor patients in the United States with plans to expand globally. We specialize in cutting-edge research related to utilizing a patient’s own immune system to attack the cancer. We are filing an Investigational New Drug Application (IND) and working closely with the Food and Drug Administration (FDA) to obtain approval for human clinical trials to determine safety and efficacy of our drug product for brain cancer patients. Once we have successfully completed the clinical trials and proven that the new therapy is safe and efficacious, we plan to commercialize the product. We also have expertise in successfully executing clinical trials, bringing products to market and increasing the market size of products through our advisory board. Our scientists are well versed in immunology, stem cell biology, neuroscience, molecular biology, imaging, small molecules development, gene therapy and other technical assays needed for protein and genetic analysis of cancer cells.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NovAccess operates as a research and development (R&amp;D) company out of Ohio and California, and our executive management and scientific advisory board provide over 15 years of extensive experience in all aspects of biopharmaceutical R&amp;D and commercialization of drug candidates.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">Going Concern</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The accompanying financial statements have been prepared on a going concern basis of accounting, which contemplates continuity of operations, realization of assets and liabilities and commitments in the normal course of business. The accompanying financial statements do not reflect any adjustments that might result if the Company is unable to continue as a going concern. The Company does not generate significant revenue, and has negative cash flows from operations, which raise substantial doubt about the Company’s ability to continue as a going concern.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The ability of the Company to continue as a going concern and appropriateness of using the going concern basis is dependent upon, among other things, additional cash infusion. The Company has obtained funds from its shareholders since its inception through the period ended March 31, 2023. Management believes the existing shareholders and the prospective new investors will provide the additional cash needed to meet the Company’s obligations as they become due and will allow the development of its business.</p> 1-for-1,000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This summary of significant accounting policies of NovAccess Global Inc. is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">Basis of Presentation</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary StemVax, LLC. All significant inter-company accounts and transactions between these entities have been eliminated in these consolidated financial statements.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying consolidated financial statements. Significant estimates made in preparing these consolidated financial statements include the estimate of the deferred tax valuation allowance, the fair value of stock options, and derivative liabilities. Actual results could differ from those estimates.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">Cash and Cash Equivalents </span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For purposes of the statements of cash flows, cash and cash equivalents include cash in banks and money markets with an original maturity of three months or less.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">Stock-Based Compensation</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Share-based Payment applies to transactions in which an entity exchanges its equity instruments for goods or services and also applies to liabilities an entity may incur for goods or services that are to follow a fair value of those equity instruments. We are required to follow a fair value approach using an option-pricing model, such as the Binomial lattice valuation model, at the date of a stock option grant. The deferred compensation calculated under the fair value method would then be amortized over the respective vesting period of the stock option. This has not had a material impact on our results of operations.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">Net Earnings (Loss) per Share Calculations</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Net earnings (Loss) per share dictates the calculation of basic earnings (loss) per share and diluted earnings (loss) per share. Basic earnings (loss) per share are computed by dividing by the weighted average number of common shares outstanding during the period. Diluted net earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the effect of stock options and stock-based awards plus the assumed conversion of convertible debt (see notes 4 and 5). </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> </td> <td id="new_id-2172" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="6" id="new_id-2173" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>For the three months ended</b></p> </td> <td id="new_id-2174" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 1%;"> </td> <td id="new_id-2175" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 1%;"> </td> <td colspan="6" id="new_id-2176" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>For the Six months ended</b></p> </td> <td id="new_id-2177" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> </td> <td id="new_id-2178" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="6" id="new_id-2179" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>March 31,</b></p> </td> <td id="new_id-2180" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; text-align: center; width: 1%;"> </td> <td id="new_id-2181" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 1%;"> </td> <td colspan="6" id="new_id-2182" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>March 31,</b></p> </td> <td id="new_id-2183" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> </td> <td id="new_id-2184" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="2" id="new_id-2185" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>2023</b></p> </td> <td id="new_id-2186" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; text-align: center; width: 1%;"> </td> <td id="new_id-2187" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 1%;"> </td> <td colspan="2" id="new_id-2188" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>2022</b></p> </td> <td id="new_id-2189" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; text-align: center; width: 1%;"> </td> <td id="new_id-2190" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 1%;"> </td> <td colspan="2" id="new_id-2191" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>2023</b></p> </td> <td id="new_id-2192" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; text-align: center; width: 1%;"> </td> <td id="new_id-2193" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;"> </td> <td id="new_id-2194" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"><b> </b></td> <td id="new_id-2195" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"><b>2022</b></td> <td id="new_id-2196" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 52%;"> </td> <td id="new_id-2197" style="width: 1%;"> </td> <td id="new_id-2198" style="width: 1%;"> </td> <td id="new_id-2199" style="width: 9%;"> </td> <td id="new_id-2200" style="width: 1%;"> </td> <td id="new_id-2201" style="width: 1%;"> </td> <td id="new_id-2202" style="width: 1%;"> </td> <td id="new_id-2203" style="width: 9%;"> </td> <td id="new_id-2204" style="width: 1%;"> </td> <td id="new_id-2205" style="width: 1%;"> </td> <td id="new_id-2206" style="width: 1%;"> </td> <td id="new_id-2207" style="width: 9%;"> </td> <td id="new_id-2208" style="width: 1%;"> </td> <td id="new_id-2209" style="width: 1%;"> </td> <td id="new_id-2210" style="width: 1%;"> </td> <td id="new_id-2211" style="width: 9%;"> </td> <td id="new_id-2212" style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Income (Loss) to common shareholders (Numerator)</p> </td> <td id="new_id-2213" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2214" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td id="new_id-2215" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">409,523</td> <td id="new_id-2216" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2217" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2218" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2219" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(1,229,785</td> <td id="new_id-2220" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;">)</td> <td id="new_id-2221" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2222" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td id="new_id-2223" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(2,221,883</td> <td id="new_id-2224" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;">)</td> <td id="new_id-2225" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2226" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2227" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(1,373,093</td> <td id="new_id-2228" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 52%;"> </td> <td id="new_id-2229" style="width: 1%;"> </td> <td id="new_id-2230" style="width: 1%;"> </td> <td id="new_id-2231" style="width: 9%;"> </td> <td id="new_id-2232" style="width: 1%;"> </td> <td id="new_id-2233" style="width: 1%;"> </td> <td id="new_id-2234" style="width: 1%;"> </td> <td id="new_id-2235" style="width: 9%;"> </td> <td id="new_id-2236" style="width: 1%;"> </td> <td id="new_id-2237" style="width: 1%;"> </td> <td id="new_id-2238" style="width: 1%;"> </td> <td id="new_id-2239" style="width: 9%;"> </td> <td id="new_id-2240" style="width: 1%;"> </td> <td id="new_id-2241" style="width: 1%;"> </td> <td id="new_id-2242" style="width: 1%;"> </td> <td id="new_id-2243" style="width: 9%;"> </td> <td id="new_id-2244" style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Basic weighted average number of common shares outstanding (Denominator)</p> </td> <td id="new_id-2245" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2246" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2247" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">20,698,747</td> <td id="new_id-2248" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2249" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2250" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2251" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">15,379,289</td> <td id="new_id-2252" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2253" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2254" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2255" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">19,832,524</td> <td id="new_id-2256" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2257" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2258" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2259" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">14,914,920</td> <td id="new_id-2260" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 52%;"> </td> <td id="new_id-2261" style="width: 1%;"> </td> <td id="new_id-2262" style="width: 1%;"> </td> <td id="new_id-2263" style="width: 9%;"> </td> <td id="new_id-2264" style="width: 1%;"> </td> <td id="new_id-2265" style="width: 1%;"> </td> <td id="new_id-2266" style="width: 1%;"> </td> <td id="new_id-2267" style="width: 9%;"> </td> <td id="new_id-2268" style="width: 1%;"> </td> <td id="new_id-2269" style="width: 1%;"> </td> <td id="new_id-2270" style="width: 1%;"> </td> <td id="new_id-2271" style="width: 9%;"> </td> <td id="new_id-2272" style="width: 1%;"> </td> <td id="new_id-2273" style="width: 1%;"> </td> <td id="new_id-2274" style="width: 1%;"> </td> <td id="new_id-2275" style="width: 9%;"> </td> <td id="new_id-2276" style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Diluted weighted average number of common shares outstanding</p> </td> <td id="new_id-2277" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2278" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2279" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">39,680,653</td> <td id="new_id-2280" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2281" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2282" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2283" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">15,379,289</td> <td id="new_id-2284" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2285" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2286" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2287" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">19,832,524,</td> <td id="new_id-2288" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2289" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2290" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2291" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">14,914,920</td> <td id="new_id-2292" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> </table><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">Fair Value of Financial Instruments</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Fair Value of Financial Instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of March 31, 2023, the balances reported for cash, prepaid expenses, accounts payable, accrued expenses approximate the fair value because of their short maturities.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We adopted Accounting Standards Codification (“ASC”) Topic 820 for financial instruments measured as fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States and expands disclosures about fair value measurements.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tr> <td style="vertical-align:middle;width:0.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:top;width:0.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="vertical-align:top;width:8.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;</p> </td> </tr> </table><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tr> <td style="vertical-align:middle;width:0.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:top;width:0.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="vertical-align:top;width:8.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</p> </td> </tr> </table><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tr> <td style="vertical-align:middle;width:0.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:top;width:0.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="vertical-align:top;width:8.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</p> </td> </tr> </table><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We measure certain financial instruments at fair value on a recurring basis. The Company had no assets that are required to be valued on a recurring basis as of March 31, 2023<b> </b>and September 30, 2022. The Company had liabilities that are required to be measured at fair value on a recurring basis as follows at March 31 2023 and September 30, 2022:</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> </td> <td id="new_id-2293" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="2" id="new_id-2294" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Total</b></p> </td> <td id="new_id-2295" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td id="new_id-2296" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="2" id="new_id-2297" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Level 1)</b></p> </td> <td id="new_id-2298" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td id="new_id-2299" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="2" id="new_id-2300" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Level 2)</b></p> </td> <td id="new_id-2301" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td id="new_id-2302" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="2" id="new_id-2303" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Level 3)</b></p> </td> <td id="new_id-2304" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 52%;"> </td> <td id="new_id-2305" style="width: 1%;"> </td> <td id="new_id-2306" style="width: 1%;"> </td> <td id="new_id-2307" style="width: 9%;"> </td> <td id="new_id-2308" style="width: 1%;"> </td> <td id="new_id-2309" style="width: 1%;"> </td> <td id="new_id-2310" style="width: 1%;"> </td> <td id="new_id-2311" style="width: 9%;"> </td> <td id="new_id-2312" style="width: 1%;"> </td> <td id="new_id-2313" style="width: 1%;"> </td> <td id="new_id-2314" style="width: 1%;"> </td> <td id="new_id-2315" style="width: 9%;"> </td> <td id="new_id-2316" style="width: 1%;"> </td> <td id="new_id-2317" style="width: 1%;"> </td> <td id="new_id-2318" style="width: 1%;"> </td> <td id="new_id-2319" style="width: 9%;"> </td> <td id="new_id-2320" style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Assets:</b></p> </td> <td id="new_id-2321" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2322" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2323" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-2324" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2325" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2326" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2327" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-2328" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2329" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2330" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2331" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-2332" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2333" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2334" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2335" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-2336" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 52%;"> </td> <td id="new_id-2337" style="width: 1%;"> </td> <td id="new_id-2338" style="width: 1%;"> </td> <td id="new_id-2339" style="width: 9%;"> </td> <td id="new_id-2340" style="width: 1%;"> </td> <td id="new_id-2341" style="width: 1%;"> </td> <td id="new_id-2342" style="width: 1%;"> </td> <td id="new_id-2343" style="width: 9%;"> </td> <td id="new_id-2344" style="width: 1%;"> </td> <td id="new_id-2345" style="width: 1%;"> </td> <td id="new_id-2346" style="width: 1%;"> </td> <td id="new_id-2347" style="width: 9%;"> </td> <td id="new_id-2348" style="width: 1%;"> </td> <td id="new_id-2349" style="width: 1%;"> </td> <td id="new_id-2350" style="width: 1%;"> </td> <td id="new_id-2351" style="width: 9%;"> </td> <td id="new_id-2352" style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Liabilities: </b></p> </td> <td id="new_id-2353" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2354" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td> <td id="new_id-2355" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 9%;"><b> </b></td> <td id="new_id-2356" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td> <td id="new_id-2357" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2358" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td> <td id="new_id-2359" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 9%;"><b> </b></td> <td id="new_id-2360" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td> <td id="new_id-2361" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2362" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td> <td id="new_id-2363" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 9%;"><b> </b></td> <td id="new_id-2364" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td> <td id="new_id-2365" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2366" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td> <td id="new_id-2367" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 9%;"><b> </b></td> <td id="new_id-2368" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 52%;"> </td> <td id="new_id-2369" style="width: 1%;"> </td> <td id="new_id-2370" style="width: 1%;"> </td> <td id="new_id-2371" style="width: 9%;"> </td> <td id="new_id-2372" style="width: 1%;"> </td> <td id="new_id-2373" style="width: 1%;"> </td> <td id="new_id-2374" style="width: 1%;"> </td> <td id="new_id-2375" style="width: 9%;"> </td> <td id="new_id-2376" style="width: 1%;"> </td> <td id="new_id-2377" style="width: 1%;"> </td> <td id="new_id-2378" style="width: 1%;"> </td> <td id="new_id-2379" style="width: 9%;"> </td> <td id="new_id-2380" style="width: 1%;"> </td> <td id="new_id-2381" style="width: 1%;"> </td> <td id="new_id-2382" style="width: 1%;"> </td> <td id="new_id-2383" style="width: 9%;"> </td> <td id="new_id-2384" style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Derivative Liability at fair value as of September 30, 2022</p> </td> <td id="new_id-2385" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2386" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2387" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,207,403</td> <td id="new_id-2388" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2389" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2390" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2391" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-2392" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2393" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2394" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2395" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-2396" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2397" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2398" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2399" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,207,403</td> <td id="new_id-2400" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Derivative Liability warrants at fair value as of September 30, 2022</p> </td> <td id="new_id-2401" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2402" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2403" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">232,609</td> <td id="new_id-2404" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2405" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2406" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2407" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-2408" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2409" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2410" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2411" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-2412" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2413" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2414" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2415" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">232,609</td> <td id="new_id-2416" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Total Derivative Liability as of September 30, 2022</b></p> </td> <td id="new_id-2417" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2418" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-2419" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>1,440,012</b></td> <td id="new_id-2420" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2421" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2422" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 1%;"><b> </b></td> <td id="new_id-2423" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 9%;"><b>-</b></td> <td id="new_id-2424" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"><b> </b></td> <td id="new_id-2425" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2426" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 1%;"><b> </b></td> <td id="new_id-2427" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 9%;"><b>-</b></td> <td id="new_id-2428" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"><b> </b></td> <td id="new_id-2429" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2430" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-2431" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>1,440,012</b></td> <td id="new_id-2432" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Derivative Liability at fair value as of March 31, 2023</p> </td> <td id="new_id-2433" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2434" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2435" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,211,565</td> <td id="new_id-2436" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2437" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2438" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 1%;"> </td> <td id="new_id-2439" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 9%;">-</td> <td id="new_id-2440" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td id="new_id-2441" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2442" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 1%;"> </td> <td id="new_id-2443" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 9%;">-</td> <td id="new_id-2444" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td id="new_id-2445" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2446" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2447" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,211,565</td> <td id="new_id-2448" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Derivative Liability warrants at fair value as of March 31, 2023</p> </td> <td id="new_id-2449" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2450" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2451" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">557,694</td> <td id="new_id-2452" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2453" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2454" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 1%;"> </td> <td id="new_id-2455" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 9%;">-</td> <td id="new_id-2456" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td id="new_id-2457" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2458" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 1%;"> </td> <td id="new_id-2459" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 9%;">-</td> <td id="new_id-2460" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td id="new_id-2461" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2462" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2463" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">557,694</td> <td id="new_id-2464" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Total Derivative Liability as of March 31, 2023</b></p> </td> <td id="new_id-2465" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2466" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-2467" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>1,769,259</b></td> <td id="new_id-2468" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2469" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2470" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 1%;"><b> </b></td> <td id="new_id-2471" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 9%;"><b>-</b></td> <td id="new_id-2472" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"><b> </b></td> <td id="new_id-2473" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2474" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 1%;"><b> </b></td> <td id="new_id-2475" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 9%;"><b>-</b></td> <td id="new_id-2476" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"><b> </b></td> <td id="new_id-2477" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2478" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-2479" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>1,769,259</b></td> <td id="new_id-2480" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> </table><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following is a reconciliation of the derivative liability for which Level 3 inputs were used in determining the approximate fair value:</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2481" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2482" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Derivative Liability </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Promissory Notes</b></p> </td> <td id="new_id-2483" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2484" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2485" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Derivative </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Liability Warrants</b></p> </td> <td id="new_id-2486" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2487" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2488" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Total </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Derivative Liability</b></p> </td> <td id="new_id-2489" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Balance as of September 30, 2021</b></p> </td> <td id="new_id-2490" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2491" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td id="new_id-2492" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>2,553,979 </b></td> <td id="new_id-2493" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2494" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2495" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td id="new_id-2496" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>372,643 </b></td> <td id="new_id-2497" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2498" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2499" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td id="new_id-2500" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>2,926,622 </b></td> <td id="new_id-2501" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Fiscal year 2022 initial derivative liabilities</p> </td> <td id="new_id-2502" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2503" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2504" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">593,297</td> <td id="new_id-2505" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2506" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2507" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2508" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">282,051</td> <td id="new_id-2509" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2510" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2511" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2512" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">875,348</td> <td id="new_id-2513" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net (Gain)/Loss on change in fair value of derivative liability</p> </td> <td id="new_id-2514" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2515" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2516" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1,662,156</td> <td id="new_id-2517" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td id="new_id-2518" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2519" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2520" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(422,086</td> <td id="new_id-2521" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td id="new_id-2522" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2523" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2524" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(2,084,242</td> <td id="new_id-2525" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Extinguishment of derivative</p> </td> <td id="new_id-2526" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2527" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2528" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(277,716</td> <td id="new_id-2529" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td id="new_id-2530" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2531" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2532" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td id="new_id-2533" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2534" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2535" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2536" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(277,716</td> <td id="new_id-2537" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Ending balance as of September 30, 2022</b></p> </td> <td id="new_id-2538" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2539" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td id="new_id-2540" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>1,207,403 </b></td> <td id="new_id-2541" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2542" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2543" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td id="new_id-2544" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>232,609 </b></td> <td id="new_id-2545" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2546" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2547" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td id="new_id-2548" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>1,440,012 </b></td> <td id="new_id-2549" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Six Months ended March 31, 2023, initial derivative liabilities</p> </td> <td id="new_id-2550" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2551" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2552" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">212,256</td> <td id="new_id-2553" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2554" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2555" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2556" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td id="new_id-2557" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2558" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2559" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2560" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">212,256</td> <td id="new_id-2561" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net (Gain)/Loss on change in fair value of derivative liability</p> </td> <td id="new_id-2562" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2563" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2564" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(69,231</td> <td id="new_id-2565" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;">)</td> <td id="new_id-2566" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2567" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2568" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">325,085</td> <td id="new_id-2569" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2570" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2571" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2572" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">255,854</td> <td id="new_id-2573" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Extinguishment of derivative</p> </td> <td id="new_id-2574" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2575" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2576" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(138,863</td> <td id="new_id-2577" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;">)</td> <td id="new_id-2578" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2579" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2580" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td id="new_id-2581" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2582" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2583" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2584" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(138,863</td> <td id="new_id-2585" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Ending balance as of March 31, 2023</b></p> </td> <td id="new_id-2586" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2587" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-2588" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>1,211,565</b></td> <td id="new_id-2589" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2590" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2591" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-2592" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>557,694</b></td> <td id="new_id-2593" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2594" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2595" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-2596" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>1,769,259</b></td> <td id="new_id-2597" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> </table><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">Recent Accounting Pronouncements</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In September 2022, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2022-04, "Liabilities-Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations". This guidance requires annual and interim disclosures for entities that use supplier finance programs in connection with the purchase of goods and services. The ASU is effective for fiscal years beginning after December 15, 2022, with early adoption permitted, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 15, 2023. We are currently evaluating the extent of the impact of this ASU, but do not expect the adoption of this standard to have a significant impact on our consolidated financial statements.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sales Restrictions, which (1) clarifies the guidance in Topic 820 on the fair value measurement of an equity security that is subject to contractual restrictions that prohibit the sale of an equity security and (2) requires specific disclosures related to such an equity security. We are currently evaluating the extent of the impact of this ASU, but do not expect the adoption of this standard to have a significant impact on our consolidated financial statements.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In March 2022, the FASB issued ASU No. 2022-02, Troubled Debt Restructurings and Vintage Disclosures ("ASU 2022-02"). ASU 2022-02 eliminates the accounting guidance on troubled debt restructurings for creditors in ASC Topic 310 and amends the guidance on "vintage disclosures" to require disclosure of current-period gross write-offs by year of origination. ASU 2022-02 also updates the requirements related to accounting for credit losses under ASC Topic 326 and adds enhanced disclosures for creditors with respect to loan refinancings and restructurings for borrowers experiencing financial difficulty. ASU 2022-02 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We are currently evaluating the extent of the impact of this ASU, but do not expect the adoption of this standard to have a significant impact on our consolidated financial statements.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Management does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">Basis of Presentation</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary StemVax, LLC. All significant inter-company accounts and transactions between these entities have been eliminated in these consolidated financial statements.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying consolidated financial statements. Significant estimates made in preparing these consolidated financial statements include the estimate of the deferred tax valuation allowance, the fair value of stock options, and derivative liabilities. Actual results could differ from those estimates.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">Cash and Cash Equivalents </span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For purposes of the statements of cash flows, cash and cash equivalents include cash in banks and money markets with an original maturity of three months or less.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">Stock-Based Compensation</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Share-based Payment applies to transactions in which an entity exchanges its equity instruments for goods or services and also applies to liabilities an entity may incur for goods or services that are to follow a fair value of those equity instruments. We are required to follow a fair value approach using an option-pricing model, such as the Binomial lattice valuation model, at the date of a stock option grant. The deferred compensation calculated under the fair value method would then be amortized over the respective vesting period of the stock option. This has not had a material impact on our results of operations.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">Net Earnings (Loss) per Share Calculations</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Net earnings (Loss) per share dictates the calculation of basic earnings (loss) per share and diluted earnings (loss) per share. Basic earnings (loss) per share are computed by dividing by the weighted average number of common shares outstanding during the period. Diluted net earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the effect of stock options and stock-based awards plus the assumed conversion of convertible debt (see notes 4 and 5). </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> </td> <td id="new_id-2172" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="6" id="new_id-2173" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>For the three months ended</b></p> </td> <td id="new_id-2174" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 1%;"> </td> <td id="new_id-2175" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 1%;"> </td> <td colspan="6" id="new_id-2176" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>For the Six months ended</b></p> </td> <td id="new_id-2177" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> </td> <td id="new_id-2178" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="6" id="new_id-2179" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>March 31,</b></p> </td> <td id="new_id-2180" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; text-align: center; width: 1%;"> </td> <td id="new_id-2181" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 1%;"> </td> <td colspan="6" id="new_id-2182" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>March 31,</b></p> </td> <td id="new_id-2183" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> </td> <td id="new_id-2184" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="2" id="new_id-2185" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>2023</b></p> </td> <td id="new_id-2186" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; text-align: center; width: 1%;"> </td> <td id="new_id-2187" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 1%;"> </td> <td colspan="2" id="new_id-2188" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>2022</b></p> </td> <td id="new_id-2189" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; text-align: center; width: 1%;"> </td> <td id="new_id-2190" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 1%;"> </td> <td colspan="2" id="new_id-2191" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>2023</b></p> </td> <td id="new_id-2192" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; text-align: center; width: 1%;"> </td> <td id="new_id-2193" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;"> </td> <td id="new_id-2194" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"><b> </b></td> <td id="new_id-2195" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"><b>2022</b></td> <td id="new_id-2196" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 52%;"> </td> <td id="new_id-2197" style="width: 1%;"> </td> <td id="new_id-2198" style="width: 1%;"> </td> <td id="new_id-2199" style="width: 9%;"> </td> <td id="new_id-2200" style="width: 1%;"> </td> <td id="new_id-2201" style="width: 1%;"> </td> <td id="new_id-2202" style="width: 1%;"> </td> <td id="new_id-2203" style="width: 9%;"> </td> <td id="new_id-2204" style="width: 1%;"> </td> <td id="new_id-2205" style="width: 1%;"> </td> <td id="new_id-2206" style="width: 1%;"> </td> <td id="new_id-2207" style="width: 9%;"> </td> <td id="new_id-2208" style="width: 1%;"> </td> <td id="new_id-2209" style="width: 1%;"> </td> <td id="new_id-2210" style="width: 1%;"> </td> <td id="new_id-2211" style="width: 9%;"> </td> <td id="new_id-2212" style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Income (Loss) to common shareholders (Numerator)</p> </td> <td id="new_id-2213" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2214" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td id="new_id-2215" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">409,523</td> <td id="new_id-2216" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2217" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2218" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2219" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(1,229,785</td> <td id="new_id-2220" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;">)</td> <td id="new_id-2221" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2222" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td id="new_id-2223" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(2,221,883</td> <td id="new_id-2224" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;">)</td> <td id="new_id-2225" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2226" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2227" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(1,373,093</td> <td id="new_id-2228" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 52%;"> </td> <td id="new_id-2229" style="width: 1%;"> </td> <td id="new_id-2230" style="width: 1%;"> </td> <td id="new_id-2231" style="width: 9%;"> </td> <td id="new_id-2232" style="width: 1%;"> </td> <td id="new_id-2233" style="width: 1%;"> </td> <td id="new_id-2234" style="width: 1%;"> </td> <td id="new_id-2235" style="width: 9%;"> </td> <td id="new_id-2236" style="width: 1%;"> </td> <td id="new_id-2237" style="width: 1%;"> </td> <td id="new_id-2238" style="width: 1%;"> </td> <td id="new_id-2239" style="width: 9%;"> </td> <td id="new_id-2240" style="width: 1%;"> </td> <td id="new_id-2241" style="width: 1%;"> </td> <td id="new_id-2242" style="width: 1%;"> </td> <td id="new_id-2243" style="width: 9%;"> </td> <td id="new_id-2244" style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Basic weighted average number of common shares outstanding (Denominator)</p> </td> <td id="new_id-2245" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2246" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2247" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">20,698,747</td> <td id="new_id-2248" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2249" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2250" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2251" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">15,379,289</td> <td id="new_id-2252" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2253" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2254" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2255" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">19,832,524</td> <td id="new_id-2256" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2257" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2258" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2259" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">14,914,920</td> <td id="new_id-2260" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 52%;"> </td> <td id="new_id-2261" style="width: 1%;"> </td> <td id="new_id-2262" style="width: 1%;"> </td> <td id="new_id-2263" style="width: 9%;"> </td> <td id="new_id-2264" style="width: 1%;"> </td> <td id="new_id-2265" style="width: 1%;"> </td> <td id="new_id-2266" style="width: 1%;"> </td> <td id="new_id-2267" style="width: 9%;"> </td> <td id="new_id-2268" style="width: 1%;"> </td> <td id="new_id-2269" style="width: 1%;"> </td> <td id="new_id-2270" style="width: 1%;"> </td> <td id="new_id-2271" style="width: 9%;"> </td> <td id="new_id-2272" style="width: 1%;"> </td> <td id="new_id-2273" style="width: 1%;"> </td> <td id="new_id-2274" style="width: 1%;"> </td> <td id="new_id-2275" style="width: 9%;"> </td> <td id="new_id-2276" style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Diluted weighted average number of common shares outstanding</p> </td> <td id="new_id-2277" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2278" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2279" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">39,680,653</td> <td id="new_id-2280" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2281" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2282" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2283" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">15,379,289</td> <td id="new_id-2284" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2285" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2286" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2287" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">19,832,524,</td> <td id="new_id-2288" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2289" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2290" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2291" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">14,914,920</td> <td id="new_id-2292" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> </table><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Net earnings (Loss) per share dictates the calculation of basic earnings (loss) per share and diluted earnings (loss) per share. Basic earnings (loss) per share are computed by dividing by the weighted average number of common shares outstanding during the period. Diluted net earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the effect of stock options and stock-based awards plus the assumed conversion of convertible debt (see notes 4 and 5). </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> </td> <td id="new_id-2172" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="6" id="new_id-2173" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>For the three months ended</b></p> </td> <td id="new_id-2174" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 1%;"> </td> <td id="new_id-2175" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 1%;"> </td> <td colspan="6" id="new_id-2176" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>For the Six months ended</b></p> </td> <td id="new_id-2177" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> </td> <td id="new_id-2178" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="6" id="new_id-2179" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>March 31,</b></p> </td> <td id="new_id-2180" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; text-align: center; width: 1%;"> </td> <td id="new_id-2181" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 1%;"> </td> <td colspan="6" id="new_id-2182" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>March 31,</b></p> </td> <td id="new_id-2183" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> </td> <td id="new_id-2184" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="2" id="new_id-2185" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>2023</b></p> </td> <td id="new_id-2186" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; text-align: center; width: 1%;"> </td> <td id="new_id-2187" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 1%;"> </td> <td colspan="2" id="new_id-2188" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>2022</b></p> </td> <td id="new_id-2189" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; text-align: center; width: 1%;"> </td> <td id="new_id-2190" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 1%;"> </td> <td colspan="2" id="new_id-2191" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>2023</b></p> </td> <td id="new_id-2192" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; text-align: center; width: 1%;"> </td> <td id="new_id-2193" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;"> </td> <td id="new_id-2194" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"><b> </b></td> <td id="new_id-2195" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"><b>2022</b></td> <td id="new_id-2196" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 52%;"> </td> <td id="new_id-2197" style="width: 1%;"> </td> <td id="new_id-2198" style="width: 1%;"> </td> <td id="new_id-2199" style="width: 9%;"> </td> <td id="new_id-2200" style="width: 1%;"> </td> <td id="new_id-2201" style="width: 1%;"> </td> <td id="new_id-2202" style="width: 1%;"> </td> <td id="new_id-2203" style="width: 9%;"> </td> <td id="new_id-2204" style="width: 1%;"> </td> <td id="new_id-2205" style="width: 1%;"> </td> <td id="new_id-2206" style="width: 1%;"> </td> <td id="new_id-2207" style="width: 9%;"> </td> <td id="new_id-2208" style="width: 1%;"> </td> <td id="new_id-2209" style="width: 1%;"> </td> <td id="new_id-2210" style="width: 1%;"> </td> <td id="new_id-2211" style="width: 9%;"> </td> <td id="new_id-2212" style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Income (Loss) to common shareholders (Numerator)</p> </td> <td id="new_id-2213" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2214" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td id="new_id-2215" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">409,523</td> <td id="new_id-2216" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2217" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2218" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2219" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(1,229,785</td> <td id="new_id-2220" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;">)</td> <td id="new_id-2221" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2222" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td id="new_id-2223" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(2,221,883</td> <td id="new_id-2224" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;">)</td> <td id="new_id-2225" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2226" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2227" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(1,373,093</td> <td id="new_id-2228" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 52%;"> </td> <td id="new_id-2229" style="width: 1%;"> </td> <td id="new_id-2230" style="width: 1%;"> </td> <td id="new_id-2231" style="width: 9%;"> </td> <td id="new_id-2232" style="width: 1%;"> </td> <td id="new_id-2233" style="width: 1%;"> </td> <td id="new_id-2234" style="width: 1%;"> </td> <td id="new_id-2235" style="width: 9%;"> </td> <td id="new_id-2236" style="width: 1%;"> </td> <td id="new_id-2237" style="width: 1%;"> </td> <td id="new_id-2238" style="width: 1%;"> </td> <td id="new_id-2239" style="width: 9%;"> </td> <td id="new_id-2240" style="width: 1%;"> </td> <td id="new_id-2241" style="width: 1%;"> </td> <td id="new_id-2242" style="width: 1%;"> </td> <td id="new_id-2243" style="width: 9%;"> </td> <td id="new_id-2244" style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Basic weighted average number of common shares outstanding (Denominator)</p> </td> <td id="new_id-2245" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2246" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2247" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">20,698,747</td> <td id="new_id-2248" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2249" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2250" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2251" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">15,379,289</td> <td id="new_id-2252" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2253" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2254" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2255" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">19,832,524</td> <td id="new_id-2256" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2257" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2258" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2259" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">14,914,920</td> <td id="new_id-2260" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 52%;"> </td> <td id="new_id-2261" style="width: 1%;"> </td> <td id="new_id-2262" style="width: 1%;"> </td> <td id="new_id-2263" style="width: 9%;"> </td> <td id="new_id-2264" style="width: 1%;"> </td> <td id="new_id-2265" style="width: 1%;"> </td> <td id="new_id-2266" style="width: 1%;"> </td> <td id="new_id-2267" style="width: 9%;"> </td> <td id="new_id-2268" style="width: 1%;"> </td> <td id="new_id-2269" style="width: 1%;"> </td> <td id="new_id-2270" style="width: 1%;"> </td> <td id="new_id-2271" style="width: 9%;"> </td> <td id="new_id-2272" style="width: 1%;"> </td> <td id="new_id-2273" style="width: 1%;"> </td> <td id="new_id-2274" style="width: 1%;"> </td> <td id="new_id-2275" style="width: 9%;"> </td> <td id="new_id-2276" style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Diluted weighted average number of common shares outstanding</p> </td> <td id="new_id-2277" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2278" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2279" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">39,680,653</td> <td id="new_id-2280" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2281" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2282" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2283" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">15,379,289</td> <td id="new_id-2284" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2285" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2286" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2287" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">19,832,524,</td> <td id="new_id-2288" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2289" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2290" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2291" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">14,914,920</td> <td id="new_id-2292" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> </table><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 409523 -1229785 -2221883 -1373093 20698747 15379289 19832524 14914920 39680653 15379289 19832524 14914920 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">Fair Value of Financial Instruments</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Fair Value of Financial Instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of March 31, 2023, the balances reported for cash, prepaid expenses, accounts payable, accrued expenses approximate the fair value because of their short maturities.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We adopted Accounting Standards Codification (“ASC”) Topic 820 for financial instruments measured as fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States and expands disclosures about fair value measurements.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tr> <td style="vertical-align:middle;width:0.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:top;width:0.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="vertical-align:top;width:8.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;</p> </td> </tr> </table><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tr> <td style="vertical-align:middle;width:0.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:top;width:0.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="vertical-align:top;width:8.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</p> </td> </tr> </table><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tr> <td style="vertical-align:middle;width:0.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:top;width:0.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="vertical-align:top;width:8.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</p> </td> </tr> </table><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We measure certain financial instruments at fair value on a recurring basis. The Company had no assets that are required to be valued on a recurring basis as of March 31, 2023<b> </b>and September 30, 2022. The Company had liabilities that are required to be measured at fair value on a recurring basis as follows at March 31 2023 and September 30, 2022:</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> </td> <td id="new_id-2293" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="2" id="new_id-2294" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Total</b></p> </td> <td id="new_id-2295" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td id="new_id-2296" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="2" id="new_id-2297" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Level 1)</b></p> </td> <td id="new_id-2298" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td id="new_id-2299" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="2" id="new_id-2300" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Level 2)</b></p> </td> <td id="new_id-2301" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td id="new_id-2302" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="2" id="new_id-2303" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Level 3)</b></p> </td> <td id="new_id-2304" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 52%;"> </td> <td id="new_id-2305" style="width: 1%;"> </td> <td id="new_id-2306" style="width: 1%;"> </td> <td id="new_id-2307" style="width: 9%;"> </td> <td id="new_id-2308" style="width: 1%;"> </td> <td id="new_id-2309" style="width: 1%;"> </td> <td id="new_id-2310" style="width: 1%;"> </td> <td id="new_id-2311" style="width: 9%;"> </td> <td id="new_id-2312" style="width: 1%;"> </td> <td id="new_id-2313" style="width: 1%;"> </td> <td id="new_id-2314" style="width: 1%;"> </td> <td id="new_id-2315" style="width: 9%;"> </td> <td id="new_id-2316" style="width: 1%;"> </td> <td id="new_id-2317" style="width: 1%;"> </td> <td id="new_id-2318" style="width: 1%;"> </td> <td id="new_id-2319" style="width: 9%;"> </td> <td id="new_id-2320" style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Assets:</b></p> </td> <td id="new_id-2321" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2322" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2323" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-2324" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2325" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2326" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2327" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-2328" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2329" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2330" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2331" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-2332" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2333" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2334" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2335" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-2336" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 52%;"> </td> <td id="new_id-2337" style="width: 1%;"> </td> <td id="new_id-2338" style="width: 1%;"> </td> <td id="new_id-2339" style="width: 9%;"> </td> <td id="new_id-2340" style="width: 1%;"> </td> <td id="new_id-2341" style="width: 1%;"> </td> <td id="new_id-2342" style="width: 1%;"> </td> <td id="new_id-2343" style="width: 9%;"> </td> <td id="new_id-2344" style="width: 1%;"> </td> <td id="new_id-2345" style="width: 1%;"> </td> <td id="new_id-2346" style="width: 1%;"> </td> <td id="new_id-2347" style="width: 9%;"> </td> <td id="new_id-2348" style="width: 1%;"> </td> <td id="new_id-2349" style="width: 1%;"> </td> <td id="new_id-2350" style="width: 1%;"> </td> <td id="new_id-2351" style="width: 9%;"> </td> <td id="new_id-2352" style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Liabilities: </b></p> </td> <td id="new_id-2353" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2354" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td> <td id="new_id-2355" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 9%;"><b> </b></td> <td id="new_id-2356" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td> <td id="new_id-2357" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2358" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td> <td id="new_id-2359" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 9%;"><b> </b></td> <td id="new_id-2360" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td> <td id="new_id-2361" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2362" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td> <td id="new_id-2363" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 9%;"><b> </b></td> <td id="new_id-2364" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td> <td id="new_id-2365" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2366" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td> <td id="new_id-2367" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 9%;"><b> </b></td> <td id="new_id-2368" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 52%;"> </td> <td id="new_id-2369" style="width: 1%;"> </td> <td id="new_id-2370" style="width: 1%;"> </td> <td id="new_id-2371" style="width: 9%;"> </td> <td id="new_id-2372" style="width: 1%;"> </td> <td id="new_id-2373" style="width: 1%;"> </td> <td id="new_id-2374" style="width: 1%;"> </td> <td id="new_id-2375" style="width: 9%;"> </td> <td id="new_id-2376" style="width: 1%;"> </td> <td id="new_id-2377" style="width: 1%;"> </td> <td id="new_id-2378" style="width: 1%;"> </td> <td id="new_id-2379" style="width: 9%;"> </td> <td id="new_id-2380" style="width: 1%;"> </td> <td id="new_id-2381" style="width: 1%;"> </td> <td id="new_id-2382" style="width: 1%;"> </td> <td id="new_id-2383" style="width: 9%;"> </td> <td id="new_id-2384" style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Derivative Liability at fair value as of September 30, 2022</p> </td> <td id="new_id-2385" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2386" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2387" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,207,403</td> <td id="new_id-2388" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2389" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2390" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2391" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-2392" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2393" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2394" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2395" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-2396" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2397" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2398" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2399" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,207,403</td> <td id="new_id-2400" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Derivative Liability warrants at fair value as of September 30, 2022</p> </td> <td id="new_id-2401" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2402" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2403" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">232,609</td> <td id="new_id-2404" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2405" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2406" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2407" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-2408" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2409" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2410" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2411" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-2412" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2413" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2414" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2415" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">232,609</td> <td id="new_id-2416" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Total Derivative Liability as of September 30, 2022</b></p> </td> <td id="new_id-2417" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2418" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-2419" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>1,440,012</b></td> <td id="new_id-2420" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2421" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2422" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 1%;"><b> </b></td> <td id="new_id-2423" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 9%;"><b>-</b></td> <td id="new_id-2424" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"><b> </b></td> <td id="new_id-2425" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2426" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 1%;"><b> </b></td> <td id="new_id-2427" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 9%;"><b>-</b></td> <td id="new_id-2428" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"><b> </b></td> <td id="new_id-2429" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2430" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-2431" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>1,440,012</b></td> <td id="new_id-2432" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Derivative Liability at fair value as of March 31, 2023</p> </td> <td id="new_id-2433" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2434" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2435" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,211,565</td> <td id="new_id-2436" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2437" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2438" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 1%;"> </td> <td id="new_id-2439" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 9%;">-</td> <td id="new_id-2440" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td id="new_id-2441" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2442" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 1%;"> </td> <td id="new_id-2443" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 9%;">-</td> <td id="new_id-2444" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td id="new_id-2445" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2446" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2447" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,211,565</td> <td id="new_id-2448" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Derivative Liability warrants at fair value as of March 31, 2023</p> </td> <td id="new_id-2449" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2450" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2451" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">557,694</td> <td id="new_id-2452" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2453" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2454" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 1%;"> </td> <td id="new_id-2455" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 9%;">-</td> <td id="new_id-2456" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td id="new_id-2457" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2458" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 1%;"> </td> <td id="new_id-2459" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 9%;">-</td> <td id="new_id-2460" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td id="new_id-2461" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2462" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2463" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">557,694</td> <td id="new_id-2464" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Total Derivative Liability as of March 31, 2023</b></p> </td> <td id="new_id-2465" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2466" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-2467" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>1,769,259</b></td> <td id="new_id-2468" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2469" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2470" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 1%;"><b> </b></td> <td id="new_id-2471" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 9%;"><b>-</b></td> <td id="new_id-2472" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"><b> </b></td> <td id="new_id-2473" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2474" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 1%;"><b> </b></td> <td id="new_id-2475" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 9%;"><b>-</b></td> <td id="new_id-2476" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"><b> </b></td> <td id="new_id-2477" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2478" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-2479" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>1,769,259</b></td> <td id="new_id-2480" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> </table><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following is a reconciliation of the derivative liability for which Level 3 inputs were used in determining the approximate fair value:</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2481" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2482" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Derivative Liability </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Promissory Notes</b></p> </td> <td id="new_id-2483" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2484" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2485" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Derivative </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Liability Warrants</b></p> </td> <td id="new_id-2486" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2487" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2488" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Total </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Derivative Liability</b></p> </td> <td id="new_id-2489" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Balance as of September 30, 2021</b></p> </td> <td id="new_id-2490" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2491" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td id="new_id-2492" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>2,553,979 </b></td> <td id="new_id-2493" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2494" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2495" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td id="new_id-2496" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>372,643 </b></td> <td id="new_id-2497" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2498" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2499" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td id="new_id-2500" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>2,926,622 </b></td> <td id="new_id-2501" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Fiscal year 2022 initial derivative liabilities</p> </td> <td id="new_id-2502" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2503" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2504" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">593,297</td> <td id="new_id-2505" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2506" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2507" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2508" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">282,051</td> <td id="new_id-2509" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2510" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2511" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2512" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">875,348</td> <td id="new_id-2513" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net (Gain)/Loss on change in fair value of derivative liability</p> </td> <td id="new_id-2514" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2515" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2516" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1,662,156</td> <td id="new_id-2517" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td id="new_id-2518" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2519" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2520" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(422,086</td> <td id="new_id-2521" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td id="new_id-2522" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2523" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2524" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(2,084,242</td> <td id="new_id-2525" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Extinguishment of derivative</p> </td> <td id="new_id-2526" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2527" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2528" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(277,716</td> <td id="new_id-2529" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td id="new_id-2530" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2531" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2532" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td id="new_id-2533" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2534" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2535" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2536" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(277,716</td> <td id="new_id-2537" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Ending balance as of September 30, 2022</b></p> </td> <td id="new_id-2538" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2539" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td id="new_id-2540" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>1,207,403 </b></td> <td id="new_id-2541" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2542" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2543" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td id="new_id-2544" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>232,609 </b></td> <td id="new_id-2545" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2546" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2547" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td id="new_id-2548" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>1,440,012 </b></td> <td id="new_id-2549" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Six Months ended March 31, 2023, initial derivative liabilities</p> </td> <td id="new_id-2550" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2551" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2552" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">212,256</td> <td id="new_id-2553" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2554" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2555" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2556" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td id="new_id-2557" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2558" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2559" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2560" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">212,256</td> <td id="new_id-2561" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net (Gain)/Loss on change in fair value of derivative liability</p> </td> <td id="new_id-2562" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2563" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2564" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(69,231</td> <td id="new_id-2565" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;">)</td> <td id="new_id-2566" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2567" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2568" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">325,085</td> <td id="new_id-2569" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2570" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2571" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2572" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">255,854</td> <td id="new_id-2573" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Extinguishment of derivative</p> </td> <td id="new_id-2574" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2575" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2576" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(138,863</td> <td id="new_id-2577" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;">)</td> <td id="new_id-2578" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2579" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2580" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td id="new_id-2581" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2582" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2583" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2584" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(138,863</td> <td id="new_id-2585" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Ending balance as of March 31, 2023</b></p> </td> <td id="new_id-2586" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2587" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-2588" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>1,211,565</b></td> <td id="new_id-2589" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2590" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2591" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-2592" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>557,694</b></td> <td id="new_id-2593" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2594" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2595" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-2596" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>1,769,259</b></td> <td id="new_id-2597" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> </table><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We measure certain financial instruments at fair value on a recurring basis. The Company had no assets that are required to be valued on a recurring basis as of March 31, 2023<b> </b>and September 30, 2022. The Company had liabilities that are required to be measured at fair value on a recurring basis as follows at March 31 2023 and September 30, 2022:</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> </td> <td id="new_id-2293" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="2" id="new_id-2294" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Total</b></p> </td> <td id="new_id-2295" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td id="new_id-2296" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="2" id="new_id-2297" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Level 1)</b></p> </td> <td id="new_id-2298" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td id="new_id-2299" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="2" id="new_id-2300" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Level 2)</b></p> </td> <td id="new_id-2301" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td id="new_id-2302" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="2" id="new_id-2303" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Level 3)</b></p> </td> <td id="new_id-2304" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 52%;"> </td> <td id="new_id-2305" style="width: 1%;"> </td> <td id="new_id-2306" style="width: 1%;"> </td> <td id="new_id-2307" style="width: 9%;"> </td> <td id="new_id-2308" style="width: 1%;"> </td> <td id="new_id-2309" style="width: 1%;"> </td> <td id="new_id-2310" style="width: 1%;"> </td> <td id="new_id-2311" style="width: 9%;"> </td> <td id="new_id-2312" style="width: 1%;"> </td> <td id="new_id-2313" style="width: 1%;"> </td> <td id="new_id-2314" style="width: 1%;"> </td> <td id="new_id-2315" style="width: 9%;"> </td> <td id="new_id-2316" style="width: 1%;"> </td> <td id="new_id-2317" style="width: 1%;"> </td> <td id="new_id-2318" style="width: 1%;"> </td> <td id="new_id-2319" style="width: 9%;"> </td> <td id="new_id-2320" style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Assets:</b></p> </td> <td id="new_id-2321" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2322" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2323" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-2324" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2325" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2326" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2327" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-2328" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2329" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2330" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2331" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-2332" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2333" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2334" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2335" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-2336" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 52%;"> </td> <td id="new_id-2337" style="width: 1%;"> </td> <td id="new_id-2338" style="width: 1%;"> </td> <td id="new_id-2339" style="width: 9%;"> </td> <td id="new_id-2340" style="width: 1%;"> </td> <td id="new_id-2341" style="width: 1%;"> </td> <td id="new_id-2342" style="width: 1%;"> </td> <td id="new_id-2343" style="width: 9%;"> </td> <td id="new_id-2344" style="width: 1%;"> </td> <td id="new_id-2345" style="width: 1%;"> </td> <td id="new_id-2346" style="width: 1%;"> </td> <td id="new_id-2347" style="width: 9%;"> </td> <td id="new_id-2348" style="width: 1%;"> </td> <td id="new_id-2349" style="width: 1%;"> </td> <td id="new_id-2350" style="width: 1%;"> </td> <td id="new_id-2351" style="width: 9%;"> </td> <td id="new_id-2352" style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Liabilities: </b></p> </td> <td id="new_id-2353" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2354" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td> <td id="new_id-2355" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 9%;"><b> </b></td> <td id="new_id-2356" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td> <td id="new_id-2357" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2358" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td> <td id="new_id-2359" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 9%;"><b> </b></td> <td id="new_id-2360" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td> <td id="new_id-2361" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2362" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td> <td id="new_id-2363" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 9%;"><b> </b></td> <td id="new_id-2364" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td> <td id="new_id-2365" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2366" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td> <td id="new_id-2367" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 9%;"><b> </b></td> <td id="new_id-2368" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 52%;"> </td> <td id="new_id-2369" style="width: 1%;"> </td> <td id="new_id-2370" style="width: 1%;"> </td> <td id="new_id-2371" style="width: 9%;"> </td> <td id="new_id-2372" style="width: 1%;"> </td> <td id="new_id-2373" style="width: 1%;"> </td> <td id="new_id-2374" style="width: 1%;"> </td> <td id="new_id-2375" style="width: 9%;"> </td> <td id="new_id-2376" style="width: 1%;"> </td> <td id="new_id-2377" style="width: 1%;"> </td> <td id="new_id-2378" style="width: 1%;"> </td> <td id="new_id-2379" style="width: 9%;"> </td> <td id="new_id-2380" style="width: 1%;"> </td> <td id="new_id-2381" style="width: 1%;"> </td> <td id="new_id-2382" style="width: 1%;"> </td> <td id="new_id-2383" style="width: 9%;"> </td> <td id="new_id-2384" style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Derivative Liability at fair value as of September 30, 2022</p> </td> <td id="new_id-2385" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2386" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2387" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,207,403</td> <td id="new_id-2388" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2389" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2390" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2391" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-2392" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2393" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2394" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2395" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-2396" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2397" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2398" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2399" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,207,403</td> <td id="new_id-2400" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Derivative Liability warrants at fair value as of September 30, 2022</p> </td> <td id="new_id-2401" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2402" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2403" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">232,609</td> <td id="new_id-2404" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2405" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2406" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2407" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-2408" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2409" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2410" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2411" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-2412" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2413" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2414" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2415" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">232,609</td> <td id="new_id-2416" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Total Derivative Liability as of September 30, 2022</b></p> </td> <td id="new_id-2417" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2418" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-2419" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>1,440,012</b></td> <td id="new_id-2420" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2421" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2422" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 1%;"><b> </b></td> <td id="new_id-2423" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 9%;"><b>-</b></td> <td id="new_id-2424" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"><b> </b></td> <td id="new_id-2425" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2426" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 1%;"><b> </b></td> <td id="new_id-2427" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 9%;"><b>-</b></td> <td id="new_id-2428" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"><b> </b></td> <td id="new_id-2429" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2430" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-2431" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>1,440,012</b></td> <td id="new_id-2432" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Derivative Liability at fair value as of March 31, 2023</p> </td> <td id="new_id-2433" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2434" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2435" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,211,565</td> <td id="new_id-2436" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2437" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2438" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 1%;"> </td> <td id="new_id-2439" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 9%;">-</td> <td id="new_id-2440" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td id="new_id-2441" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2442" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 1%;"> </td> <td id="new_id-2443" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 9%;">-</td> <td id="new_id-2444" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td id="new_id-2445" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2446" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2447" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,211,565</td> <td id="new_id-2448" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Derivative Liability warrants at fair value as of March 31, 2023</p> </td> <td id="new_id-2449" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2450" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2451" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">557,694</td> <td id="new_id-2452" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2453" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2454" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 1%;"> </td> <td id="new_id-2455" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 9%;">-</td> <td id="new_id-2456" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td id="new_id-2457" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2458" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 1%;"> </td> <td id="new_id-2459" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 9%;">-</td> <td id="new_id-2460" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td id="new_id-2461" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2462" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-2463" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">557,694</td> <td id="new_id-2464" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Total Derivative Liability as of March 31, 2023</b></p> </td> <td id="new_id-2465" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2466" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-2467" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>1,769,259</b></td> <td id="new_id-2468" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2469" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2470" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 1%;"><b> </b></td> <td id="new_id-2471" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 9%;"><b>-</b></td> <td id="new_id-2472" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"><b> </b></td> <td id="new_id-2473" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td id="new_id-2474" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 1%;"><b> </b></td> <td id="new_id-2475" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); width: 9%;"><b>-</b></td> <td id="new_id-2476" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"><b> </b></td> <td id="new_id-2477" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2478" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-2479" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>1,769,259</b></td> <td id="new_id-2480" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> </table><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> 0 0 0 0 1207403 0 0 1207403 232609 0 0 232609 1440012 0 0 1440012 1211565 0 0 1211565 557694 0 0 557694 1769259 0 0 1769259 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following is a reconciliation of the derivative liability for which Level 3 inputs were used in determining the approximate fair value:</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2481" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2482" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Derivative Liability </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Promissory Notes</b></p> </td> <td id="new_id-2483" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2484" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2485" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Derivative </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Liability Warrants</b></p> </td> <td id="new_id-2486" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2487" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2488" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Total </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Derivative Liability</b></p> </td> <td id="new_id-2489" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Balance as of September 30, 2021</b></p> </td> <td id="new_id-2490" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2491" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td id="new_id-2492" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>2,553,979 </b></td> <td id="new_id-2493" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2494" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2495" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td id="new_id-2496" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>372,643 </b></td> <td id="new_id-2497" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2498" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2499" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td id="new_id-2500" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>2,926,622 </b></td> <td id="new_id-2501" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Fiscal year 2022 initial derivative liabilities</p> </td> <td id="new_id-2502" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2503" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2504" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">593,297</td> <td id="new_id-2505" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2506" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2507" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2508" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">282,051</td> <td id="new_id-2509" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2510" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2511" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2512" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">875,348</td> <td id="new_id-2513" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net (Gain)/Loss on change in fair value of derivative liability</p> </td> <td id="new_id-2514" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2515" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2516" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1,662,156</td> <td id="new_id-2517" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td id="new_id-2518" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2519" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2520" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(422,086</td> <td id="new_id-2521" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td id="new_id-2522" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2523" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2524" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(2,084,242</td> <td id="new_id-2525" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Extinguishment of derivative</p> </td> <td id="new_id-2526" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2527" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2528" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(277,716</td> <td id="new_id-2529" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td id="new_id-2530" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2531" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2532" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td id="new_id-2533" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2534" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2535" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2536" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(277,716</td> <td id="new_id-2537" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Ending balance as of September 30, 2022</b></p> </td> <td id="new_id-2538" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2539" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td id="new_id-2540" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>1,207,403 </b></td> <td id="new_id-2541" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2542" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2543" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td id="new_id-2544" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>232,609 </b></td> <td id="new_id-2545" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2546" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2547" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td id="new_id-2548" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>1,440,012 </b></td> <td id="new_id-2549" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Six Months ended March 31, 2023, initial derivative liabilities</p> </td> <td id="new_id-2550" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2551" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2552" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">212,256</td> <td id="new_id-2553" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2554" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2555" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2556" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td id="new_id-2557" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2558" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2559" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2560" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">212,256</td> <td id="new_id-2561" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net (Gain)/Loss on change in fair value of derivative liability</p> </td> <td id="new_id-2562" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2563" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2564" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(69,231</td> <td id="new_id-2565" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;">)</td> <td id="new_id-2566" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2567" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2568" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">325,085</td> <td id="new_id-2569" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2570" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2571" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2572" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">255,854</td> <td id="new_id-2573" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Extinguishment of derivative</p> </td> <td id="new_id-2574" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2575" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2576" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(138,863</td> <td id="new_id-2577" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;">)</td> <td id="new_id-2578" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2579" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2580" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td id="new_id-2581" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2582" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2583" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2584" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(138,863</td> <td id="new_id-2585" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Ending balance as of March 31, 2023</b></p> </td> <td id="new_id-2586" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2587" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-2588" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>1,211,565</b></td> <td id="new_id-2589" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2590" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2591" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-2592" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>557,694</b></td> <td id="new_id-2593" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2594" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2595" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-2596" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>1,769,259</b></td> <td id="new_id-2597" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> </table><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> 2553979 372643 2926622 593297 282051 875348 -1662156 -422086 -2084242 -277716 0 -277716 1207403 232609 1440012 212256 0 212256 -69231 325085 255854 -138863 0 -138863 1211565 557694 1769259 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">Recent Accounting Pronouncements</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In September 2022, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2022-04, "Liabilities-Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations". This guidance requires annual and interim disclosures for entities that use supplier finance programs in connection with the purchase of goods and services. The ASU is effective for fiscal years beginning after December 15, 2022, with early adoption permitted, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 15, 2023. We are currently evaluating the extent of the impact of this ASU, but do not expect the adoption of this standard to have a significant impact on our consolidated financial statements.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sales Restrictions, which (1) clarifies the guidance in Topic 820 on the fair value measurement of an equity security that is subject to contractual restrictions that prohibit the sale of an equity security and (2) requires specific disclosures related to such an equity security. We are currently evaluating the extent of the impact of this ASU, but do not expect the adoption of this standard to have a significant impact on our consolidated financial statements.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In March 2022, the FASB issued ASU No. 2022-02, Troubled Debt Restructurings and Vintage Disclosures ("ASU 2022-02"). ASU 2022-02 eliminates the accounting guidance on troubled debt restructurings for creditors in ASC Topic 310 and amends the guidance on "vintage disclosures" to require disclosure of current-period gross write-offs by year of origination. ASU 2022-02 also updates the requirements related to accounting for credit losses under ASC Topic 326 and adds enhanced disclosures for creditors with respect to loan refinancings and restructurings for borrowers experiencing financial difficulty. ASU 2022-02 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We are currently evaluating the extent of the impact of this ASU, but do not expect the adoption of this standard to have a significant impact on our consolidated financial statements.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Management does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3. CAPITAL STOCK</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of March 31, 2023 the Company’s authorized stock consisted of 2,000,000,000 shares of common stock, with no par value. Effective August 25, 2020, we filed articles of amendment to our articles of incorporation with the Colorado Secretary of State to effectuate a 1-for-1,000 reverse stock split of the Company’s outstanding shares of common stock.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company is also authorized to issue 50,000,000 shares of preferred stock with a par value of $0.01 per share. The rights, preferences and privileges of the holders of the preferred stock are determined by the Board of Directors prior to issuance of such shares.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">Preferred Stock</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of March 31, 2023, the Company had 600 shares of issued and outstanding Series B Preferred. On September 4, 2020, the Company issued 25,000 shares of unregistered Series B Convertible Preferred stock, $0.01 par value per share, to TN3, LLC, a Wyoming limited liability company owned by Daniel G. Martin (“TN3”), in exchange for the redemption of all 5,000 shares of Series A preferred stock that TN3 previously held. At the time, Mr. Martin was our Chief Executive Officer and sole Board Member. On March 14, 2022, NovAccess redeemed 24,400 shares of the Company’s Series B Convertible Preferred Stock held by TN3. Irvin Consulting LLC, a company owned by Dwain Irvin, the CEO of NovAccess, purchased the remaining 600 shares (please refer to Note 11 for more details).</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Each share of outstanding Series B Preferred Stock entitles the holder to cast 40,000 votes. Each share of Series B Preferred Stock is convertible at the option of the holder into 10,000 common shares. In the event of any voluntary or involuntary liquidation, dissolution, or winding-up of the Corporation, the holders of shares of Series B Preferred Stock shall be paid out based on an as converted basis. Dividends for Series B Preferred Stock shall be declared on an as converted basis.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">Common Stock</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During the six months ended March 31, 2023, the Company issued 2,515,521 shares of common stock.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company issued 1,490,521 shares to various vendors for services provided, including 216,500 shares issued to a related party for services provided, amounting to $259,702 recorded at the fair value of shares on the respective grant dates.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company issued 525,000 shares in relation to stock subscriptions.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company issued 500,000 shares as commitment fees in connection with the letter agreement issued on February 9, 2023. These shares were recorded at fair value as on the date of issuance.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During the six months ended March 31, 2022, the Company issued 3,119,643 shares of common stock. 1,502,670 shares were issued to TN3 as part of the transaction to redeem 24,400 shares of Series B Preferred Stock, 265,973 shares were issued to various vendors for services provided; 791,000 shares were issued in relation to stock subscriptions; 300,000 shares were issued as a commitment fee on a promissory note payable; 250,000 shares were issued as repayment of bridge loans (please refer to Note 4 for more details); and 10,000 shares were issued to related parties (please refer to Note 12 for more details).</p> 2000000000 1-for-1,000 50000000 0.01 600 25000 0.01 24400 600 Each share of outstanding Series B Preferred Stock entitles the holder to cast 40,000 votes. Each share of Series B Preferred Stock is convertible at the option of the holder into 10,000 common shares 2515521 1490521 216500 259702 525000 500000 3119643 1502670 24400 265973 791000 300000 250000 10000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4. CONVERTIBLE PROMISSORY NOTES</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Convertible Promissory notes </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>as on March 31, 2023</b></p> </td> <td id="new_id-2598" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" id="new_id-2599" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Principal Amount</b></p> </td> <td id="new_id-2600" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2601" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" id="new_id-2602" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Unamortized balance of Debt Discount</b></p> </td> <td id="new_id-2603" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2604" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" id="new_id-2605" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Outstanding balance as on March 31, 2023</b></p> </td> <td id="new_id-2606" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2607" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" id="new_id-2608" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Derivative balance as on March 31, 2023</b></p> </td> <td id="new_id-2609" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2610" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" id="new_id-2611" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Warrant liability balance as on March 31, 2023</b></p> </td> <td id="new_id-2612" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1"> </td> <td id="new_id-2613"> </td> <td id="new_id-2614"> </td> <td id="new_id-2615"> </td> <td id="new_id-2616"> </td> <td id="new_id-2617"> </td> <td id="new_id-2618"> </td> <td id="new_id-2619"> </td> <td id="new_id-2620"> </td> <td id="new_id-2621"> </td> <td id="new_id-2622"> </td> <td id="new_id-2623"> </td> <td id="new_id-2624"> </td> <td id="new_id-2625"> </td> <td id="new_id-2626"> </td> <td id="new_id-2627"> </td> <td id="new_id-2628"> </td> <td id="new_id-2629"> </td> <td id="new_id-2630"> </td> <td id="new_id-2631"> </td> <td id="new_id-2632"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2013 Note</p> </td> <td id="new_id-2633" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2634" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2635" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">12,000</td> <td id="new_id-2636" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2637" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2638" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2639" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td id="new_id-2640" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2641" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2642" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2643" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">12,000</td> <td id="new_id-2644" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2645" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2646" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2647" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td id="new_id-2648" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2649" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2650" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2651" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;">-</td> <td id="new_id-2652" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2014 Note</p> </td> <td id="new_id-2653" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2654" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2655" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">50,880</td> <td id="new_id-2656" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2657" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2658" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2659" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td id="new_id-2660" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2661" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2662" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2663" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">50,880</td> <td id="new_id-2664" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2665" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2666" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2667" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">215,591</td> <td id="new_id-2668" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2669" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2670" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2671" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;">-</td> <td id="new_id-2672" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2017 Note</p> </td> <td id="new_id-2673" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2674" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2675" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">115,000</td> <td id="new_id-2676" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2677" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2678" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2679" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td id="new_id-2680" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2681" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2682" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2683" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">115,000</td> <td id="new_id-2684" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2685" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2686" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2687" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">453,384</td> <td id="new_id-2688" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2689" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2690" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2691" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;">-</td> <td id="new_id-2692" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August 2021 Note</p> </td> <td id="new_id-2693" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2694" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2695" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td id="new_id-2696" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2697" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2698" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2699" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td id="new_id-2700" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2701" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2702" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2703" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td id="new_id-2704" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2705" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2706" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2707" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td id="new_id-2708" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2709" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2710" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2711" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">151,920</td> <td id="new_id-2712" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">February 2022 Note</p> </td> <td id="new_id-2713" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2714" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2715" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">250,000</td> <td id="new_id-2716" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2717" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2718" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2719" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td id="new_id-2720" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2721" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2722" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2723" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">250,000</td> <td id="new_id-2724" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2725" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2726" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2727" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">81,815</td> <td id="new_id-2728" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2729" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2730" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2731" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">76,762</td> <td id="new_id-2732" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">May 2022 Note</p> </td> <td id="new_id-2733" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2734" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2735" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,000,000</td> <td id="new_id-2736" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2737" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2738" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2739" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td id="new_id-2740" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2741" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2742" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2743" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,000,000</td> <td id="new_id-2744" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2745" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2746" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2747" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">245,784</td> <td id="new_id-2748" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2749" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2750" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2751" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">171,753</td> <td id="new_id-2752" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August 2022 Note</p> </td> <td id="new_id-2753" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2754" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2755" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">100,000</td> <td id="new_id-2756" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2757" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2758" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2759" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">27,517</td> <td id="new_id-2760" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2761" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2762" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2763" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">72,483</td> <td id="new_id-2764" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2765" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2766" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2767" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">48,797</td> <td id="new_id-2768" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2769" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2770" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2771" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;">-</td> <td id="new_id-2772" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">November 2022 Note</p> </td> <td id="new_id-2773" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2774" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2775" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">55,000</td> <td id="new_id-2776" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2777" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2778" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2779" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">32,937</td> <td id="new_id-2780" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2781" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2782" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2783" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">22,063</td> <td id="new_id-2784" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2785" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2786" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2787" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">48,883</td> <td id="new_id-2788" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2789" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2790" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2791" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;">-</td> <td id="new_id-2792" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 2022 Note</p> </td> <td id="new_id-2793" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2794" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2795" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">55,000</td> <td id="new_id-2796" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2797" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2798" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2799" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">37,207</td> <td id="new_id-2800" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2801" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2802" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2803" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">17,793</td> <td id="new_id-2804" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2805" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2806" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2807" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">49,719</td> <td id="new_id-2808" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2809" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2810" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2811" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;">-</td> <td id="new_id-2812" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">February 2023 Note</p> </td> <td id="new_id-2813" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2814" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2815" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">265,000</td> <td id="new_id-2816" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;"> </td> <td id="new_id-2817" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2818" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2819" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">60,146</td> <td id="new_id-2820" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;"> </td> <td id="new_id-2821" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2822" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2823" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">204,854</td> <td id="new_id-2824" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;"> </td> <td id="new_id-2825" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2826" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2827" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">63,650</td> <td id="new_id-2828" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;"> </td> <td id="new_id-2829" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2830" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2831" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">157,259</td> <td id="new_id-2832" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Total</b></p> </td> <td id="new_id-2833" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td id="new_id-2834" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td id="new_id-2835" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><b>1,902,880 </b></td> <td id="new_id-2836" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; white-space: nowrap;"> </td> <td id="new_id-2837" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td id="new_id-2838" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td id="new_id-2839" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><b>157,807 </b></td> <td id="new_id-2840" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; white-space: nowrap;"> </td> <td id="new_id-2841" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td id="new_id-2842" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td id="new_id-2843" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><b>1,745,073 </b></td> <td id="new_id-2844" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; white-space: nowrap;"> </td> <td id="new_id-2845" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td id="new_id-2846" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td id="new_id-2847" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><b>1,207,624 </b></td> <td id="new_id-2848" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; white-space: nowrap;"> </td> <td id="new_id-2849" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td id="new_id-2850" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td id="new_id-2851" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><b>557,694 </b></td> <td id="new_id-2852" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; white-space: nowrap;"> </td> </tr> </table><p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> </p><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Convertible Promissory note, </b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>related party as on March 31, 2023</b></p> </td> <td id="new_id-2853" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" id="new_id-2854" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Principal Amount</b></p> </td> <td id="new_id-2855" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2856" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" id="new_id-2857" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Unamortized balance of Debt Discount</b></p> </td> <td id="new_id-2858" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2859" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" id="new_id-2860" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Outstanding balance as on March 31, 2023</b></p> </td> <td id="new_id-2861" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2862" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" id="new_id-2863" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Derivative balance as on March 31, 2023</b></p> </td> <td id="new_id-2864" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2865" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" id="new_id-2866" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Warrant liability balance as on March 31, 2023</b></p> </td> <td id="new_id-2867" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1"> </td> <td id="new_id-2868"> </td> <td id="new_id-2869"> </td> <td id="new_id-2870"> </td> <td id="new_id-2871"> </td> <td id="new_id-2872"> </td> <td id="new_id-2873"> </td> <td id="new_id-2874"> </td> <td id="new_id-2875"> </td> <td id="new_id-2876"> </td> <td id="new_id-2877"> </td> <td id="new_id-2878"> </td> <td id="new_id-2879"> </td> <td id="new_id-2880"> </td> <td id="new_id-2881"> </td> <td id="new_id-2882"> </td> <td id="new_id-2883"> </td> <td id="new_id-2884"> </td> <td id="new_id-2885"> </td> <td id="new_id-2886"> </td> <td id="new_id-2887"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">July 2022 Note</p> </td> <td id="new_id-2888" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2889" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2890" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">12,500</td> <td id="new_id-2891" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2892" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2893" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2894" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td id="new_id-2895" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2896" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2897" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2898" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">12,500</td> <td id="new_id-2899" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2900" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2901" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2902" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3,941</td> <td id="new_id-2903" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2904" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2905" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2906" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td id="new_id-2907" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> </table><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration:underline">2013 Note</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On October 1, 2013, Company issued an unsecured convertible promissory note (the “2013 Note”) in the amount of $12,000 to a former Board member (the “Holder”) in exchange for retention as a director during the fiscal year ending September 30, 2014. The Note can be converted into shares of common stock by the Holder for $4.50 per share. The Note matured on October 1, 2015 and bore a one-time interest charge of $1,200 which was applied to the principal on October 1, 2014. As of March 31, 2023, the outstanding principal balance was $12,000.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration:underline">2014 Note </span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On November 20, 2014, the Company issued a 10% unsecured convertible promissory note (the “2014 Note”) for the principal sum of up to $400,000 plus accrued interest on any advanced principal funds. The 2014 Note matured eighteen months from each advance. The 2014 Note may be converted by the lender into shares of common stock of the Company at the lesser of $12.50 per share or (b) fifty percent (50%) of the lowest traded prices following issuance of the 2014 Note or (c) the lowest effective price per share granted to any person or entity. On November 20, 2014, the lender advanced $50,000 to the Company under the 2014 Note at inception. On various dates from February 18, 2015 through September 30, 2016, the lender advanced an additional $350,000 under the 2014 Note. During the period ended September 30, 2021, the Company and lender agreed to extend the maturity date for the outstanding balance to June 30, 2023. As of March 31, 2023, outstanding principal balance was $50,880.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">2017 Note</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On May 10, 2017, the Company issued a 10% unsecured convertible promissory note (the “2017 Note”) for the principal sum of up to $150,000 plus accrued interest on any advanced principal funds. The lender may pay additional consideration at the lender’s discretion. The Company received a tranche in the amount of $25,000 upon execution of the 2017 Note. On various dates, the Company received additional tranches in the aggregate sum of $90,000. The 2017 Note matured twelve months from each tranche. Within thirty (30) days prior to the maturity date, the lender may extend the maturity date to sixty (60) months. During the period ended September 30, 2021, the Company and lender agreed to extend the maturity date for the outstanding balance to June 30, 2023. The 2017 Note may be converted by the lender into shares of common stock of the Company at the lesser of $10 per share or (b) fifty percent (50%) of the lowest traded price of common stock recorded on any trade day after the effective date, or (c) the lowest effective price per share granted to any person or entity. As of March 31, 2023 the outstanding principal balance was $115,000.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">May 2021 Note</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On May 28, 2021, the Company issued a 12% unsecured convertible promissory note (the “May 2021 Note”) for the principal sum of $55,500 plus accrued interest. The May 2021 Note was to mature on May 28, 2022. The May 2021 Note was convertible after November 23, 2021, by the lender into shares of common stock of the Company at sixty-one percent (61%) of the lowest traded price of common stock recorded during the fifteen (15) trading days prior to conversion. On October 5, 2021, the Company paid the balance of this note to the lender. As of March 31, 2023, the balance of the May 2021 Note was $0.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">July 2021 Note</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On July 6, 2021, the Company issued a 12% unsecured convertible promissory note (the “July 2021 Note”) for the principal sum of $38,750 plus accrued interest with a maturity date of July 6, 2022. The July 2021 Note was convertible after January 1, 2022, by the lender into shares of common stock of the Company at sixty-one percent (61%) of the lowest trade price of common stock recorded during the fifteen (15) trading days prior to conversion. On December 30, 2021, the Company paid the balance of this note to the lender. As of March 31, 2023, the balance of the July 2021 Note was $0.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">August 2021 Note</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On August 20, 2021, the Company issued a 10% secured promissory note (the “August 2021 Note”) for the principal sum of $500,000 plus accrued interest. The August 2021 Note was to mature on February 20, 2022, unless extended for up to an additional six months. The August 2021 Note could be converted, only following an event of default, by the lender into shares of common stock of the Company at the lesser of 90% (representing a 10% discount) multiplied by the lowest trading price during the previous twenty (20) trading day period ending on the issuance date, or during the previous twenty (20) trading day period. The Company issued 1,000,000 warrants at a price of $1.50 in connection with the note (note 7 below) and issued 400,000 shares as a commitment fee. In February 2022, the Company extended the term of the August 2021 Note for an additional six months. The Company repaid the August 2021 Note on May 9, 2022 in connection with the issuance of the May 2022 Note described below. As of March 31, 2023, the balance on the August 2021 Note was $0.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On February 9, 2023, the Company entered into a letter agreement in connection with the August 2021 Note, whereby the exercise price of the warrants issued on the August 2021 Note was reduced to $0.20 per share.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">February 2022 Note</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On February 15, 2022, the Company issued a 10% secured promissory note (the “February 2022 Note”) for the principal sum of $250,000 plus accrued interest. The February 2022 Note was to mature on August 15, 2022, unless extended for up to an additional six months. The February 2022 Note may be converted, only following an event of default, by the lender into shares of common stock of the Company at the lesser of 90% (representing a 10% discount) multiplied by the lowest trading price during the previous twenty (20) trading day period ending on the issuance date, or during the previous twenty (20) trading day period. In July 2022, the Company extended the term of the February 2022 note for another six months until February 16, 2023. In connection with the note, the Company issued 500,000 warrants with an exercise price of $1.50 (see note 7 below). The February 2022 Note had an original issuance discount amounting to $25,000, debt issuance cost amounting to $12,000 and the Company issued 300,000 shares as a commitment fee valued at $111,000 based on the share price on the date of the agreement, amortized over the term of the loan. The initial recognition of derivative and warrant liability was recorded as debt discount and amortized over the term of the loan. The debt discount is fully amortized and the balance in debt discount as on March 31, 2023, was $0. As of March 31, 2023, the balance outstanding net of debt discount was $250,000.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On February 9, 2023, the Company entered into a letter agreement in connection with the February 2022 Note, whereby the Company extended the due date of the loan to May 9, 2023 and deferred all interest payments for the period from January 1, 2023 until May 9, 2023. Pursuant to the letter agreement the exercise price of the warrants issued with the February 2022 Note was reduced to $0.20 per share. The warrants contained a ratchet provision and the difference in fair value of $44,241 upon the reduction of exercise price as mentioned above  is being treated as a deemed dividend for the down round provision.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The company did not make the payment of $258,958 due on May 9, 2023. The lender has agreed to waive the default provisions until June 1, 2023, or pending conclusion of negotiations on an extension of the loans.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">May 2022 Note</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On May 5, 2022, the Company issued a 12% secured promissory note (the “May 2022 Note”) for the principal sum of $1,000,000 plus accrued interest. The May 2022 Note was to mature on November 5, 2022, unless extended for up to an additional six months. If extended, the interest rate increased to 15% for the remaining six months. The May 2022 Note may be converted, only following an event of default, by the lender into shares of common stock of the Company at the lesser of the lowest trading price during the previous twenty (20) trading day period ending on the issuance date, or during the previous twenty (20) trading day period before conversion. The Company used some of the proceeds from the May 2022 Note to pay off the August 2021 Note. In November 2022, the Company extended the May 2022 Note for another six months until May 5, 2023. In connection with the loan the Company issued 1,000,000 warrants at an exercise price of $0.01 (see note 7 below). The May 2022 Note had an original issuance discount amounting to $100,000, debt issuance costs of $ 25,500 and the Company issued 875,000 shares as a commitment fee valued at $259,875 based on the share price on the date of the agreement. The initial recognition of derivative liability of $412,065 and warrant liability amounting to $282,051 was recorded as debt discount and amortized over the term of the loan. The balance in debt discount as on March 31, 2023, was $0. As of March 31, 2023, the balance outstanding net of debt discount was $1,000,000.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On February 9, 2023, the Company entered into a letter agreement in connection with the May 2022 Note deferring all interest payments from January 1, 2023 until May 9, 2023.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The company did not make the payment of $1,053,750 due on May 9, 2023. The lender has agreed to waive the default provisions until June 1, 2023, or pending conclusion of negotiations on an extension of the loans.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">August 2022 Note</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On August 8, 2022, the Company issued a 12% unsecured promissory note (the “August 2022 Note”) for the principal sum of $100,000 plus accrued interest. The August 2022 Note matures on August 8, 2023, provided, however that after October 31, 2022, if the Company receives debt or equity financing of at least $3 million, the holder may call for payments of outstanding principal and interest at any time from such date giving notice of at least five business days before the date the payment is due. The holder shall have the right, until the date of payment in full of all amounts outstanding to convert unpaid principal and interest and any other amounts into fully paid shares of common stock of the Company at a conversion price of $0.15. The initial recognition of derivative liability of $77,259 was recorded as debt discount and amortized over the term of the loan. The balance in debt discount as on March 31, 2023 was $27,517. As of March 31, 2023 the balance outstanding net of debt discount was $72,483.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">September 2022 Note</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On September 22, 2022, the Company issued an 8% secured promissory note (the “September 2022 Note”) for the principal sum of $79,250 plus accrued interest. The September 2022 Note matures on September 22, 2023. In case of default in repayment of the outstanding amount on the due date the balance shall bear interest of 22% per annum. The holder shall have the right, after six months, until the date of payment in full of all amounts outstanding to convert unpaid principal and interest and any other amounts into fully paid shares of common stock of the Company at a variable conversion price equal to 65% multiplied by the market price. Market price means the average of the three lowest trading prices for the Common Stock during the fifteen-trading day period ending on the latest complete trading day prior to the conversion date. The initial recognition of derivative liability amounting to $75,000 was recorded as debt discount and amortized over the term of the loan. The debt issuance cost of $4,250 was recorded as debt discount and amortized over the term of the loan. The Company repaid the loan in full including interest of $3,127 on March 12, 2023. The prepayment penalty amounted to $20,594. The balance in debt discount as on March 31, 2023 was $0. As of March 31, 2023 the balance outstanding net of debt discount was $0.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">November 2022 Note</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On November 1, 2022, the Company issued an 8% secured promissory note (the “November 2022 Note”) for the principal sum of $55,000 plus accrued interest. The November 2022 Note matures on November 1, 2023. In case of default in repayment of the outstanding amount on the due date the balance shall bear interest of 22% per annum. Beginning on April 30, 2023, 1800 Diagonal Lending may convert the amount outstanding under the note into shares of NovAccess common stock at a conversion price equal to 65% of the average of the three lowest trading prices of the stock during the fifteen trading days before the conversion date. The initial recognition of derivative liability amounting to $50,700 was recorded as debt discount and amortized over the term of the loan. The debt issuance cost of $4,250 was recorded as debt discount and amortized over the term of the loan. The balance in debt discount as on March 31, 2023, was $32,938. As of March 31, 2023, the balance outstanding net of debt discount was $22,063.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">December 2022 Note</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On December 7, 2022, the Company issued an 8% secured promissory note (the “December 2022 Note”) for the principal sum of $55,000 plus accrued interest. The December 2022 Note matures on December 7, 2023. In case of default in repayment of the outstanding amount on the due date the balance shall bear interest of 22% per annum. Beginning on June 5, 2023, 1800 Diagonal Lending may convert the amount outstanding under the note into shares of NovAccess common stock at a conversion price equal to 65% of the average of the three lowest trading prices of the stock during the fifteen trading days before the conversion date. The initial recognition of derivative liability amounting to $50,700 was recorded as debt discount and amortized over the term of the loan. The debt issuance cost of $4,250 was recorded as debt discount and amortized over the term of the loan. The balance in debt discount as on March 31, 2023, was $37,207. As of March 31, 2023, the balance outstanding net of debt discount was $17,793.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">February 2023 Letter Agreement</span></p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On February 9, 2023 the Company entered into a letter agreement, whereby the Company drew an additional loan amounting to $265,000, which was added to the May 2022 Note. The $265,000 loan has an original issuance discount of 10% of the principal and bears interest at 10% a year. This loan is due on May 9, 2023. The initial recognition of derivative liability amounting to $110,576 was recorded as debt discount and amortized over the term of the loan. The original issuance discount of $26,500 was recorded as debt discount and amortized over the term of the loan. The balance in debt discount as on March 31, 2023, was $60,146. As of March 31, 2023, the balance outstanding net of debt discount was $204,854.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Also pursuant to the letter agreement , the Company paid a commitment fee of 500,000 unregistered shares of the Company’s common stock (the “commitment fee shares”). If the investor is unable to sell the commitment fee shares for $0.20 a share, then investor may require the Company to issue additional shares or pay cash in the amount of the shortfall. The Company also issued a common stock purchase warrant to purchase 1.0 million shares of the company’s Common stock for $0.20 a share. The warrant expires on February 9, 2028. The company recorded expense of 82,500 in respect of the commitment fee shares and 157,933 in respect of the warrant.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company did not make the payment of $271,551 due on May 9, 2023. The lender has agreed to waive the default provisions until June 1, 2023, or pending conclusion of negotiations on an extension of the loans.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We evaluated the financing transactions in accordance with ASC Topic 815, Derivatives and Hedging, and determined that the conversion feature of the convertible promissory notes was not afforded the exemption for conventional convertible instruments due to its variable conversion rate. The notes have no explicit limit on the number of shares issuable so they did not meet the conditions set forth in current accounting standards for equity classification. The Company elected to recognize the notes under paragraph 815-15-25-4, whereby, there would be a separation into a host contract and derivative instrument. The Company elected to initially and subsequently measure the notes in their entirety at fair value, with changes in fair value recognized in earnings. The Company recorded a derivative liability representing the imputed interest associated with the embedded derivative. The derivative liability is adjusted periodically according to the stock price fluctuations based upon the Binomial lattice model calculation.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The convertible notes issued and described in this Note do not have fixed settlement provisions because their conversion prices are not fixed. The conversion feature has been characterized as a derivative liability to be re-measured at the end of every reporting period with the change in value reported in the statement of operations.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We record the full value of the derivative as a liability at issuance with an offset to valuation discount, which will be amortized over the life of the notes.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For purpose of determining the fair market value of the derivative liability for the embedded conversion, the Company used Binomial lattice valuation model. The significant assumptions used in the Binomial lattice valuation of the derivatives are as follows:</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tr> <td style="vertical-align:bottom;width:3.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Risk free interest rate</p> </td> <td style="vertical-align:bottom;width:0.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Between 4.74% and 4.955%</p> </td> </tr> <tr> <td style="vertical-align:bottom;width:3.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stock volatility factor</p> </td> <td style="vertical-align:bottom;width:0.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Between 141% and 177.6%</p> </td> </tr> <tr> <td style="vertical-align:bottom;width:3.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Years to Maturity</p> </td> <td style="vertical-align:bottom;width:0.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">0.28 years</p> </td> </tr> <tr> <td style="vertical-align:bottom;width:3.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Expected dividend yield</p> </td> <td style="vertical-align:bottom;width:0.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">None</p> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Convertible Promissory notes </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>as on March 31, 2023</b></p> </td> <td id="new_id-2598" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" id="new_id-2599" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Principal Amount</b></p> </td> <td id="new_id-2600" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2601" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" id="new_id-2602" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Unamortized balance of Debt Discount</b></p> </td> <td id="new_id-2603" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2604" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" id="new_id-2605" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Outstanding balance as on March 31, 2023</b></p> </td> <td id="new_id-2606" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2607" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" id="new_id-2608" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Derivative balance as on March 31, 2023</b></p> </td> <td id="new_id-2609" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2610" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" id="new_id-2611" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Warrant liability balance as on March 31, 2023</b></p> </td> <td id="new_id-2612" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1"> </td> <td id="new_id-2613"> </td> <td id="new_id-2614"> </td> <td id="new_id-2615"> </td> <td id="new_id-2616"> </td> <td id="new_id-2617"> </td> <td id="new_id-2618"> </td> <td id="new_id-2619"> </td> <td id="new_id-2620"> </td> <td id="new_id-2621"> </td> <td id="new_id-2622"> </td> <td id="new_id-2623"> </td> <td id="new_id-2624"> </td> <td id="new_id-2625"> </td> <td id="new_id-2626"> </td> <td id="new_id-2627"> </td> <td id="new_id-2628"> </td> <td id="new_id-2629"> </td> <td id="new_id-2630"> </td> <td id="new_id-2631"> </td> <td id="new_id-2632"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2013 Note</p> </td> <td id="new_id-2633" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2634" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2635" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">12,000</td> <td id="new_id-2636" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2637" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2638" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2639" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td id="new_id-2640" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2641" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2642" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2643" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">12,000</td> <td id="new_id-2644" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2645" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2646" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2647" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td id="new_id-2648" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2649" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2650" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2651" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;">-</td> <td id="new_id-2652" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2014 Note</p> </td> <td id="new_id-2653" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2654" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2655" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">50,880</td> <td id="new_id-2656" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2657" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2658" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2659" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td id="new_id-2660" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2661" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2662" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2663" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">50,880</td> <td id="new_id-2664" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2665" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2666" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2667" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">215,591</td> <td id="new_id-2668" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2669" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2670" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2671" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;">-</td> <td id="new_id-2672" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2017 Note</p> </td> <td id="new_id-2673" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2674" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2675" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">115,000</td> <td id="new_id-2676" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2677" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2678" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2679" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td id="new_id-2680" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2681" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2682" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2683" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">115,000</td> <td id="new_id-2684" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2685" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2686" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2687" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">453,384</td> <td id="new_id-2688" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2689" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2690" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2691" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;">-</td> <td id="new_id-2692" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August 2021 Note</p> </td> <td id="new_id-2693" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2694" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2695" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td id="new_id-2696" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2697" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2698" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2699" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td id="new_id-2700" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2701" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2702" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2703" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td id="new_id-2704" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2705" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2706" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2707" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td id="new_id-2708" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2709" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2710" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2711" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">151,920</td> <td id="new_id-2712" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">February 2022 Note</p> </td> <td id="new_id-2713" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2714" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2715" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">250,000</td> <td id="new_id-2716" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2717" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2718" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2719" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td id="new_id-2720" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2721" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2722" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2723" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">250,000</td> <td id="new_id-2724" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2725" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2726" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2727" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">81,815</td> <td id="new_id-2728" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2729" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2730" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2731" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">76,762</td> <td id="new_id-2732" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">May 2022 Note</p> </td> <td id="new_id-2733" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2734" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2735" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,000,000</td> <td id="new_id-2736" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2737" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2738" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2739" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td id="new_id-2740" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2741" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2742" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2743" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,000,000</td> <td id="new_id-2744" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2745" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2746" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2747" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">245,784</td> <td id="new_id-2748" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2749" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2750" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2751" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">171,753</td> <td id="new_id-2752" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August 2022 Note</p> </td> <td id="new_id-2753" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2754" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2755" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">100,000</td> <td id="new_id-2756" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2757" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2758" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2759" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">27,517</td> <td id="new_id-2760" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2761" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2762" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2763" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">72,483</td> <td id="new_id-2764" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2765" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2766" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2767" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">48,797</td> <td id="new_id-2768" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2769" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2770" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2771" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;">-</td> <td id="new_id-2772" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">November 2022 Note</p> </td> <td id="new_id-2773" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2774" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2775" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">55,000</td> <td id="new_id-2776" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2777" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2778" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2779" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">32,937</td> <td id="new_id-2780" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2781" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2782" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2783" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">22,063</td> <td id="new_id-2784" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2785" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2786" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2787" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">48,883</td> <td id="new_id-2788" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2789" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2790" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2791" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;">-</td> <td id="new_id-2792" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 2022 Note</p> </td> <td id="new_id-2793" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2794" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2795" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">55,000</td> <td id="new_id-2796" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2797" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2798" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2799" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">37,207</td> <td id="new_id-2800" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2801" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2802" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2803" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">17,793</td> <td id="new_id-2804" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2805" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2806" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2807" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">49,719</td> <td id="new_id-2808" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2809" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2810" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2811" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;">-</td> <td id="new_id-2812" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">February 2023 Note</p> </td> <td id="new_id-2813" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2814" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2815" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">265,000</td> <td id="new_id-2816" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;"> </td> <td id="new_id-2817" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2818" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2819" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">60,146</td> <td id="new_id-2820" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;"> </td> <td id="new_id-2821" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2822" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2823" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">204,854</td> <td id="new_id-2824" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;"> </td> <td id="new_id-2825" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2826" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2827" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">63,650</td> <td id="new_id-2828" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;"> </td> <td id="new_id-2829" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2830" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2831" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">157,259</td> <td id="new_id-2832" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Total</b></p> </td> <td id="new_id-2833" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td id="new_id-2834" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td id="new_id-2835" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><b>1,902,880 </b></td> <td id="new_id-2836" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; white-space: nowrap;"> </td> <td id="new_id-2837" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td id="new_id-2838" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td id="new_id-2839" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><b>157,807 </b></td> <td id="new_id-2840" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; white-space: nowrap;"> </td> <td id="new_id-2841" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td id="new_id-2842" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td id="new_id-2843" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><b>1,745,073 </b></td> <td id="new_id-2844" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; white-space: nowrap;"> </td> <td id="new_id-2845" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td id="new_id-2846" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td id="new_id-2847" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><b>1,207,624 </b></td> <td id="new_id-2848" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; white-space: nowrap;"> </td> <td id="new_id-2849" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td id="new_id-2850" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td id="new_id-2851" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><b>557,694 </b></td> <td id="new_id-2852" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; white-space: nowrap;"> </td> </tr> </table><p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> </p><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Convertible Promissory note, </b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>related party as on March 31, 2023</b></p> </td> <td id="new_id-2853" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" id="new_id-2854" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Principal Amount</b></p> </td> <td id="new_id-2855" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2856" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" id="new_id-2857" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Unamortized balance of Debt Discount</b></p> </td> <td id="new_id-2858" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2859" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" id="new_id-2860" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Outstanding balance as on March 31, 2023</b></p> </td> <td id="new_id-2861" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2862" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" id="new_id-2863" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Derivative balance as on March 31, 2023</b></p> </td> <td id="new_id-2864" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2865" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" id="new_id-2866" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Warrant liability balance as on March 31, 2023</b></p> </td> <td id="new_id-2867" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1"> </td> <td id="new_id-2868"> </td> <td id="new_id-2869"> </td> <td id="new_id-2870"> </td> <td id="new_id-2871"> </td> <td id="new_id-2872"> </td> <td id="new_id-2873"> </td> <td id="new_id-2874"> </td> <td id="new_id-2875"> </td> <td id="new_id-2876"> </td> <td id="new_id-2877"> </td> <td id="new_id-2878"> </td> <td id="new_id-2879"> </td> <td id="new_id-2880"> </td> <td id="new_id-2881"> </td> <td id="new_id-2882"> </td> <td id="new_id-2883"> </td> <td id="new_id-2884"> </td> <td id="new_id-2885"> </td> <td id="new_id-2886"> </td> <td id="new_id-2887"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">July 2022 Note</p> </td> <td id="new_id-2888" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2889" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2890" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">12,500</td> <td id="new_id-2891" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2892" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2893" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2894" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td id="new_id-2895" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2896" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2897" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2898" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">12,500</td> <td id="new_id-2899" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2900" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2901" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2902" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3,941</td> <td id="new_id-2903" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2904" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2905" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2906" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td id="new_id-2907" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> </table><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 12000 0 12000 0 0 50880 0 50880 215591 0 115000 0 115000 453384 0 0 0 0 0 151920 250000 0 250000 81815 76762 1000000 0 1000000 245784 171753 100000 27517 72483 48797 0 55000 32937 22063 48883 0 55000 37207 17793 49719 0 265000 60146 204854 63650 157259 1902880 157807 1745073 1207624 557694 12500 0 12500 3941 0 12000 4.5 1200 0.10 400000 P18M The 2014 Note may be converted by the lender into shares of common stock of the Company at the lesser of $12.50 per share or (b) fifty percent (50%) of the lowest traded prices following issuance of the 2014 Note or (c) the lowest effective price per share granted to any person or entity 50000 350000 50880 0.10 150000 25000 90000 The 2017 Note may be converted by the lender into shares of common stock of the Company at the lesser of $10 per share or (b) fifty percent (50%) of the lowest traded price of common stock recorded on any trade day after the effective date, or (c) the lowest effective price per share granted to any person or entity 115000 0.12 55500 The May 2021 Note was convertible after November 23, 2021, by the lender into shares of common stock of the Company at sixty-one percent (61%) of the lowest traded price of common stock recorded during the fifteen (15) trading days prior to conversion. 0 0.12 38750 The July 2021 Note was convertible after January 1, 2022, by the lender into shares of common stock of the Company at sixty-one percent (61%) of the lowest trade price of common stock recorded during the fifteen (15) trading days prior to conversion. 0 0.10 500000 The August 2021 Note could be converted, only following an event of default, by the lender into shares of common stock of the Company at the lesser of 90% (representing a 10% discount) multiplied by the lowest trading price during the previous twenty (20) trading day period ending on the issuance date, or during the previous twenty (20) trading day period. 1000000 1.5 400000 0 0.2 0.10 250000 The February 2022 Note may be converted, only following an event of default, by the lender into shares of common stock of the Company at the lesser of 90% (representing a 10% discount) multiplied by the lowest trading price during the previous twenty (20) trading day period ending on the issuance date, or during the previous twenty (20) trading day period 500000 1.5 25000 12000 300000 111000 0 250000 0.2 44241 258958 0.12 1000000 If extended, the interest rate increased to 15% for the remaining six months The May 2022 Note may be converted, only following an event of default, by the lender into shares of common stock of the Company at the lesser of the lowest trading price during the previous twenty (20) trading day period ending on the issuance date, or during the previous twenty (20) trading day period before conversion 1000000 0.01 100000 25500 875000 259875 282051 0 1000000 1053750 0.12 100000 The August 2022 Note matures on August 8, 2023, provided, however that after October 31, 2022, if the Company receives debt or equity financing of at least $3 million, the holder may call for payments of outstanding principal and interest at any time from such date giving notice of at least five business days before the date the payment is due 0.15 77259 27517 72483 0.08 79250 2023-09-22 0.22 The holder shall have the right, after six months, until the date of payment in full of all amounts outstanding to convert unpaid principal and interest and any other amounts into fully paid shares of common stock of the Company at a variable conversion price equal to 65% multiplied by the market price. Market price means the average of the three lowest trading prices for the Common Stock during the fifteen-trading day period ending on the latest complete trading day prior to the conversion date. 75000 4250 3127 20594 0 0 0.08 55000 2023-11-01 0.22 Beginning on April 30, 2023, 1800 Diagonal Lending may convert the amount outstanding under the note into shares of NovAccess common stock at a conversion price equal to 65% of the average of the three lowest trading prices of the stock during the fifteen trading days before the conversion date. 50700 4250 32938 22063 0.08 55000 2023-12-07 50700 4250 37207 17793 265000 0.10 0.10 2023-05-09 110576 26500 60146 204854 500000 If the investor is unable to sell the commitment fee shares for $0.20 a share, then investor may require the Company to issue additional shares or pay cash in the amount of the shortfall. 1000000 0.2 82500 157933 271551 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For purpose of determining the fair market value of the derivative liability for the embedded conversion, the Company used Binomial lattice valuation model. The significant assumptions used in the Binomial lattice valuation of the derivatives are as follows:</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tr> <td style="vertical-align:bottom;width:3.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Risk free interest rate</p> </td> <td style="vertical-align:bottom;width:0.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Between 4.74% and 4.955%</p> </td> </tr> <tr> <td style="vertical-align:bottom;width:3.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stock volatility factor</p> </td> <td style="vertical-align:bottom;width:0.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Between 141% and 177.6%</p> </td> </tr> <tr> <td style="vertical-align:bottom;width:3.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Years to Maturity</p> </td> <td style="vertical-align:bottom;width:0.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">0.28 years</p> </td> </tr> <tr> <td style="vertical-align:bottom;width:3.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Expected dividend yield</p> </td> <td style="vertical-align:bottom;width:0.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">None</p> </td> </tr> </table> 4.74 4.955 141 177.6 0.28 0 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">5. CONVERTIBLE PROMISSORY NOTES, RELATED PARTY</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">July 2022 Note, related party</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On July 28, 2022, the Company issued a 12% unsecured promissory note (the “July 2022 Note”) for the principal sum of $12,500 plus accrued interest. All amounts outstanding under the July 2022 Note were payable on the earlier of: (a) October 31, 2022, or (b) the receipt by the Company of debt or equity financing of $3 million. In November 2022, the holder agreed to extend the term of the note until April 2023 and in April 2023 agreed to a further extension until August 31, 2023. The holder has the right, until the date of payment in full of all amounts outstanding to convert unpaid principal and interest and any other amounts into fully paid shares of common stock of the Company at conversion price of $0.15. The initial recognition of derivative liability of $12,500 was recorded as debt discount and amortized over the term of the loan. The balance in debt discount as on March 31, 2023, was $0. As of March 31, 2023, the balance outstanding net of debt discount was $12,500.</p> 0.12 12500 the earlier of: (a) October 31, 2022, or (b) the receipt by the Company of debt or equity financing of $3 million 0.15 12500 0 12500 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">6. SHORT TERM LOAN, RELATED PARTY</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On July 28, 2022, the Company entered into a short-term interest free loan agreement amounting to $12,500, with Jason M. Anderson, an independent member of our board of directors, to fund the operations until longer term financing can be obtained by the Company. The loan terms required repayment of all amounts outstanding under the loan on the earlier of: (a) October 31, 2022 or (b) the receipt by the Company of debt or equity financing of $3 million In November, 2022, the Board Member signed a waiver and extension agreement changing the due date to April 30, 2023 and in April 2023, agreed to a further extension until August 31, 2023.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On February 9, 2023, NovAccess entered into a second interest-free loan agreement with Mr. Anderson. Reflecting his faith in NovAccess and our management team, Mr. Anderson loaned the Company $8,500. The loan does not bear interest (except on default) and is due on the earlier of August 31, 2023 or our receipt of debt or equity financing of at least $3.0 million.</p> 12500 The loan terms required repayment of all amounts outstanding under the loan on the earlier of: (a) October 31, 2022 or (b) the receipt by the Company of debt or equity financing of $3 million 2023-04-30 8500 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">7. WARRANTS</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On August 20, 2021, for value received in connection with the issuance of the August 2021 Note (see note 4 for more details), the Company issued 1,000,000 warrants to the lender with an exercise price of $1.50 per share with a five-year exercise period. On February 9, 2023, the Company entered into a letter agreement in connection with the August 2021 Note, whereby the exercise price of the warrants issued on the August 2021 Note was reduced to $0.20 per share.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On February 16, 2022, for value received in connection with the issuance of the February 2022 Note (see note 4 for more details), the Company issued 500,000 warrants to the lender with an exercise price of $1.50 per share with a five-year exercise period. On February 9, 2023, the Company entered into a letter agreement in connection with the August 2021 Note, whereby the exercise price of the warrants issued on the August 2021 Note was reduced to $0.20 per share.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On May 10, 2022, for value received in connection with the issuance of the May 2022 Note (see note 4 for more details), the Company issued 1,000,000 warrants to the lender with an exercise price of $0.01 per share with a five-year exercise period. On February 9, 2023, for value received in connection with the issuance of the February 2023 Note (see note 4 for more details), the Company issued 1,000,000 warrants to the lender with an exercise price of $0.20 per share with a five-year exercise period. The fair value of the warrant issued in relation to the letter agreement issued on February 2023 , is recorded as stock compensation expense amounting to $148,500.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On March 31, 2023 the fair value of the derivative liability of the warrants was $557,694 and $232,609 as of September 30, 2022.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For the purpose of determining the fair market value of the derivative liability for the embedded conversion, the Company used the Binomial lattice valuation model. The significant assumptions used in the Binomial lattice valuation of the derivatives are as follows:</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tr> <td style="vertical-align:bottom;width:3.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Risk free interest rate</p> </td> <td style="vertical-align:bottom;width:0.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Between 3.6% and 3.81%</p> </td> </tr> <tr> <td style="vertical-align:bottom;width:3.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stock volatility factor</p> </td> <td style="vertical-align:bottom;width:0.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Between 147% and 164%</p> </td> </tr> <tr> <td style="vertical-align:bottom;width:3.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Years to Maturity</p> </td> <td style="vertical-align:bottom;width:0.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.25 years</p> </td> </tr> <tr> <td style="vertical-align:bottom;width:3.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Expected dividend yield</p> </td> <td style="vertical-align:bottom;width:0.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">None</p> </td> </tr> </table><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Per guidance on ASC 260, the Company determined that the repricing of warrants discussed above, was an exchange of the existing 1,500,000 warrants and the difference between the fair value of the warrants immediately prior to modification of terms and immediately after the adjustment was a s a deemed dividend. The difference between the fair value of the warrants immediately prior to modification of terms and immediately after the adjustment was calculated as $44,241, using a Black Scholes model based on the following significant inputs: On February 9, 2023: common stock price of $0.165; company volatility of 156%-159%; remaining term 3.2-4.1 years; dividend yield of 0% and risk-free interest rate of 3.81-3.71%.</p> 1000000 1.5 0.2 500000 1.5 0.2 1000000 0.01 1000000 0.2 148500 557694 232609 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For the purpose of determining the fair market value of the derivative liability for the embedded conversion, the Company used the Binomial lattice valuation model. The significant assumptions used in the Binomial lattice valuation of the derivatives are as follows:</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tr> <td style="vertical-align:bottom;width:3.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Risk free interest rate</p> </td> <td style="vertical-align:bottom;width:0.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Between 3.6% and 3.81%</p> </td> </tr> <tr> <td style="vertical-align:bottom;width:3.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stock volatility factor</p> </td> <td style="vertical-align:bottom;width:0.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Between 147% and 164%</p> </td> </tr> <tr> <td style="vertical-align:bottom;width:3.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Years to Maturity</p> </td> <td style="vertical-align:bottom;width:0.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.25 years</p> </td> </tr> <tr> <td style="vertical-align:bottom;width:3.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Expected dividend yield</p> </td> <td style="vertical-align:bottom;width:0.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">None</p> </td> </tr> </table><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 3.6 3.81 147 164 4.25 0 1500000 44241 0.165 156 -159 3.2 4.1 0 3.81 3.71 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">8. OPTIONS</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On June 2, 2020, the Company issued 2,000,000,000 options, on a pre reverse split basis, to purchase common stock to the then directors of the Company as compensation for serving on the board during 2019. These options are exercisable on a cashless basis for a period of ten years from September 30, 2022 at an exercise price of $0.00001. The number of options on the post stock split basis is 2,000,000, and the exercise price of $0.01 per share.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For purpose of determining the fair market value of the options issued on June 2, 2020, the Company used the Black Scholes valuation model. The significant assumptions used in the Black Scholes valuation model for the options are as follows:</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tr> <td style="vertical-align:bottom;width:16.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Risk Free Interest Rate</p> </td> <td style="vertical-align:bottom;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:27.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">0.32%</p> </td> </tr> <tr> <td style="vertical-align:bottom;width:16.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stock Volatility Factor</p> </td> <td style="vertical-align:bottom;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:27.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">146.0%</p> </td> </tr> <tr> <td style="vertical-align:bottom;width:16.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Weighted Average Expected Option Life</p> </td> <td style="vertical-align:bottom;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:27.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5 Years</p> </td> </tr> <tr> <td style="vertical-align:bottom;width:16.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Expected Dividend Yield</p> </td> <td style="vertical-align:bottom;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:27.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">None</p> </td> </tr> </table><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On March 13, 2023, the Company entered into non-qualified stock option agreements and granted vested ten-year options to purchase shares of the Company’s common stock for $0.175 a share, the closing price on the grant date. The Company issued options to purchase a total of 3,542,857 shares as follows: (a) 857,143 to each of the independent directors, (b) 428,571 to the chief financial officer, and 571,429 to the president of our StemVax Therapeutics subsidiary; (c) 57,143 to each of our scientific advisory board members; and (d) the remaining 542,857 to staff members and other officers.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Vesting Schedule. The Options are 100% vested and exercisable on the grant date, March 31, 2023.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Expiration. The Option will expire on the tenth anniversary from the grant date which falls on March 31, 2033.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For purpose of determining the fair market value of the options, the Company used the Black Scholes valuation model. The significant assumptions used in the Black Scholes valuation model for the options are as follows:</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tr> <td style="vertical-align:bottom;width:16.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Risk Free Interest Rate</p> </td> <td style="vertical-align:bottom;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:27.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.68%</p> </td> </tr> <tr> <td style="vertical-align:bottom;width:16.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stock Volatility Factor</p> </td> <td style="vertical-align:bottom;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:27.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">146.79%</p> </td> </tr> <tr> <td style="vertical-align:bottom;width:16.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Weighted Average Expected Option Life</p> </td> <td style="vertical-align:bottom;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:27.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5 Years</p> </td> </tr> <tr> <td style="vertical-align:bottom;width:16.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Expected Dividend Yield</p> </td> <td style="vertical-align:bottom;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:27.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">None</p> </td> </tr> </table><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">A summary of the Company’s options activity and related information follows for the quarter ended March 31, 2023:</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2908" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" id="new_id-2909" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b> March 31, 2023</b></p> </td> <td id="new_id-2910" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2911" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2912" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td id="new_id-2913" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td id="new_id-2914" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td id="new_id-2915" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2916" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Weighted</b></p> </td> <td id="new_id-2917" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2918" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2919" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Number</b></p> </td> <td id="new_id-2920" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2921" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2922" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>average</b></p> </td> <td id="new_id-2923" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2924" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2925" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Of</b></p> </td> <td id="new_id-2926" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2927" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2928" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>exercise</b></p> </td> <td id="new_id-2929" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2930" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2931" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Options</b></p> </td> <td id="new_id-2932" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2933" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2934" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>price</b></p> </td> <td id="new_id-2935" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 62%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Outstanding - beginning of period</p> </td> <td id="new_id-2936" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2937" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2938" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,000,000</td> <td id="new_id-2939" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2940" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2941" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td id="new_id-2942" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">.01</td> <td id="new_id-2943" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Granted</p> </td> <td id="new_id-2944" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2945" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2946" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3,542,857</td> <td id="new_id-2947" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2948" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2949" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td id="new_id-2950" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.175</td> <td id="new_id-2951" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Exercised</p> </td> <td id="new_id-2952" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2953" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2954" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td id="new_id-2955" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2956" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2957" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td id="new_id-2958" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td id="new_id-2959" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Forfeited</p> </td> <td id="new_id-2960" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2961" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2962" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td id="new_id-2963" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2964" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2965" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td id="new_id-2966" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td id="new_id-2967" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Outstanding - end of period</p> </td> <td id="new_id-2968" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2969" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2970" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,542,857</td> <td id="new_id-2971" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2972" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2973" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td id="new_id-2974" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.115</td> <td id="new_id-2975" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> </table><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">At March 31, 2023, the weighted average remaining contractual life of options outstanding:</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 80%; margin-left: 10%; margin-right: 10%;"> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td colspan="10" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 51%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b> March 31, 2023</b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td colspan="2" style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td colspan="2" style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td colspan="2" style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining</b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td colspan="2" style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercisable</b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td colspan="2" style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td colspan="2" style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td colspan="2" style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Contractual</b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Prices </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Outstanding </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercisable </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life (years)</b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">$</p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">.01</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">2,000,000</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">2,000,000</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">7.17</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">$</p> </td> <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">0.175</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">3,542,857</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">3,542,857</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">9.95</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> </table><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The entire stock-based compensation expense amounting to $563,314 was recorded in the income statement on the grant date as the options are fully vested and exercisable on the grant date.</p> 2000000000 P10Y 0.00001 2000000 0.01 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For purpose of determining the fair market value of the options issued on June 2, 2020, the Company used the Black Scholes valuation model. The significant assumptions used in the Black Scholes valuation model for the options are as follows:</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tr> <td style="vertical-align:bottom;width:16.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Risk Free Interest Rate</p> </td> <td style="vertical-align:bottom;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:27.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">0.32%</p> </td> </tr> <tr> <td style="vertical-align:bottom;width:16.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stock Volatility Factor</p> </td> <td style="vertical-align:bottom;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:27.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">146.0%</p> </td> </tr> <tr> <td style="vertical-align:bottom;width:16.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Weighted Average Expected Option Life</p> </td> <td style="vertical-align:bottom;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:27.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5 Years</p> </td> </tr> <tr> <td style="vertical-align:bottom;width:16.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Expected Dividend Yield</p> </td> <td style="vertical-align:bottom;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:27.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">None</p> </td> </tr> </table><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tr> <td style="vertical-align:bottom;width:16.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Risk Free Interest Rate</p> </td> <td style="vertical-align:bottom;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:27.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.68%</p> </td> </tr> <tr> <td style="vertical-align:bottom;width:16.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stock Volatility Factor</p> </td> <td style="vertical-align:bottom;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:27.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">146.79%</p> </td> </tr> <tr> <td style="vertical-align:bottom;width:16.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Weighted Average Expected Option Life</p> </td> <td style="vertical-align:bottom;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:27.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5 Years</p> </td> </tr> <tr> <td style="vertical-align:bottom;width:16.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Expected Dividend Yield</p> </td> <td style="vertical-align:bottom;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;width:27.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">None</p> </td> </tr> </table><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 0.0032 1.46 P5Y 0 0.175 3542857 857143 428571 571429 57143 542857 1 0.0368 1.4679 P5Y 0 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">A summary of the Company’s options activity and related information follows for the quarter ended March 31, 2023:</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2908" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" id="new_id-2909" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b> March 31, 2023</b></p> </td> <td id="new_id-2910" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2911" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2912" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td id="new_id-2913" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td id="new_id-2914" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td id="new_id-2915" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2916" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Weighted</b></p> </td> <td id="new_id-2917" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2918" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2919" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Number</b></p> </td> <td id="new_id-2920" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2921" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2922" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>average</b></p> </td> <td id="new_id-2923" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2924" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2925" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Of</b></p> </td> <td id="new_id-2926" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2927" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2928" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>exercise</b></p> </td> <td id="new_id-2929" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2930" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2931" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Options</b></p> </td> <td id="new_id-2932" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2933" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2934" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>price</b></p> </td> <td id="new_id-2935" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 62%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Outstanding - beginning of period</p> </td> <td id="new_id-2936" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2937" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2938" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,000,000</td> <td id="new_id-2939" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2940" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2941" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td id="new_id-2942" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">.01</td> <td id="new_id-2943" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Granted</p> </td> <td id="new_id-2944" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2945" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2946" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3,542,857</td> <td id="new_id-2947" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2948" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2949" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td id="new_id-2950" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.175</td> <td id="new_id-2951" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Exercised</p> </td> <td id="new_id-2952" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2953" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2954" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td id="new_id-2955" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2956" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2957" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td id="new_id-2958" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td id="new_id-2959" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Forfeited</p> </td> <td id="new_id-2960" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2961" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-2962" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td id="new_id-2963" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2964" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2965" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td id="new_id-2966" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td id="new_id-2967" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Outstanding - end of period</p> </td> <td id="new_id-2968" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2969" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2970" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,542,857</td> <td id="new_id-2971" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2972" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2973" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td id="new_id-2974" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.115</td> <td id="new_id-2975" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> </table><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> 2000000 0.01 3542857 0.175 0 0 0 0 5542857 0.115 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">At March 31, 2023, the weighted average remaining contractual life of options outstanding:</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 80%; margin-left: 10%; margin-right: 10%;"> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td colspan="10" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 51%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b> March 31, 2023</b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td colspan="2" style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td colspan="2" style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b> </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td colspan="2" style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining</b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td colspan="2" style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercisable</b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td colspan="2" style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td colspan="2" style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td colspan="2" style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Contractual</b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Prices </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Outstanding </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercisable </b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life (years)</b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">$</p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">.01</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">2,000,000</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">2,000,000</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">7.17</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">$</p> </td> <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">0.175</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">3,542,857</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">3,542,857</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 22%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">9.95</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> </table><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 0.01 2000000 2000000 P7Y2M1D 0.175 3542857 3542857 P9Y11M12D 563314 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">9. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued expenses and accrued other current liabilities consisted of the following at March 31, 2023 and September 30, 2022:</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2976" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2977" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>March 31, 2023</b></p> </td> <td id="new_id-2978" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2979" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2980" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>September 30, 2022</b></p> </td> <td id="new_id-2981" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 62%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued liabilities</p> </td> <td id="new_id-2982" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2983" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2984" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,570</td> <td id="new_id-2985" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2986" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2987" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2988" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,370</td> <td id="new_id-2989" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Interest payable</p> </td> <td id="new_id-2990" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2991" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2992" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">159,506</td> <td id="new_id-2993" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2994" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2995" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2996" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">94,251</td> <td id="new_id-2997" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Provision for guaranteed commitment fees *</p> </td> <td id="new_id-2998" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2999" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3000" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">886,875</td> <td id="new_id-3001" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-3002" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3003" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3004" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">961,000</td> <td id="new_id-3005" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued payroll</p> </td> <td id="new_id-3006" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3007" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3008" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7,367</td> <td id="new_id-3009" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-3010" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3011" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3012" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,740</td> <td id="new_id-3013" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred compensation</p> </td> <td id="new_id-3014" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3015" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3016" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">485,421</td> <td id="new_id-3017" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-3018" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3019" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3020" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">344,983</td> <td id="new_id-3021" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">License Fees Payable</p> </td> <td id="new_id-3022" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3023" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3024" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">40,402</td> <td id="new_id-3025" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-3026" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3027" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3028" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">40,402</td> <td id="new_id-3029" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Insurance finance liability</p> </td> <td id="new_id-3030" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3031" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-3032" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">69,133</td> <td id="new_id-3033" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-3034" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3035" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-3036" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">36,815</td> <td id="new_id-3037" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3038" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3039" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-3040" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>1,654,274</b></td> <td id="new_id-3041" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-3042" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3043" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-3044" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>1,486,561</b></td> <td id="new_id-3045" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> </table><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">* Under the terms of the August 2021 Note, February 2022 Note, May 2022 Note and February 2023 Note the Company issued a total of 2,075,000 shares of common stock as commitment fees. If the lender is unable to sell the shares for more than $1,250,000, it may make a one-time claim for each note to be reimbursed for the difference between their sale proceeds and $1,250,000. The difference between the fair value of the 2,075,000 shares as on March 31, 2023 and the exercise amount of $1,250,000 was recorded as a provision for guaranteed commitment fees and included in the table above.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued expenses and accrued other current liabilities consisted of the following at March 31, 2023 and September 30, 2022:</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2976" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2977" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>March 31, 2023</b></p> </td> <td id="new_id-2978" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-2979" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" id="new_id-2980" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>September 30, 2022</b></p> </td> <td id="new_id-2981" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 62%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued liabilities</p> </td> <td id="new_id-2982" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2983" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2984" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,570</td> <td id="new_id-2985" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2986" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2987" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2988" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,370</td> <td id="new_id-2989" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Interest payable</p> </td> <td id="new_id-2990" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2991" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2992" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">159,506</td> <td id="new_id-2993" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-2994" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2995" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2996" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">94,251</td> <td id="new_id-2997" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Provision for guaranteed commitment fees *</p> </td> <td id="new_id-2998" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-2999" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3000" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">886,875</td> <td id="new_id-3001" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-3002" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3003" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3004" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">961,000</td> <td id="new_id-3005" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued payroll</p> </td> <td id="new_id-3006" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3007" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3008" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7,367</td> <td id="new_id-3009" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-3010" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3011" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3012" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,740</td> <td id="new_id-3013" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred compensation</p> </td> <td id="new_id-3014" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3015" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3016" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">485,421</td> <td id="new_id-3017" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-3018" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3019" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3020" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">344,983</td> <td id="new_id-3021" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">License Fees Payable</p> </td> <td id="new_id-3022" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3023" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3024" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">40,402</td> <td id="new_id-3025" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-3026" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3027" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3028" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">40,402</td> <td id="new_id-3029" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Insurance finance liability</p> </td> <td id="new_id-3030" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3031" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-3032" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">69,133</td> <td id="new_id-3033" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-3034" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3035" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-3036" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">36,815</td> <td id="new_id-3037" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3038" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3039" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-3040" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>1,654,274</b></td> <td id="new_id-3041" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-3042" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td id="new_id-3043" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-3044" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>1,486,561</b></td> <td id="new_id-3045" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> </table><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">* Under the terms of the August 2021 Note, February 2022 Note, May 2022 Note and February 2023 Note the Company issued a total of 2,075,000 shares of common stock as commitment fees. If the lender is unable to sell the shares for more than $1,250,000, it may make a one-time claim for each note to be reimbursed for the difference between their sale proceeds and $1,250,000. The difference between the fair value of the 2,075,000 shares as on March 31, 2023 and the exercise amount of $1,250,000 was recorded as a provision for guaranteed commitment fees and included in the table above.</p> 5570 4370 159506 94251 886875 961000 7367 4740 485421 344983 40402 40402 69133 36815 1654274 1486561 2075000 If the lender is unable to sell the shares for more than $1,250,000, it may make a one-time claim for each note to be reimbursed for the difference between their sale proceeds and $1,250,000. 1250000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10. BRIDGE LOAN PAYABLE</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration:underline">Related parties</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In December 2021, the Company’s CEO and CFO each advanced funds to the Company for operating expenses in the total amount of $50,000. The notes were payable on demand with a five business day written notice and bore interest at a rate of 10% per annum. The Company could prepay all or any part of the balance owed without penalty.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In March, 2022, our CEO purchased 600 shares of Series B Preferred stock and the Company applied $18,616 of the loan balance against this purchase. The remaining balance of $6,384 was paid to our CEO in several payments with the final balance being paid in May, 2022. The Company recognized and paid interest expense in the amount of $583 to our CEO during the year ended September 30, 2022. No balance is due to our CEO as March 31, 2023.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On January 25, 2022, the Company issued 125,000 shares of its common stock in settlement of the bridge loan to the Company’s CFO and recognized a loss on extinguishment of debt in the amount of $17,313. Any potential gain would not have been recognized on extinguishment of this loan due to the nature of the relationship between the parties. The Company recognized and paid interest expense in the amount of $237 to our CFO during the year ended September 30, 2022. No balance is due to our CFO as of March 31, 2023.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration:underline">Service provider, related party</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In December 2021, one of the Company’s service providers advanced funds to the Company for operating expenses in the total amount of $25,000. On February 14, 2022, the Company issued 125,000 shares of its common stock to the service provider in settlement of the note payable. The Company recognized a loss on extinguishment of debt in the amount of $37,500. During the year ended September 30, 2022, the Company recognized and paid interest expense of $226 in relation to this loan. No balance was outstanding on the note payable to our service provider as of March 31, 2023.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The total loss on account of extinguishment of debt on the CFO Note and service provider note amounting to $54,813 was recorded in the income statement.</p> 0.10 600 18616 6384 583 125000 -17313 237 25000 125000 -37500 226 -54813 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">11. DUE TO RELATED PARTIES</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Due to Innovest Global</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During the periods prior to the year ended September 30, 2022, Innovest Global, Inc. (“Innovest”) advanced funds to the Company for operating expenses in the amount of $86,217. As of March 31, 2023, the amount has not been reimbursed to Innovest. Our former Chairman Daniel Martin was the CEO of Innovest when the funds were advanced.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Due to TN3 LLC</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On January 31, 2022, the Company entered into a preferred stock redemption agreement with Daniel G. Martin, at the time, our sole board member and chairman, TN3, LLC, a company owned by Mr. Martin, Dwain K. Irvin, our chief executive officer, and Irvin Consulting, LLC, a company owned by Dr. Irvin. TN3 owned 25,000 shares of the Series B convertible preferred stock. Pursuant to the redemption agreement, on March 14, 2022, NovAccess redeemed 24,400 of the preferred shares and Irvin Consulting purchased 600 of the preferred shares from TN3. The Company also issued to TN3 1,502,670 shares of unregistered common stock, at $ 0.35 amounting to $525,934 which was equal to 10% of our outstanding common stock on the date the redemption agreement was signed. Upon completion of the redemption transaction, the Company is obligated to pay to TN3 a total of $250,000 over a period of eleven months, with payment accelerated if the Company raises at least $2.5 million of equity capital. As of March 31, 2023, the Company owed TN3 $95,000 of the redemption price.</p> 86217 25000 24400 600 1502670 0.35 525934 0.10 250000 95000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">12. COMMITMENTS AND CONTINGENCIES</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">There are no material pending legal proceedings to which we are a party, nor are there any such proceedings known to be contemplated by governmental authorities. None of our directors, officers, or affiliates is involved in a proceeding adverse to our business or has a material interest adverse to our business.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Under the terms of the August 2021 Note, February 2022 Note, May 2022 Note and February 2023 Note the Company issued a total of 2,075,000 shares of common stock as commitment fees. If the lender is unable to sell the shares for more than $1,250,000, it may make a onetime claim for each note to be reimbursed for the difference between their sale proceeds and $1,250,000. The difference between the fair value of the 1,575,000 shares as on March 31, 2023, and the exercise amount of $1,250,000 was recorded as a make-whole provision for commitment fees and included in the accrued expenses.</p> 2075000 1250000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">13. RELATED PARTY TRANSACTIONS</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On February 9, 2023, NovAccess entered into an interest-free loan agreement with Jason M. Anderson, an independent member of our board of directors. Reflecting his faith in NovAccess and our management team, Mr. Anderson loaned the company $8,500. The loan does not bear interest (except on default) and is due on the earlier of August 31, 2023 or our receipt of debt or equity financing of at least $3.0 million. We will use the proceeds of the loan for general working capital purposes.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On July 28, 2022, the Company entered into a short-term interest free loan agreement amounting to $12,500 with Mr. Anderson to fund operations until longer term financing can be obtained by the Company. The loan terms required repayment of all amounts outstanding under this agreement on the earlier of: (a) October 31, 2022 or (b) the receipt by the Company of debt or equity financing of $3 million. In November 2022 Mr. Anderson signed a waiver and extension agreement changing the due date to April 30, 2023 and in April 2023 Mr. Anderson agreed to extend the due date to August 31, 2023. The balance outstanding on March 31, 2023 was $12,500.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On July 28, 2022, the Company issued a convertible promissory note to Letzhangout, LLC, a company that provides accounting consulting services to NovAccess and also employs our chief financial officer, Neil J. Laird. Pursuant to the note, Letzhangout loaned the Company $12,500 on July 29, 2022. All amounts outstanding under this agreement were payable on the earlier of: (a) October 31, 2022, or (b) the receipt by the Company of debt or equity financing of $3 million. In November 2022, the holder agreed to extend the term of the note until April 2023 and in April 2023 agreed to extend the due date to August 31, 2023. The holder has the right, until the date of payment in full. to convert all amounts outstanding under the note and unpaid principal and interest and any other amounts into fully paid shares of common stock of the Company at conversion price of $0. 15. As of March 31, 2023, the balance of the July 2022 Note was $12,500.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On January 31, 2022, the Company entered into a preferred stock redemption agreement with Daniel G. Martin, at the time our sole board member and chairman, TN3, LLC, a company owned by Mr. Martin, Dwain K. Irvin, our chief executive officer, and Irvin Consulting, LLC, a company owned by Dr. Irvin. TN3 owned 25,000 shares of the Series B convertible preferred stock. Pursuant to the redemption agreement, on March 14, 2022, NovAccess redeemed 24,400 of the preferred shares and Irvin Consulting purchased 600 of the preferred shares from TN3.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Upon completion of the redemption transaction, the Company was obligated to pay to TN3 a total of $250,000 over a period of eleven months, with payment accelerated if the Company raises at least $2.5 million of equity capital. As of March 31, 2023, the Company owed TN3 $95,000 of the redemption price. Pursuant to the redemption agreement, the Company also issued to TN3 1,502,670 shares of unregistered common stock, which was equal to 10% of our outstanding common stock on the date the redemption agreement was signed. Upon completion of the redemption transaction, Mr. Martin resigned from the NovAccess board and was replaced by John A. Cassarini and Dr. Irvin.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Also in connection with closing the redemption transaction, on March 14, 2022, the Company entered into a common stock distribution agreement with Innovest Global, Inc. Innovest acquired 7.5 million shares of the Company’s common stock when Innovest sold StemVax, LLC to NovAccess in September 2020. Pursuant to the stock distribution agreement, Innovest agreed to distribute its NovAcess common stock to Innovest’s shareholders. Innovest is currently in the process of effectuating the distribution.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In December 2021, the Company’s CEO and CFO each advanced funds to the Company for operating expenses in the total amount of $25,000 each. The notes were payable on demand with a five business-day written notice and bore interest at a rate of 10% per annum. The Company could prepay all or any part of the balance owed without penalty. On January 25, 2022, the Company issued 125,000 shares of its common stock in settlement of a bridge loan to the Company’s CFO and recognized a loss on extinguishment of debt in the amount of $17,313. Any potential gain would not have been recognized on extinguishment of this loan due to the nature of the relationship between the parties. The Company recognized and paid interest expense in the amount of $237 to our CFO during the year ended September 30, 2022. No balance is due to our CFO as March 31, 2023. In March, 2022, our CEO purchased 600 shares of Series B Preferred stock and the Company applied $18,616 of the loan balance against this purchase. The remaining balance of $6,384 was paid to our CEO in several payments with the final balance being paid in May, 2022. The Company recognized and paid interest expense in the amount of $583 to our CEO during the year ended March 31, 2023. No balance is due to our CEO as of March 31, 2023.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On September 4, 2020, the Company entered into a management services agreement with TN3, LLC. Pursuant to the agreement, TN3 provided the Company with office space in Chesterland, Ohio and management, administrative, marketing, bookkeeping and IT services for a fee of $30,000 a month. The initial term of the agreement was three years, with subsequent one-year renewals. We paid TN3 $40,000 under the agreement in fiscal 2022. In connection with the redemption of TN3’s preferred shares, the management services agreement was terminated and outstanding amounts cancelled, and as of March 31, 2023 there were no amounts owed under this agreement.</p> 8500 12500 12500 12500 0 12500 25000 24400 600 250000 over a period of eleven months, with payment accelerated if the Company raises at least $2.5 million of equity capital 1502670 0.10 7500000 25000 The notes were payable on demand with a five business-day written notice 0.10 125000 -17313 237 600 18616 6384 583 30000 P3Y 40000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">14. SUBSEQUENT EVENTS</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On April 11, 2023, the Company entered into a securities purchase agreement (the “SPA”) with a lender and issued a convertible promissory note in the original principal amount of $79,250 (the “note”) pursuant to the SPA. The loan funded on April 14, 2023. The Company will use the proceeds of the loan for general working capital purposes.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company provided typical representations and agreed to standard covenants pursuant to the SPA. The SPA does not include any financial covenants.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The note bears interest at 8% a year and is due on April 11, 2024. The Company may prepay the note upon payment of a prepayment penalty ranging from 15-25% of the amount outstanding on the note when prepaid. Under the terms of the note, the Company may not sell a significant portion of its assets without the approval of the lender, must comply with the company’s reporting requirements under the Securities Exchange Act of 1934, and must maintain the listing of the Company’s common stock on the OTCQB Market or other exchange. The Company’s failure to comply with any of these covenants, among other matters, would constitute an event of default. Upon an event of default, the note will bear interest at 22% and the lender will be entitled to its costs of collection.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Beginning on October 8, 2023, the lender may convert the amount outstanding under the note into shares of the Company’s common stock at a conversion price equal to 65% of the average of the three lowest trading prices of the stock during the fifteen trading days before the conversion date.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On April 24, 2023, the Company entered into a securities purchase agreement (the “<i>SPA</i>”) with a lender and issued a convertible promissory note in the original principal amount of $54,250 (the “<i>note</i>”) to the lender pursuant to the SPA. The loan funded on April 28, 2023. The Company will use the proceeds of the loan for general working capital purposes.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The note bears interest at 8% a year and is due on April 24, 2024. The Company may prepay the note upon payment of a prepayment penalty ranging from 15-25% of the amount outstanding on the note when prepaid. Under the terms of the note, the Company may not sell a significant portion of its assets without the approval of 1800 Diagonal Lending, must comply with the Company’s reporting requirements under the Securities Exchange Act of 1934, and must maintain the listing of the Company’s common stock on the OTCQB Market or other exchange. The Company’s failure to comply with any of these covenants, among other matters, would constitute an event of default. Upon an event of default, the note will bear interest at 22% and the lender will be entitled to its costs of collection.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Beginning on October 21, 2023, the lender may convert the amount outstanding under the note into shares of the Company’s common stock at a conversion price equal to 65% of the average of the three lowest trading prices of the stock during the fifteen trading days before the conversion date.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company did not make the payment of $1,584,260 including principal and interest, due on May 9, 2023 on the notes issued on Feb 2022, May 2022 and Feb 2023. The lender has agreed to waive the default provisions until June 1, 2023, or pending conclusion of negotiations on an extension of the loans.</p> 79250 0.08 0.15 0.25 0.22 the lender may convert the amount outstanding under the note into shares of the Company’s common stock at a conversion price equal to 65% of the average of the three lowest trading prices of the stock during the fifteen trading days before the conversion date 54250 0.08 0.15 0.25 0.22 the lender may convert the amount outstanding under the note into shares of the Company’s common stock at a conversion price equal to 65% of the average of the three lowest trading prices of the stock during the fifteen trading days before the conversion date 1584260 false --09-30 Q2 2023 0001039466 true NONE Under the terms of the August 2021 Note, February 2022 Note, May 2022 Note and February 2023 Note the Company issued a total of 2,075,000 shares of common stock as commitment fees. If the lender is unable to sell the shares for more than $1,250,000, it may make a one-time claim for each note to be reimbursed for the difference between their sale proceeds and $1,250,000. The difference between the fair value of the 2,075,000 shares as on March 31, 2023 and the exercise amount of $1,250,000 was recorded as a provision for guaranteed commitment fees and included in the table above. EXCEL 60 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 61 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 62 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 228 233 1 true 59 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.xsunx.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.xsunx.com/role/ConsolidatedBalanceSheet CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 002 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://www.xsunx.com/role/ConsolidatedBalanceSheet_Parentheticals CONSOLIDATED BALANCE SHEETS (Parentheticals) Statements 3 false false R4.htm 003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.xsunx.com/role/ConsolidatedIncomeStatement CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 004 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Sheet http://www.xsunx.com/role/ShareholdersEquityType2or3 CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Statements 5 false false R6.htm 005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.xsunx.com/role/ConsolidatedCashFlow CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 006 - Disclosure - ORGANIZATION AND LINE OF BUSINESS Sheet http://www.xsunx.com/role/ORGANIZATIONANDLINEOFBUSINESS ORGANIZATION AND LINE OF BUSINESS Notes 7 false false R8.htm 007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.xsunx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 008 - Disclosure - CAPITAL STOCK Sheet http://www.xsunx.com/role/CAPITALSTOCK CAPITAL STOCK Notes 9 false false R10.htm 009 - Disclosure - CONVERTIBLE PROMISSORY NOTES Notes http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTES CONVERTIBLE PROMISSORY NOTES Notes 10 false false R11.htm 010 - Disclosure - CONVERTIBLE PROMISSORY NOTE, RELATED PARTY Sheet http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTERELATEDPARTY CONVERTIBLE PROMISSORY NOTE, RELATED PARTY Notes 11 false false R12.htm 011 - Disclosure - SHORT TERM LOAN, RELATED PARTY Sheet http://www.xsunx.com/role/SHORTTERMLOANRELATEDPARTY SHORT TERM LOAN, RELATED PARTY Notes 12 false false R13.htm 012 - Disclosure - WARRANTS Sheet http://www.xsunx.com/role/WARRANTS WARRANTS Notes 13 false false R14.htm 013 - Disclosure - OPTIONS Sheet http://www.xsunx.com/role/OPTIONS OPTIONS Notes 14 false false R15.htm 014 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Sheet http://www.xsunx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Notes 15 false false R16.htm 015 - Disclosure - BRIDGE LOANS PAYABLE Sheet http://www.xsunx.com/role/BRIDGELOANSPAYABLE BRIDGE LOANS PAYABLE Notes 16 false false R17.htm 016 - Disclosure - DUE TO RELATED PARTIES Sheet http://www.xsunx.com/role/DUETORELATEDPARTIES DUE TO RELATED PARTIES Notes 17 false false R18.htm 017 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.xsunx.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 18 false false R19.htm 018 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONS RELATED PARTY TRANSACTIONS Notes 19 false false R20.htm 019 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.xsunx.com/role/SUBSEQUENTEVENTS SUBSEQUENT EVENTS Notes 20 false false R21.htm 020 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.xsunx.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies 21 false false R22.htm 021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.xsunx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.xsunx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES 22 false false R23.htm 022 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Tables) Notes http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESTables CONVERTIBLE PROMISSORY NOTES (Tables) Tables http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTES 23 false false R24.htm 023 - Disclosure - WARRANTS (Tables) Sheet http://www.xsunx.com/role/WARRANTSTables WARRANTS (Tables) Tables http://www.xsunx.com/role/WARRANTS 24 false false R25.htm 024 - Disclosure - OPTIONS (Tables) Sheet http://www.xsunx.com/role/OPTIONSTables OPTIONS (Tables) Tables http://www.xsunx.com/role/OPTIONS 25 false false R26.htm 025 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) Sheet http://www.xsunx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) Tables http://www.xsunx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES 26 false false R27.htm 026 - Disclosure - ORGANIZATION AND LINE OF BUSINESS (Details) Sheet http://www.xsunx.com/role/ORGANIZATIONANDLINEOFBUSINESSDetails ORGANIZATION AND LINE OF BUSINESS (Details) Details http://www.xsunx.com/role/ORGANIZATIONANDLINEOFBUSINESS 27 false false R28.htm 027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Earnings Per Share, Basic and Diluted Sheet http://www.xsunx.com/role/ScheduleofEarningsPerShareBasicandDilutedTable SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Earnings Per Share, Basic and Diluted Details http://www.xsunx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables 28 false false R29.htm 028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Sheet http://www.xsunx.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Details http://www.xsunx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables 29 false false R30.htm 029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation Sheet http://www.xsunx.com/role/FairValueNetDerivativeAssetLiabilityMeasuredonRecurringBasisUnobservableInputReconciliationTable SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation Details http://www.xsunx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables 30 false false R31.htm 030 - Disclosure - CAPITAL STOCK (Details) Sheet http://www.xsunx.com/role/CAPITALSTOCKDetails CAPITAL STOCK (Details) Details http://www.xsunx.com/role/CAPITALSTOCK 31 false false R32.htm 031 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details) Notes http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails CONVERTIBLE PROMISSORY NOTES (Details) Details http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESTables 32 false false R33.htm 032 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt Notes http://www.xsunx.com/role/ScheduleofDebtTable CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt Details http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESTables 33 false false R34.htm 033 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details) - Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques Notes http://www.xsunx.com/role/FairValueMeasurementsRecurringandNonrecurringValuationTechniquesTable CONVERTIBLE PROMISSORY NOTES (Details) - Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques Details http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESTables 34 false false R35.htm 034 - Disclosure - CONVERTIBLE PROMISSORY NOTE, RELATED PARTY (Details) Sheet http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTERELATEDPARTYDetails CONVERTIBLE PROMISSORY NOTE, RELATED PARTY (Details) Details http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTERELATEDPARTY 35 false false R36.htm 035 - Disclosure - SHORT TERM LOAN, RELATED PARTY (Details) Sheet http://www.xsunx.com/role/SHORTTERMLOANRELATEDPARTYDetails SHORT TERM LOAN, RELATED PARTY (Details) Details http://www.xsunx.com/role/SHORTTERMLOANRELATEDPARTY 36 false false R37.htm 036 - Disclosure - WARRANTS (Details) Sheet http://www.xsunx.com/role/WARRANTSDetails WARRANTS (Details) Details http://www.xsunx.com/role/WARRANTSTables 37 false false R38.htm 037 - Disclosure - WARRANTS (Details) - Fair Value Measurement Inputs and Valuation Techniques Sheet http://www.xsunx.com/role/FairValueMeasurementInputsandValuationTechniquesTable WARRANTS (Details) - Fair Value Measurement Inputs and Valuation Techniques Details http://www.xsunx.com/role/WARRANTSTables 38 false false R39.htm 038 - Disclosure - OPTIONS (Details) Sheet http://www.xsunx.com/role/OPTIONSDetails OPTIONS (Details) Details http://www.xsunx.com/role/OPTIONSTables 39 false false R40.htm 039 - Disclosure - OPTIONS (Details) - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions Sheet http://www.xsunx.com/role/ScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsTable OPTIONS (Details) - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions Details http://www.xsunx.com/role/OPTIONSTables 40 false false R41.htm 040 - Disclosure - OPTIONS (Details) - Share-Based Payment Arrangement, Option, Activity Sheet http://www.xsunx.com/role/ShareBasedPaymentArrangementOptionActivityTable OPTIONS (Details) - Share-Based Payment Arrangement, Option, Activity Details http://www.xsunx.com/role/OPTIONSTables 41 false false R42.htm 041 - Disclosure - OPTIONS (Details) - Share-based Payment Arrangement, Option, Exercise Price Range Sheet http://www.xsunx.com/role/SharebasedPaymentArrangementOptionExercisePriceRangeTable OPTIONS (Details) - Share-based Payment Arrangement, Option, Exercise Price Range Details http://www.xsunx.com/role/OPTIONSTables 42 false false R43.htm 042 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) Sheet http://www.xsunx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) Details http://www.xsunx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables 43 false false R44.htm 043 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - Schedule of Accounts Payable and Accrued Liabilities Sheet http://www.xsunx.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - Schedule of Accounts Payable and Accrued Liabilities Details http://www.xsunx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables 44 false false R45.htm 044 - Disclosure - BRIDGE LOANS PAYABLE (Details) Sheet http://www.xsunx.com/role/BRIDGELOANSPAYABLEDetails BRIDGE LOANS PAYABLE (Details) Details http://www.xsunx.com/role/BRIDGELOANSPAYABLE 45 false false R46.htm 045 - Disclosure - DUE TO RELATED PARTIES (Details) Sheet http://www.xsunx.com/role/DUETORELATEDPARTIESDetails DUE TO RELATED PARTIES (Details) Details http://www.xsunx.com/role/DUETORELATEDPARTIES 46 false false R47.htm 046 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.xsunx.com/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.xsunx.com/role/COMMITMENTSANDCONTINGENCIES 47 false false R48.htm 047 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails RELATED PARTY TRANSACTIONS (Details) Details http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONS 48 false false R49.htm 048 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.xsunx.com/role/SUBSEQUENTEVENTSDetails SUBSEQUENT EVENTS (Details) Details http://www.xsunx.com/role/SUBSEQUENTEVENTS 49 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - novaccess20230331_10q.htm 6792 novaccess20230331_10q.htm ex_519542.htm ex_519543.htm ex_519544.htm xsnx-20230331.xsd xsnx-20230331_cal.xml xsnx-20230331_def.xml xsnx-20230331_lab.xml xsnx-20230331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 66 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "novaccess20230331_10q.htm": { "axisCustom": 0, "axisStandard": 16, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 706, "http://xbrl.sec.gov/dei/2023": 29 }, "contextCount": 228, "dts": { "calculationLink": { "local": [ "xsnx-20230331_cal.xml" ] }, "definitionLink": { "local": [ "xsnx-20230331_def.xml" ] }, "inline": { "local": [ "novaccess20230331_10q.htm" ] }, "labelLink": { "local": [ "xsnx-20230331_lab.xml" ] }, "presentationLink": { "local": [ "xsnx-20230331_pre.xml" ] }, "schema": { "local": [ "xsnx-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd" ] } }, "elementCount": 397, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 7, "total": 7 }, "keyCustom": 9, "keyStandard": 224, "memberCustom": 29, "memberStandard": 25, "nsprefix": "xsnx", "nsuri": "http://www.xsunx.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.xsunx.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - CONVERTIBLE PROMISSORY NOTES", "menuCat": "Notes", "order": "10", "role": "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTES", "shortName": "CONVERTIBLE PROMISSORY NOTES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - CONVERTIBLE PROMISSORY NOTE, RELATED PARTY", "menuCat": "Notes", "order": "11", "role": "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTERELATEDPARTY", "shortName": "CONVERTIBLE PROMISSORY NOTE, RELATED PARTY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - SHORT TERM LOAN, RELATED PARTY", "menuCat": "Notes", "order": "12", "role": "http://www.xsunx.com/role/SHORTTERMLOANRELATEDPARTY", "shortName": "SHORT TERM LOAN, RELATED PARTY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - WARRANTS", "menuCat": "Notes", "order": "13", "role": "http://www.xsunx.com/role/WARRANTS", "shortName": "WARRANTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - OPTIONS", "menuCat": "Notes", "order": "14", "role": "http://www.xsunx.com/role/OPTIONS", "shortName": "OPTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "menuCat": "Notes", "order": "15", "role": "http://www.xsunx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - BRIDGE LOANS PAYABLE", "menuCat": "Notes", "order": "16", "role": "http://www.xsunx.com/role/BRIDGELOANSPAYABLE", "shortName": "BRIDGE LOANS PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - DUE TO RELATED PARTIES", "menuCat": "Notes", "order": "17", "role": "http://www.xsunx.com/role/DUETORELATEDPARTIES", "shortName": "DUE TO RELATED PARTIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "18", "role": "http://www.xsunx.com/role/COMMITMENTSANDCONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - RELATED PARTY TRANSACTIONS", "menuCat": "Notes", "order": "19", "role": "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://www.xsunx.com/role/ConsolidatedBalanceSheet", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "20", "role": "http://www.xsunx.com/role/SUBSEQUENTEVENTS", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Accounting Policies, by Policy (Policies)", "menuCat": "Policies", "order": "21", "role": "http://www.xsunx.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "menuCat": "Tables", "order": "22", "role": "http://www.xsunx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Tables)", "menuCat": "Tables", "order": "23", "role": "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESTables", "shortName": "CONVERTIBLE PROMISSORY NOTES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c175", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - WARRANTS (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.xsunx.com/role/WARRANTSTables", "shortName": "WARRANTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c175", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - OPTIONS (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.xsunx.com/role/OPTIONSTables", "shortName": "OPTIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.xsunx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c44", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - ORGANIZATION AND LINE OF BUSINESS (Details)", "menuCat": "Details", "order": "27", "role": "http://www.xsunx.com/role/ORGANIZATIONANDLINEOFBUSINESSDetails", "shortName": "ORGANIZATION AND LINE OF BUSINESS (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c6", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Earnings Per Share, Basic and Diluted", "menuCat": "Details", "order": "28", "role": "http://www.xsunx.com/role/ScheduleofEarningsPerShareBasicandDilutedTable", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Earnings Per Share, Basic and Diluted", "subGroupType": "details", "uniqueAnchor": null }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis", "menuCat": "Details", "order": "29", "role": "http://www.xsunx.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://www.xsunx.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "CONSOLIDATED BALANCE SHEETS (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c2", "decimals": "0", "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscountCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "b", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation", "menuCat": "Details", "order": "30", "role": "http://www.xsunx.com/role/FairValueNetDerivativeAssetLiabilityMeasuredonRecurringBasisUnobservableInputReconciliationTable", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c15", "decimals": "0", "lang": null, "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - CAPITAL STOCK (Details)", "menuCat": "Details", "order": "31", "role": "http://www.xsunx.com/role/CAPITALSTOCKDetails", "shortName": "CAPITAL STOCK (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c206", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details)", "menuCat": "Details", "order": "32", "role": "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "shortName": "CONVERTIBLE PROMISSORY NOTES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c69", "decimals": "0", "lang": null, "name": "us-gaap:DebtInstrumentFeeAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "b", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt", "menuCat": "Details", "order": "33", "role": "http://www.xsunx.com/role/ScheduleofDebtTable", "shortName": "CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c143", "decimals": "0", "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c153", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EmbeddedDerivativeLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details) - Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques", "menuCat": "Details", "order": "34", "role": "http://www.xsunx.com/role/FairValueMeasurementsRecurringandNonrecurringValuationTechniquesTable", "shortName": "CONVERTIBLE PROMISSORY NOTES (Details) - Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c153", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EmbeddedDerivativeLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c155", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - CONVERTIBLE PROMISSORY NOTE, RELATED PARTY (Details)", "menuCat": "Details", "order": "35", "role": "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTERELATEDPARTYDetails", "shortName": "CONVERTIBLE PROMISSORY NOTE, RELATED PARTY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c155", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c206", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - SHORT TERM LOAN, RELATED PARTY (Details)", "menuCat": "Details", "order": "36", "role": "http://www.xsunx.com/role/SHORTTERMLOANRELATEDPARTYDetails", "shortName": "SHORT TERM LOAN, RELATED PARTY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c161", "decimals": "0", "lang": null, "name": "us-gaap:ProceedsFromShortTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c161", "decimals": "0", "first": true, "lang": null, "name": "xsnx:ClassOfWarrantOrRightsGranted", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - WARRANTS (Details)", "menuCat": "Details", "order": "37", "role": "http://www.xsunx.com/role/WARRANTSDetails", "shortName": "WARRANTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c161", "decimals": "0", "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c180", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EmbeddedDerivativeLiabilityMeasurementInput", "reportCount": 1, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - WARRANTS (Details) - Fair Value Measurement Inputs and Valuation Techniques", "menuCat": "Details", "order": "38", "role": "http://www.xsunx.com/role/FairValueMeasurementInputsandValuationTechniquesTable", "shortName": "WARRANTS (Details) - Fair Value Measurement Inputs and Valuation Techniques", "subGroupType": "details", "uniqueAnchor": null }, "R39": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c184", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - OPTIONS (Details)", "menuCat": "Details", "order": "39", "role": "http://www.xsunx.com/role/OPTIONSDetails", "shortName": "OPTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c182", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c6", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "menuCat": "Statements", "order": "4", "role": "http://www.xsunx.com/role/ConsolidatedIncomeStatement", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c6", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c184", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - OPTIONS (Details) - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions", "menuCat": "Details", "order": "40", "role": "http://www.xsunx.com/role/ScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsTable", "shortName": "OPTIONS (Details) - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c184", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - OPTIONS (Details) - Share-Based Payment Arrangement, Option, Activity", "menuCat": "Details", "order": "41", "role": "http://www.xsunx.com/role/ShareBasedPaymentArrangementOptionActivityTable", "shortName": "OPTIONS (Details) - Share-Based Payment Arrangement, Option, Activity", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c191", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - OPTIONS (Details) - Share-based Payment Arrangement, Option, Exercise Price Range", "menuCat": "Details", "order": "42", "role": "http://www.xsunx.com/role/SharebasedPaymentArrangementOptionExercisePriceRangeTable", "shortName": "OPTIONS (Details) - Share-based Payment Arrangement, Option, Exercise Price Range", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c191", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "link:footnote", "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c195", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesOther", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)", "menuCat": "Details", "order": "43", "role": "http://www.xsunx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "link:footnote", "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c195", "decimals": null, "lang": "en-US", "name": "us-gaap:DebtInstrumentFee", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - Schedule of Accounts Payable and Accrued Liabilities", "menuCat": "Details", "order": "44", "role": "http://www.xsunx.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - Schedule of Accounts Payable and Accrued Liabilities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c214", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - BRIDGE LOANS PAYABLE (Details)", "menuCat": "Details", "order": "45", "role": "http://www.xsunx.com/role/BRIDGELOANSPAYABLEDetails", "shortName": "BRIDGE LOANS PAYABLE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c55", "decimals": "0", "lang": null, "name": "us-gaap:InterestExpenseDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c201", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromRelatedPartyDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - DUE TO RELATED PARTIES (Details)", "menuCat": "Details", "order": "46", "role": "http://www.xsunx.com/role/DUETORELATEDPARTIESDetails", "shortName": "DUE TO RELATED PARTIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c205", "decimals": "2", "lang": null, "name": "us-gaap:PreferredStockConvertibleConversionPrice", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "link:footnote", "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c195", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesOther", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "menuCat": "Details", "order": "47", "role": "http://www.xsunx.com/role/COMMITMENTSANDCONTINGENCIESDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R48": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c161", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromOtherDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - RELATED PARTY TRANSACTIONS (Details)", "menuCat": "Details", "order": "48", "role": "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c204", "decimals": "-5", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c223", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - SUBSEQUENT EVENTS (Details)", "menuCat": "Details", "order": "49", "role": "http://www.xsunx.com/role/SUBSEQUENTEVENTSDetails", "shortName": "SUBSEQUENT EVENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c223", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "b", "td", "tr", "table", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c9", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)", "menuCat": "Statements", "order": "5", "role": "http://www.xsunx.com/role/ShareholdersEquityType2or3", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "td", "tr", "table", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c9", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c6", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "6", "role": "http://www.xsunx.com/role/ConsolidatedCashFlow", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - ORGANIZATION AND LINE OF BUSINESS", "menuCat": "Notes", "order": "7", "role": "http://www.xsunx.com/role/ORGANIZATIONANDLINEOFBUSINESS", "shortName": "ORGANIZATION AND LINE OF BUSINESS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "8", "role": "http://www.xsunx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - CAPITAL STOCK", "menuCat": "Notes", "order": "9", "role": "http://www.xsunx.com/role/CAPITALSTOCK", "shortName": "CAPITAL STOCK", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "novaccess20230331_10q.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 59, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCKDetails", "http://www.xsunx.com/role/DUETORELATEDPARTIESDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCKDetails", "http://www.xsunx.com/role/DUETORELATEDPARTIESDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag", "terseLabel": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r549" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.xsunx.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r457", "r511", "r539", "r576", "r584", "r585", "r586" ], "lang": { "en-us": { "role": { "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Entity [Member]" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.xsunx.com/role/DUETORELATEDPARTIESDetails" ], "xbrltype": "domainItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r567" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.xsunx.com/role/BRIDGELOANSPAYABLEDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "srt_ChiefFinancialOfficerMember": { "auth_ref": [ "r567" ], "lang": { "en-us": { "role": { "label": "Chief Financial Officer [Member]", "terseLabel": "Chief Financial Officer [Member]" } } }, "localname": "ChiefFinancialOfficerMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.xsunx.com/role/BRIDGELOANSPAYABLEDetails", "http://www.xsunx.com/role/OPTIONSDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r567", "r601" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.xsunx.com/role/OPTIONSDetails", "http://www.xsunx.com/role/SHORTTERMLOANRELATEDPARTYDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r209", "r210", "r211", "r212", "r276", "r368", "r391", "r429", "r430", "r488", "r490", "r491", "r492", "r502", "r512", "r513", "r521", "r527", "r531", "r535", "r573", "r589", "r590", "r591", "r592", "r593", "r594" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.xsunx.com/role/FairValueMeasurementInputsandValuationTechniquesTable", "http://www.xsunx.com/role/FairValueMeasurementsRecurringandNonrecurringValuationTechniquesTable", "http://www.xsunx.com/role/SUBSEQUENTEVENTSDetails", "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r209", "r210", "r211", "r212", "r276", "r368", "r391", "r429", "r430", "r488", "r490", "r491", "r492", "r502", "r512", "r513", "r521", "r527", "r531", "r535", "r573", "r589", "r590", "r591", "r592", "r593", "r594" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.xsunx.com/role/FairValueMeasurementInputsandValuationTechniquesTable", "http://www.xsunx.com/role/FairValueMeasurementsRecurringandNonrecurringValuationTechniquesTable", "http://www.xsunx.com/role/SUBSEQUENTEVENTSDetails", "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r209", "r210", "r211", "r212", "r268", "r276", "r304", "r305", "r306", "r367", "r368", "r391", "r429", "r430", "r488", "r490", "r491", "r492", "r502", "r512", "r513", "r521", "r527", "r531", "r535", "r538", "r569", "r573", "r590", "r591", "r592", "r593", "r594" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.xsunx.com/role/FairValueMeasurementInputsandValuationTechniquesTable", "http://www.xsunx.com/role/FairValueMeasurementsRecurringandNonrecurringValuationTechniquesTable", "http://www.xsunx.com/role/SUBSEQUENTEVENTSDetails", "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r209", "r210", "r211", "r212", "r268", "r276", "r304", "r305", "r306", "r367", "r368", "r391", "r429", "r430", "r488", "r490", "r491", "r492", "r502", "r512", "r513", "r521", "r527", "r531", "r535", "r538", "r569", "r573", "r590", "r591", "r592", "r593", "r594" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.xsunx.com/role/FairValueMeasurementInputsandValuationTechniquesTable", "http://www.xsunx.com/role/FairValueMeasurementsRecurringandNonrecurringValuationTechniquesTable", "http://www.xsunx.com/role/SUBSEQUENTEVENTSDetails", "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://www.xsunx.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "totalLabel": "Accrued expenses and accrued other current liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r16", "r534" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r21" ], "calculation": { "http://www.xsunx.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrent": { "auth_ref": [ "r21", "r516" ], "calculation": { "http://www.xsunx.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": { "order": 4.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Salaries, Current", "terseLabel": "Accrued payroll" } } }, "localname": "AccruedSalariesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r85", "r534", "r602" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r311", "r312", "r313", "r408", "r562", "r563", "r564", "r580", "r604" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalPreferredStock": { "auth_ref": [ "r85" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholder in nonredeemable preferred stock-related transaction in excess of par value, value contributed to entity and value received from other stock-related transaction. Includes, but is not limited to, preferred stock redeemable solely at option of issuer. Excludes common stock.", "label": "Additional Paid in Capital, Preferred Stock", "terseLabel": "Paid in capital, preferred stock" } } }, "localname": "AdditionalPaidInCapitalPreferredStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Adjustments to Additional Paid in Capital, Other", "terseLabel": "Deemed dividend warrant protection reserve" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r8", "r50", "r109" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Adjustments to Additional Paid in Capital, Warrant Issued" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustment to reconcile net loss to net cash provided by (used in) operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r245", "r350", "r525", "r526", "r557" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt discount and debt issuance costs recorded as interest expense" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r116", "r132", "r156", "r187", "r193", "r197", "r202", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r321", "r323", "r341", "r384", "r450", "r534", "r546", "r571", "r572", "r587" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r279", "r280", "r281", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r303", "r304", "r305", "r306", "r307" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/OPTIONSDetails", "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Accounting, Policy [Policy Text Block]" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r38", "r131", "r514" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r38", "r97", "r152" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "CASH, END OF PERIOD", "periodStartLabel": "CASH, BEGINNING OF PERIOD" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r1", "r97" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "NET INCREASE (DECREASE) IN CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r127", "r133", "r134", "r135", "r156", "r176", "r177", "r180", "r182", "r185", "r186", "r202", "r214", "r216", "r217", "r218", "r221", "r222", "r252", "r253", "r256", "r259", "r265", "r341", "r400", "r401", "r402", "r403", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r438", "r459", "r480", "r504", "r505", "r506", "r507", "r508", "r553", "r559", "r565" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/BRIDGELOANSPAYABLEDetails", "http://www.xsunx.com/role/CAPITALSTOCKDetails", "http://www.xsunx.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.xsunx.com/role/DUETORELATEDPARTIESDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)", "verboseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Class of Warrant or Right, Outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r102", "r207", "r208", "r510", "r570" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/COMMITMENTSANDCONTINGENCIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r536", "r537", "r538", "r540", "r541", "r542", "r543", "r562", "r563", "r580", "r599", "r604" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNoParValue": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value common stock.", "label": "Common Stock, No Par Value", "terseLabel": "Common stock, no par value (in Dollars per share)" } } }, "localname": "CommonStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r84", "r438" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "verboseLabel": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCKDetails", "http://www.xsunx.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r8", "r84", "r438", "r456", "r604", "r606" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r84", "r386", "r534" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, no par value; 2,000,000,000 authorized common shares 21,185,028 and 18,669,507 shares issued and outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountIssued1": { "auth_ref": [ "r41", "r42", "r43" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Amount Issued", "terseLabel": "Conversion of Stock, Amount Issued" } } }, "localname": "ConversionOfStockAmountIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/DUETORELATEDPARTIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r41", "r42", "r43" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Converted", "terseLabel": "Conversion of Stock, Shares Converted" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCKDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r41", "r42", "r43" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Issued", "terseLabel": "Conversion of Stock, Shares Issued", "verboseLabel": "Conversion of Stock, Shares Issued (in Shares)" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCKDetails", "http://www.xsunx.com/role/DUETORELATEDPARTIESDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r15", "r118", "r598" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible Debt", "terseLabel": "Outstanding balance", "verboseLabel": "Convertible Debt" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.xsunx.com/role/ScheduleofDebtTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r81" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible Debt, Current", "terseLabel": "Convertible promissory notes, net of debt discount and debt issuance costs of $157,807 and $340,503 respectively" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r104", "r224", "r225", "r235", "r236", "r237", "r241", "r242", "r243", "r244", "r245", "r522", "r523", "r524", "r525", "r526" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Debt [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESTables" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r92", "r156", "r202", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r341", "r571" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "negatedLabel": "COST OF GOODS SOLD" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r41", "r43" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Debt Conversion, Converted Instrument, Shares Issued", "verboseLabel": "Debt Conversion, Converted Instrument, Shares Issued (in Shares)" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/BRIDGELOANSPAYABLEDetails", "http://www.xsunx.com/role/CAPITALSTOCKDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDefaultLongtermDebtAmount": { "auth_ref": [ "r154" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.", "label": "Debt Instrument, Debt Default, Amount", "terseLabel": "Debt Instrument, Debt Default, Amount", "verboseLabel": "Debt Instrument, Debt Default, Amount (in Dollars)" } } }, "localname": "DebtDefaultLongtermDebtAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r103", "r154", "r223", "r229", "r230", "r231", "r232", "r233", "r234", "r239", "r246", "r247", "r248" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt Disclosure [Text Block]" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTES" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r15", "r81", "r82", "r117", "r118", "r159", "r224", "r225", "r226", "r227", "r228", "r230", "r235", "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r244", "r245", "r351", "r522", "r523", "r524", "r525", "r526", "r560" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTERELATEDPARTYDetails", "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESTables", "http://www.xsunx.com/role/ScheduleofDebtTable", "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r105", "r226" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Debt Instrument, Convertible, Conversion Price (in Dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTERELATEDPARTYDetails", "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature": { "auth_ref": [ "r27", "r54", "r107", "r108" ], "lang": { "en-us": { "role": { "documentation": "Description of conversion terms for debt instrument.", "label": "Debt Instrument, Convertible, Terms of Conversion Feature", "terseLabel": "Debt Instrument, Convertible, Terms of Conversion Feature" } } }, "localname": "DebtInstrumentConvertibleTermsOfConversionFeature", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentDescription": { "auth_ref": [ "r15", "r54", "r76", "r81", "r117", "r118" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.", "label": "Debt Instrument, Description", "terseLabel": "Debt Instrument, Description" } } }, "localname": "DebtInstrumentDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r71", "r73", "r224", "r351", "r523", "r524" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "netLabel": "Debt Instrument, Face Amount (in Dollars)", "terseLabel": "Principal Amount", "verboseLabel": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTERELATEDPARTYDetails", "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.xsunx.com/role/SHORTTERMLOANRELATEDPARTYDetails", "http://www.xsunx.com/role/SUBSEQUENTEVENTSDetails", "http://www.xsunx.com/role/ScheduleofDebtTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFee": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Description of a fee associated with the debt instrument, including a commitment fee on unborrowed portions of a lender's total contractual commitment.", "label": "Debt Instrument, Fee", "terseLabel": "Debt Instrument, Fee" } } }, "localname": "DebtInstrumentFee", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails", "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFeeAmount": { "auth_ref": [ "r28" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.", "label": "Debt Instrument, Fee Amount", "terseLabel": "Debt Instrument, Fee Amount" } } }, "localname": "DebtInstrumentFeeAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r24", "r225" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/BRIDGELOANSPAYABLEDetails", "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTERELATEDPARTYDetails", "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.xsunx.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r126", "r522", "r582" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "terseLabel": "Debt Instrument, Maturity Date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/SHORTTERMLOANRELATEDPARTYDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentMaturityDateDescription": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.", "label": "Debt Instrument, Maturity Date, Description", "terseLabel": "Debt Instrument, Maturity Date, Description" } } }, "localname": "DebtInstrumentMaturityDateDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTERELATEDPARTYDetails", "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.xsunx.com/role/SHORTTERMLOANRELATEDPARTYDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r29", "r159", "r224", "r225", "r226", "r227", "r228", "r230", "r235", "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r244", "r245", "r351", "r522", "r523", "r524", "r525", "r526", "r560" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESTables", "http://www.xsunx.com/role/ScheduleofDebtTable", "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPaymentTerms": { "auth_ref": [ "r26", "r77" ], "lang": { "en-us": { "role": { "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.", "label": "Debt Instrument, Payment Terms", "terseLabel": "Debt Instrument, Payment Terms" } } }, "localname": "DebtInstrumentPaymentTerms", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt Instrument, Term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r70", "r73", "r574" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Unamortized balance of Debt Discount", "verboseLabel": "Debt Instrument, Unamortized Discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTERELATEDPARTYDetails", "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/ScheduleofDebtTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "auth_ref": [ "r70", "r73" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.", "label": "Debt Instrument, Unamortized Discount, Current", "terseLabel": "Convertible promissory note related party, debt discount and debt issuance cost (in Dollars)" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": { "auth_ref": [ "r70", "r73" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.", "label": "Debt Instrument, Unamortized Discount, Noncurrent", "terseLabel": "Debt Instrument, Unamortized Discount, Noncurrent" } } }, "localname": "DebtInstrumentUnamortizedDiscountNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r72", "r235", "r249", "r523", "r524" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "terseLabel": "Convertible promissory notes, debt discount and debt issuance costs (in Dollars)", "verboseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts": { "auth_ref": [ "r95" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses.", "label": "Debt Related Commitment Fees and Debt Issuance Costs", "terseLabel": "Stock issued as commitment fee on promissory note payable" } } }, "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationLiabilityCurrent": { "auth_ref": [ "r55", "r111" ], "calculation": { "http://www.xsunx.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": { "order": 5.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.", "label": "Deferred Compensation Liability, Current", "terseLabel": "Deferred compensation" } } }, "localname": "DeferredCompensationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r137", "r138", "r340", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r429", "r430", "r444", "r445", "r494", "r497", "r498", "r499", "r500", "r501", "r517", "r538", "r600" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "Assets:" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [ "r427", "r430", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r451", "r452", "r453", "r454", "r468", "r469", "r470", "r471", "r474", "r475", "r476", "r477", "r494", "r495", "r498", "r500", "r536", "r538" ], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/FairValueNetDerivativeAssetLiabilityMeasuredonRecurringBasisUnobservableInputReconciliationTable", "http://www.xsunx.com/role/ScheduleofDebtTable" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r579" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.xsunx.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "negatedLabel": "Loss on change in derivative liability", "terseLabel": "Gain (Loss) on change in derivative liability" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow", "http://www.xsunx.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r62", "r64", "r65", "r66", "r427", "r430", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r451", "r452", "r453", "r454", "r468", "r469", "r470", "r471", "r474", "r475", "r476", "r477", "r494", "r495", "r498", "r500", "r517", "r536", "r538" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/FairValueMeasurementsRecurringandNonrecurringValuationTechniquesTable", "http://www.xsunx.com/role/FairValueNetDerivativeAssetLiabilityMeasuredonRecurringBasisUnobservableInputReconciliationTable", "http://www.xsunx.com/role/ScheduleofDebtTable", "http://www.xsunx.com/role/WARRANTSTables" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r137", "r138", "r340", "r420", "r421", "r422", "r423", "r425", "r426", "r427", "r429", "r430", "r451", "r453", "r454", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r517", "r600" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Total Derivative Liability", "verboseLabel": "Derivative balance" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ScheduleofDebtTable", "http://www.xsunx.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r137" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Current", "terseLabel": "Derivative and warrants liabilities" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r277", "r278", "r308", "r309", "r310", "r532" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Payment Arrangement [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/OPTIONS" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DisclosureTextBlockSupplementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Text Block Supplement [Abstract]" } } }, "localname": "DisclosureTextBlockSupplementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r146", "r165", "r166", "r167", "r168", "r169", "r173", "r176", "r180", "r181", "r182", "r183", "r333", "r334", "r382", "r390", "r518" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "BASIC INCOME (LOSS) PER SHARE (in Dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r146", "r165", "r166", "r167", "r168", "r169", "r176", "r180", "r181", "r182", "r183", "r333", "r334", "r382", "r390", "r518" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "DILUTED INCOME (LOSS) PER SHARE (in Dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r44", "r45" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "auth_ref": [ "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.", "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability", "terseLabel": "Derivative Liability warrants at fair value", "verboseLabel": "Embedded Derivative, Fair Value of Embedded Derivative Liability" } } }, "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable", "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmbeddedDerivativeFinancialInstrumentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative instrument embedded in host contract.", "label": "Embedded Derivative Financial Instruments [Member]", "terseLabel": "Embedded Derivative Financial Instruments [Member]" } } }, "localname": "EmbeddedDerivativeFinancialInstrumentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/FairValueMeasurementsRecurringandNonrecurringValuationTechniquesTable", "http://www.xsunx.com/role/FairValueNetDerivativeAssetLiabilityMeasuredonRecurringBasisUnobservableInputReconciliationTable", "http://www.xsunx.com/role/ScheduleofDebtTable" ], "xbrltype": "domainItemType" }, "us-gaap_EmbeddedDerivativeLiabilityMeasurementInput": { "auth_ref": [ "r582" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure embedded derivative liability.", "label": "Embedded Derivative Liability, Measurement Input", "terseLabel": "Fair Value Measurement Input", "verboseLabel": "Embedded Derivative Liability, Measurement Input" } } }, "localname": "EmbeddedDerivativeLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/FairValueMeasurementInputsandValuationTechniquesTable", "http://www.xsunx.com/role/FairValueMeasurementsRecurringandNonrecurringValuationTechniquesTable", "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/OPTIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r8", "r128", "r141", "r142", "r143", "r160", "r161", "r162", "r164", "r170", "r172", "r184", "r203", "r204", "r267", "r311", "r312", "r313", "r319", "r320", "r325", "r326", "r327", "r328", "r329", "r330", "r332", "r342", "r343", "r344", "r345", "r346", "r347", "r352", "r392", "r393", "r394", "r408", "r480" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCKDetails", "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r0", "r4" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "terseLabel": "Fair Value Adjustment of Warrants" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/FairValueMeasurementInputsandValuationTechniquesTable", "http://www.xsunx.com/role/FairValueMeasurementsRecurringandNonrecurringValuationTechniquesTable" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/FairValueMeasurementInputsandValuationTechniquesTable", "http://www.xsunx.com/role/FairValueMeasurementsRecurringandNonrecurringValuationTechniquesTable" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESTables", "http://www.xsunx.com/role/WARRANTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r237", "r269", "r270", "r271", "r272", "r273", "r274", "r336", "r364", "r365", "r366", "r523", "r524", "r528", "r529", "r530" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/FairValueNetDerivativeAssetLiabilityMeasuredonRecurringBasisUnobservableInputReconciliationTable", "http://www.xsunx.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r237", "r269", "r274", "r336", "r364", "r528", "r529", "r530" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r237", "r269", "r274", "r336", "r365", "r523", "r524", "r528", "r529", "r530" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r237", "r269", "r270", "r271", "r272", "r273", "r274", "r336", "r366", "r523", "r524", "r528", "r529", "r530" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/FairValueNetDerivativeAssetLiabilityMeasuredonRecurringBasisUnobservableInputReconciliationTable", "http://www.xsunx.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r68" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTERELATEDPARTYDetails", "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "terseLabel": "Extinguishment of derivative" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/FairValueNetDerivativeAssetLiabilityMeasuredonRecurringBasisUnobservableInputReconciliationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r237", "r269", "r270", "r271", "r272", "r273", "r274", "r364", "r365", "r366", "r523", "r524", "r528", "r529", "r530" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/FairValueNetDerivativeAssetLiabilityMeasuredonRecurringBasisUnobservableInputReconciliationTable", "http://www.xsunx.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/FairValueNetDerivativeAssetLiabilityMeasuredonRecurringBasisUnobservableInputReconciliationTable" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r10", "r13" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/FairValueNetDerivativeAssetLiabilityMeasuredonRecurringBasisUnobservableInputReconciliationTable" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": { "auth_ref": [ "r10", "r13" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings": { "auth_ref": [ "r338", "r339" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings", "terseLabel": "Net (Gain)/Loss on change in fair value of derivative liability" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/FairValueNetDerivativeAssetLiabilityMeasuredonRecurringBasisUnobservableInputReconciliationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues": { "auth_ref": [ "r13", "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of issuances of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues", "terseLabel": "Initial derivative liabilities" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/FairValueNetDerivativeAssetLiabilityMeasuredonRecurringBasisUnobservableInputReconciliationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": { "auth_ref": [ "r13", "r67" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/FairValueNetDerivativeAssetLiabilityMeasuredonRecurringBasisUnobservableInputReconciliationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r5", "r14" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments, Policy [Policy Text Block]" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "terseLabel": "Derivative Liability at fair value" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r62" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.xsunx.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "negatedLabel": "Extinguishment of derivatives", "terseLabel": "Extinguishment of derivatives" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow", "http://www.xsunx.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r4", "r51", "r52" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedCashFlow": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.xsunx.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Extinguishment of debt", "terseLabel": "Extinguishment of debt", "verboseLabel": "Gain (Loss) on Extinguishment of Debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/BRIDGELOANSPAYABLEDetails", "http://www.xsunx.com/role/ConsolidatedCashFlow", "http://www.xsunx.com/role/ConsolidatedIncomeStatement", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnRestructuringOfDebt": { "auth_ref": [ "r7" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedIncomeStatement": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.", "label": "Gains (Losses) on Restructuring of Debt", "terseLabel": "Change in commitment fee guarantee" } } }, "localname": "GainsLossesOnRestructuringOfDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r91", "r156", "r187", "r192", "r196", "r198", "r202", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r341", "r520", "r571" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "GROSS PROFIT" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_GuaranteeObligationsCurrentCarryingValue": { "auth_ref": [ "r213" ], "calculation": { "http://www.xsunx.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees.", "label": "Guarantor Obligations, Current Carrying Value", "terseLabel": "Provision for guaranteed commitment fees *" } } }, "localname": "GuaranteeObligationsCurrentCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r37", "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Taxes paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r3" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r3" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses and interest on notes payable" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in Assets and Liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r3" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedCashFlow": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndDebtExpense": { "auth_ref": [ "r6" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity.", "label": "Interest and Debt Expense", "terseLabel": "Non-cash interest expense on bridge loan" } } }, "localname": "InterestAndDebtExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestCostsCapitalized": { "auth_ref": [ "r69" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest capitalized during the period.", "label": "Interest Costs Capitalized", "terseLabel": "Accrued interest capitalized into convertible note" } } }, "localname": "InterestCostsCapitalized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r72", "r121", "r144", "r190", "r349", "r465", "r544", "r603" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedIncomeStatement": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r95", "r243", "r250", "r525", "r526" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Interest Expense, Debt" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/BRIDGELOANSPAYABLEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r558" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities", "terseLabel": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/BRIDGELOANSPAYABLEDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r148", "r150", "r151" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r21" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses and other current liabilities" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r75", "r596" ], "calculation": { "http://www.xsunx.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest Payable", "terseLabel": "Interest payable" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterimPeriodCostsNotAllocableDomain": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred.", "label": "Interim Period, Costs Not Allocable [Domain]" } } }, "localname": "InterimPeriodCostsNotAllocableDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentOwnedBalanceShares": { "auth_ref": [ "r420", "r428", "r489", "r493", "r503", "r538" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of investment owned.", "label": "Investment Owned, Balance, Shares", "terseLabel": "Investment Owned, Balance, Shares", "verboseLabel": "Investment Owned, Balance, Shares (in Shares)" } } }, "localname": "InvestmentOwnedBalanceShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/DUETORELATEDPARTIESDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r4" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Issuance of Stock and Warrants for Services or Claims", "terseLabel": "Stock issued and issuable for services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r20", "r156", "r202", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r322", "r323", "r324", "r341", "r437", "r519", "r546", "r571", "r587", "r588" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r89", "r119", "r388", "r534", "r561", "r568", "r583" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r23", "r130", "r156", "r202", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r322", "r323", "r324", "r341", "r534", "r571", "r587", "r588" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-Term Debt [Text Block]", "terseLabel": "Long-Term Debt [Text Block]" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTERELATEDPARTY" ], "xbrltype": "textBlockItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r581" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]", "terseLabel": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/FairValueMeasurementInputsandValuationTechniquesTable", "http://www.xsunx.com/role/FairValueMeasurementsRecurringandNonrecurringValuationTechniquesTable", "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r581" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/FairValueMeasurementInputsandValuationTechniquesTable", "http://www.xsunx.com/role/FairValueMeasurementsRecurringandNonrecurringValuationTechniquesTable", "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r581" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/FairValueMeasurementInputsandValuationTechniquesTable", "http://www.xsunx.com/role/FairValueMeasurementsRecurringandNonrecurringValuationTechniquesTable", "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r581" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/FairValueMeasurementInputsandValuationTechniquesTable", "http://www.xsunx.com/role/FairValueMeasurementsRecurringandNonrecurringValuationTechniquesTable", "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/FairValueMeasurementInputsandValuationTechniquesTable", "http://www.xsunx.com/role/FairValueMeasurementsRecurringandNonrecurringValuationTechniquesTable", "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfExpenseAxis": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cost or expense.", "label": "Nature of Expense [Axis]" } } }, "localname": "NatureOfExpenseAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r149" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r97", "r98", "r99" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r90", "r99", "r120", "r129", "r139", "r140", "r143", "r156", "r163", "r165", "r166", "r167", "r168", "r171", "r172", "r178", "r187", "r192", "r196", "r198", "r202", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r334", "r341", "r389", "r458", "r478", "r479", "r520", "r544", "r571" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.xsunx.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "NET INCOME (LOSS)", "verboseLabel": "Net Loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow", "http://www.xsunx.com/role/ConsolidatedIncomeStatement", "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r147", "r165", "r166", "r167", "r168", "r173", "r174", "r179", "r182", "r187", "r192", "r196", "r198", "r520" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "(Loss) to common shareholders (Numerator) (in Dollars)", "totalLabel": "Net income loss attributable to common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedIncomeStatement", "http://www.xsunx.com/role/ScheduleofEarningsPerShareBasicandDilutedTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURES OF NON CASH TRANSACTIONS" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r94" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "TOTAL OTHER INCOME/(EXPENSES)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "OTHER INCOME/(EXPENSES)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedBalanceSheet": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "terseLabel": "Convertible promissory note related party, net of debt discount and debt issuance cost of $0 and $2,132, respectively", "verboseLabel": "Notes Payable, Current" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTERELATEDPARTYDetails", "http://www.xsunx.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.xsunx.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "TOTAL OPERATING EXPENSES" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "OPERATING EXPENSES" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r187", "r192", "r196", "r198", "r520" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "LOSS FROM OPERATIONS BEFORE OTHER INCOME/(EXPENSES)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r79", "r115", "r397", "r398" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ORGANIZATIONANDLINEOFBUSINESS" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r21" ], "calculation": { "http://www.xsunx.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": { "order": 6.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "License Fees Payable" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r75" ], "calculation": { "http://www.xsunx.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": { "order": 7.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other.", "label": "Other Accrued Liabilities", "terseLabel": "Insurance finance liability" } } }, "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails", "http://www.xsunx.com/role/CAPITALSTOCKDetails", "http://www.xsunx.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.xsunx.com/role/DUETORELATEDPARTIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other future obligation.", "label": "Other Commitments [Domain]" } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCKDetails", "http://www.xsunx.com/role/DUETORELATEDPARTIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesAndSharesSubjectToMandatoryRedemptionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]" } } }, "localname": "OtherLiabilitiesAndSharesSubjectToMandatoryRedemptionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r21", "r534" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Due to related parties" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other liabilities.", "label": "Other Liabilities Disclosure [Text Block]", "terseLabel": "Other Liabilities Disclosure [Text Block]" } } }, "localname": "OtherLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/BRIDGELOANSPAYABLE" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other liabilities.", "label": "Other Liabilities [Table Text Block]", "terseLabel": "Other Liabilities [Table Text Block]" } } }, "localname": "OtherLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/DUETORELATEDPARTIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1": { "auth_ref": [ "r41", "r42", "r43" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.", "label": "Other Significant Noncash Transaction, Value of Consideration Given", "terseLabel": "Cash payable to TN3 for preferred stock" } } }, "localname": "OtherSignificantNoncashTransactionValueOfConsiderationGiven1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r34" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire preferred stock during the period.", "label": "Payments for Repurchase of Preferred Stock and Preference Stock", "negatedLabel": "Payments related party for redemption of preferred stock" } } }, "localname": "PaymentsForRepurchaseOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r96" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "terseLabel": "Payments to Acquire Investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/DUETORELATEDPARTIESDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockConversionBasis": { "auth_ref": [ "r54", "r83" ], "lang": { "en-us": { "role": { "documentation": "Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.", "label": "Preferred Stock, Conversion Basis", "terseLabel": "Preferred Stock, Conversion Basis" } } }, "localname": "PreferredStockConversionBasis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCKDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockConvertibleConversionPrice": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Per share conversion price of preferred stock.", "label": "Preferred Stock, Convertible, Conversion Price", "terseLabel": "Preferred Stock, Convertible, Conversion Price" } } }, "localname": "PreferredStockConvertibleConversionPrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/DUETORELATEDPARTIESDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [ "r536", "r537", "r540", "r541", "r542", "r543", "r599", "r604" ], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r83", "r252" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par (in Dollars per share)", "verboseLabel": "Preferred Stock, Par or Stated Value Per Share (in Dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCKDetails", "http://www.xsunx.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockRedemptionAmount": { "auth_ref": [ "r30", "r53" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The redemption (or callable) amount of currently redeemable preferred stock. Includes amounts representing dividends not currently declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer.", "label": "Preferred Stock, Redemption Amount", "terseLabel": "Preferred Stock, Redemption Amount" } } }, "localname": "PreferredStockRedemptionAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/DUETORELATEDPARTIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r83", "r438" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "verboseLabel": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCKDetails", "http://www.xsunx.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r83", "r252" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r83", "r438", "r456", "r604", "r606" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCKDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r83", "r385", "r534" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock Series B, $0.01 par value, 25,000 authorized 25,000 and 25,000 shares issued and outstanding, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r54", "r83" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Preferred Stock, Voting Rights", "terseLabel": "Preferred Stock, Voting Rights" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCKDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r136", "r205", "r206", "r515" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r33" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Principal payments on convertible debt", "verboseLabel": "Proceeds from Convertible Debt" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r2" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Stock subscriptions received" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r2" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds from Issuance of Convertible Preferred Stock", "terseLabel": "Proceeds from Issuance of Convertible Preferred Stock" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/BRIDGELOANSPAYABLEDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLoans": { "auth_ref": [ "r36" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from principal payments made on loans related to operating activities.", "label": "Proceeds from Loans", "terseLabel": "Proceeds from related parties notes payable" } } }, "localname": "ProceedsFromLoans", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r33" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from Notes Payable", "terseLabel": "Proceeds from convertible notes payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromOtherDebt": { "auth_ref": [ "r33" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from debt classified as other.", "label": "Proceeds from Other Debt", "terseLabel": "Proceeds from Other Debt" } } }, "localname": "ProceedsFromOtherDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/BRIDGELOANSPAYABLEDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r33" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from Related Party Debt", "terseLabel": "Proceeds from Related Party Debt" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/DUETORELATEDPARTIESDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "auth_ref": [], "calculation": { "http://www.xsunx.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.", "label": "Proceeds from (Repayments of) Related Party Debt", "terseLabel": "Due to related party" } } }, "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromShortTermDebt": { "auth_ref": [ "r33" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from Short-Term Debt", "terseLabel": "Proceeds from Short-Term Debt" } } }, "localname": "ProceedsFromShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/SHORTTERMLOANRELATEDPARTYDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r275", "r356", "r357", "r432", "r433", "r434", "r435", "r436", "r455", "r457", "r487" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/BRIDGELOANSPAYABLEDetails", "http://www.xsunx.com/role/DUETORELATEDPARTIESDetails", "http://www.xsunx.com/role/OPTIONSDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.xsunx.com/role/SHORTTERMLOANRELATEDPARTYDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyMember": { "auth_ref": [ "r157", "r158", "r356", "r357", "r358", "r359", "r432", "r433", "r434", "r435", "r436", "r455", "r457", "r487" ], "lang": { "en-us": { "role": { "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family.", "label": "Related Party [Member]", "terseLabel": "Related Party [Member]" } } }, "localname": "RelatedPartyMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCKDetails", "http://www.xsunx.com/role/ScheduleofDebtTable" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r74", "r356" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Related Party Transaction, Amounts of Transaction" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r356", "r357", "r586" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCKDetails", "http://www.xsunx.com/role/ScheduleofDebtTable" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCKDetails", "http://www.xsunx.com/role/ScheduleofDebtTable" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r275", "r356", "r357", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r432", "r433", "r434", "r435", "r436", "r455", "r457", "r487", "r586" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/BRIDGELOANSPAYABLEDetails", "http://www.xsunx.com/role/DUETORELATEDPARTIESDetails", "http://www.xsunx.com/role/OPTIONSDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.xsunx.com/role/SHORTTERMLOANRELATEDPARTYDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r353", "r354", "r355", "r357", "r360", "r405", "r406", "r407", "r462", "r463", "r464", "r484", "r486" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions Disclosure [Text Block]" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONS" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r556" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.", "label": "Repayments of Debt", "terseLabel": "Repayments of Debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/BRIDGELOANSPAYABLEDetails", "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r35" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments of Related Party Debt", "negatedLabel": "Payment on the related parties loans payable" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r78", "r318", "r595" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r86", "r109", "r387", "r395", "r396", "r404", "r439", "r534" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r128", "r160", "r161", "r162", "r164", "r170", "r172", "r203", "r204", "r311", "r312", "r313", "r319", "r320", "r325", "r327", "r328", "r330", "r332", "r392", "r394", "r408", "r604" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r145", "r156", "r188", "r189", "r191", "r194", "r195", "r199", "r200", "r201", "r202", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r341", "r383", "r571" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "SALES" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Debt [Table Text Block]" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r566" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/SharebasedPaymentArrangementOptionExercisePriceRangeTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "terseLabel": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/OPTIONSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r11", "r12", "r57" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/OPTIONSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/OPTIONSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r93" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r554", "r555", "r575" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [ "r554", "r555", "r575" ], "lang": { "en-us": { "role": { "documentation": "Series B preferred stock.", "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/BRIDGELOANSPAYABLEDetails", "http://www.xsunx.com/role/CAPITALSTOCKDetails", "http://www.xsunx.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.xsunx.com/role/DUETORELATEDPARTIESDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r3" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock compensation expense", "verboseLabel": "Share-Based Payment Arrangement, Noncash Expense (in Dollars)" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow", "http://www.xsunx.com/role/OPTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected Dividend Yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Stock Volatility Factor" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk Free Interest Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Options Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/SharebasedPaymentArrangementOptionExercisePriceRangeTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/OPTIONSDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/OPTIONSDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "terseLabel": "Forfeited, Number of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ShareBasedPaymentArrangementOptionActivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted, Number of Options", "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/OPTIONSDetails", "http://www.xsunx.com/role/ShareBasedPaymentArrangementOptionActivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r283", "r284" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, Number of Options", "periodStartLabel": "Outstanding, Number of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ShareBasedPaymentArrangementOptionActivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r283", "r284" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, Weighted average exercise price", "periodStartLabel": "Outstanding, Weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ShareBasedPaymentArrangementOptionActivityTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r279", "r280", "r281", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r303", "r304", "r305", "r306", "r307" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/OPTIONSDetails", "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised, Weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ShareBasedPaymentArrangementOptionActivityTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited, Weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ShareBasedPaymentArrangementOptionActivityTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted, Weighted average exercise price", "verboseLabel": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/OPTIONSDetails", "http://www.xsunx.com/role/ShareBasedPaymentArrangementOptionActivityTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r277", "r282", "r301", "r302", "r303", "r304", "r307", "r314", "r315", "r316", "r317" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Payment Arrangement [Policy Text Block]" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/SharebasedPaymentArrangementOptionExercisePriceRangeTable" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/SharebasedPaymentArrangementOptionExercisePriceRangeTable" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "terseLabel": "Exercisable Prices (in Dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/SharebasedPaymentArrangementOptionExercisePriceRangeTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding", "terseLabel": "Options Outstanding" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/SharebasedPaymentArrangementOptionExercisePriceRangeTable" ], "xbrltype": "sharesItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share Price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r577" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/OPTIONSDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/OPTIONSDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Weighted Average Expected Option Life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/SharebasedPaymentArrangementOptionExercisePriceRangeTable" ], "xbrltype": "durationItemType" }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "auth_ref": [ "r106", "r112" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).", "label": "Shareholders' Equity and Share-Based Payments [Text Block]", "terseLabel": "Shareholders' Equity and Share-Based Payments [Text Block]" } } }, "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/WARRANTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r80", "r117", "r534", "r597" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-Term Debt", "terseLabel": "Short term loan, related party" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtTextBlock": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for short-term debt.", "label": "Short-Term Debt [Text Block]", "terseLabel": "Short-Term Debt [Text Block]" } } }, "localname": "ShortTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/SHORTTERMLOANRELATEDPARTY" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-Term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r100", "r153" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies [Text Block]" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r127", "r133", "r134", "r135", "r156", "r176", "r177", "r180", "r182", "r185", "r186", "r202", "r214", "r216", "r217", "r218", "r221", "r222", "r252", "r253", "r256", "r259", "r265", "r341", "r400", "r401", "r402", "r403", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r438", "r459", "r480", "r504", "r505", "r506", "r507", "r508", "r553", "r559", "r565" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/BRIDGELOANSPAYABLEDetails", "http://www.xsunx.com/role/CAPITALSTOCKDetails", "http://www.xsunx.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.xsunx.com/role/DUETORELATEDPARTIESDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r8", "r32", "r128", "r141", "r142", "r143", "r160", "r161", "r162", "r164", "r170", "r172", "r184", "r203", "r204", "r267", "r311", "r312", "r313", "r319", "r320", "r325", "r326", "r327", "r328", "r329", "r330", "r332", "r342", "r343", "r344", "r345", "r346", "r347", "r352", "r392", "r393", "r394", "r408", "r480" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCKDetails", "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r160", "r161", "r162", "r184", "r369", "r399", "r419", "r431", "r432", "r433", "r434", "r435", "r436", "r438", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r451", "r452", "r453", "r454", "r455", "r457", "r460", "r461", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r480", "r539" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r160", "r161", "r162", "r184", "r369", "r399", "r419", "r431", "r432", "r433", "r434", "r435", "r436", "r438", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r451", "r452", "r453", "r454", "r455", "r457", "r460", "r461", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r480", "r539" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r83", "r84", "r109" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Stock Issued During Period, Shares, Acquisitions (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r8", "r31", "r54", "r109", "r240" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Preferred stock redemption (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Common Stock issued for services (in Shares)", "verboseLabel": "Stock Issued During Period, Shares, Issued for Services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCKDetails", "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r8", "r83", "r84", "r109", "r400", "r480", "r505" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "netLabel": "Stock Issued During Period, Shares, New Issues (in Shares)", "terseLabel": "Common Stock issued, subscriptions (in Shares)", "verboseLabel": "Stock Issued During Period, Shares, New Issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/BRIDGELOANSPAYABLEDetails", "http://www.xsunx.com/role/CAPITALSTOCKDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Shares, Other", "netLabel": "Stock Issued During Period, Shares, Other (in Shares)", "terseLabel": "Common stock issued as commitment fee on promissory note payable (in Shares)", "verboseLabel": "Stock Issued During Period, Shares, Other" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails", "http://www.xsunx.com/role/CAPITALSTOCKDetails", "http://www.xsunx.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/DUETORELATEDPARTIESDetails", "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease": { "auth_ref": [ "r8", "r604", "r605" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the number of shares issued.", "label": "Stock Issued During Period, Shares, Period Increase (Decrease)", "terseLabel": "Stock Issued During Period, Shares, Period Increase (Decrease)" } } }, "localname": "StockIssuedDuringPeriodSharesPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCKDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r8", "r83", "r84", "r109" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Stock compensation cost (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r8", "r83", "r84", "r109", "r288" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Exercised, Number of Options" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ShareBasedPaymentArrangementOptionActivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r8", "r32", "r109" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Preferred stock redemption" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments", "terseLabel": "Common stock issued as repayment of loans" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Common Stock issued for services", "verboseLabel": "Stock Issued During Period, Value, Issued for Services (in Dollars)" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCKDetails", "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r8", "r83", "r84", "r109", "r408", "r480", "r505", "r545" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Common Stock issued, subscriptions" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Common stock issued as commitment fee on promissory note payable", "verboseLabel": "Stock Issued During Period, Value, Other" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails", "http://www.xsunx.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r59", "r83", "r84", "r109" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Stock compensation cost" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r84", "r87", "r88", "r101", "r440", "r456", "r481", "r482", "r534", "r546", "r561", "r568", "r583", "r604" ], "calculation": { "http://www.xsunx.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "TOTAL SHAREHOLDERS' DEFICIT" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet", "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "SHAREHOLDERS' DEFICIT" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r106", "r155", "r251", "r253", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r267", "r331", "r483", "r485", "r509" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Equity [Text Block]", "terseLabel": "Equity [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCK" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityOtherShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of increase (decrease) in shares of stock classified as other.", "label": "Stockholders' Equity, Other Shares", "terseLabel": "Common stock issued as repayment of loans (in Shares)" } } }, "localname": "StockholdersEquityOtherShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders' Equity, Reverse Stock Split", "terseLabel": "Stockholders' Equity, Reverse Stock Split" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCKDetails", "http://www.xsunx.com/role/ORGANIZATIONANDLINEOFBUSINESSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r348", "r362" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r348", "r362" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r361", "r363" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/SUBSEQUENTEVENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_UnamortizedDebtIssuanceExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.", "label": "Unamortized Debt Issuance Expense", "terseLabel": "Unamortized Debt Issuance Expense" } } }, "localname": "UnamortizedDebtIssuanceExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r47", "r48", "r49", "r122", "r123", "r124", "r125" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [ "r536", "r537", "r540", "r541", "r542", "r543" ], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ScheduleofDebtTable", "http://www.xsunx.com/role/WARRANTSDetails", "http://www.xsunx.com/role/WARRANTSTables" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r175", "r182" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted weighted average number of common shares outstanding (Denominator)", "verboseLabel": "DILUTED (in Shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedIncomeStatement", "http://www.xsunx.com/role/ScheduleofEarningsPerShareBasicandDilutedTable" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r173", "r182" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "BASIC (in Shares)", "terseLabel": "Basic weighted average number of common shares outstanding (Denominator)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.xsunx.com/role/ConsolidatedIncomeStatement", "http://www.xsunx.com/role/ScheduleofEarningsPerShareBasicandDilutedTable" ], "xbrltype": "sharesItemType" }, "xsnx_ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) [Line Items]" } } }, "localname": "ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetailsLineItems", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "stringItemType" }, "xsnx_ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) [Table]" } } }, "localname": "ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetailsTable", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "stringItemType" }, "xsnx_AdditionalPaidInCapitalCommonStockWarrants": { "auth_ref": [], "calculation": { "http://www.xsunx.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from common stock warrant related transactions that are in excess of par value or stated value and amounts received from other warrant-related transactions. Includes only common stock warrant transactions.", "label": "Additional Paid In Capital Common Stock Warrants", "terseLabel": "Paid in capital, common stock option and warrants" } } }, "localname": "AdditionalPaidInCapitalCommonStockWarrants", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "xsnx_AdditionalPaidInCapitalPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional paid in capital on preferred stock.", "label": "Additional Paid In Capital Preferred Stock Member", "terseLabel": "Additional Paid in Capital Preferred Stock [Member]" } } }, "localname": "AdditionalPaidInCapitalPreferredStockMember", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "xsnx_AdditionalPaidInCapitalStockOptionsWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about additional paid in capital stock options and warrants.", "label": "Additional Paid In Capital Stock Options Warrants Member", "terseLabel": "Additional Paid in Capital Stock Options / Warrants [Member]" } } }, "localname": "AdditionalPaidInCapitalStockOptionsWarrantsMember", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "xsnx_AgreementMonthlyAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Monthly amount per agreement.", "label": "Agreement Monthly Amount", "terseLabel": "Agreement, Monthly Amount" } } }, "localname": "AgreementMonthlyAmount", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "xsnx_AgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of agreement.", "label": "Agreement Term", "terseLabel": "Agreement, Term" } } }, "localname": "AgreementTerm", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "durationItemType" }, "xsnx_August2022NoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "August2022 Note Member", "terseLabel": "August 2022 Note [Member]" } } }, "localname": "August2022NoteMember", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/ScheduleofDebtTable" ], "xbrltype": "domainItemType" }, "xsnx_AugustNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of debt instrument.", "label": "August Note Member", "terseLabel": "August Note [Member]" } } }, "localname": "AugustNoteMember", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/ScheduleofDebtTable", "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "domainItemType" }, "xsnx_BRIDGELOANSPAYABLEDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BRIDGE LOANS PAYABLE (Details) [Line Items]" } } }, "localname": "BRIDGELOANSPAYABLEDetailsLineItems", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/BRIDGELOANSPAYABLEDetails" ], "xbrltype": "stringItemType" }, "xsnx_BRIDGELOANSPAYABLEDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BRIDGE LOANS PAYABLE (Details) [Table]" } } }, "localname": "BRIDGELOANSPAYABLEDetailsTable", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/BRIDGELOANSPAYABLEDetails" ], "xbrltype": "stringItemType" }, "xsnx_BoardMemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Board Member Member", "terseLabel": "Board Member [Member]" } } }, "localname": "BoardMemberMember", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "xsnx_CAPITALSTOCKDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CAPITAL STOCK (Details) [Line Items]" } } }, "localname": "CAPITALSTOCKDetailsLineItems", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCKDetails" ], "xbrltype": "stringItemType" }, "xsnx_CAPITALSTOCKDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CAPITAL STOCK (Details) [Table]" } } }, "localname": "CAPITALSTOCKDetailsTable", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCKDetails" ], "xbrltype": "stringItemType" }, "xsnx_COMMITMENTSANDCONTINGENCIESDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES (Details) [Line Items]" } } }, "localname": "COMMITMENTSANDCONTINGENCIESDetailsLineItems", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "xsnx_COMMITMENTSANDCONTINGENCIESDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES (Details) [Table]" } } }, "localname": "COMMITMENTSANDCONTINGENCIESDetailsTable", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "xsnx_CONVERTIBLEPROMISSORYNOTERELATEDPARTYDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONVERTIBLE PROMISSORY NOTE, RELATED PARTY (Details) [Line Items]" } } }, "localname": "CONVERTIBLEPROMISSORYNOTERELATEDPARTYDetailsLineItems", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTERELATEDPARTYDetails" ], "xbrltype": "stringItemType" }, "xsnx_CONVERTIBLEPROMISSORYNOTERELATEDPARTYDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONVERTIBLE PROMISSORY NOTE, RELATED PARTY (Details) [Table]" } } }, "localname": "CONVERTIBLEPROMISSORYNOTERELATEDPARTYDetailsTable", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTERELATEDPARTYDetails" ], "xbrltype": "stringItemType" }, "xsnx_CONVERTIBLEPROMISSORYNOTESDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONVERTIBLE PROMISSORY NOTES (Details) [Line Items]" } } }, "localname": "CONVERTIBLEPROMISSORYNOTESDetailsLineItems", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails" ], "xbrltype": "stringItemType" }, "xsnx_CONVERTIBLEPROMISSORYNOTESDetailsScheduleofDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Line Items]" } } }, "localname": "CONVERTIBLEPROMISSORYNOTESDetailsScheduleofDebtLineItems", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/ScheduleofDebtTable" ], "xbrltype": "stringItemType" }, "xsnx_CONVERTIBLEPROMISSORYNOTESDetailsScheduleofDebtTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONVERTIBLE PROMISSORY NOTES (Details) - Schedule of Debt [Table]" } } }, "localname": "CONVERTIBLEPROMISSORYNOTESDetailsScheduleofDebtTable", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/ScheduleofDebtTable" ], "xbrltype": "stringItemType" }, "xsnx_CONVERTIBLEPROMISSORYNOTESDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONVERTIBLE PROMISSORY NOTES (Details) [Table]" } } }, "localname": "CONVERTIBLEPROMISSORYNOTESDetailsTable", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails" ], "xbrltype": "stringItemType" }, "xsnx_CONVERTIBLEPROMISSORYNOTESTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONVERTIBLE PROMISSORY NOTES (Tables) [Line Items]" } } }, "localname": "CONVERTIBLEPROMISSORYNOTESTablesLineItems", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESTables" ], "xbrltype": "stringItemType" }, "xsnx_CONVERTIBLEPROMISSORYNOTESTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONVERTIBLE PROMISSORY NOTES (Tables) [Table]" } } }, "localname": "CONVERTIBLEPROMISSORYNOTESTablesTable", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESTables" ], "xbrltype": "stringItemType" }, "xsnx_ClassOfWarrantOrRightsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate amount of each class of warrants or rights granted.", "label": "Class Of Warrant Or Rights Granted", "terseLabel": "Class of Warrant or Rights, Granted (in Shares)", "verboseLabel": "Class of Warrant or Rights, Granted" } } }, "localname": "ClassOfWarrantOrRightsGranted", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "sharesItemType" }, "xsnx_CommitmentFeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitment Fee Member", "terseLabel": "Commitment Fee [Member]" } } }, "localname": "CommitmentFeeMember", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails", "http://www.xsunx.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails" ], "xbrltype": "domainItemType" }, "xsnx_CommonStockIssuableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Issuable Member", "terseLabel": "Common Stock Issuable [Member]" } } }, "localname": "CommonStockIssuableMember", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "xsnx_CommonStockOutstandingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of common stock outstanding.", "label": "Common Stock Outstanding Percentage", "terseLabel": "Common Stock Outstanding, Percentage" } } }, "localname": "CommonStockOutstandingPercentage", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/DUETORELATEDPARTIESDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "percentItemType" }, "xsnx_ConvertibleNotePayableTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Convertible Note Payable Two Member", "terseLabel": "Convertible Note Payable Two [Member]" } } }, "localname": "ConvertibleNotePayableTwoMember", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails" ], "xbrltype": "domainItemType" }, "xsnx_DUETORELATEDPARTIESDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DUE TO RELATED PARTIES (Details) [Line Items]" } } }, "localname": "DUETORELATEDPARTIESDetailsLineItems", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/DUETORELATEDPARTIESDetails" ], "xbrltype": "stringItemType" }, "xsnx_DUETORELATEDPARTIESDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DUE TO RELATED PARTIES (Details) [Table]" } } }, "localname": "DUETORELATEDPARTIESDetailsTable", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/DUETORELATEDPARTIESDetails" ], "xbrltype": "stringItemType" }, "xsnx_DebtDefaultInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Default interest rate.", "label": "Debt Default Interest Rate", "terseLabel": "Debt, Default Interest Rate" } } }, "localname": "DebtDefaultInterestRate", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "percentItemType" }, "xsnx_DebtDiscountRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Discount rate for debt.", "label": "Debt Discount Rate", "terseLabel": "Debt, Discount Rate" } } }, "localname": "DebtDiscountRate", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails" ], "xbrltype": "percentItemType" }, "xsnx_DebtPrepaymentPenaltyPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt prepayment percentage.", "label": "Debt Prepayment Penalty Percentage", "terseLabel": "Debt Prepayment Penalty, Percentage" } } }, "localname": "DebtPrepaymentPenaltyPercentage", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "percentItemType" }, "xsnx_December2022NoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "December2022 Note Member", "terseLabel": "December 2022 Note [Member]" } } }, "localname": "December2022NoteMember", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/ScheduleofDebtTable" ], "xbrltype": "domainItemType" }, "xsnx_DeemedDividendOnWarrantRepricing": { "auth_ref": [], "calculation": { "http://www.xsunx.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deemed dividend on warrant re-pricing.", "label": "Deemed Dividend On Warrant Repricing", "negatedLabel": "Deemed dividend on warrant re-pricing" } } }, "localname": "DeemedDividendOnWarrantRepricing", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "xsnx_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.xsunx.com/20230331", "xbrltype": "stringItemType" }, "xsnx_FairValueMeasurementInputsAndValuationTechniquesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs And Valuation Techniques Abstract" } } }, "localname": "FairValueMeasurementInputsAndValuationTechniquesAbstract", "nsuri": "http://www.xsunx.com/20230331", "xbrltype": "stringItemType" }, "xsnx_FairValueMeasurementsRecurringAndNonrecurringValuationTechniquesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements Recurring And Nonrecurring Valuation Techniques Abstract" } } }, "localname": "FairValueMeasurementsRecurringAndNonrecurringValuationTechniquesAbstract", "nsuri": "http://www.xsunx.com/20230331", "xbrltype": "stringItemType" }, "xsnx_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Input Reconciliation Abstract" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract", "nsuri": "http://www.xsunx.com/20230331", "xbrltype": "stringItemType" }, "xsnx_February2023NoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "February2023 Note Member", "terseLabel": "February 2023 Note [Member]" } } }, "localname": "February2023NoteMember", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/ScheduleofDebtTable" ], "xbrltype": "domainItemType" }, "xsnx_FebruaryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "February Note Member", "terseLabel": "February Note [Member]" } } }, "localname": "FebruaryNoteMember", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/ScheduleofDebtTable", "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "domainItemType" }, "xsnx_IrvinConsultingLLCICMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Irvin Consulting LLCICMember", "terseLabel": "Irvin Consulting, LLC (\"IC\") [Member]" } } }, "localname": "IrvinConsultingLLCICMember", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCKDetails", "http://www.xsunx.com/role/DUETORELATEDPARTIESDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "xsnx_July2022NoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "July2022 Note Member", "terseLabel": "July 2022 Note [Member]" } } }, "localname": "July2022NoteMember", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTERELATEDPARTYDetails", "http://www.xsunx.com/role/ScheduleofDebtTable" ], "xbrltype": "domainItemType" }, "xsnx_JulyNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of debt instrument.", "label": "July Note Member", "terseLabel": "July Note [Member]" } } }, "localname": "JulyNoteMember", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails" ], "xbrltype": "domainItemType" }, "xsnx_LetzhangoutLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Letzhangout LLCMember", "terseLabel": "Letzhangout, LLC [Member]" } } }, "localname": "LetzhangoutLLCMember", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "xsnx_May2022NoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "May2022 Note Member", "terseLabel": "May 2022 Note [Member]" } } }, "localname": "May2022NoteMember", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/ScheduleofDebtTable" ], "xbrltype": "domainItemType" }, "xsnx_MayNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "May Note Member", "terseLabel": "May Note [Member" } } }, "localname": "MayNoteMember", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails" ], "xbrltype": "domainItemType" }, "xsnx_Note2013Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note2013 Member", "terseLabel": "2013 Note [Member]" } } }, "localname": "Note2013Member", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/ScheduleofDebtTable" ], "xbrltype": "domainItemType" }, "xsnx_Note2014Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note2014 Member", "terseLabel": "2014 Note [Member]" } } }, "localname": "Note2014Member", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/ScheduleofDebtTable" ], "xbrltype": "domainItemType" }, "xsnx_Note2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note2017 Member", "terseLabel": "2017 Note [Member]" } } }, "localname": "Note2017Member", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/ScheduleofDebtTable" ], "xbrltype": "domainItemType" }, "xsnx_November2022NoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "November2022 Note Member", "terseLabel": "November 2022 Note [Member]" } } }, "localname": "November2022NoteMember", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails", "http://www.xsunx.com/role/ScheduleofDebtTable" ], "xbrltype": "domainItemType" }, "xsnx_OPTIONSDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPTIONS (Details) [Line Items]" } } }, "localname": "OPTIONSDetailsLineItems", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/OPTIONSDetails" ], "xbrltype": "stringItemType" }, "xsnx_OPTIONSDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPTIONS (Details) [Table]" } } }, "localname": "OPTIONSDetailsTable", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/OPTIONSDetails" ], "xbrltype": "stringItemType" }, "xsnx_OptionsAt0175Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Options At0175 Member", "terseLabel": "Options at $0.175 [Member]" } } }, "localname": "OptionsAt0175Member", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/SharebasedPaymentArrangementOptionExercisePriceRangeTable" ], "xbrltype": "domainItemType" }, "xsnx_OptionsAt01Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Options At01 Member", "terseLabel": "Options at .01 [Member]" } } }, "localname": "OptionsAt01Member", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/SharebasedPaymentArrangementOptionExercisePriceRangeTable" ], "xbrltype": "domainItemType" }, "xsnx_PreferredStock50000000SharesAuthorizedSharesIssuedAndOutstandingDesignatedAsFollowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock50000000 Shares Authorized Shares Issued And Outstanding Designated As Follows Abstract", "terseLabel": "Preferred stock 50,000,000 shares authorized, shares issued and outstanding designated as follows:" } } }, "localname": "PreferredStock50000000SharesAuthorizedSharesIssuedAndOutstandingDesignatedAsFollowsAbstract", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "xsnx_PresidentOfStemVaxTherapeuticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "President Of Stem Vax Therapeutics Member", "terseLabel": "President of StemVax Therapeutics [Member]" } } }, "localname": "PresidentOfStemVaxTherapeuticsMember", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/OPTIONSDetails" ], "xbrltype": "domainItemType" }, "xsnx_RELATEDPARTYTRANSACTIONSDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS (Details) [Line Items]" } } }, "localname": "RELATEDPARTYTRANSACTIONSDetailsLineItems", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "xsnx_RELATEDPARTYTRANSACTIONSDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS (Details) [Table]" } } }, "localname": "RELATEDPARTYTRANSACTIONSDetailsTable", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "xsnx_SHORTTERMLOANRELATEDPARTYDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SHORT TERM LOAN, RELATED PARTY (Details) [Line Items]" } } }, "localname": "SHORTTERMLOANRELATEDPARTYDetailsLineItems", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/SHORTTERMLOANRELATEDPARTYDetails" ], "xbrltype": "stringItemType" }, "xsnx_SHORTTERMLOANRELATEDPARTYDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SHORT TERM LOAN, RELATED PARTY (Details) [Table]" } } }, "localname": "SHORTTERMLOANRELATEDPARTYDetailsTable", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/SHORTTERMLOANRELATEDPARTYDetails" ], "xbrltype": "stringItemType" }, "xsnx_SUBSEQUENTEVENTSDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS (Details) [Line Items]" } } }, "localname": "SUBSEQUENTEVENTSDetailsLineItems", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "xsnx_SUBSEQUENTEVENTSDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS (Details) [Table]" } } }, "localname": "SUBSEQUENTEVENTSDetailsTable", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "xsnx_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]" } } }, "localname": "SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisLineItems", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable" ], "xbrltype": "stringItemType" }, "xsnx_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table]" } } }, "localname": "SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable" ], "xbrltype": "stringItemType" }, "xsnx_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Accounts Payable And Accrued Liabilities Abstract" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract", "nsuri": "http://www.xsunx.com/20230331", "xbrltype": "stringItemType" }, "xsnx_ScheduleOfDebtAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Debt Abstract" } } }, "localname": "ScheduleOfDebtAbstract", "nsuri": "http://www.xsunx.com/20230331", "xbrltype": "stringItemType" }, "xsnx_ScheduleOfEarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Earnings Per Share Basic And Diluted Abstract" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://www.xsunx.com/20230331", "xbrltype": "stringItemType" }, "xsnx_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Abstract" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract", "nsuri": "http://www.xsunx.com/20230331", "xbrltype": "stringItemType" }, "xsnx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Abstract" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract", "nsuri": "http://www.xsunx.com/20230331", "xbrltype": "stringItemType" }, "xsnx_ScientificAdvisoryBoardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Scientific Advisory Board Member", "terseLabel": "Scientific Advisory Board [Member]" } } }, "localname": "ScientificAdvisoryBoardMember", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/OPTIONSDetails" ], "xbrltype": "domainItemType" }, "xsnx_September2022NoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "September2022 Note Member", "terseLabel": "September 2022 Note [Member]" } } }, "localname": "September2022NoteMember", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CONVERTIBLEPROMISSORYNOTESDetails" ], "xbrltype": "domainItemType" }, "xsnx_ShareBasedPaymentArrangementOptionActivityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement Option Activity Abstract" } } }, "localname": "ShareBasedPaymentArrangementOptionActivityAbstract", "nsuri": "http://www.xsunx.com/20230331", "xbrltype": "stringItemType" }, "xsnx_ShareBasedPaymentArrangementOptionExercisePriceRangeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement Option Exercise Price Range Abstract" } } }, "localname": "ShareBasedPaymentArrangementOptionExercisePriceRangeAbstract", "nsuri": "http://www.xsunx.com/20230331", "xbrltype": "stringItemType" }, "xsnx_StaffMembersAndOfficersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Staff Members And Officers Member", "terseLabel": "Staff Members and Officers [Member]" } } }, "localname": "StaffMembersAndOfficersMember", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/OPTIONSDetails" ], "xbrltype": "domainItemType" }, "xsnx_StockSubscriptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Subscriptions Member", "terseLabel": "Stock Subscriptions [Member]" } } }, "localname": "StockSubscriptionsMember", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCKDetails" ], "xbrltype": "domainItemType" }, "xsnx_TN3LLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TN3 LLCMember", "terseLabel": "TN3, LLC [Member]" } } }, "localname": "TN3LLCMember", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/CAPITALSTOCKDetails", "http://www.xsunx.com/role/DUETORELATEDPARTIESDetails", "http://www.xsunx.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "xsnx_WARRANTSDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WARRANTS (Details) [Line Items]" } } }, "localname": "WARRANTSDetailsLineItems", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "stringItemType" }, "xsnx_WARRANTSDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WARRANTS (Details) [Table]" } } }, "localname": "WARRANTSDetailsTable", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/WARRANTSDetails" ], "xbrltype": "stringItemType" }, "xsnx_WARRANTSTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WARRANTS (Tables) [Line Items]" } } }, "localname": "WARRANTSTablesLineItems", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/WARRANTSTables" ], "xbrltype": "stringItemType" }, "xsnx_WARRANTSTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WARRANTS (Tables) [Table]" } } }, "localname": "WARRANTSTablesTable", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/WARRANTSTables" ], "xbrltype": "stringItemType" }, "xsnx_WeightedAverageCommonSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Common Shares Outstanding Abstract", "terseLabel": "WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING" } } }, "localname": "WeightedAverageCommonSharesOutstandingAbstract", "nsuri": "http://www.xsunx.com/20230331", "presentation": [ "http://www.xsunx.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.B)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20,24)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.27(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.C.Q3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(4)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "270", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13A(Column E))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column E))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column H))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r547": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r548": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r549": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r551": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r552": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(3)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481408/470-60-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 67 0001185185-23-000522-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001185185-23-000522-xbrl.zip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�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end